Western University

Scholarship@Western
Canadian Journal of Surgery

Digitized Special Collections

9-1-1984

Volume 27, issue 5
Canadian Medical Association

Follow this and additional works at: https://ir.lib.uwo.ca/cjs
Part of the Surgery Commons

Recommended Citation
Canadian Medical Association, "Volume 27, issue 5" (1984). Canadian Journal of Surgery. 161.
https://ir.lib.uwo.ca/cjs/161

This Book is brought to you for free and open access by the Digitized Special Collections at Scholarship@Western.
It has been accepted for inclusion in Canadian Journal of Surgery by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

journal

Coated for fluid
performance

COATED

VTCRYI

(polyglactin 910)
suture

1

Snugs down and
hoick even in
the presence of
body fluids
□ The first coated synthetic
absorbable — the standard of
performance in surgery
□ Allows adjustable knot tension
for precise placement in the presence
of body fluids
□ Provides smooth tissue passage
□ Complete absorption between 60
and 90 days
Notice: See package insert for full
product information.
f

ETH ICO N
Innovators in wound closure

f

Ethicon Sutures Ltd., Peterborough, Ontari•Trademar

'

SEPTEMBER 1984 SEPTEMBRE

VOLUME 27, NUMBER 5

nkg Le
journal
canadien
cy de chirurgie

ISSN 0008-428X

LIST OF CONTENTS
QUILL ON SCALPEL
417

arcinoma of the Esophagus: a Dilemma

-i

M. Goldberg
417

As the Wheel Turns

C. Heughan
418

leal
l< Conduit or Ileal Bladder?

M.M. Elhilali

CORRESPONDENCE
421

Carcinoma of the Esophagus

J.L. Stoller
Tube Duodenostomy — a Safe Method for Managing Perforated Duodenal Diverticulum

r

421

O. Zamir, O.Z. Lernau, S. Nissan

REVIEW ARTICLE
423

Pneumatic Antishock Trousers

F.J. Baxter, R.A. Kessaram, F. Baillie

SYMPOSIUM ON CROHN’S DISEASE
1. Crohn’s Disease: Emerging Pathologic and Bacterial Spectrum

431

H.J. Freeman
2.

C lo s tr id iu m d if f ic ile

in Crohn’s Disease

435

J.M. Wright, S.P. Adams, M.J. Gribble, W.R. Bowie
3. Infection and the Use of Antibiotics in Crohn’s Disease

438

M.R.B. Keighley

WALTER C. MacKENZIE RESEARCH DAY (SUMMARIES)
Monitoring Epidural and Fontanel Pressure: a Clinical and Experimental Study

443

L.P. Ivan
Intestinal Transplantation: a Reality for the Future

444

Z. Cohen
Surface Analytical Methods for Elbow-Joint Replacement

445

C. Sorbie, R. Shiba, D. Siu
Experimental Study of the Microsurgical Transfer of Growth Plates

446

V. Bowen, B.M, O’Brien
Encircling Endocardial Resection for Sustained Drug-Resistant Ventricular Tachycardia

447

R.W. Landymore, C.E. Kinley, M. Gardner

VOLUME 27, NO. 5, SEPTEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

409

1
1

m

^ ____
Sodium F u sid a te B.P.

knows
no
barriers
staphylococcal
infection!

Leo Laboratories Canada Ltd
1305 Sheridan Mall Pkwy., Suite 704
Pickering, Ontario L1V 3P2
Telephone: (416) 831-2332
* trade m ark

PRODUCT MONOGRAPH AVAILABLE ON REQUEST.
PAAB

For prescribing information see page 427

I

LIST O F C O N T E N T S C o n t’d
A
T h e In t e s t in e H a s a C o m p le x : H o u s e k e e p e r o r H e ir lo o m ?

448

W .E . W a te rfa ll

V P o s t o p e r a t iv e R e s p ir a to r y F a ilu r e in C o n g e n ita l D ia p h r a g m a t ic H e r n ia

449

R .J.P . C lo u tie r
450

M o tilin a n d P o s t v a g o to m y D ia r r h e a in D o g s

D .P . T ass e , P. P o itra s

C a u s e a n d N o n in v a s iv e D e t e c t io n o f R e c u r r e n t S te n o s is a f t e r C a r o t id E n d a r t e r e c t o m y

450

A . S a lv ia n , J.D . B a k e r, H .l. M a c h le d e r, R .W . B u s u ttil, W .F . B a rk e r, W .S . M o o re
451

T h e O d o n t o id P ro c e s s

*

D .C . R e id , P. Y e u n g

S u t u r e “ S t a y in g P o w e r ” : A b s o r b a b le v e r s u s N o n a b s o r b a b le

451

D .C . B ird s e ll

P h o t o k e r a t o p a th y a n d O t h e r D e le t e r io u s E ffe c ts o f L ig h t o n t h e E y e
A

452

G .J. J o h n s o n
453

M a in ta in in g B o d y P r o te in in C a t a b o lic P a tie n ts

R. F in le y

P e r s p e c t iv e o n M y o c a r d ia l P r o t e c t io n : C o ld a n d N o u r is h e d

454

R .C -J. C h iu

S h o r t - t e r m S to r a g e o f A r t ic u la r C a r tila g e in T is s u e C u lt u r e

r

455

R .C . L o ch t, R. R o g a ls k y

S Y M P O S IU M ON T R A U M A
1 . S u r g e r y in th e R e s u s c ita tio n o f C r itic a lly In ju r e d P a tie n ts

461

C .M . B u rn s

>2. L e s y n d r o m e d e la c e in t u r e d e s e c u r ite : u n e p a th o lo g ie a b d o m in a le n o u v e lle

464

H. A tla s , M . A lla rd , R. D e n is , E. F a rk o u h
466

3 . C h e s t In ju r ie s in C h ild r e n

J.D . B u rrin g to n
472

4 . A b d o m in a l In ju r ie s in C h ild r e n
*

D .E . W e s s o n

CAG S G U E S T LE C T U R E
479

S h o ck T ra u m a

D .D . T ru n k e y

O R IG IN A L A R T IC L E S

*

C o m p u t e r iz e d A r t h r o t o m o g r a p h y in R e c u r r in g S h o u ld e r D is lo c a t io n s a n d S u b lu x a t io n s

487

P. K in n a rd , D. G o rd o n , R .Y . L e v e s q u e , D. B e rg e ro n
P a llia tio n a f t e r O p e r a tio n a n d a f t e r R a d io th e r a p y f o r C a n c e r o f t h e E s o p h a g u s

491

J .L . S to lle r, M .L. B ru m w e ll
■«
P a te n t U r a c h u s a n d In f e c t e d U r a c h a l C y s t in a n A d u lt: a C a s e R e p o r t

496

M .B . B u c k s p a n
U s e o f a P y lo n fo r E a r ly A m b u la t io n a f t e r B e lo w -K n e e A m p u t a t io n : a P r e lim in a r y R e p o r t

500

I.J. H a rrin g to n , S .l. E sses, R .C . W h ite

VOLUME 27, NO. 5, SEPTEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

411

DA VIS+GECK

INTRODUCES

NEW
We started with a
superior core
.
(Dexon* ‘S’)...

The finer, tighter braid is smooth and
strong. This produces the suppleness
and flexibility necessary for easier
tying as well as superior knot
j
security — high standards
y
which have been proven
over years of use.

...and
added
a superior
surface
treatment
Poloxamer m L
1 8 8 treatment is
thinner and noticeably
■
smoother than other coatings.
Smoother tissue passage allows for
simplified closings and reduced tissue
trauma which in turn helps
speed healing.
And the surface treatment is rapidly absorbed
— once the job is done, it’s gone. This
means better in vivo knot security than with comparable products.1

NEW DEXON* PLUS

Excellent knot security plus superior handling
and smoother tissue passage.
DAVIS+GECK
Cyanamid Canada Inc.

A TRADITION OF INNOVATION

Atria North, 2255 Sheppard Avenue East, Willowdale, (Ontario) M2J 4Y5

Registered Trademark of Cyanamid Canada Inc.

1 data on file

For pre scrib in g in fo rm a tio n see page 4 1 9

2 data available on request

LIST O F C O N TE N TS C ont.’d
504

Continent, Nonrefluxing Urinary Reservoir Constructed from Ileum: Report of Two Cases
Z. C o h e n , M . J e w e tt, J. L u s tg a rte n , A .W . B ru c e , S .R . N o rd g re n , J .V . T h a c h il

509

Magnetic Resonance Imaging and Surgical Clips
D. B a rra fa to , R .M . H e n k e lm a n

513

Vibration-Induced White Finger Disease: a Case Report
E .H . Lee, J .G . E vans

O U R S U R G IC A L H E R IT A G E
»
W.V. Cone Remembered

515

J .L . S h u g a r

Reminiscences of William Cone

516

H .J. R o se n

William Vernon Cone

518

J .P . R o b b

Notices

427

SESAP IV Question

433

Books Received

463

SESAP IV Critique

486

Classified Advertising

519

Advertisers’ Index

520

V

»

>The Canadian Journal of
Surgery

*

Le journal canadien de
chirurgie
( 613)

►
^

■*
A

{

731-9331

+The Canadian Journal of Surgery is pub
lished by the Canadian Medical Association
and sponsored by the Royal College of Physicians and Surgeons o f Canada. The estab
lis h m e n t o f e d ito ria l p o lic y is the
responsibility o f the Royal College. The
objectives of the Journal, endorsed by the
Council o f the College, are: (1) to contribute
to the effective continuing education of
Canadian surgical specialists, using innova^ tive techniques when feasible and (2) to pro
vide Canadian surgeons with an effective
vehicle for the dissemination of their observations in the area o f clinical research.

Published every 2 months by the Canadian
Medical Association, PO Box 8650, Ottawa,
Ont. K1G 0G8. Printed b y HarpelTs Press

Cooperative, Gardenvale, PQ HOA 1B0.
Second-class mail registration No. 5375.
Return postage guaranteed. All reproduction
rights reserved. Subscription rate for Cana
da and USA $30.00 p e r year ($15.00 per
year for trainees in surgery in Canada only),
for all other countries $35.00 per year. Sin
gle copies (current issue) available at $5.00
each, back issues a t $6.00 each.

Instructions to Contributors
Detailed instructions to contributors, in En
glish and French, appear on page 83 of the
January 1984 issue.
Coeditors
Corddacteurs
L.D. MacLEAN, Montreal, PQ
C.B. MUELLER, Hamilton, Ont.
Senior Associate Editor
Redacteur assocte en chef
J.L. SHUGAR
Associate Editor
Rddactrice assoctee
G. PANCIROV

The Canadian Medical Association
L’Association m edicale canadienne

Editorial Advisory Board
Conseil consultant de redaction
S.A. Awad, Halifax, NS
R.J. Blanchard, Winnipeg, Man.
M.M. Cohen, Toronto, O nt.
P.J.E. Cruse, Calgary, Alta.
J.B.*Freem an, Ottawa, O nt.
W.J. Keon, Ottawa, Ont.
M.
J. Rheault, Montreal, PQ
N. M. Sheiner, Montreal, PQ
C. Sorbie, Kingston, Ont.
H.T.G. W illiams, Edmonton, Alta.
P.P. Morgan (ex officio)

The Royal College of Physicians
and Surgeons of Canada
Le College royal des m edecins et
chirurgiens du Canada

President / president
T.A. McPherson, MD, PhD, FRACP
Secretary General
Secretaire general
B.E. Freamo
Director o f Publications
Directeur des publications
David Woods
Director o f Advertising Sales
Directeur de la publicity
N. Hutton (416) 821-8112
Montreal Sales M anager
Chef du service des ventes a M ontreal
R. Stapleton (514) 620-8877
Production M anager
Chef du service de la production
K.A. Freamo

ccab

President / president
L.E. McLeod, MD, FRCP(C)
Executive Director
Directeur general
J.H. Darragh, MD, FRCP(C)

PAAB
CCPP

Note: All prescription drug advertisements
in the Journal have been precleared
by the Pharmaceutical Advertising
Advisory Board.

VOLUME 27, NO. 5, SEPTEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

413

As an adjunct to surgery

FLAGYL 5 0 0

can dramatically reduce
the risk of antibiotic failure
in anaerobic infections

4

against virtually all clinically
important anaerobes. In fact, Flagyl
500 Inj. is “ the only compound...
with consistent bactericidal activity
against anaerobic bacteria, including
B. fragilis} ”

1
i

*

consistently bactericidal

i

Comparative efficacy o f 4 antimicrobial agents
against isolates o f Bacteroides in a mouse model
of sc abscesses

DRUG

Decrease vs.
controlst
(log cfu)

Flagyl 500 Inj.

> 6 .7+ 0 .6

1

Clindamycin

5.0± 0.6

2

Moxalactam

3.8± 0.6

2,3

Cefoxitin

3.5±0.5

3

Statistical
analysis*

penetrates
rapidly into colonic tissue, achieving a
significant reduction in Bacteroides
content of the colon within one hour.2
Flagyl 500 Inj. is distributed in all
body tissues and fluids, including
abscesses.3,4

concentrates
at bactericidal levels in wound tissue.
In an animal study comparing Flagyl
500 Inj. with clindamycin and
cefoxitin, only Flagyl 500 Inj.
achieved therapeutic concentrations in
both fresh and healing colonic tissue.5

eradicates
pathogens from within the abscess
cavity, achieving significantly greater
reductions in B acteroides count than
clindamycin or cefoxitin.4

+Mice given no antibiotic had mean (± SEM) counts of
109.9+
pgf abscess at five days.
*Results for drugs with the same numerical designation were
not significantly different (P >0.05) by Student’s t- test o f
independent means.

Excellent safety profile
Flagyl 500 Inj. is well tolerated, with a
low incidence of side effects.6
Pseudomembranous colitis is unlikely
to occur, as Flagyl 500 Inj. is highly
effective against C. difficile?’8 which is
usually associated with this disease5
Clindamycin and cefoxitin, on the
other hand, show little activity against
C. difficile ,7,8

RHONEPOULENC PHARMA Inc.

8580 Esplanade
Montreal, Quebec
®authorized user

w henever anaerobic infection cannot be ruled o!

LAGYL 5 0 0

jtronidazole)

a selective anaerobicide

See brief prescribing information on page 416

Whenever anaerobic infection cannot be ruled out

FLAGYL 5 0 0
(metronidazole)

o

A selective anaerobicide
ACTIONS
Flagyl (m etronidazole) is bactericidal against
anaerobic bacteria, it exerts trichom onacidal activity
and is also active against Giardia lamblla and
Entamoeba histolytica. Its exact m echanism o f action
has not been entirely determined as yet. It has been
proposed that an interm ediate in the reduction of
metronidazole, produced only in anaerobic bacteria
and protozoa is bound to deoxyribonucleic acid and
proteins, and inhibits subsequent nucleic acid
synthesis.

INDICATIONS AND CLINICAL USES
Bacterial Infections: The treatment o f serious
anaerobic abdominal infections due to susceptible
anaerobic bacteria, such as Bacteroldes fragilis (and
other species o f B acteroides), Clostridium ,
Fusobacterium, Peptococcus, and Peptostreptococcus
species.
Culture and susceptibility studies should be
perform ed to determ ine the causative organisms and
their susceptibility to metronidazole. Based on clinical
judgm ent and anticipated bacteriological findings,
therapy may be started while awaiting the results of
these tests. In mixed aerobic and anaerobic infections,
consideration should be given to the concomitant
administration o f an antibiotic appropriate for the
treatment of the aerobic component o f the infection.
(S ee Warnings).
Flagyl (m etronidazole) has also been used in the
treatm ent o f a sm all number o f cases o f brain or lung
infections (some w ith abscesses) caused by anaerobic
bacteria.

CONTRAINDICATIONS
Flagyl (m etronidazole) is contraindicated in
patients with a prior history o f hypersensitivity to
metronidazole o r oth er nitroimidazole derivatives.
Flagyl should n ot be administered to patients with
active neurological disorders or a history o f blood
dyscrasia, hypothyroidism and hypoadrenalism.

WARNINGS
Flagyl (m etronidazole) has no direct activity
against aerobic o r facultative anaerobic bacteria. In
patients with m ixed aerobic/anaerobic infections,
appropriate concom itant antibiotics active against the
aerobic component should be considered.
Known or previously unrecognized moniliasis may
present more prom inent symptoms after treatment
with Flagyl.
Studies in rats and m ice have provided some
evidence that metronidazole m ay cause tumors in
these species when administered orally for a long
period at high doses. The relevance o f these findings
in humans is not known.
Severe neurological disturbances (i.e. convulsive
seizures and peripheral neuropathy) have been
reported in patients treated with Flagyl (administered
orally or intravenously). These have been observed
very infrequently.

PRECAUTIONS
Patients taking Flagyl (m etronidazole) should be
warned against consuming alcohol, because o f a
possible disulfiram-like reaction. F or the same
reason, patients receiving Flagyl should not be
administered disulfiram concomitantly.
Transient eosinophilia and leukopenia have been
observed during treatment with Flagyl. Regular total
and differential leukocyte counts are advised if
administration fo r m ore than 10 days or a second
course o f therapy is considered to be necessary.
M etronidazole crosses the placental barrier.
Although Flagyl has been given to pregnant women
without apparent com plication, it is advisable that
oral administration be avoided in pregnant patients
and Flagyl be w ithheld during the first trimester o f
pregnancy. In serious anaerobic infections, if the
administration o f Flagyl to pregnant patients is
considered to be necessary, its use requires that the
potential benefits be weighed against the possible
risks to the fetus.

M etronidazole is secreted in breast milk in
concentrations similar to those found in plasma.
Intravenous or oral administration o f Flagyl should be
avoided in the nursing mother.
M etronidazole has been reported to potentiate the
anticoagulant effect o f warfarin resulting in a
prolongation o f prothrombin time. This possible drug
interaction should be considered when Flagyl is
prescribed for patients on this type o f anticoagulant
therapy. Clinical experience in children is very limited.
The m onitoring o f this group o f patients is particularly
important. The safety and effectiveness o f intravenous
Flagyl in children has not been established.
A rare case o f reversible but profound neurological
deterioration has been reported following a single oral
dose o f Flagyl; it is therefore advisable that a patient
taking Flagyl for the first tim e not be left unattended
for a period o f tw o hours. The appearance o f abnormal
neurologic signs demands prompt discontinuation o f
Flagyl therapy and, when severe, immediate medical
attention. Gastric lavage m ay be considered if no
m ore than two or three hours have elapsed since
administration o f the drug.
Treatment with Flagyl should be discontinued if
ataxia or any other symptom o f C N S involvement
occurs.
Patients with severe hepatic disease metabolize
m etronidazole slowly with resultant accumulation of
metronidazole and its m etabolites in the plasma.
Accordingly, for such patients, doses o f Flagyl below
those usually recom m ended should be administered
and with caution. The determination o f serum
glutam ic oxaloacetic transaminase (S G O T ) by the
Technicon S M A 12/60 system in blood samples from
patients receiving Flagyl m ay give abnormally low
values. This abnorm ality is artifactual and caused by
the absorption o f m etronidazole at the wavelength
where the enzymatic reaction is monitored
spectrophotometrically.

ADVERSE REACTIONS
Gastrointestinal: diarrhea, nausea, vomiting,
anorexia, epigastric distress, dyspepsia, constipation.
Month: furred tongue, dry mouth, unpleasant
m etallic taste.
Hematopoietic: transient eosinophilia or
leucopenia.
Derm atologic: rash and pruritus.
Cardiovascular: palpitation and chest pain.
Central Nervous System: convulsive seizures,
peripheral neuropathy, transient ataxia, dizziness,
drowsiness, confusion, insomnia and headache.
Peripheral neuropathies have been reported in a few
patients on m oderately high to high-dose prolonged
oral treatment with m etronidazole. It would appear
that the occurence is not directly related to the daily
dosage and that an important predisposing factor is
the continuation o f oral and/or I.V. medication for
several weeks or months. Profound neurological
deterioration, within 2 hours after Flagyl
administration has been reported. The occurrence is
not directly related to the dosage level.
Metabolic: An antithyroid effect has been reported
by som e investigators but three different clinical
studies failed to confirm this.
Local Reactions: Thrombophlebitis has occurred
with I.V. administration.
Other: Proliferation o f Candida albicans in the
vagina, vaginal dryness and burning; dysuria;
occasional flushing and headaches, especially with
concomitant ingestion o f alcohol; altered taste o f
alcoholic beverages. Darkening o f the urine has been
reported. This is probably due to a metabolite o f
m etronidazole and seems to have no clinical
significance.

SYMPTOMS AND TREATMENT OF
OVERDOSAGE

4

>

Symptoms
M assive ingestion m ay produce vom iting and slight *
disorientation.

Trsatmsnt
There is no specific antidote. Early gastric lavage
m ay rem ove a large amount o f the drug; otherwise,
sym ptom atic treatment.

DOSAGE AND ADMINISTRATION
TREATMENT OF ANAEROBIC
INFECTIONS

1
'

*

Treatment should be initiated by the I.V. route. Oral
m edication m ay be substituted when it is feasible
and/or practical. Duration o f therapy depends upon
^
clinical and bacteriological assessment. Treatment for
seven days should be satisfactory for most patients.
How ever in cases where infection sites cannot be
drained or which are liable to endogenous
recontamination by anaerobic pathogens, a longer
1
treatment m ay be required.
*1

I.V. ADMINISTRATION:
100 m L (500 m g) by intravenous infusion every 8 *
^
hours. T he injection should be infused intravenously
at the rate o f 5 mL per minute.
Flagyl injection is compatible in a volume ratio o f
A*
1:5 with normal saline, dextrose-saline, dextrose 5 per
cent w/v o r potassium chloride injections (20 mmol
and 40 m m ol). It should not be mixed with sodium
•*
lactate injection 5% w/v, or dextrose injection 10%
w/v.

AVAILABILITY
Injection 0.5% w/v in Viaflex* plastic bags o f
100 m L (500 m g) for intravenous infusion.
FU LL P R O D U C T M O N O G R A P H A V AILAB LE O N
REQUEST.

References:
l.F in e g o ld SM. Metronidazole: Selected proceedings
o f the international metronidazole conference.
Excerpta M edica 1979; 141-6. 2 . Hinchey EJ et al.
^
Ann Surg 1980; 192(2): 221-6. 3 . Product
monograph. 4 . Joiner K et al. J Infect Dis 1982;
145(4): 561-8. 5 . Chou S et al. Can J Surg 1982;
25(5): 527-31. 6. Willis A T. Metronidazole: Selected
proceedings o f the international metronidazole
conference. Excerpta M edica 1979; 209-15. 7 . Dzink
r
J, Bartlett JG. Antimicrob Agents Chem other 1980;
17(4): 695-8. 8 . Rolfe RD, Finegold SM. Antimicroh
Agents Chem other 1981; 20(5): 600-9.
*
1

RHONEPOULENC PHARMA Inc
8580 Esplanade
Montreal, Quebec
®authorized user

-.-«■»■ ______

l"“ AC J [ PAAH *

*-

*

QUILL ON SCALPEL

+►

This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Carcinoma of the Esophagus: a Dilemma
In this issue (pages 491 to 495), Stoller
v and Brumwell address a difficult issue
that remains unresolved — the appropriY ate treatment of esophageal carcinoma.
Successful operation for tumour is usually
* *gauged by survival or time of recurrence
after operation. With esophageal carci* noma, particularly squamous carcinoma
of the upper and middle thirds, it is pal
liation that must be evaluated since sur
vival beyond 3 years is rare no matter
what the form of treatment. To date, no
, controlled, prospective, randomized
study has been performed to compare the
>- ^efficacy of surgery with that of radio
therapy.
t
The data collection sheet of Stoller
identifies five categories that are assessed
* subjectively by patients at intervals after
primary treatment. Somewhat arbitrarily,
a point value has been placed on the effec„ ytiveness of palliation for subgroups in
these categories, with 100 as the maxiy- mum score. Unfortunately, because of
the arbitrary nature of the individual

point scores (varying subjectively in
importance from physician to physician
and patient to patient) it is impossible to
draw statistically valid conclusions no
matter what analytic method is used.
Of the 17 adenocarcinomas, 16 were in
the lower one third of the esophagus and
were presumably cardiac in origin. Such
tumours have, for decades, been shown
to be effectively treatable for cure and
palliation by operation alone. The
authors, without exception, treated all of
these tumours by operation. The remain
ing squamous- and undifferentiated-cell
lesions were treated by primary irradia
tion in 53 instances and by operation in
12. The authors do not specify the sites
of the squamous carcinomas that were
treated initially by operation.
The results state that of the 53 irradi
ated patients, 24 (45%) required a secon
dary surgical procedure to prolong palli
ation; it succeeded in 21. Obviously, the
patients at this stage of their disease were
less than optimal candidates for operation

and this is reflected in the postoperative
mortality of 35% (7 of 24). Also, only 29
of 53 patients (55%) were palliated by
radiotherapy alone without the benefit of
secondary surgery. In the surgical series
of 29 patients, 21 (72%) were improved
after operation alone.
The importance of identifying the
appropriate treatment for esophageal car
cinoma must be emphasized and has been
addressed to some degree by Stoller and
Brunwell. In order to do this objectively,
there still remains the need for valid, wellcontrolled, prospective, randomized
studies to identify beyond doubt the
differences between surgery and radio
therapy.
M elvyn G o ld berg ,

m d , fa c s , frcsic ]

Division of Thoracic Surgery,
Mount Sinai Hospital,
University of Toronto,
Toronto, Ont.
M5G 1X5
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As the Wheel Turns
r

►

Twenty-five years ago, when I was a med
ical student, internists were physicians
r who relied on a thorough history, care
ful examination and results of some basic
tests to diagnose and occasionally to treat
their patients. Some were credited with
A * legendary powers of intuitive and brilli
ant bedside diagnosis. The revelation of
' a classic roseolar spot on a patient whose
. fever had baffled platoons of lesser mor7 tals and the finding of lepromatous nod
ules on a patient with an obscure neu

ropathy are still vivid memories. Even a
student could occasionally pull off a
masterly diagnosis, one by sending, in a
fit of pique, some extra blood from a
venepuncture for the most obscure and
irrelevant test he could think of. When
the test result was shown to be strongly
positive and he had the wit lavishly to
embroider his reasons for requesting it,
his reputation for brilliance survived 5
years of mediocrity.
Surgeons, by contrast, were the brain

less technicians, to be consulted by tact
ful internists for their opinion only on the
assumption that they were sufficiently
perceptive to realize that an operation was
already decided upon. Less tactful inter
nists would request the surgeon to
“ Please see with a view to gastrectomy” ,
and one man’s reputation for acerbic wit
was increased by his habit of requesting
the operation by name and adding gratui
tous instructions concerning the incision
and some of the technical details.
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Presumably, the surgeon’s self-esteem
was restored by his Rolls-Royce and lush
country retreat.
Having been bred as one whose life’s
work confines him to the intellectually
lower stratum, it comes as a shock to be
asked to see patients whose symptoms
have defied the efforts of internists,
backed-up by the formidable technology
of 1984, rather like the humble woodcut
ter who found himself abruptly invested
with royal panoply and regalia.
The fact o f the matter is, in the best
psychosocial gobbledegook, that we have
suffered a role reversal. Our friends the
internists have splintered into subspecial
ties, each obsessed by its technical appli
ances. Lights, tubes, lasers, cauteries and
balloons are coaxed into almost every part
of the human body and a rich harvest of
nonspecific, insensitive or irrelevant
information is produced. These proce
dures demand a degree of technical train

ing and are rewarded by the exorbitant
fees that society bestows on the modern,
the technologically advanced and the
invasive. Technology has bypassed the
general surgeon. We have seized the coat
tails of the gastroenterologists as they
whirl around on their fiberoptic merrygo-round. We have advanced, but seldom
by introducing new, exotic materials or
lavishly expensive equipment.
So who but the humble general surgeon
still relies on the history and physical
examination? Simple tests and roentgeno
grams are normally all we need and com
puterized tomography and endoscopy are
done with guilty feelings that we have
failed as clinicians. Who else could be the
salvation of patients with angiogram
negative chest pain, many of whom have
classic symptoms of reflux? Where else
can the patient with normal findings on
endoscopy, colonoscopy, endoscopic
retrograde cholangiopancreatography,

computerized axial tomography and 14
contrast studies, who still has stomach
pain, go to but a general surgeon?
The wheel has turned through 180°, so
now I feel a glow of pride tinged witl* intellectual snobbery as I climb into my
rusty car in the evening. I still hope for *
the lucky flash of inspiration that will
place me alongside the legendary clinical
internists of yesteryear.
I never ask my colleagues to “ Please
do an ERCP” or to prescribe this week’*
antiarrhythmic or beta blocker, but
always politely request their opinion,
knowing that they usually have the wit to
do what is required.
1

C . HEUGHAN, M B, B C H IR , FRCS, FRCS[C],
FACS
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Ileal Conduit or Ileal Bladder?
Whether to create a urinary diversion is
one of the most serious decisions a urol
ogist must make. It is superfluous to say
that all other options should be consi
dered first. The ideal urinary diversion for
some patients may not be ideal for others.
The disease process and life expectancy
must be considered.
Recently, there has been a trend to
restore urinary flow to the bladder in
patients who still have it, provided cer
tain requirements can be met. The
socioeconomic status of the patient may
be an important factor in the type of solu
tion offered; available appliances and the
services of a stomotherapist are unafford
able luxuries for some patients.
The ideal diversion should fulfil certain
criteria: low operative mortality and mor
bidity, maintenance of kidney function,
low infection rate, low rate of reopera
tion and its acceptance by the patient.
Social acceptability is greatly enhanced if
the diversion is associated with urinary
continence. We must, however, consider
the sacrifices involved in achieving this
goal. Before considering a diversion in a
patient with a neurogenic bladder, inter
mittent catheterization or pharmacologic
manipulation, or both, might be used to
maintain a continent reservoir and pro
tect kidney function.
Ureteroileostomy or ileal conduit, as
418

described by Bricker,1 is the most fre
quently used form of urinary diversion in
North America. It is occasionally referred
to by patients and physicians as an ileal
bladder. To be termed a bladder it should
function as a continent reservoir and have
the ability to empty. The ileal conduit was
intended to be a free-draining system
from ureters to skin without the difficulty
of fitting appliances that is frequently
encountered with ureterocutaneous
anastomosis. The diversion is simple to
perform and can be combined in a single
procedure with cystectomy. Long-term
results, however, have not been so satis
factory. The incidence of stomal steno
sis and the deterioration of kidney func
tion, which is largely related to the
absence of an antireflux mechanism, were
appreciable in a large series of patients
followed up for 10 years.2
The next logical step was the use of
colon to prevent stomal stenosis and, as
an antireflux mechanism, to protect kid
ney function. Unfortunately, reflux and
stomal stenosis still occur in many
patients.3 When the risk of colonic
cancer, theoretical as it may be, is added,
this choice seems hardly worthwhile. An
ileal valve that prevents reflux while keep
ing the conduit free-draining would be an
appropriate compromise.
In order to achieve a continent diver

sion, which is the only acceptable meas- *.
ure under certain circumstances, many
techniques have been devised, such as the "
ureterosigmoid diversion. This early techj
nique was frequently associated with pye- r
lonephritis, hyperchloremic acidosis and
;
deterioration of kidney function. The
Mayo Clinic4 showed that this technique
has by no means been abandoned, but it
requires a continent anal sphincter, which is not always available in patients with
neurogenic dysfunction. The ureterosig- *
moid diversion was followed by a proce•
dure that established a perineal stoma" 4
through the anal sphincter, and by the
I
rectal bladder with the term inal 4
colostomy, which was more readily ^
acceptable than a wet diversion requiring
an appliance.5
Surgical ingenuity has led to the
development of several types of continent4 -<
reservoirs, with variable success after
short-term follow-up. These include the 4
ileocecal reservoir, in which continence is
maintained by the antiperistaltic function 4
of the terminal ileum, the action of the
ileocecal valve and by the small ileal skin
stoma.6 The results obtained with this* j.
technique have not been consistent.
Another form is the ileal spout valve f
anastomosed to the ileocecal reservoir
within the cecum. An ink-well valve was ^
used at the end of an ileocecal reservoir,
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with success in a limited number o f
patients.7
k
The principle of a double ileal valve,
one to control reflux and the other to
> •maintain continence, was originally
introduced by Kock and associates8 in
* their pioneering work with a continent
ileal pouch following total proctocolec* tomy. Their method o f intussuscepting
ileal valves was successful in maintaining
continence and preventing reflux. Many
H waives broke down and had to be oper
ated upon again to obtain continence. To
*- prevent some of these complications, rein
forcement with Marlex mesh was introduced. In this issue (pages 504 to 507)
Cohen and associates report on their
^ experience with the double ileal valve
( procedure.
The preliminary results with this tech^ nique are encouraging but we have yet to
see the long-term results. There is no rea► son to believe that preservation o f kidney
function will be better with a double ileal
r
valve than with a free-draining diversion
and antireflux procedures, whether ileal
■ or colonic. Long-term continence and
k the urinary tract infection rate are

important and must be followed up care
fully. This kind o f diversion should still
be considered experimental and thus
reserved for certain centres so that the
necessary answers, at least with respect to
morbidity, can be obtained. Other
experimental models designed to retain
continence have been described but are
still under investigation; these include the
use o f subcutaneous magnets or a pure
vitreous carbon stoma.
Future research may bring the ideal
continent reservoir closer. Work is being
done to develop scaffolds for bladder
regeneration, but this is still far from real
ity. An artificial bladder capable o f per
forming both functions, once thought to
be in the realm o f science fiction, may
well be realized in the future.

M .M . E lhilali,
FRCSfC]
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DEXON * “S ”
POLYGLYCOLIC ACID SUTURE
SYNTHETIC, ABSORBABLE
USP
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INDICATIONS: DEXON “S” Sutures and DEXON PLUS Sutures are
indicated whenever absorbable sutures and ligatures are employed.

DEXON* PLUS

POLYGLYCOLIC ACID SUTURE
COATED WITH POLOXAMER 188
SYNTHETIC, ABSORBABLE
USP
DESCRIPTION: DEXON “S" polyglycolic acid Suture - Synthetic
Absorbable, USP and DEXON PLUS polyglycolic acid Suture - Syn
thetic, Absorbable, USP are homopolymers of glycolic acid, con
structed of filaments finer than in an original DEXON Suture to
provide optimal handling properties. DEXON PLUS Suture, in addi
tion. is coated with poloxamer 188, a surfactant. The coating material
is inert, non-collagenous, non-antigenic and non-pyrogenic.
The sutures are sterile, inert, non-collagenous, non-antigenic, nonpyrogenic, and flexible. The braided and monofilament sutures are
colored green to enhance visibility in tissue. DEXON “S” and
DEXON PLUS braided sutures are also available undyed with a nat
ural beige color. They are uniform in size and tensile strength, but are
smaller in diameter than other absorbable surgical sutures of equiva
lent tensile strength.
ACTIONS: When DEXON “S” Sutures or DEXON PLUS Sutures are
placed in tissues, a minimal tissue reaction occurs which is followed by
a microscopic layer of fibrous connective tissue which grows into the
suture material.
Absorption studies in animals show DEXON “S” Sutures and
DEXON PLUS Sutures to be equivalent to original DEXON Sutures.
Studies in rabbits revealed minimal absorption at 7 to 15 days, signifi
cant absorption at 30 days and maximum resorption after 60-90 days.
With DEXON PLUS Sutures, 80% to 97% of the coating was excreted
in the urine during the first 3 days following implantation in rabbits.
The remainder was excreted within 40 days.
Tensile strength, not being a function of the absorption rate, may vary
from tissue to tissue depending in part on the rate of hydrolysis. The
early tensile strength of DEXON “S” Sutures and DEXON PLUS
Sutures is reported to be greater than that of comparable chromic cat
gut. In animal studies (subcutaneous tissue in rats) it has been shown
that at two weeks post-implantation approximately 55% of the original
tensile strength of a DEXON “S” or DEXON PLLJS Suture remains,
while at three weeks approximately 20% of its original strength is
retained.

CONTRAINDICATIONS: DEXON “S” Sutures and DEXON PLUS
Sutures are contraindicated where extended approximation of tissues
under strain must be maintained.
WARNINGS: The safe use of this suture in neural tissue and in car
diovascular surgery has not been established.
Under certain circumstances, notably orthopedic procedures, im
mobilization by external support may be employed at the discretion of
the surgeon.
Do not resterilize. Discard opened, unused sutures.
PRECAUTIONS: Acceptable surgical practice should be followed
with respect to drainage and closure of infected wounds.
The knot with DEXON "S” polyglycolic acid Suture must be properly
placed to be secure. Therefore, place the first throw in precise position
for the final knot using a double loop; tie the second throw square
using horizontal tension; additional throws may be used as desired.
DEXON PLUS Sutures, which are treated to enhance handling char
acteristics, require the standard surgical technique of flat and square
ties with additional throws if indicated by surgical circumstances and
the experience of the surgeon.
Skin sutures which remain in place for periods of longer than seven
days may cause localized topical irritation and the extended portion of
the suture may be snipped off after five to seven days, as indicated.
ADVERSE REACTIONS: Those reactions that have been reported
include tissue reaction or inflammation, fibrous or granulation tissue,
bleeding, wound separation in the eye, and accumulation of fluid
around subcuticular stitches.
DOSAGE AND ADMINISTRATION: Use as required
HOW SUPPLIED: DEXON “S” and DEXON PLUS Sutures sizes 8-0
braided through 2 braided (metric size 0 .4 —5) dyed green, and 7-0
braided through 2 braided (metric size 0.5 —5) natural beige.
Supplied in cut lengths or ligating reels, non- needled or affixed to the
various Davis + Geek ATRAUMATIC® needles or D-TACH® remova
ble needles USP in one, two and three dozen packages. DEXON“S”
Suture, monofilament, dyed green, is available in size 9-0 (metric size
0.3) in a variety of lengths with needles in one dozen packages.
1 data on file

u
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2 data available on request
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C an R ob Tbe B o d y O f Valuable Vitam ins.
The depletion of B-complex and
C vitamins during periods of
stress has been well documented.
In recent years, zinc loss or
deficiency during metabolically
stressful conditions—ranging
from alcoholism, diarrhea and
surgery, to chronic debilitated
states — has also been confirmed
by clinical evidence.
Stresstabs® 600 with Zinc was
developed because of this
growing body of clinical evidence.

Also available are Stresstabs® -<
600, the basic stress formula
vitamin. And Stresstabs® 600" M
with Iron, specifically formulated
for a woman’s special needs.
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Carcinoma of the Esophagus

To the editors.— I am grateful for hav
ing had the opportunity to review Dr.
v Goldberg’s editorial (page 417) and
I would like to make a few additional
i ^observations.
For further information the 12 patients
F with squamous cancer treated primarily
by surgical excision (referred to by Dr.
v Goldberg in his third paragraph) were dis
tributed as one might have expected with
* 9 in the lower third and 3 in the middle
> i third of the esophagus.
Secondly, in deference to other sura
geons in British Columbia, I should say
that I personally operated on only a few
*■ ot the patients in the series. Clearly, the
surgical community here maintains an
orthodox approach to adenocarcinomas
of the esophagus.
The cutoff levels of each grade in my
, r palliation score system are indeed “ some
what arbitrary” . However, in the high
ly incidence age groups, I would argue that
the ability to enjoy painless eating, sleep
► and leisure is of overriding importance.
In fact, colleagues have urged me to
v
remove sleeping, leisure and work questions, since a person with dysphagia or
'r
persistent pain, or both, is hardly likely
to be doing any of these things with much
enthusiasm! I do not believe the sympi- y toms a physician believes are important
should be considered in any palliation
scoring system. The end-point of all ther
apy is how well the patient feels — not
y * how well the medical attendant thinks the
patient ought to feel. My aim in using a
scoring system is to follow the dictum
r (coined I believe by Kelvin) that it is only
when you can attach numbers to somer
thing that you can begin to understand
it. As previously stated,1 I would welr * come modifications, and I hope that
others will experiment with and improve
* on this initial version. Until it is further
evaluated, I believe this scoring system
can reasonably be used to compare
patients’ responses to different therapies.
Again, in the spirit of Kelvin, Dr. Gold- 4 berg wisely advises that firm, scientifically
based conclusions require well-controlled,
* prospective, randomized trials between
proposed therapies. However, the logis’ tics of such a research protocol in this dis
ease process would seem to scuttle the

The diverticulum is carefully freed
project before one could hope to set sail.
The informed consent sheets would sur from the adjacent tissue and is resected
ely make interesting reading in view of the at its base. A Pezzer catheter is inserted
morbidity, mortality and longevity figures through the defect into the duodenum
one would be required to quote to a and is reinforced by two layers of chro
prospective trial entrant. One wonders if mic catgut purse-string sutures. A wide
randomization is ever possible when such tube gastrostomy to drain the stomach
wide disparities in morbidity and mortal and a feeding jejunostomy should also be
ity exist between any two treatments, inserted. The abscess area is drained with
especially when the long-term results are a soft rubber drain.
much the same.
This method was used in a 72-year-old
Until we can either prevent esophageal
squamous cancer or detect it at an asymp ■woman who was operated upon for acute right
tomatic stage, we might do worse than sided abdominal pain, tentatively diagnosed as
cholecystitis. At operation, a large
follow the advice of Hippocrates: “What acute
retroperitoneal abscess was found on the right
you should put first in all the practice of side of the duodenum. The gallbladder and
our art is how to make the patient well; common bile duct contained stones. Chole
if he can be made well in many ways, one cystectomy and choledocholithotomy were per
should choose the least troublesome.”
formed and the duodenum was mobilized by
J ulius L. Stoller,

md, frcs, frcsici

316-888 West 8th Avenue,
Vancouver, BC
V5Z 3Y1
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Tube Duodenostomy —
a Safe Method for Managing
Perforated Duodenal Diverticulum
To the editors.—Perforation is a rare
complication of duodenal diverticulum.
Preoperative diagnosis is difficult and the
operative mortality exceeds 30%. Exci
sion of the diverticulum, with direct
suture of its neck, has been suggested as
the treatment of choice of this complica
tion. However, pancreatitis, biliary
obstruction and especially leakage from
the suture line in the duodenum are com
mon sequelae of this operation, because
of the proximity of the diverticulum to
the papilla of Vater and the friability of
the inflamed duodenal wall.1,2 To pre
vent these serious, often fatal, complica
tions, alternative procedures such as
Roux-en-Y diverticulojejunostomy and
gastrojejunostomy have been used.1'3
The following method is a modification
of two previously suggested techni
ques.4,5 It is intended to reduce the
postoperative complications.

a Kocher maneuver. This exposed a perforated
diverticulum arising from the posteromedial
aspect of the second portion of the duodenum.
The diverticulum consisted o f a partially
necrotic wall with a friable neck, 2 cm in
diameter. The sac was carefully debrided and
excised and the defect in the duodenum was
closed over a tube duodenostomy as previously
described. The postoperative course was
smooth. All tubes were removed within 6
weeks; the patient has been asymptomatic for
the past 2 years.

This method is recommended for com
plicated perforated diverticula of the
duodenum. It seems to be safer than
direct suture of the defect and ensures
drainage of the duodenal contents, thus
obviating the danger of free leakage into
the peritoneal cavity.
O ded Zamir, md
O mri Z. Lernau,
Shemuel Nissan,

md
md , facs, faap

Department of Surgery,
Hadassah University Hospital,
Mount Scopus,
Jerusalem, Israel
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Closed transection of the vagina
lessens the potential for contam ination of the peritoneal cavity.
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Pneumatic Antishock Trousers

r
*

was used in the operating room to main
tain the blood pressure of patients who
underwent head and neck surgery in the
sitting position. Despite its successful use
on a patient in hemorrhagic shock, the
device was abandoned because it tended
to leak.1-3
The same principle was applied in the
development of the “ G-suit” , used by
pilots of high performance aircraft to pre
*
vent transient retinal ischemia associated
Revue de la physiologie et du mode
with rapid acceleration.3 This suit, after
d'emploi du pantalon pneumatique antimodification, was also used on patients
L
choc qui joue un role important, dont
who underwent neurosurgical procedures
I'efficacite est prouvee, dans le traitein the sitting position and to control
► *• ment du malade hypotendu avant et
anesthesia-induced hypotension.
apres son arrivee a I'hopital. Ce pantalon
During the Vietnam War, Cutler and
fest en voie de devenir un objet d'usage
Daggett4 used pneumatic trousers to
courant dans beaucoup d'hopitaux
control hemorrhage caused by trauma
canadiens.
to the lower limbs, pelvis and perineum,
"V
usually inflicted by land mines. Of eight
The pneumatic antishock garment, com- patients who would have been expected
monly known as the military antishock to die, four survived after early applica
trouser (MAST), is designed to increase tion of the garment in the field.
Pneumatic garments have gained wide
blood pressure in the hypotensive patient.
1- r In 1903, a rubber suit was developed that acceptance and are used extensively by
compressed the extremities and trunk,1 ambulance attendants and in hospitals in
>■ and was inflated with a bicycle pump. It
►

The pneumatic antishock garment is an
important adjunct in the prehospital and
k hospital management of the hypotensive
patient. This apparatus is becoming stanr
dard equipment in many hospitals in
A Canada. Its effectiveness in the manage
ment of hypotension has been established. This paper reviews the physiology
and application of the garment.

the United States.5'10 The American Col
lege of Surgeons has listed them as essen
tial equipment in the ambulance.11 Their
use is becoming more widespread in
Canada.12,13
Description

The trousers contain inflatable com
partments to provide pressure to the limbs
and abdomen (Fig. 1). The garment is
applied by laying the patient on it (or
positioning it under the patient) and
securing each compartment around the
lower limbs and abdomen below the
costal margin. The compartments are
fastened with Velcro. Each compartment
can be inflated or deflated individually
and is accompanied by either a safety
valve that releases pressure at approxi
mately 100 mm Hg or a gauge that moni
tors compartmental pressure. There is an
opening at the perineum to allow rectal
examination and bladder catheterization.
The newer models allow better access to
femoral blood vessels and visualization of
skin through clear plastic.
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Physiology
It has been estimated that there is an
autotransfusion of 750 to 1000 mL of
blood from the lower limbs to the central
circulation upon inflatio n o f the
trousers ,914-15 although recently this esti
mate has been challenged .16 Venous
return is increased, thus increasing stroke
volume. In hypovolemic patients, cardiac
output increases, thereby increasing blood
pressure.
The hemostatic efficacy of the garment
can be explained by referring to the laws
of Laplace and Poiseuille .15-17 Laplace’s
law states that the wall tension of a ves
sel (for example, a blood vessel) is directly
proportional to the transmural pressure
(i.e., pressure across the wall) multiplied
by the radius of the vessel. Application
of circumferential pressure to the outside
wall of a blood vessel therefore decreases
transmural pressure across the wall, thus
decreasing wall tension. Since vessel-wall
tension determines, to some extent, the
size of a defect in the vessel wall, a
decrease in wall tension (as caused by
increase of circumferential pressure)
should diminish the size of any defect in
the vessel wall. The effect is to decrease
the size of any leak of blood from a blood
vessel, thus minimizing blood loss.

Application of circumferential pressure
to a blood vessel also decreases the radius
of the vessel. Poiseuille’s law states that
(laminar) flow through a tube is directly
proportional to the fourth power of the
radius of that tube as determined by the
following equation:
Q
8nl

where Q = flow, P = pressure gradient,
r = vessel radius, n = viscosity, 1 = ves
sel length. Thus, with a reduction in the
vessel radius resulting from circumferen
tial pressure, Poiseuille’s law explains the
fact that flow in the compressed blood
vessel is also decreased.
Both these laws have been invoked as
an explanation for the effectiveness of
pneumatic antishock garments. They
effectively tamponade both arterial and
venous bleeding in areas of the body they
compress. The third mechanism by which
they reduce hypotension is by the increase
in peripheral resistance which is produced
by compression of vessels of the lower
extremities and abdomen. Recent studies
indicate that this may be the major phys
iologic effect of pneumatic antishock
garments . 16-18
Carotid blood flow has been shown to
increase by approximately 25% to 50%

when antishock trousers are applied,
while blood flow through the femoral
artery is reduced by 50%.17-19 Renal func
tion is not impaired, although it has been
recommended that renal function be*
monitored by checking the urine output
closely.9-17
*
Respiratory function may be com
promised when the abdominal compart- *
ment of the garment is inflated because
it limits movement of the diaphragm .15-17
Specifically, vital capacity is reduced by .4 ,
approximately 18% in human volunteers.
Clinically, this has not usually been
-i
detrimental.7-9-20
Results of studies in dogs indicate that "*
lactic acidosis and hyperkalemia may
develop in the limbs while the pneumatic
1
antishock trousers are in place ,17-21 b u t«
this has not been a problem in
humans .17-22 It has been recommended
4
that values for arterial pH and serum
potassium be monitored if the device is ->
in place for a long time . 15
1

Indications
Hypotension, as a result of bleeding,
dehydration or peripheral pooling, is a
primary indication for application of the
pneumatic antishock garment. It has been
used successfully in patients with leaking
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proctitis and pruritus ani
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+Darke, A.C., Rudd, W.W.H.: Reformulation of Two Hemorrhoidal Ointment Preparations: Double-blind Clinical
Com parison with Existing Formulations; Curr. Therap. Res. 30; 6:880-885,1981.

abdominal aortic aneurysms14,17'23 and in
gynecologic patients with pelvic bleed
ing.24,25 The trousers may also act as air
j
splints for fractures of the lower limbs
tend to minimize blood loss into the
;
fracture site.7,9,14 Pelvic fractures have
become a major indication for use of the
. garment, as hemorrhage decreases due to
r splinting of the fracture site by the
abdominal compartment of the trousers
j
and by the tamponade effect.22,26-28
► Pneumatic antishock trousers are radii
olucent and need not be removed for radi► ologic examination. Indeed, if they are
applied before undertaking radiologic
studies, they will minimize movement of
the lower limbs and pelvis.
Work is in progress to determine
,whether use of the antishock garment will
improve the effectiveness of cardiopulmoV nary resuscitation but at present this
application is experimental.5,29'31
► Antishock trousers have been used in
|
cardiogenic shock as a “ reversible fluid
*
challenge” .32 Their use for this indicai ^tion is not universally accepted. It has
been suggested that increased afterload,
k rather than autotransfusion, is responsi
ble for the increase in blood pressure
» observed.16 Increased afterload will
increase oxygen demand, which may be
detrimental to the ischemic myocardium
J

of a cardiac patient.16 They may be use
ful in the cardiac patient who is hypoten
sive as a result of relative hypovolemia.32
Inflation of the antishock trousers dis
tends the peripheral and central veins,
making intravenous cannulation easier.15
The trousers have also been used effec
tively to control bleeding in patients with
disseminated intravascular coagulation
and other coagulopathies, particularly
those resulting from gynecologic prob
lem s,23-25 allowing time for the
coagulopathy to be corrected.
Contraindications and Concerns
The only absolute contraindication to
the use of pneumatic antishock garments
is congestive heart failure. They increase
afterload and preload, thus worsening the
heart failure and pulmonary edema. Since
they increase afterload, they increase
myocardial oxygen demand, which may,
theoretically, increase the size of a
myocardial infarction.16
While the garment may be used suc
cessfully in in trath o racic injuries
associated with hypotension,7,9,15,20 con
cern has been raised that this may increase
blood loss by “ centralizing” blood
volume to the area of bleeding.14,17
External counterpressure may improve

vital organ perfusion temporarily but the
loss o f blood volume may subsequently
increase.
Pericardial tamponade results in an
increase in intrapericardial pressure, caus
ing a reduction in effective ventricular fill
ing pressure and a decrease in stroke
volume and cardiac output. Application
of the antishock garment with inflation
of the abdominal compartment may
increase intrathoracic pressure, thus
increasing tamponade pressure by further
compressing the heart. Thus, the garment
might prove detrimental to the patient
who has cardiac tamponade with com
pensation.14,33,34 On the other hand, use
of the garment increases venous return
and thus the increased cardiac filling pres
sure should be beneficial. An animal
model supports the efficacy of the gar
m ent in cardiac tam ponade.34 It is
recommended that the trousers be used
in cases of pericardial tamponade only if
the patient is decompensated and only
with pressure sufficient to raise the sys
tolic blood pressure to 80 to 100 mm
H g,14,34 until definitive treatment is car
ried out.
The patient with tension pneumotho
rax also experiences a decrease in venous
return due to reduced ventricular filling
pressure. Application of the pneumatic
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antishock garment with inflation of the
abdominal compartment increases intrathoracic pressure and decreases the
already diminished ventricular filling
pressure.33 It is advisable to inflate only
the limb portions of the garment in the
presence of tension pneumothorax,33
release of the pneumothorax by at least
needle thoracostomy being of paramount
importance.
In chest trauma when the patient’s
respiratory function is compromised, the
decreased vital capacity that follows infla
tion of the abdominal portion of the gar
ment may further inhibit respiratory func
tion, which should be carefully
observed.7,9'20
Concern has been expressed about
the use of antishock trousers to treat
shock in the presence of head injury,
because of the rise in intracranial
pressure33’35 as a result of increased cen
tral venous pressure. However, correction
of hypotension improves mean arterial
pressure. Since cerebral perfusion pres
sure is equal to mean arterial pressure
minus intracranial pressure, an increase
in mean arterial pressure improves
cerebral perfusion, thus reducing cerebral
ischemia that may itself cause cerebral
edema.7 A deleterious increase in
intracranial pressure was not observed
when the suits were applied to dogs with
an artificially induced intracranial
mass.33’35’36 Head injury is not a con
traindication to the use of the trousers in
the hypotensive, hypovolemic patient.
Pneumatic antishock garments may
increase tissue damage when applied over
burns14 but they may be necessary if
there is shock. Similarly, use of the abdo
minal portion in pregnancy may harm the
fetus, but may be required if the patient
is in shock. The limb portions may be
applied without inflation of the abdo
minal portion.13'14
Diaphragmatic rupture may lead to
diaphragmatic herniation on inflation of
the abdominal compartment.13 How
ever, the garment should be used in the
patient requiring immediate resuscitation
unless evidence of diaphragmatic rupture
exists.
With bleeding esophageal varices,
inflation of the abdominal portion may
increase variceal bleeding. Probably only
the leg com partm ents should be
inflated.7’14’17
It is imperative that trousers not be
removed suddenly from the hypovolemic
patient. This opens the previously com
pressed venous bed and suddenly
decreases peripheral resistance.7'10'14'16’17
The result is a drastic fall in blood pres
sure even to levels below the previous
hypotension. The garment may remain on
the patient to the time of operation.17 If
abdominal surgery is anticipated, the
abdominal portion may be deflated
426

slowly, leaving the legs inflated, after
legs may be fitted in one adult leg if
induction and when all is prepared for
necessary.
surgical intervention. Sudden deflation of
the garment may result in irreversible Air Transport
4
shock and cardiac arrest.7'13'15,23
Compartment syndrome has been re
Patients who are transported in an
ported after the use of the pneumatic
unpressurized aircraft will experience an *
antishock trousers, particularly when
increase in pressure on their limbs if the ^
applied over lower-extremity fractures.37 antishock trousers are inflated on the
The cause and effect relation between the
ground. Similarly, if they are inflated in
two has been challenged.38 A report of
the air, the pressure will drop in the
bilateral anterior and lateral compartment
trousers as the aircraft descends. These*
syndrome after application of the trousers
changes should be anticipated.
for 140 minutes to the uninjured legs of
If the trousers are inflated in a cold “*
an 18-year-old trauma victim suggests
environment and the patient is then taken
that this relation may exist.39 This report
to a warm environment, pressure will 4
strengthens the recommendation that the
increase marginally in the trousers and
trousers be removed as soon as the
vice versa.
hemodynamic status has stabilized.
-•>
A compartment syndrome of the thigh Summary
following hip fracture and use of the gar
■f
ment was attributed to the fact that the
While pneumatic antishock trousers are
abdominal portion of the garment was
a useful adjunct for the initial manage- 4
left inflated following deflation of the
ment of hypotension, they do not replace,
limb segments.40 This emphasizes the
but can augment, fluid replacement and 1
importance of using the correct inflation
other resuscitative procedures. They canA
and deflation sequence.
be applied quickly and are relatively safe
If prolonged use of the garment is when used in the manner recommended, a
anticipated before inflation, bony promi They must not be used in a patient with
nences such as the iliac crests should be congestive heart failure. Finally, it is a
protected with soft padding. If applied
imperative that they are not removed sud
over clothing, all objects should be denly from the hypovolemic, hypotensive
patient.
removed from the pockets. Preferably,
the patient should be undressed before
application of the garment, but this may
not be feasible in the field.
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PRESCRIBING INFORMATION: ADVERSE REACTIONS AND
PRECAUTIONS:
Fucidin is indicated for the treatment of severe skin and soft tissue
infections and osteomyelitis due to susceptible strains of Staphy
lococcus aureus. As Fucidin is excreted mainly in the bile a revers
ible jaundice may appear especially where high doses are used or
when the drug is given for prolonged periods. Liver function should
be monitored in patients with liver dysfunction when used for
prolonged periods.
Safety in pregnant women and nursing mothers has not been
established. There is evidence suggesting Fucidin penetrates the
placental barrier and Fucidin is detectable in the milk of nursing
mothers.
Rare adverse reactions may include gastrointestinal upset and al
lergic reactions. Local Venospasm and thrombophlebitis have been
associated with intravenous therapy.

DOSAGE RANGE
FUCIDIN TABLETS
(each white tablet contains 250 mg sodium fusidate, enteric coated)
Two 250 mg tablets 3 times daily given with food. In severe infec
tions four 250 mg tablets 3 times daily.
FUCIDIN SUSPENSION
(each 5 ml of aqueous banana-flavoured suspension contains the
therapeutic equivalent of 175 mg sodium fusidate)
0-1 years:

1 m l/k g body weight
daily divided into 3 equal doses.
1- 5 years: 5 ml 3 times per day.
5-12 years: 10 ml 3 times per day.
Adult dose: 15 ml 3 times per day.

NOTICES
Stereotactic and
Functional Neurosurgery

Refresher Course in
Genitourinary Radiology

The 9th meeting o f the World Society for
Stereotactic and Functional Neurosurgery
will be held July 4-7, 1985 at the Chelsea
Hotel and the University o f Toronto,
Toronto, Ont. It will be immediately fol
lowed by the International Congress o f
Neurological Surgery.
For further information please write
Mrs. Rae Ryan, Administrative Coordi
nator, Division o f Neurosurgery, Eaton
Bldg. North 7-221, Toronto General
Hospital, 101 College St., Toronto, Ont.
M5G 1L7 or call (416) 595-3443.

The biannual Refresher Course in Geni
tourinary Radiology, offered by the Uni
versity o f Toronto, will be held Oct. 18
and 19, 1984 at the Mount Sinai Hospi
tal, Toronto, Ont. This course will deal
with recent advances in genitourinary
imaging and will review selected areas o f
general interest. Topics will include digi
tal subtraction angiography, computed
tomography, ultrasonography, nuclear
magnetic resonance, nuclear imaging,
interventional techniques and the inves
tigation o f impotence.
For further information contact Dr.
Robin R. Gray, Course Director, Depart
ment o f Radiology, The Wellesley Hos
pital, 160 Wellesley St. E, Toronto, Ont.
M4Y 1J3 or call (416) 966-6810.

Practical Hand Surgery
The 14th annual meeting o f the Ameri
can Association for Hand Surgery will be
held in conjunction with the Mexican
Society for Surgery of the Hand and the
’Caribbean Society for Hand Surgery,
Nov. 25-28, 1984 at the Acapulco Prin
cess Hotel, Acapulco, Mexico.
The theme for this year’s meeting will
be the management of practical problems
of hand surgery. Emphasis will be on cost
effectiveness o f accurate, quality, hand
"^surgery care.
For further information contact Dr.
Robert J. Demuth, Central Office, Ame
rican Association for Hand Surgery, 2564
Branch St., Middleton, Wise. 53562,
USA.

FUCIDIN for INTRAVENOUS INFUSION
Vial 1 - diethanolamine fusidate BPC dry powder 580 mg (equiv
alent to 500 mg sodium fusidate B.P.)
Vial 2 - 50 ml sterile phosphate-citrate buffer (pH 7 .4 -7 6)
Adults weighing more than 50 kg: 580 mg diethanolamine fusidate
three times daily. Children and adults weighing less than 50 kg:
7 mg diethanolamine fusidate per kg body weight three times daily.

RECOMMENDED PROCEDURE FOR PREPARING SINGLE DOSES:
1 For adults weighing more than 50 kg: Dissolve 580 mg
diethanolamine fusidate powder (Vial 1) in the 50 ml buffer
provided (Vial 2). Add this fusidate/buffer solution to 500 ml of
sodium chloride injection or other suitable infusion fluid and infuse
slowly over a period of not less than six hours
2. For children and adults weighing less than 50 kg: Dissolve
580 mg diethanolamine fusidate powder (Vial 1) in the 50 ml buffer
provided (Vial 2). Take 0.7 ml of this fusidate/buffer solution for
every kg body weight. This volume of fusidate/buffer solution
should be further diluted, at least tenfold, with the appropriate
infusion fluid, and infused slowly over a period of not less than six
hours.
Infusion should be made into a wide bore vein with a good blood
flow.
Suitable Infusion Fluids include:
Saline, Dextrose, Dextrose-Saline
OFFICIAL PRODUCT MONOGRAPH AVAILABLE ON REQUEST.

International Congress on
Craniofacial Anomalies
The fifth international congress on cleft
palate and related craniofacial anomalies
will take place in Monte Carlo from Sept.
2 to 7, 1985 at the Congress Center. The
congress chairman is Dr. Rene Malek.
This important meeting will be o f parti
cular interest to plastic, dental pediatric
and maxillofacial surgeons, to orthodon
tists, otorhinolaryngologists and speech
pathologists, and all others working in
this field. The deadline for the submiscontinued on page 512
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Recent Research Suggests...
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enhances
HOST DEFENSE
Recent in-vitro research has shown that clindamycin concentrates within
the PMN in amounts greater than are found outside of the PMN.1 The
rates of chemotaxis, phagocytosis and killing of bacteria by PMNs are also
enhanced by the presence of this antibiotic.2*3 These characteristics may
help explain clindamycin’s outstanding record of clinical efficacy in both
anaerobic and gram-positive aerobic infections.
Since host defense factors may be crucial in determining the outcome of
an infection, selection of antibiotics based on host defense parameters
may become a trend in infectious disease therapy.
1) Klempner MS, et al (Nov 1981) J Infect Dis 144( 5)
2) Johnson JD, et al (March 1980) J Lab Clin Med 95(3)
3) Gemmell C, et al (1980) Current Chemotherapy and Infectious Disease
(eds. J Nelson, C Grassi) Am Soc Microbiol Vol 2
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Dalacin C Phosphate Phosphate S.S.
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also
by causing a reduction in the rate of synthesis of nucleic acids.

Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infec
tions where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as B acteroides species, peptostreptococcus. anaerobic streptococci, Clostridium
species and m icroaerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections d ue to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and p neum ococa) when
the patient is intolerant of. o r the organism resistant to o ther appropriate antibiotics.

Contraindications: The use of Dalacin C Phosphate (clindam ycin phosphate) is contraindicated
in patients previously found to be hypersensitive to this com p ou nd , the parent co m p ou nd , clinda
mycin, or clindamycin palmitate. Although cross-sensitization with Lincocin®(lincomydn hydrochloride)
has not been dem onstrated, it is recom m ended that Dalacin C Phosphate not be used in patients
w h o have dem onstrated lincom ycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn
(infants below 30 d ays of age), or in pregnant women

Warnings: Some cases of severe and persistent diarrhea have been reported d uring o r after ther
apy with Dalacin C P hosphate (clindamycin phosphate). This diarrhea has been occasionally asso
ciated with blood a n d m u cus in the stools and has at times resulted in acute colitis. When endos
c o p y has been p erform ed, som e of these cases have show n pseudom em brane formation.
If significant diarrhea o ccurs during therapy, this d rug should be discontinued or, if necessary, con
tin ue d o nly with clo se observation. Significant diarrhea occurrin g up to several weeks post-therapy
should be m anaged as if antibiotic-associated.
If colitis is suspected, e nd oscopy is recom m ended. Mild cases showing minim al m ucosal changes
m ay respond to sim p le d ru g discontinuance. Moderate to severe cases, including those showing
ulceration or p seudom em brane formation, should be m an ag ed with fluid, electrolyte, and protein
supplementation a s indicated. C orticoid retention enem as a nd systemic corticoids m ay b e of help
in persistent cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes
of co lris should be considered.
Studies, indicate a toxin(s) pro du ced by Clostridia (especially Clostridium difficile) m ay be a princi
pal cause of clindam ycin a nd other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancom ycin. When 125 m g to 5 00 m g of vanco
m ycin were adm inistered orally four tim es a day for 5 - 1 0 o r m ore days, there was a rapid observed
disappearance of th e toxin from faecal samples and a coincidental recovery from the diarrhea.

Clinical and Laboratory Findings: Patients treated d uring clinical trials of Dalacin C Phosphate
(dindam ydn phosphate) were followed with dinical laboratory tests, induding complete hematology,
urinalysis and liver and kidney fu n d io n tests. Som e of these tests were abnormal initially and return
ed to normal during therapy with D aladn C Phosphate, while others were normal initially and became
abnorm al during therapy. Overall evaluation of clinical laboratory values in these patients does not *
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic o r renal
systems. Transient elevations of serum transaminases have occurred in some patients, but d h e r liv e ry
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and
there have not been d inical signs of drug-induced hepatic toxicity.

Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No
specific antidote is known. Doses as high as 1200 m g every six hours (4800 mg/day) by infusion for
five days have been given without adverse effeds.
DOSAGE A N D ADMINISTRATION

Adults
Intramuscular Injection: 600 m g/day in 2 equal doses.
Moderately severe infections: 600 to 1200 m g/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 m g/day in 2 ,3 or 4 equal doses. Intramuscular injections of m ore
than 600 m g into a single site are not recom m ended.

Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior
to I.V. administration to a dilution of 3 00 m g in 50 ml of diluent (6 m g/m l) o r more, and infused in not
less than 10 minutes. Administration of m ore than 1200 m g in a single 1 hour infusion is not recomm ended. Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 9 00 to 1800 m g/day by continuous d rip or in 2 or 3 equal doses, each ^
infused over 20 minutes o r longer.
Severe infections: 1800 to 2700 m g/day by continuous d rip or in 3 o r 4 equal doses, each infused
over 20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by continuous
drip or in 3 or 4 equal doses each infused over 20 minutes or longer may be given.

Dilution and infusion rates:

It shou ld be noted tha t serious relapses have occurred up to o ne month after apparently successful
treatment. A relatively pro lon g ed period of continuing observation is therefore recom m ended.

Precautions: D alacin C Phosphate (clindamycin phosphate), like any drug, shou ld be prescribed
with caution in a to p ic individuals.
Dalacin C Phosphate must be diluted for intravenous administration. (See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organism s - particularly
yeasts. Should superinfections occur, appropriate measures should be taken as dictated by the clin
ical situation.
A s with all antibiotics, perform culture and sensitivity studies in conjunction with d ru g therapy.
S ince abnormalities of liver function tests have been noted occasionally in anim als a nd m an, peri
o d ic liver function tests should be perform ed during p rolonged therapy. Blood counts should also
be monitored d uring extended therapy.
D alacin C Phosphate m ay be used in anuretic patients. Since the serum half-life o f clindam ycin in
patients with im paired hepatic function is greater than that found in normal patients, the dose of
D alacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are
not effective means of removing the com pound from the blood. Penodic serum levels should be deter
m ine d in patients w ith severe hepatic a nd renal insufficiency.

A d verse

R eactio n s: L ocal.

(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin phosphate)
intramuscularly (w ith a solution containing 150 mg/mL), six (1.5%) demonstrated local reactions as
follows: Two com plained of pain at the injection site, two dem onstrated induration at the injection site
a n d two developed sterile abscesses.
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous infusion,
14 (7.3% ) demonstrated local reactions. Eleven patients developed superficial throm bophlebitis and
one patient developed both superficial and deep throm bophlebitis. The m ajority of these cases
developed in co njunction with the use of indwelling I.V. catheters and it is difficult to know how much
the d ru g contributed to the irritation. Two patients developed localized erythema, swelling a nd pain
at the site of the infusion.

Systemic Side Effects: Twenty-aght patients of 596 treated with Dalacin C Phosphate (dindam ydn
phosphate) by either the intramuscular or intravenous routes developed systemic side effeds as follows:
N u m b e r o f Patients
R a s h ................................................................................................................................................................ ....
U rtic a ria ..............................................................................................................................................................1
P r u r it u s ........................................................................................................................................................... ...
Fever, Leucocytosis.......................................................................................................................................... 1
Nausea, with or w ith ou t v o m itin g .................................................................................................................. 1
D iarrhea (See also u nder ‘W arnings’) .........................................................................................................4
H ypote nsion ....................................................................................................................................................... 1
H yp e rte n s io n .....................................................................................................................................................1
Shortness of Breath ........................................................................................................................................1
S up e rm fe dio n *..................................................................................................................................................4
C ardiac arrest* * ............................................................................................................................................... 1
B ad o r bitter taste in m o u th ...........................................................................................................................5
'S uperinfection is a com plication of antibiotic therapy in general and is not necessarily a true
side effed of clindam ycin phosphate.
'D u e to underlying m yocarditis in this patient.
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Dose

Diluent

Time

300 mg
600 mg
900 m g
1200 m g

50 ml
100 ml
150 ml
200 ml

10 min.
20 min.
30 min.
45 min.

Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed
by continuous I.V. infusion as follows:
To maintain serum
clindamycin levels

Rapid
infusion rate

Maintenance
infusion rate

A bove 4 mcg/ml
A bove 5 mcg/ml
A bove 6 mcg/ml

10m g/m in. for 30 min.
15m g/m in. for 30 min.
20 mg/min. for 3 0 min.

0.75 mg/min.
1.00 mg/min.
1.25 mg/min.

•1

Children: (Over one month of age)
Intram uscular injection: 10 to 15 m g/kg/day in 2 ,3 or 4 equal doses.
Moderately severe infections: 15 to 20 m g/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 m g/kg/day in 3 or 4 equal doses.

Intravenous Administration:
M oderately severe infections: 15 to 25 m g/kg/day by continuous d rip or in 3 or 4 equal doses, eaciT
infused over 20 minutes or longer. In severe infections, it is recom m ended that children be given no
less than 300 mg/day regardless of bod y weight. (Dilute Dalacin C Phosphate Sterile Solution in the
same m anner as for adults.)

Dilution and Compatibility:
4 ml (600 mg) Dalacin C Phosphate when diluted with 1000 ml of the following com m only used in
fusion solutions was found to be physically com patible and dem onstrated no significant change in
pH or antim icrobial potency over a period of 24 hours:
Sodium chloride injection
Dextrose 5 % in water
Dextrose 5 % in saline
Dextrose 5 % in Ringer's Solution
Dextrose 5 % in half-strength saline plus 4 0 m E q potassium chloride
Dextrose 2 1/ 2% in Lactated Ringer's Solution (Hartm ann’s Solution).

-<

4

Dalacin C Phosphate was not stable w hen a dd ed to Dextrose 5 % in water plus vitamins. Therefore
it is not recom m ended that Dalacin C Phosphate be m ixed with any infusion solution containing B
vitamins.

Supplied:
Dalacin C Phosphate contains the following per ml of sterile solution:
Clindamycin phosphate equivalent to clindam ycin base 150 m g
Benzyl alcohol 5 m g
Disodium edetate 0.5 m g
Water for injection q.s.
When necessary the pH is adjusted with sodium hydroxide a n d /or hydrochloric acid to maintain a
pH range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.

NOTE: Do not store below 15°C.
Product Monograph available u pon request,
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SYMPOSIUM ON CROHN’S DISEASE

*

H ugh J. F reem a n ,

►

1. Crohn’s Disease: Emerging Pathologic
and Bacterial Spectrum

'The evolution, in recent years, of con
cepts of inflammatory bowel disease in
part reflect improved methods of defin
ing disease, especially with modern
microbiologic methods, endoscopy and
mucosal biopsy. Although clinicians have
focused on idiopathic ulcerative colitis
*and Crohn's disease, a host of new enti
ties are now becoming recognized. Many
of these are bacterial, such as Yersiniaox Campylobacter-associated enterocoli
tis. Thus, a "new " group of inflamma
tory bowel diseases has recently
emerged, some with newly described
pathologic features and others reflecting
improved methods of detection with
►newer microbiologic methods. With
evolving methods of recognition, other
entities will likely be described as causes
of inflammatory bowel disease.
►

[.'evolution au cours des dernieres
^annees du concept de maladie inflammatoire intestinale reflete en partie I'amelio. ration des methodes utilisees pour definir
la maladie, tout specialement les methor des microbiologiques modernes, I'endoscopie et la biopsie de la muqueuse. Bien
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que les cliniciens se soient surtout interesses a la colite ulcereuse idiopathique
et a la maladie de Crohn, toute une serie
de nouvelles entites sont maintenant
reconnues. Plusieurs sont d'origine bacterienne, telles les enterocolite a Yersinia
ou a Campylobacter. Un "nouveau"
groupe de maladie inflammatoire de
I'intestin est done recemment apparu,
certaines repondant a des caracteristiques pathologiques nouvellement decrites alors que d'autres refletent ('amelio
ration des methodes de detection a I'aide
de methodes microbiologiques plus
recentes. Avec revolution des methodes
de diagnostic, il est probable que
d'autres entites seront decrites comme
causes des maladies inflammatoires
intestinales.

. . . it seems probable that Crohn’s disease has
had, as a new disease, too enthusiastic and
uncritical a reception, and that other disorders
have been too lightly discarded as clinical and
pathological entities . . .
A.W. Taylor, 19451

The first case of Crohn’s disease was
probably reported in 1769.2 This was fol
lowed by the initial description of ulcer
ative colitis in 1865.3 The modern history
of inflammatory bowel disease, however,
began in 1932 when Crohn and associ
ates4 described “ a disease of the termi
nal ileum affecting mainly young adults,
characterized by a subacute or chronic
necrotizing and cicatrizing inflamma
tion. .
Although the majority of their
first 14 patients were apparently studied
by Ginzburg, the names of the authors
were listed in alphabetical order: thus,
Crohn’s disease was born.5 Since then,
concepts of inflammatory bowel disease
have evolved, reflecting improved
methods of defining the disease, espe
cially with microbiologic techniques,
endoscopy and mucosal biopsy.
Pathologic Spectrum

Just as the methods of assessing

patients with inflammatory bowel disease
have evolved, so has its definition. It is,
in the broadest sense, characterized by
morphologic evidence of bowel inflam
mation. In former years, clinicians
became focused on two apparently differ
ent conditions, ulcerative colitis and
Crohn’s disease.
Ulcerative Colitis
This condition is characterized clini
cally by rectal bleeding, diarrhea,
abdominal pain and weight loss and histo
logically by diffuse mucosal inflamma
tory change. The rectum is involved with
proximal extension of disease for varia
ble distances. Rectal biopsy findings mir
ror the endoscopic findings with diffuse
inflammatory changes extending across
the mucosa (i.e., transmucosal disease).
Crypt abscesses are frequently present as
markers of inflammation — they are not
pathognomonic of ulcerative colitis.
Crohn’s Disease
Crohn’s disease is characterized clini
cally by fever, abdominal pain, diarrhea,
weight loss and slowing of growth in chil
dren. Histologically, changes are most
often focal or segmental; radiologically,
maximal involvement is most often local
ized to the distal ileum and proximal
colon. A focal, so-called aphthoid ulcer
may be seen, while the mucosa between
ulcers or between involved bowel seg
ments may appear normal. This appear
ance may be parallelled by a histologic
pattern of inflammation characterized by
patchy or focal inflammatory change seen
in a single section of a biopsy specimen
or, if discrepancies in the degree of
inflammatory change are observed, in
biopsies from similar sites. Crypt
abscesses may also be seen. Occasionally,
microgranulomas containing epithelioid
or giant cells are present. These are seen
more often in mucosa than submucosa
because of the limited depth of endo
scopic biopsy specimens. Many believe
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microgranulomas are characteristic, if not
diagnostic, of Crohn’s disease. Detection
of microscopic granulomas depends, to
some degree, on the care and interest of
those who obtain, process and interpret
the biopsy specimens. With single-step
sections, 7% of patients with Crohn’s dis
ease were found to have granulomas in
the rectal biopsy specimen.6 Careful
study of serial sections, however, may
yield a frequency of granulomas as high
as 28%, and they may be found in grossly
normal mucosa as often as in grossly
abnormal mucosa.7 Although less fre
quent, similar observations are reported
in endoscopic gastric and duodenal biopsy
specimens. These findings, particularly
from radiologically normal sites, provide
strong evidence that Crohn’s disease is a
far more extensive process8 so the fre
quency of recurrent disease, especially
after surgical resection, becomes less
surprising.
Other Entities
Although the patterns of inflammatory
change observed with a combination of
diagnostic methods, including radiologic,
endoscopic and biopsy, may be consi
dered characteristic of these diseases,
other entities, especially infection, may
produce similar changes. A broadening
spectrum of these disorders has emerged
because of increased awareness of patho
logic features shown by endoscopic
biopsy and improved microbiologic
methods for defining the presence of
infection.
An apparently rare form of inflamma
tory bowel disease was first described in
two patients with profound watery diar
rhea.9 The findings on colonoscopic
examination were normal but biopsy
specimens showed a unique lesion — an
eosinophilic, trichrome-positive band of
material with entrapped cells in the super
ficial lamina propria region of the colonic
mucosa. Some of this material was col
lagen,9 and the entity was subsequently
called collagenous colitis.10 In some
patients, colitis may have a vascular basis.
While the classic roentgenographic ap
pearance of mesenteric vascular occlusion
localized to “ watershed areas” such as
the splenic flexure is well appreciated,
localized ischemic proctitis has become
increasingly recognized, especially in the
elderly. The features may be indistin
guishable from ulcerative colitis and may
have a nonocclusive basis.11 Radiation
enterocolitis also occurs, possibly due to
small-vessel injury; in some cases, telan
giectasia may be seen.12 In acute graftversus-host disease13-14 following success
ful allogeneic marrow transplantation for
leukemia or aplastic anemia, a syndrome
consisting of skin rash, hepatocellular
dysfunction and diarrhea may occur.
432

Loss of fluid, electrolytes, protein and
blood from mucosal inflammatory dis
ease is seen. In such immunocom
promised patients, differentiation from
the effects of toxic drugs and ubiquitous
infections may be necessary and a rela
tively specific abnormality, the popcorn
lesion, characterized by focal rectal crypt
cell degeneration, has been described.14
Drugs (e.g., gold) may also cause colitis.
Antibiotics are most often implicated and
a classic lesion, the pseudomembrane,
may be seen, although it is not specific
for antibiotic-related disease.15 In most
patients, it is now appreciated that a
cytotoxin from Clostridium difficile is
present in stool specimens.16 Purgatives
may cause colonic changes including
melanosis coli, cathartic colon and soap
colitis, which is a marked mucosal reac
tion from cleansing soapsuds enemas.17
Fleet’s phospho-soda and bisacodyl
enemas may induce rectal changes simi
lar to those seen in ulcerative proctitis.18
Thus, sigmoidoscopy in patients sus
pected of having inflammatory bowel dis
ease is best performed in unprepared
bowel or after saline enemas.18
Bacterial Spectrum
Many infectious causes of inflamma
tory bowel disease have been reported.
Recognition depends largely on culture
and serologic findings although some
causes, such as amebiasis or cytomega
lovirus, may be detected in the rectal
biopsy specimen.19-20 Infectious agents
usually cause self-limited colitis (e.g.,
Salmonella) or ileitis (e.g., Yersinia), or
both, but symptomatic recurrences occur
even in patients with idiopathic disease.
Thus, repeated stool studies during the
course of the disease are critical. Sexually
transmitted disorders may result from
ingestion or anal inoculation of one or
more infectious organisms. Shigellosis,
amebiasis and salmonellosis may present
as enteric syndromes, especially in
homosexual men, with endoscopic and
biopsy appearances indistinguishable
from other forms of inflammatory bowel
disease. Proctitis following anal inter
course may be associated with herpes sim
plex, syphilis, gonorrhea, and infection
by Chlamydia trachomatis, especially
lymphogranuloma venereum strains, and
Neisseria meningiditis.2' Special exper
tise, often not available in many hospi
tals, may be required to isolate and iden
tify some of these agents. Giant cell
granulomas have been observed in pa
tients with lymphogranuloma venereum
proctocolitis. Because the histologic
appearances of these diseases are not
specific, a careful history of sex practices
should be obtained from all patients
presenting with inflammatory bowel dis
ease. Several cases of a severe, apparently

acquired, immunodeficiency syndrome,
predominantly of the cell-mediated
immune system, have been reported,
usually, but not exclusively, in homosex
ual men. Some of them have severe'*
unrelenting herpes proctitis with coexis
tent cytomegaloviral infection, Pneu- * '
mocystis carinii infection, cryptosporidiosis, candidiasis and Kaposi’s sarcoma.22 *
The underlying cause of this syndrome is
unknown.
Two groups of pathogens of partial--*
lar interest that have emerged are Yersinia
and Campylobacter. Yersinia enterocolit- 4
ica is a gram-negative organism that has
become increasingly frequent world wide
as a human pathogen and is thus better
recognized. Yersinia infections may cause
acute enteritis with fever and diarrhea,v
especially in children. In adolescents and
adults, acute terminal ileitis and mesen- i
teric adenitis seem to occur more frequently. Other features include erythema 4
nodosum and polyarthritis as well as septicemia and metastatic abscesses. Recent
studies, using endoscopy and roentgeno-A
graphy,23 document a high frequency of
colonic disease. Although treatment A
seems effective, an appreciable number of
j
patients may have persistent ileitis.23 In A
1980, this agent was reclassified into Yerj
sinia enterocolitica sensu stricto and a
variety of new Yersinia species formerly
.
labelled atypical and based on differing
biochemical features.24 Detection of Yer- 4
sinia has also been substantially improved
j|
with the development of highly selective A
growth media and use of cold incubation
i
enrichment methods.
■>
One of the biochemically atypical spe
cies, Yersinia frederiksenii, differs from
4
Y. enterocolitica sensu stricto in its abil-^
ity to ferment rham nose.24 Recent
studies25'26 indicate that Y. frederiksenii T
is often associated with a syndrome of
diarrhea, which is frequently bloody, -i •
abdominal pain and joint symptoms,
including monoarthritis, polyarthritis and
Reiter’s syndrome. The condition appears
to be self-limited, although some patients
had giant cell granulomas in serially sectioned mucosal biopsies. The long-term
prognosis of this infection is not known, 4
Another particularly interesting infec
tion is newly recognized Campylobacter
je ju n iP In less than a decade, this
organism has emerged from obscurity as**
an animal pathogen to a leading cause of
enteritis in humans. It is a curved or
spiral, motile, gram-negative rod with
fastidious growth characteristics (a tem
perature of 42°C at 5% to 10% oxygen
and 3% to 10% carbon dioxide). In many
patients, clinical features are similar to ♦
those of ulcerative colitis28 or Crohn’s
disease.29 They present with fever, *
abdominal pain, diarrhea and some
times with rectal bleeding. Relapses,
with symptoms, may occur30 and toxic
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megacolon,31 pseudomembranous coli
tis32 and profuse hemorrhage33 have been
recorded. Diagnosis may be made by
direct stool examination, using dark►field or phase-contrast microscopy, and
confirmed by positive stool or blood cultures.34 Most patients improve without
therapy although with severe or
* prolonged symptoms, a course of
erythromycin has been recommended.34
In the past, patients with Campylobacter
infections undoubtedly showed a notable
response to treatment (including the use
^ of steroids) and may have been provided
with an uncertain prognosis.
[

Conclusion

A “ new” group of inflammatory
bowel diseases has recently emerged,
y
some with newly described pathologic
features and others reflecting improved
*- methods of detection with microbiologic
techniques. With evolving methods of
‘ recognition, other entities will likely be
k k described as causes of these diseases.
y
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SESAP IV Question
Patients with granulomatous colitis (Crohn’s disease), or ulcerative colitis, may develop acute toxic megacolon.
50. When this serious complication is present, colonic distention is usually most prominent in the

►

y

►

(A)
(B)
(C)
(D)
(E)

cecum
ascending colon
transverse colon
descending colon
sigmoid colon

►

1 4

51. This complication may be precipitated by all of the following factors EXCEPT
(A)
(B)
(C)
(D)
(E)

large doses of corticosteroids
barium enema
anticholinergic drugs
opiates
antidiarrheal drugs

For the incomplete statements above select the one answer for each that is best of the five given. For the critique of Items
50 and 51 see page 486.
(Reproduced by permission from SESAP IVSyllabus: Surgical Education and Self-Assessment Program No. 4. For enrol
ment in the Surgical Education and Self-assessment Program No. 4, please apply to the American College of Surgeons,
55 East Erie St., Chicago. 1L 60611.)
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The most advanced and reliable
CO, surgical laser available
With the Coherent
System 450 you can select
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Unparalleled for
surgical procedures
Specially designed to
provide unsurpassed
precision and versatility
in tissue ablation, excision or
coagulation, the System 450
offers many advantages over
conventional surgical techniques.
C 0 2laser surgery has
become an accepted modality
in gynecology, neurosurgery,
otolaryngology and orthopedics.

Greater flexibility
For maximum surgical flex
ibility, the System 450’s wide
range of delivery systems may
be attached to the laser's
articulated arm. Plus, the laser
head and surgical arm can be
separated from the console, a
unique design concept giving
the surgeon the ultimate in
operating room space flexibility.

Service across Canada
As with all equipment sold by
Zeiss the System 450 is serviced
by Zeiss. Quickly. Efficiently.
In Canada. Sales and service
facilities are available in major
centres from coast to coast.
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System 450 lasers are
optically matched for use with
the full line of Zeiss operating
microscopes and colposcopes.
There is never a problem with
compatibility.
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S u rg e o n s
E a r, N o s e ,
T h ro a t
G yne

G e n e ra l
S u rg e ry
O rth o 
p e d ic
O p h th a l
m o lo g y

Phone or write
For complete information on the
Coherent System 450 call the
surgical laser specialist in the
Zeiss office in your area, or
v
contact Carl Zeiss Canada Ltd.,
45 Valleybrook Drive, Don Mills,
-r
Ontario M3B 2S6.
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Optical Compatibility
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System 450 offers more
delivery systems to cover
more applications and pro- ■*
cedures, including:
• A microsurgical adapter for all operating room
microscopes
• A surgical handpiece ^
for free hand surgery
„
• An endoscopic coupler for endoscopic procedures,
bronchoscopy, laparoscopy,
• A surgical probe - for
invasive microsurgical
4
procedures
A
• A stereotactic neurosurgical
system - for unexcelled, precise
neuro-surgical tumor removal
• An arthroscopic adapter for use in orthopedic procedures-*
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Toronto 416/449-4660
Halifax 902/422-9614
Quebec 418/653-7391
Montreal 514/384-3063
Ottawa 613/232-4576
Guelph 519/824-9660
Winnipeg 204/253-2319
Edmonton 403/487-3372
Calgary 403/278-2969
Vancouver 604/984-0451

The great
name in
surgical
microscopy
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Clostridium difficile

in Crohn’s Disease

w

Clostridium difficile has been detected in
the stools of some patients with relapse
of Crohn's disease. The authors looked
■prospectively for present or previous
exposure to C. difficile cytotoxin in 10
^ patients with mild to severe Crohn's
disease.
None of 25 stool samples from these
10 patients was positive for C. difficile
cytotoxin. These negative stool
‘ultrafiltrates had mild cytotoxin neutraliz
ing activity, but this finding did not differ
^ from that in 30 cytotoxin-negative stools
from patients with other diarrheal dis
eases. Serum from these patients also
showed no cytotoxin neutralizing
activity.
,
Review of the literature reveals that C.
difficile can cause complications ranging
•from diarrhea to toxic megacolon in a
small but variable proportion of patients
with Crohn's disease. There is no evi
dence that C. difficile plays a part in the
pathogenesis of the disease.

r

,Du Clostridium difficile a ete decele dans
les selles de certains malades a I'occasion d'une rechute de la maladie de
Crohn. Les auteurs ont recherche de
> *- facon prospective la possibility d'une
exposition pr£sente ou passee a la cytotoxine de C. difficile chez 10 patients
^souffrant d'une maladie de Crohn dont
I'intensite allait de benigne a severe.
^
La recherche de la cytotoxine de C.
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difficile dans 25 echantillons de selle preleves chez ces 10 patients s'est averee
negative. Ces ultrafiltrats negatifs possedaient une faible activity neutralisante
contre la cytotoxine, mais elle ne differait pas de celle qu'on a mesure dans 30
selles negatives pour la cytotoxine provenant de patients souffrant d'autres affec
tions diarrheiques. De plus, les sera de
ces patients ne montraient egalement
aucune activity anti-cytotoxine.
La revue de la littyrature revele que C.
difficile peut causer des complications
allant de la simple diarrhee au megacolon
toxique chez un nombre petit mais varia
ble de victimes de la maladie de Crohn. II
n'existe aucune preuve que C. difficile
participe a la pathogenese de la maladie.

Early in 1977, Bartlett and Gorbach1
reviewed antibiotic-associated pseu
domembranous colitis, a clinical syn
drome o f which the etiology was
unknown. They remarked that one of the
factors hampering discovery of the etiol
ogy was the lack of an animal model; they
questioned whether the Syrian hamster
model of clindamycin-induced cecitis was
the same disease. In 1977, Larson and
associates2 reported a previously
undescribed toxin in stool ultrafiltrates of
five patients with pseudomembranous
colitis. Between 1977 and 1978, antibioticassociated colitis in hamsters and man
was found to be caused by toxins
produced by Clostridium difficile A* The
Syrian hamster model proved to be and
continues to be invaluable in studying the
pathogenesis and treatment of this disease
in man.7
One of the immediate questions posed
by this discovery is whether C. difficile
was involved in the etiology of inflamma
tory bowel disease. The results of initial
studies looking for cytotoxin in patients
with ulcerative colitis were negative.3’4
However, subsequently, several reports
have associated symptom relapse in
patients with inflammatory bowel disease
with the presence of C. difficile cyto
toxin.8' 12
We have m easured C. difficile
cytotoxin levels in the stools and C.
difficile toxin neutralizing activity in the

serum and stools of patients with Crohn’s
disease to elucidate a possible role of this
organism. We have also reviewed the pub
lished literature on the association of C.
difficile and Crohn’s disease.
Patients and Methods
Stool samples were obtained from 110
patients with suspected an tib io ticassociated colitis. In addition, 10 patients
with documented Crohn’s disease were
selected for study from inpatients and
outpatients at the Vancouver General
Hospital and the Health Sciences Centre
Hospital in Vancouver. Two or three
stool samples were collected from each
patient. A serum sample was also
obtained from some of the patients.
Stool Samples
Fresh stool samples were collected in
plastic containers (Sage Products Inc.,
Elk Grove Village, 111.) and immediately
frozen (-70°C). Stools were thawed and
diluted 1:2 with isotonic saline, mixed and
centrifuged at 4800 g for 60 minutes. The
supernatants were sequentially filtered
through a l-/*m Millipore filter and a
0.2-pm Nalgene filter and stored (-70°C)
for assay.
Assay
McCoy mouse heteroploid fibroblast
cells were obtained from Dr. E.R. Alex
ander at the University of Washington.
This cell line is a continuous line and is
commonly used for culturing Chlamydia
trachomatis. 13 We have found this cell
line to be much more sensitive to C.
difficile cytotoxin than two other cell lines
that we have used — baby hamster kid
ney cells and human amnion Edmonton-70 cells. Culture flasks containing the
McCoy cells were washed once with glucose-potassium-normal saline solution (9
g /L NaCl; 0.4 g/L KC1; 1 g/L glucose)
to remove any dead cells in the flasks. A
0.2°7o trypsin solution (1 mL) was added
to each flask and the cells were incubated
at 37°C until they were released from the
flask surface. The cells were suspended
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in Eagle’s minimal essential medium sup
plemented with 10% fetal calf serum, 2
mM glutamine, 7 mM N aH C 03, 5%
glucose, 25 U /m L nystatin and 5 ftg/mL
gentamicin at pH 7.5, and the cell clumps
were broken up to make a homogenous
mixture. Viable cells were counted in a
hem ocytom eter to determ ine the
appropriate dilution volume of medium
to be added to achieve 50 000 cells/mL.
One millilitre of cell suspension was
added to 4-mL glass cell-culture vials and
the vials were incubated at 37°C until
ready for assay.
Stool ultrafiltrates were diluted 1:10
plus serial threefold dilutions with culture
medium. The culture medium of 3- or
4-day-old cells was removed and replaced
with the 1-mL sample dilutions. Each
dilution was performed in duplicate.
Results were read at 24 and 48 hours with
an inverted microscope; the degree of tox
icity was graded according to the percen
tage of cells that were rounded; 0 = less
than 20%, 1+ = 20% to 40%, 2+ =
40% to 60%, 3+ = 60% to 80% and 4+
= more than 80%. A sample was judged
to contain C. difficile cytotoxin if it pro
duced a toxic effect on the cells and this
effect was prevented by the addition of
20 /jtL of Clostridium sordellii antitoxin
(Bureau of Biologies, Bethesda, Md.).
The toxin titre was determined by aver
aging the value of the duplicate readings
for each dilution and determining by
interpolation the logarithm of the titre
required to achieve a 2+ reading (approx
imately 50% effect).

for cytotoxin, indicating that the disease
was present in the community.
In order to determine whether the
patients with Crohn’s disease had been
previously exposed to C. difficile
cytotoxins, we checked for cytotoxin neu
tralizing activity in the sera and stool sam
ples. The results of these experiments are
shown in Table II. Sera from patients
with Crohn’s disease and from patients
with other diarrheal disorders, whether
they had stools positive for cytotoxin or
not, did not show significant cytotoxin
neutralizing activity. On the other hand,
the stool ultrafiltrates of those with
Crohn’s disease did possess some neu
tralizing activity. However, this was not
different from that produced by negative
ultrafiltrates from patients with other
diarrheal conditions (Table II).

Patient
no.
1
2
3
4
5
6
7
8
9
10

Discussion
In this prospective study of 10 patients
with Crohn’s disease in various sites, we
failed to find C. difficile cytotoxin in any'
of the 25 stool specimens. We reviewed
the literature and summarized the find
ings o f six other studies (Table
IU9-i2,i4,i5) o u r study is in keeping with
all except the study of Trnka and
L aM o n t.11 They found C. difficile
cytotoxin in 7 of 24 patients with relapses
of Crohn’s disease; the presence of
cytotoxin was associated with severe
symptoms and most patients responded
to treatment with vancomycin by reduc
tion of their symptoms. Dorman and
associates14 failed to detect cytotoxin in
32 patients with inactive disease and 18,with active disease. They did, however,

Table I—Clinical Details of Patients with Crohn's Disease
Disease
Age, duration, _______Site_______
Previous
Sex yr
Colon
Ileum
surgery
Activity
yr
—
—
+
M 42
0.5
Severe
+
+
F 46
0.5
Ileocolectomy
Severe
F
M
M
F
M
F
M
M

37
21
46
33
21
44
30
38

12
3
17
5
6
9
11
17

+

+

—

+

-

—

-

+

Distal ileum

+

+

—

+

+

Colectomy

-

+

-

+

—

—

+

+

Hemicolectomy
distal ileum

Severe
Mild
Severe
Severe
Severe
Severe
Mild
Severe

Antibiotics
given
_

Ampicillin,
clindamycin
Ampicillin
Salazopyrin
—
—

Salazopyrin
Salazopyrin
Salazopyrin
-

+ =present.

Neutralizing Activity
Serum from patients and the stool
ultrafiltrates from cytotoxin-negative
stool samples were tested for neutralizing
activity. For these experiments a standard
toxin ultrafiltrate was prepared, as
already described, from the pooled cecal
contents o f Syrian hamsters dying of
clindamycin-induced cecitis. Aliquots of
this standard toxin were frozen at -70°C.
A new toxin standard was used for each
experiment. The titre of the toxin alone
was compared with the titre of the toxin
plus 20 yL of serum or stool ultrafiltrate
added to each 1-mL vial.
Statistics
Sample means were compared by oneway analysis of variance.
Results
The clinical details of the 10 patients
with Crohn’s disease are shown in Table
I. All 25 stool samples from these 10
patients were negative for cytotoxin.
Stool samples from 110 patients with sus
pected antibiotic-associated colitis were
also assayed. Of these, 18 were positive
436

Hamster
toxin
+
+
+
+
+
+

Table II—Cytotoxin Neutralizing Activity in Sera and Stool Ultrafiltrates
Additive,
Stool
No. of
Log10 titre
20 pL
cytotoxin
samples
± SE
—
Normal saline
30
4.72 ± 0.03
Crohn's sera
-ve
8
4.71 ± 0.04
Other sera
-ve
7
4.60 ± 0.08
Other sera
+ ve
4.60 ± 0.12
5
Crohn's stool
-ve
4.32 ± 0.09
10
Other stool
-ve
4.32 ± 0.05
30

+ “ present.
* = p > 0 .0 1 compared with hamster toxin alone.

Table III--Clostridium difficile in Crohn's Disease
Patients
Positive
Series
tested
cytotoxin
Bolton and associates, 19809
7
1
Meyers and associates, 198110
26
1
Trnka and LaMont, 198111
24
7
Keighley and associates, 198212
48
3
Dorman and associates, 198214
50
0
Rolny and associates, 19 8 3 15
14
1
Total
169
13
ND-not done.
'Stool cultures performed in only 27 of 48 patients.

Positive
culture
ND
ND
ND
9*
4
ND
13
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culture C. difficile from the stools of four
patients, all with quiescent disease. This
is in keeping with the isolation rate of C.
I difficile from asymptomatic patients.16
! ►Positive cultures by themselves are not
\ indicative of C. difficile-induced
-*■ disease.17
The discrepant incidences between
studies is unlikely to be related to differ
ent measurement techniques. Different
cell cultures have varying sensitivities and
| >ihe starting stool dilution is greater in
i
some reports than others. However, poor
- sensitivity would only result in failure to
{ detect cytotoxin in stools of low titre and
*" is unlikely to explain the large differences
in incidence in the reported studies. These
|
discrepancies are best explained by the
j, vwell-known differences in incidence of
S antibiotic-associated colitis both geo, graphically and temporally,18 which are
,j presumably related to the infectious
►nature of the organism. Therefore, the
; failure to detect C. difficile in relapse of
’ inflammatory bowel disease at one time
; kdoes not mean that the organism will not
| be found in the future and does not mean
y that it is unnecessary to look for it.15
X
Two individual cases in which C.
► difficile cytotoxin was associated with
(
Crohn’s disease merit mention. The first
\
case was a patient who had had an
i
ileocolectomy for Crohn’s disease.8 This
patient had a symptomatic increase in
^ ileostomy output associated with C.
difficile cytotoxin in the ileostomy fluid.
The symptoms resolved when vancomyj
cin was given and the toxin disappeared,
r suggesting that C. difficile can cause ente
ritis in addition to colitis.
In the second case, toxic megacolon
( ^developed associated with positive C.
difficile cytotoxin in a patient with
^ Crohn’s colitis.19 Treatment with
metronidazole caused the symptoms to
*- resolve and the cytotoxin disappeared.
This is an important observation because
C. difficile toxins may be a major cause
I of toxic megacolon. It is imperative that
''stool contents be tested for C. difficile
cytotoxin in all patients suspected of havr ing toxic megacolon, as well as in those
r requiring colectomy or dying with the
diagnosis of toxic megacolon. Early
recognition and detection of cytotoxin in
such patients may substantially reduce
►morbidity and mortality.
We could not detect serum cytotoxin
neutralizing activity in our patients with
Crohn’s disease. This does not, however,
rule out any previous exposure to C.
difficile toxins. In the majority of patients
with proven C. difficile colitis, cytotoxin
Jneutralizing activity is not demonstrable
(Table II).20
'T
This is the first report to our knowledge
v of an attempt to measure cytotoxin neu* tralizing activity in stool ultrafiltrates.
The neutralizing activity we demonstrated

in the Crohn’s patients was weak and is
probably nonspecific as it was also
present in patients with other diarrheal
disorders. However, the neutralizing
activity could interfere with accurate
measurement of cytotoxin.
We think that it is important to con
tinue to look for specific antibodies to C.
difficile toxins in the serum and stool of
patients with inflammatory bowel disease.
Enzyme-linked immunosorbent assay
(ELISA) techniques for this are now
available.20’21 In fact, the ELISA is
more sensitive than the neutralizing tech
nique in detecting serum antibodies in
patients with pseudomembranous coli
tis.20 It is still conceivable that bacterial
toxins, by causing mucosal damage, may
play a role in the pathogenesis of Crohn’s
disease.22’23
Summary

We were unabale to demonstrate the
presence of or previous exposure to C.
difficile cytotoxin in 10 patients with
Crohn’s disease. Review of the published
literature reveals that from 0% to 29%
of patients with symptomatic relapse of
Crohn’s disease have positive C. difficile
cytotoxin. The variable incidence is in
keeping with the infectious nature of the
organism,24 and it is not surprising that
these patients, who receive a lot of antibi
otics, can suffer this complication.
However, it is still not known whether
patients with Crohn’s disease are more
susceptible to C. difficile colitis than other
patients with a similar exposure to antibi
otics. It has also not been established
whether mucosal damage caused by C.
difficile toxins can initiate a relapse of
underlying Crohn’s disease.
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3. Infection and the Use of Antibiotics in Crohn’s Disease
Many patients with Crohn's disease
present with the complications of infec
tion. Hence, antibiotics play an important
role in the medical management of acute
inflammatory disease, persistent perianal
disease and as prophylaxis for surgical
operations. The author's group has
demonstrated that bacteria colonize the
serosa of the bowel in patients with
Crohn's disease in 2 7 % of cases. Fur
thermore, pathogenic bacteria could be
recovered from the lymph nodes in 3 3 %
of patients with Crohn's disease,
compared with only 5 % in a controlled
population. Extraintestinal bacterial
colonization was, therefore, present in
approximately half of all patients requir
ing an operation for Crohn's disease. The
principal bacteria isolated at these sites
were Escherichia coii, Streptococcus
faecalis, Bacteroides fragilis, Proteus sp
and diphtheroids. A prospective con
trolled trial on the use of 1 month's
antimicrobial therapy in patients with
relapse of Crohn's disease revealed that
metronidazole was associated with a
5 7 % response rate, compared with a
response of only 1 7 % in patients receiv
ing no metronidazole. These interim find
ings suggest that metronidazole may
have a role in the management of acute
relapse in patients with Crohn's disease.
Plusieurs des patients qui souffrent de
maladie de Crohn pr£sentent des compli
cations infectieuses. Les antibiotiques
ont done un role important & jouer dans
le traitement medical des poussees
inflammatoires aigues, des atteintes peri-

From the Department o f Surgery, General
Hospital, Birmingham, England
Presented as part o f a symposium on
Crohn’s disease by the Royal College o f
Physicians and Surgeons o f Canada in
cooperation with the Canadian Association
o f Gastroenterology and the Canadian
Association o f General Surgeons, Calgary,
Alta., Sept. 22, 1983
Accepted fo r publication Feb. 10, 1984
Reprint requests to: Mr. M.R.B. Keighley,
Department o f Surgery, The General
Hospital, Steelhouse Lane, Birmingham
B4 6NH, England
438

n£ales persistantes ou en prophylaxie
lors des interventions chirurgicales. Le
groupe auquel I'auteur appartient a
demontre que les bacteries colonisent la
sereuse intestinale chez les patients
atteints de la maladie de Crohn dans
2 7 % des cas. Plus, des bacteries pathogenes ont pu etre recouvrees des gan
glions lymphatiques chez 3 3 % des victimes de la maladie de Crohn
comparativement a seulement 5 % dans
une population temoin. Une colonisation
bacterienne extra-intestinale etait done
presente chez environ la moiti£ des
patients necessitant une operation pour
la maladie de Crohn. Les principales bac
teries isolees de ces sites anatomiques
ont ete Escherichia coli. Streptococcus
faecalis, Bacteroides fragilis, Proteus sp.
et des bacteries du groupe diphteroTde.
Une etude prospective controlee sur I’utilisation d'une antibiotherapie d'un mois
chez des patients en rechute de la mala
die de Crohn a revele que le metronida
zole etait accompagne d'un taux de
reponse de 5 7 % comparativement a seu
lement 17% chez les patients qui ne
recevaient pas de metronidazole. Ces
resultats preliminaires indiquent que le
metronidazole peut jouer un role dans le
traitement des rechutes aigues chez les
patients qui ont la maladie de Crohn.

Sepsis is a common manifestation of
Crohn’s disease.1 It is related to an
abnormal intestinal microflora. There is
evidence that sites outside the bowel
lumen, such as bowel serosa, lymph
nodes, liver and portal bloodstream,
become colonized by bacteria in acute
inflammatory disease without complica
tions. Established sepsis in Crohn’s dis
ease is found in patients with intra
abdominal or pelvic abscess and in
patients with enterocutaneous, enterovaginal and enteroenteric fistulas. It is
also a common manifestation of perianal
Crohn’s disease, particularly when the
disease is complicated by abscess or
fistula. For surgeons, one of the most
important aspects of sepsis in Crohn’s dis
ease is when it occurs as a complication
of an operative procedure.

Intestinal Microflora and
Crohn’s Disease

"*

There is substantial evidence that the
intestinal microflora of the entire gas--1
trointestinal tract is abnormal in patients
with Crohn’s disease.2 Counts of aerobes 3
and anaerobes are increased in approxi
mately 30% of patients with jejunal ^
Crohn’s disease. They are also increased
in the ileum in patients who have had a
previous ileocecal resection, in patients*
with terminal ileal obstruction or a previ
ous side-to-side bypass procedure and in A
those with acute florid ileocecal disease.
\
A numerical increase in bacterial counts *
is also observed in patients with smallbowel obstruction secondary to Crohn’s
disease.
The colonic microflora is also abnor\
mal in Crohn’s disease but, contrary to»
expectations, counts of anaerobes appear
to be decreased, particularly in patients -»
with acute disease and fulminating diar
rhea. This may be a consequence of more 1
rapid colonic transit.
We have investigated the intestinal
microflora in 52 patients with acute,
relapse of Crohn’s disease. The only
specific pathogens isolated were Shigella r
sp, Yersinia sp and Clostridium difficile
without toxin, in one patient each. We y
also investigated the incidence of C.
difficile in 74 inpatients with Crohn’s dis
ease and identified that organism in 13.3
However, in only 3 of the 13 was there
evidence of C. difficile toxin. In this
I
group of 13 patients, 5 had undergone a
recent operation and had received antibi- <
otics perioperatively and 5 others were
taking sulfasalazine on a long-term basis.
We have never isolated amoebae, Cam
pylobacter or Salmonella from the feces'4
of patients with acute relapse of Crohn’s
disease.
4
Antibiotics must be used with caution
in patients with Crohn’s disease who
already have an abnormal intestinal
microflora. We investigated the influence
of a variety of agents on intestinal!microflora. There was no change in fecal
flora and no evidence of the emergence F
of C. difficile with the following penicil
lins: benzylpenicillin, ampicillin, mezlocil- '
lin, piperacillin and ticarcillin (six sub-
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jects each). There were small changes in
fecal flora but the difference never
exceeded log2 after administration of six
cephalosporins (six subjects each). Clos
tridium difficile was not identified in the
patients receiving cephaloridine, but was
isolated in one patient receiving cephazolin, in three receiving cefoxitin, in two
^ receiving cefotaxime, in one recieving
cefuroxim e and in five receiving
latamoxef. Intravenously administered
(metronidazole alone and with gentamicin
was associated with a log2 reduction in
anaerobes but no emergence of C.
difficile, as was orally administered
metronidazole. However, when used with
neomycin, orally administered metronida
zole was associated with a log4 reduction
jn aerobes and a log6 reduction in
anaerobes. Orally administered neomycin
y
alone gave a log4 reduction in aerobes.
Despite this enormous change in fecal
x flora, C. difficile was not detected.
^Acute Inflammatory Disease
The clinical and biochemical features
► of patients with acute Crohn’s disease are
fever, abdominal mass, leukocytosis, an
* increased erythrocyte sedimentation rate,
increased levels of C-reactive protein and
orosomucoids and depressed levels of
, serum albumin and hemoglobin. The
manifestations of acute inflammatory dis
ease may be due to the panmural nature
of the disease, predisposing to infection
v in the bowel wall and its adjacent
lymphatics.
Y
We studied the incidence of bacteria in
the serosa, lymph nodes, liver paren’ chyma, portal blood and some splenic
^cultures in 45 patients with Crohn’s dis
ease and compared the findings with
r those from 41 control patients. Samples
were collected at operation and the study
x was confined to patients who had no evi
dence of bacterial contamination outside
the bowel. This excluded patients with
enterocutaneous fistulas, preoperative
' "stoma, abscess or suppurative complications. The results are shown in Table I.
The incidence of bacteria from the lymph
►nodes draining the small bowel of patients
with Crohn’s disease was significantly (p
• < 0.02, x2 analysis) greater than in con
trols. The majority of bacteria isolated
' *from the serosa and lymph nodes of con
trols were exogenous. The organisms
colonizing these extraintestinal sites in the
^ Crohn’s disease group were mostly enteric
(Table II). The incidence of bacterial
colonization in patients with Crohn’s dis
ease was much greater in the 16 patients
i )who had active disease than in those
whose hematologic and biochemical
measurements (Table III) indicated quies. cent disease.
'
A prospective, randomized, control
trial of patients with known Crohn’s dis

13 patients within 6 months of operation.
Abscesses were present postoperatively in
17 patients (15%) and were multiple in 6
of these. The sites of preoperative intra
abdominal abscess were as follows: local
ized to diseased bowel in nine, psoas
sheath two, pelvis nine, interloop two,
subhepatic two; diffuse abdominal sep
sis was recorded in two patients follow
ing intestinal perforation. There was a
high incidence of streptococcal isolates in
these patients; we believe that one of the
reasons for recurrence of abscess is the
failure to cover streptococci adequately
by many modern antibiotic regimens. It
has been emphasized by others5 that
Streptococcus milleri is a cause o f recur
rent abscess in Crohn’s disease.
One of the principal problems in
patients with Crohn’s disease is to
differentiate between an abscess and acute
inflammatory bowel disease. Both groups
of patients have anemia, a high erythro
cyte sedimentation rate, hypoalbuminemia and elevated levels of orosomucoids.
Abscess in Crohn’s disease may be

ease in relapse was carried out to define
the value of medium-term antimicrobial
therapy for acute Crohn’s disease. The
criteria for entry included the presence of
fever, pain, diarrhea, weight loss,
abdom inal mass or complications.
Excluded from the study were patients
with exacerbation of perianal disease
alone.
Four groups of 13 patients were ran
domly allocated to receive the following
for 1 month: two placebo preparations,
placebo and cotrimoxazole, placebo and
metronidazole, and cotrimoxazole and
metronidazole. Six patients were with
drawn because they did not complete the
therapy. Assessment of response to ther
apy was by clinical scoring, hematologic
and biochemical measurement and a microbiologic assessment of change in fecal
flora. Improvement was recorded in 2 of
12 patients receiving the double placebo
preparation, 2 of 11 patients receiving
placebo and cotrimoxazole, 7 o f 11 pa
tients receiving placebo and metronida
zole and 6 of 12 patients receiving
cotrimoxazole and metronidazole. If the
response to therapy is analysed accord
ing to whether the patients received
metronidazole, there is a significant
difference (p < 0.05) in the response rate:
4 (17%) patients who did not receive
metronidazole improved compared with
13 (57%) who did.

T a b le I I — P r in c ip a l B a c t e r ia
C o lo n iz in g E x t r a in t e s t in a l S it e s
N o . of
s o la t e s

O rg a n is m
E s c h e r ic h ia
P ro te u s

17

c o li

6

sp

S tre p to c o c c u s

Abscess

f a e c a lis

8

v ir id a n s

2
5

a n a e r o b ic

In 111 patients operated on for Crohn’s
disease between 1973 and 1983,4 abs
cesses were present preoperatively in 13
(12%). The abscesses were unsuspected in
eight of these patients and were localized
to a single site in one. Despite resection
of diseased bowel and drainage of the
abscesses, the abscesses recurred in 5 of the

B a c te r o id e s
C lo s t r id iu m

8

fr a g ih s

3

sp

9
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1
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4
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C r o h n 's d is e a s e
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45)

C o n t r o ls
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41)
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1 2 (2 7 )

6 (1 5 )

Lym ph nodes
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2
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1

(2 )
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1
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L iv e r

(2 )
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4 5 P a t ie n t s w it h C r o h n 's D is e a s e
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Lym ph nodes
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demonstrated by plain films, gallium
scanning, computerized tomography or
imaging using leukocytes labelled with
indium 111. We have used indium leuko
cyte scanning in 24 patients with Crohn’s
disease in an attempt to differentiate
abscess from acute disease. In two
patients the scan identified an abscess and
active disease which was verified at
laparotomy. In five patients the scan iden
tified an abscess alone, and the abscess
was located at laparotomy in all cases.
Four patients were identified as having
active disease. In all four, the condition
resolved with medical therapy; three of
the patients had a laparotomy and no evi
dence of abscess was identified. Thirteen
patients had normal scans; none of them
have required laparotomy and in all cases
symptoms have resolved.
The management of abscess complicat
ing Crohn’s disease is by resection of the
bowel and drainage of the abscess. For
abscesses occurring early after operation
when a second laparotomy might be dan
gerous and associated with increased mor
bidity, we have used percutaneous drain
age under roentgenographic control. In
such patients it is usually possible to iden
tify the abscess using a long needle, to
introduce contrast material into the cavity
and to insert a portex drainage tube at the
most appropriate site for management.
We believe that percutaneous drainage
should always be performed under anti
biotic cover and we advise the use of
metronidazole and mezlocillin.
Fistula
We have reported on the incidence of
fistula in 149 patients with Crohn’s dis
ease seen between 1970 and 1980.6 Of 39
fistulas found, 9 were not associated with
active disease, 16 were associated with
active disease but no abscess and 14 com
plicated active disease associated with an
abscess. O f these fistulas, 28 (72%) were
associated with gross malnutrition and 22
(56%) with clinical sepsis. The origin of
the fistulas was as follows: duodenum 1,
jejunum 2, ileum 20, colon 7 and intesti
nal anastomosis 9. None of these fistulas
arose from the appendiceal stump. In our
experience all fistulas that occurred as a

Table IV—Manifestations of
Perianal Disease in 109 Patients
No. of
patients (%)
Manifestation
69 (45)
Fissures
75(69)
Fistula
5(5)
Abscess alone
73 (6 6 )
Tags
Stenosis
6(6)
Rectovaginal fistula
8(8)
Ulcers
17(16)
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complication of appendectomy originated
from the terminal ileum.
In our management of patients with an
enterocutaneous fistula, we first deter
mine whether there is active disease and
whether there is distal obstruction. If
there is active disease as indicated by
hematologic and biochemical measure
ments, we have been able to achieve heal
ing in 80% of patients using total paren
teral nutrition alone. Most patients with
distal stenosis, as evidenced by detailed
radiologic study, require surgical treat
ment with excision of the distal stenotic
area. However, total parenteral nutrition
is an important means of improving the
clinical state before an elective operation.
If an enterocutaneous fistula is compli
cated by an abscess, we believe the abscess
should first be drained under antibiotic
cover and the patient’s condition should
be reassessed after the local sepsis has
resolved.
Perianal Disease
We reviewed the incidence of perianal
disease in 153 consecutive patients with
known Crohn’s disease attending the out
patient clinic. Fourteen patients merely
had skin tags and no other manifestations
of anal disorder, 109 patients (71%) had
evidence of additional features of perianal
Crohn’s disease and 30 had no evidence
of perianal Crohn’s disease (Table IV).
Many patients had more than one mani
festation of perianal Crohn’s disease.
This condition is commonly associated
with sepsis due to mixed organisms, the
principal bacterial isolates being Bacteroides fragilis, Escherichia coli, Proteus
sp and Staphylococcus aureus.
We recently reported on a 10-year
follow-up of patients with perianal dis
ease.7 One hundred and eighteen patients
who were known to have perianal disease
10 years before were followed up in our
inflammatory bowel disease clinic. Of
these patients, 10 subsequently underwent
rectal excision (5 because of perianal dis
ease), 14 have died, 15 refused detailed
examination, 18 have been lost to follow
up and 61 were examined. Of the 29
patients with a fistula in 1968, only 6 had
evidence of a persistent fistula 10 years
later, although a new fistula had deve
loped in 3. Of the 54 patients with fissures
seen in 1968, only 10 had a persistent fis

sure; new fissures had developed in 7. Of
the 12 patients who had anorectal ulcers
in 1968, only 2 had ulcers 10 years later.
Our management of perianal Crohn’s
disease is as follows: patients with anal*
fissure are treated conservatively
whenever possible, the underlying bowel *•
disease being managed medically; if the
fissure persists with severe pain, gentle "*
dilatation is sometimes considered.
Patients with a low-lying fistula-in-ano
without evidence of macroscopic disease
in the rectum are explored under general
anesthesia and the low-lying fistula is laid ■*
open. However, most patients with a
fistula complicating Crohn’s disease have
associated destructive anorectal sepsis and
for such patients treatm ent with
metronidazole is advisable. Perianal,
abscesses complicating Crohn’s disease
j
are drained. Skin tags are always left ^
alone and anorectal strictures can be
•*
managed by gentle dilatation.
Brandt and associates8 have reported
excellent results with metronidazole in 18
patients with chronic unremitting perianal
i
disease. They reported healing in 10 of the
patients, with improvement in 5 others. ^
Therapy is usually prolonged in such
patients and there is often a high inci- a
dence of side effects such as nausea,
metallic taste and occasional peripheral
neuropathy in patients requiring long
term treatment.
Postoperative Sepsis

Of 107 patients who underwent opera- J
tion for Crohn’s disease between 1973
and 1977, 19 (18%) had a wound infec
tion, 14 (13%) an abscess and 4 (4%) had
an episode of septicemia postoperatively.9 The incidence of perianal sepsis* •
postoperatively was 39%. The rate of
postoperative sepsis was unrelated to ■*
preoperative weight or to administration
of steroids, but was notably more com- y
mon in patients with a fistula and abscess.
We recently compared the effect of a
)
24-hour perioperative course of prophy *.
laxis using metronidazole and gentamicin
with a 5-day course using the same
drugs given intravenously and started
immediately before operation; the results <
were compared with those in patients
receiving no antibiotics (Table V).10 We
found that short-term perioperative*
antibiotic coverage did not appreciably

Table V--Postoperative Infections with Use of Antibiotics Prophylactically
Metronidazole (IV)
Metronidazole (IV)
Type of
+ gentamicin for 24 h,
+ gentamicin for 5 d,
infection
no. (%) In - 30)
no. (%) (n - 30)
Abdominal wounds
7(23)
4(13)
Abscess
3(10)
1 (3)
Septicemia
3(10)
-(0 )
Perineal wounds, no./total no. (%)
118 (12)
3(6(50)
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Placebo,
no. (%)
(n - 27)
10(37)
3(11)
2(7)
4/6 (66)
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reduce the incidence of postoperative sep
sis compared with patients receiving no
antibiotics. Only after the administration
of metronidazole intravenously with gen►tamicin for 5 days was the incidence of
infection notably reduced. We believe
that there are five reasons for failure of
short-term perioperative antibiotic cover
age:
• Many patients already have a stoma
preoperatively.
t. • The frequency of fistula and abscess
is high.
• Many patients have suppurative peri
anal disease.
• There is frequent bacterial contami
nation of lymph nodes and serosa.
• The intestinal microflora is abnormal
y in Crohn’s disease.
Our policy for preventing sepsis in
patients who undergo operations for
Crohn’s disease is as follows:
• Avoid vigorous mechanical bowel
preparation.
k • Minimize gross contamination by
intestinal contents.
• Ensure that meticulous hemostasis is
achieved.
• Always use a proximal stoma when
the viability of the anastomosis is in
doubt.

□
□
□
□

• Use at least 5 days of perioperative
antibiotic coverage.
• Leave grossly contaminated wounds
open.
Since formulating this policy we have
obtained sepsis rates of less than 15% in
all operations for Crohn’s disease.
Anaerobic sepsis is no longer a problem
in the surgical management of Crohn’s
disease and this is largely attributed to the
efficacy of metronidazole. The infections
that do occur in surgery for Crohn’s dis
ease are generally due to E. coli, Proteus
sp, S. aureus or Klebsiella sp.
Conclusions

Many patients with Crohn’s disease
present with complications of infection,
hence antibiotics play an important part
in the medical management of acute
inflammatory disease, persistent perianal
disease and as prophylaxis for surgical
operations. We believe that antimicrobial
agents which encourage overgrowth by C.
difficile should be avoided. There is now
considerable evidence to support the
notion that the primary treatment of
infection in Crohn’s disease should be
directed principally against the fecal
anaerobes. It is for this reason that

metronidazole has made such an impact
on the management of many of the infec
tive complications of this disorder.
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Monitoring Epidural and Fontanel Pressure:
a Clinical and Experimental Study

y

Since 1978, we have used the Ladd
y epidural fiberoptic sensor and monitor
ing system to record intracranial pressure,
'
both in clinical and experimental work.
^ This system evolved from the Numoto
switch and has been described in the medk ical literature by Levin1 and our
group.2-4 During the past 5 years, we
a have endeavoured to find answers to the
following questions: (a) How safe is in
tracranial pressure monitoring by this
method? (b) What impact does it have on
patient management? (c) How accurate is
the fiberoptic system? (d) Can the system
be used for monitoring fontanel pressure
in infants and with what degree of con
fidence?
*■
Concerning the safety of the equip
ment, we have used intracranial pressure
^ monitoring from the epidural space with
the fiberoptic technique, both in the in' ’’tensive care unit and in the operating
room, in more than 300 instances. Of
r these, 70% were used for periods rangr ing from 24 hours to 31 days and 30%
for less than 24 hours, intraoperatively or
postoperatively. There were no deaths or
infectious complications related to the use
v of the system. There were no hemorrhagic
complications except for one episode in
* which a small epidural clot developed at
the site of the probe; it was detected and
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removed within a few hours and without
complication.
The impact of intracranial pressure
monitoring is still being evaluated. No
statistically significant figures are avail
able to show whether our 23% mortality
with severe head injuries before 1978 has
improved. We can state, however, that in
tracranial pressure monitoring introduced
a more rational use of hyperosmotic
agents and a number of prompt correc
tive measures, which can prevent un
manageable rise of intracranial pressure.
The accuracy of the system was tested
in eight dogs by comparing cisternal pres
sure with epidural pressure. When cister
nal pressure was raised by injecting
physiologic saline into the cisterna magna, simultaneous cisternal and epidural
pressure recording revealed almost iden
tical readings. When epidural pressures
were plotted against cisternal pressures,
statistical analysis of the data revealed a
correlation coefficient of 0.95 or higher.
Fontanel pressure measurement with
the epidural sensor branched into three
areas. First, we tested the consistency of
the readings, comparing three holding
devices in 200 newborn infants; we found
no statistically significant difference in the
mean pressures obtained with any of the
three devices. The mean fontanel pressure
in newborn infants was significantly
(p < 0.05) lower than in older infants up
to 10 months of age. Second, artificial
fontanels were created in dogs and the
pressures compared to cisternal pressure
readings. The readings were identical in
80% of the dogs and the false readings
in 20% were attributed to incorrect ap
plication force. Finally, when we com
pared various cerebrospinal fluid
compartments (intraventricular, suba
rachnoid) by epidural and fontanel pres
sure monitoring, we found that fontanel
pressure was extremely close to the

epidural pressure and that lum bar
subarachnoid pressure was almost iden
tical to fontanel pressure. On the other
hand, ventricular fluid pressure was con
sistently about 10 mm Hg lower than
epidural pressure.
We were able to draw four conclusions
from our study.
• The fiberoptic epidural monitoring
system is reliable and easy to use. The
method has a wider margin of safety, with
respect to hemorrhagic and infectious
complications, than other measuring tech
niques.
• The method makes the management
of coma (severe head injuries, meningi
tis, Reye’s syndrome, spontaneous in
tracranial hem orrhage) much m ore
rational, although we cannot yet com 
ment on whether the outcome in children
with severe head injuries was significant
ly altered by this technique.
• The method is accurate, not only for
clinical use but also for scientific inquiry,
although ventricular fluid pressure is
lower than epidural pressure.
• The fiberoptic probe is suitable for
fontanel pressure measurement and the
method approximates the true intracrani
al pressure readings from intracranial
compartments.
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Intestinal Transplantation: a Reality for the Future
Before 1972, several w orkers1,2
attempted to transplant small intestine in
man to treat diseases that lead to major
losses of the small intestine. These dis
eases include small-bowel infarction and
extensive Crohn’s disease. No patient sur
vived for longer than 76 days, despite
intensive immunosuppression using Imu
ran and steroids. In fact, five of seven
patients died during the first 12 days and
the one longer term survivor did not have
useful gastrointestinal function. During
the past 10 years, techniques of total
parenteral nutrition (TPN) have so
improved that it is possible to maintain
many of these patients at home. A num 
ber of patients cannot consume food so
they obtain the required daily energy
needs through their indwelling catheter.
Although many of these patients have
returned to a useful, functional life, there
are serious problems with this system.
Catheter sepsis has required changing the
catheter in many cases and, because of the
long-term nature of these programs,
venous access becomes limited. Psychoso
cial difficulties have meant that some
patients have not been able to adjust to
this life-style. At the Toronto General
Hospital, the divisions of gastroenterol
ogy and general surgery have been at the
forefront of TPN and, currently, more
than 30 patients are maintained on TPN.
However, TPN is expensive and each year
the cost per patient is more than $35 000.
An alternative might be small intestinal
transplantation, particularly if the
immunologic problems related to this
fo rm of tra n sp la n ta tio n can be
minimized.
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Allotransplantation of small intestine
has been investigated in laboratory
anim als since 1959. Lillehei and
associates1 reported the results of
allotransplantation of various lengths of
small intestine in a canine model. The sur
gical techniques for successful transplan
tation and the methods for graft preser
vation were clarified. W ith these
techniques, autotransplanted total small
bowel of dogs survived indefinitely. In
dogs that underwent total small intesti
nal allotransplantation, the mean survival
varied from 8 to 15 days.3,4 At autopsy
these animals showed hemorrhagic necro
sis of the transplanted bowel and dense,
submucosal and mucosal infiltration by
lymphocytes and plasma cells.4 In addi
tion to acute rejection, graft-versus-host
disease has also been seen in some dogs.
These animals died 6 to 9 days following
allotransplantation. The transplanted
bowel was grossly and microscopically
normal. Despite the fact that lymphoid
infiltrates were not found, it was con
cluded that graft-versus-host disease was
the cause of death. Graft-versus-host dis
ease has been shown to be caused by T
cells of dominant origins that react
against tissues of the recipient, produc
ing a clinical spectrum that is character
ized by weight loss, diarrhea and cutane
ous manifestations and usually results in
the death of the animal.5,6 It has been
shown in a rat hybrid model that the
severity of graft-versus-host disease
produced in animals receiving small intes
tinal allografts can be directly correlated
with the quantity of lymphatic tissue
transplanted — that is the length of small
intestine transplanted.5 Attempts to
prolong survival of dogs receiving total
small intestinal allografts have been made
using prednisone, azathioprine and
antilymphocyte globulin. But with con
ventional methods and manipulating the
donor bowel with irradiation, survival has
been limited.
Immunologic monitoring in intestinal
allotransplantation has met with only
limited success because techniques permit
ting sequential evaluation of in-vivo
generated rejection responses have been

lacking. Histologic methods, however,
have been used to monitor the trans
planted small intestine.7 By construction5
of cutaneous stomas of the transplant, it
has been possible to follow the process of
rejection of allotransplanted small intes
tine in rats, mice, pigs and dogs. The
sequence of rejection has been followed
in human intestinal transplantation as
described by Fortner and associates.8 A
Cyclosporine is a cyclic endecapeptide
derived from the fermentation broth of
fungi Cyclindrocarpon lucidum Booth
and Tricoderma polysporum Rifai.9
Originally, it was described as an antibi
otic but it is now used as an extremely
potent immunosuppressant and it has
probably been the major advance in
transplantation surgery in the past -*
decade. It has a predominant effect on the
T cell and it inhibits lymphocyte activa
tion in cytotoxic T-cell generation follow
ing allogeneic stim ulation.10 It is
extremely effective as an immunosuppres
sive agent in the treatment of rejection in
animals and man following kidney, liver,
pancreas and heart transplantation.11,12
It is also effective in preventing and treat
ing graft-versus-host disease in patients
receiving bone-marrow transplants. Bac
terial sepsis is a relatively less-important
problem in using this immunosuppressive
agent. Because of its stated effects against 4
both rejection and graft-versus-host dis
ease, it appears to be an ideal
immunosuppressant for use in transplan
tation of the small intestine.
In our early work, we studied the
results of parenterally administered
cyclosporine on the survival of dogs that
underwent allotransplantation of th e M
whole small bowel.13 Cyclosporine, 25
mg/kg daily given intramuscularly and
then orally, greatly prolonged survival, to
a mean of 103 days compared with only
12 days in dogs not receiving any
immunosuppressive agent. Two of the
dogs lived for more than 200 days and one ^
lived for more than 400 days.
These extremely encouraging results
have led us to do further studies to moni
tor graft rejection by using both histologic
and physiologic means. We have also
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begun to study the pharmacokinetics of
cyclosporine in an attempt to determine
the optimal dose and route of adminis
tration of the drug.
** With the advent of cyclosporine and
possibly its analogues as well as the interaction of the field of molecular biology
in transplantation, we believe that total
r or segmental intestinal transplantation is
becoming more of a reality.
Our hope is that small intestinal trans
plantation would be applicable in certain
clinical situations as an alternative to total
k parenteral nutrition.
►

References
1. L illeh ei RC, G oo tt B, M iller FA: The physiological response of the small bowel of the dog to ischemia

r

including prolonged in vitro preservation o f the bowel
with successful replacement and survival. A n n Surg 1959;
50: 543-60
2. M anax w g , Bloch JH , E yal Z, L illehei RC:
Experimental preservation of the small bowel. Am J Surg
1965; 109: 26-31
3. HOLMES JT: Small-bowel transplantation: an experimen
tal study. A nn R Coll Surg Engl 1973; 52: 165-81

8. FORTNER JG , SICHUK G , LlTWIN SD , BEATTIE E J JR:

Immunological responses to an intestinal allograft with
HL-A-identical donor-recipient. Transplantation 1972;
14: 531-5
9. BOREL JF, FEURER C, MAGNEE C, STAHELIN H:
Effects o f the new anti-lymphocytic peptide cyclosporin
A in animals. Immunology 1977; 32: 1017-25
10

4. T o led o -P ereyra LH, Simmons RL, N ajarian JS:
Prolonged survival of canine orthotopic small intestinal
allografts preserved for 24 hours by hypothermic blood
less perfusion. Surgery 1974; 75: 368-76

K eow n PA, St iller CR, U lan RA, S in cla ir NR,
W all W J, C arruthers G, H owson W: Immunolog
ical and pharmacological monitoring in the clinical use
o f cyclosporin A. Lancet 1981; 1: 686-9

5. MONCHIK G J, RUSSELL PS: Transplantation of small
bowel in the rat: technical and immunological consider
ations. Surgery 1971; 70: 693-702

11. C aln e RY: Immunosuppression for organ grafting —
observations on cyclosporin A. Im m unol Rev 1979; 46:
113-24

6. DELTZ E, MULLER-HERMELINK HK, ULRICHS K,
THIEDE A, Muller -R uch holtz W: Development of
graft-versus-host reaction in various target organs after
small intestine transplantation. Transplant Proc 1981;
13(1 pt 2): 1215-6

12. Sta r z l TE, iw atsuk i S, K lintm alm G, Sc h r o ter
GP, WEIL R III, Ko ep LJ, P orter KA: Liver transplan
tation, 1980, with particular reference to cyclosporin-A.
Transplant Proc 1981; 13(1 pt 1): 281-5

7. Kun lin A, G aston JP, S hiu MH, W inawer SJ,
FORTNER JG: The isolated allograft pouch: a useful
method for monitoring small bowel allografts. Surg
Forum 1971; 22: 237-8

13. C rad dock GN, Nord g ren SR, Reznick RK, G ilas
T, L ossing AG, Co h en Z, Stiller CR, C u llen JB,
L anger B: Small bowel transplantation in the dog using
cyclosporine. Transplantation 1983; 35: 284-8

r

►

C . SORBIE, MB, FRCS(EDIN), FRCS[C];

R.

SHIBA, MD;

D.

S lU , MD

4k

Surface Analytical Methods for Elbow-Joint Replacement
►

Currently used hinge or semisurface
replacements for the elbow have had an
unacceptably high failure rate. Perfor’’ mance was poor because the prosthetic
designs did not comply with the complex
kinematics of the elbow joint. Most of
.these prostheses have been cemented to
bone and failure has become obvious by
V cement breakdown and loosening of joint
components. Few units were able to
t restore, while functional, normal joint
movement.
In a general sense, replacement of the
^damaged joint cartilage and subchondral
bone alone has the advantage of retainr ing the pre-existing joint structure, liga
ments, capsule, muscular motors and
>- alignment. Components that serve this
purpose, however, must reproduce, as
faithfully as possible, the original geom
etry and dimensions of the joint surfaces.
*" The Clinical Mechanics Unit at Queen’s
-
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University developed a surface analytical
technique to obtain the data necessary to
design the components and manufacture
a prototype.
Basic anthropomorphic data were
obtained by precise measurement of bone
features of the lower humerus and upper
ulna using standardized roentgenograms
of 56 elbows in living adults and 60 speci
mens from cadavers. All but one meas
urement bore a consistent proportional
relation to the others and to the
interepicondylar distance. In other words,
if the interepicondylar distance was large,
the other measured dimensions were
proportionately large and vice versa.
Four adult elbows (distal humerus and
upper ulna with cartilage intact from two
men and two women) were mounted on
a milling machine with precise orientation
and sliced at 0.76-mm intervals. The cut
surfaces were photographed after each
slicing and the films projected on a
digitizer. One hundred points on the car
tilage surface of each projected bone out
line were plotted and the position in rela
tion to two axes was recorded on
computer discs. A program was written
using Cartesian geometry and matrix
mathematics to locate the centroid of each
circular cut surface and to provide the
mathematical model by which profiles of
the trochlea, capitellum and olecranon
fossa could be displayed.

The reconstruction, by com puter
graphics, of each cut bone allowed the
conclusion that the outlines of the troch
lea and capitellum, when viewed from a
medial-lateral direction, are parts of cir
cles whose centres, if linked, form a
straight line. This line, in a transverse or
medial-lateral direction, lies at an aver
age slope of 2.5° to the interepicondylar
line on a plane at 45° to 55° from the
coronal plane of the humerus. It is also
possible to state that the curvatures of the
articular facets on the ulna, that is, the
coronoid and olecranon facets, do not
have a common centre.
The profiles of the joint surfaces can
be viewed by computer manipulation, at
any degree of rotation. These profiles
converted to metal templates can be used
to guide milling machines in the prepa
ration of prototype joint replacement sur
faces to reproduce the original shapes.
The anthropomorphic studies, using
roentgenograms and direct measure
ments, gave the necessary information for
total component dimensions to provide
up to seven sizes for fitting, with close
tolerance, the majority of adult patients.
The technology developed in this study
can be applied to almost any human joint
as a means of determining the surface
geometry, axes of rotation and produc
tion of prototype surface replacement
components.
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Experimental Study of the Microsurgical Transfer
of Growth Plates
The idea of transplanting a functioning
growth plate is not new. For many years,
surgeons have attempted to use the tech
nique to manage growth-plate disorders,
but the results have been unpredictable.1
Some reported continued function, while
others described unsatisfactory growth or
complete failure.
Because continued growth depends
upon the transplant surviving an initial
period of ischemia, the major thrust of
experimental research has been to inves
tigate methods of maintaining viability
after transfer.
As a result of the development of
microsurgical techniques, viable freetissue transfers can be made with predic
table success.2,3 The transfer for vascula
rized bone segments has now become a
standard surgical procedure.4 These liv
ing bone grafts are often transferred on
their periosteal circulation alone, as it has
been shown that exclusion of the nutrient
artery is not detrimental to viability.5
With the use of microsurgical revas
cularization, growth plates have been
transferred as components of composite
grafts in replantation,6 toe-to-hand7 and
whole-joint transfers.8,9 Long-term
follow-up has shown preservation of
growth-plate morphology and continued
linear growth.
The growth plate is supplied by two
separate circulations.10 The epiphyseal
circulation is responsible for linear growth
while the metaphyseal circulation helps to
ossify and remodel the cartilaginous
columns.11 Thus, for successful transfer
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of a growth plate by itself, both the beyond normal length, however, was
epiphyseal and metaphyseal circulations much less satisfactory. Early results were
must be restored.
encouraging with total limb growth rates
Previously, the only microsurgical of up to 200%. Subsequently, however,
transfers of growth plates by themselves fractures occurred in the accessory growth1
had been reported by Donski and plates and these caused malalignment and
associates12 and Donski and O’Brien.13 decreased growth rates. Biomechanical '
For a model they used the distal ulnar factors were thought to be responsible, as
growth plate in immature dogs. They the diaphyseal accessory growth plate
demonstrated that growth plates consis would be subjected to magnified moment
tently survive and grow in length, but only forces from the abnormally long lever
to two thirds of normal. They postulated arm between itself and the wrist.
■*
that the lack of full growth resulted
In conclusion, growth-plate transfers t
because only the metaphyseal circulation with microsurgical revascularization of *
was revascularized or because of the both metaphyseal and epiphyseal circu
tethering effect of an intact radius.
lations predictably provide growth at
We developed a technique for isolating near-normal rates. When used to restore
the immature dog’s distal ulnar growth growth in place of a nonfunctioning I
plate with both its metaphyseal and growth plate, results were satisfactory,
epiphyseal circulations, transferring it to but before the technique can be used as ;
a single, untethered long bone and com a diaphyseal accessory to provide greater-*
paring its rate of growth to a control, than normal growth in a short bone, the
which was the unoperated forelimb of the biomechanical problems that accompany same dog.
overgrowth must be solved.
A pilot study demonstrated that after
excision of the distal two thirds of the
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Encircling Endocardial Resection for Sustained
Drug-Resistant Ventricular Tachycardia

Sustained ventricular tachycardia is a
well-recognized complication of ischemic
heart disease and is usually a direct sequel
'of acute myocardial infarction. Ven^ tricular arrhythmias may result from
enhanced automaticity or from re-entry,
►which is the commonest mechanism
responsible for chronic sustained ven
tricular tachycardia.1 Re-entrant ar
rhythmias, as opposed to automatic
^tachycardias, may be induced and ter
minated in the electrophysiology labora^ tory by programmed electrical stimulak tion. Experimental electrophysiologic
investigations have demonstrated that
sustained ventricular arrhythmias ori
ginate from the border zone surrounding
a myocardial infarction.2 The border
zone is characterized by areas of normally
♦"perfused myocardium interdigitating with
areas of ischemia and infarcted muscle.
" This array of disorganized myocardium
surrounding an infarction provides the
electroanatomic substrate necessary to
generate sustained re-entrant tachycardia.
Traditionally, these arrhythmias have
.-been managed with antiarrhythmic agents
alone or in combination with left ventric-r ular aneurysm resection or resection of
postinfarction scar. Although initial
* reports emphasized the efficacy of sim
ple aneurysm resection,3'5 subsequent
ones6,7 have shown that aneurysmectomy
^ in combination with coronary artery
bypass is ineffective in controlling sus-
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tained ventricular arrhythmias, demon
strating that 70% of patients still have
recurrent ventricular tachycardia follow
ing operation. More recently, elec
trophysiologic investigations have enabled
the clinician to identify the ventricular site
responsible for the generation of these
arrhythmias. As a result, specific opera
tions have been designed to interrupt re
entrant pathways. Endocardial resection,
as originally described by Harken and
associates,7 has been used effectively to
eliminate re-entrant ventricular tachy
cardia. The endocardial origin of the
tachycardia is identified by preoperative
and intraoperative mapping and then the
endocardium is excised in this region.
However, even with electrophysiologically guided endocardial resection, 24%
of patients reported in the Philadelphia
series had recurrent ventricular tachy
cardia following operative intervention.8
The failure of electrophysiologically
directed surgery to eliminate ventricular
tachycardia in all patients is probably
because some of these patients had more
than one re-entrant circuit. This observa
tion is supported by our preoperative elec
trophysiologic stimulation and mapping
data, which indicated that patients with
sustained ventricular tachycardia often
have a number of morphologically dis
tinct tachycardias that can be easily
reproduced by programmed electrical
stimulation. This observation is predicta
ble when one considers that ventricular
tachycardia originates from the disor
ganized array of muscle surrounding the
myocardial infarction, indicating that
there may be a number of regions that
have the electroanatomic substrate neces
sary to generate these arrhythmias.
Recently, we have employed encircling
endocardial resection without intraoper
ative mapping in seven patients with
recurrent sustained drug-resistant ventric
ular tachycardia as identified by preoper
ative electrophysiologic stimulation. We
did not perform intraoperative mapping
because it is time-consuming and con
siderably prolongs the bypass period in
these seriously ill patients and because the
identification of a specific ventricular
activation site does not necessarily

guarantee that this site is the only region
responsible for recurring ventricular
tachycardia. We have, therefore, em
ployed encircling endocardial resection
with complete removal of all endocardial
scar. Re-entrant pathways were ablated
in six of the seven patients using this
approach. One patient with drug-resistant
ventricular tachycardia who required fre
quent preoperative cardioversion had no
clinical arrhythmias following endo
cardial resection. However, we were able
to induce ven tricu lar ta ch y card ia
postoperatively with programmed electri
cal stimulation, but not after loading with
procainamide. In this patient we obvi
ously failed to ablate the re-entrant path
way but altered the electrophysiologic
substrate sufficiently to be able to con
trol the arrhythmia with drug therapy.
We believe that encircling endocardial
resection should effectively ablate re
entrant pathways in most patients as this
direct surgical procedure is designed to
remove all potential sites of generation of
re-entrant tachyarrhythmias.
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The Intestine Has a Complex: Housekeeper or Heirloom? .
Contrary to expectation, the gut in the in
terdigestive state is not resting but under
going rhythmic contractions that begin
in the duodenum and are propelled to the
ileocecal valve. This myoelectrical pattern
has been called the migrating myoelectri
cal complex and is present in man only
in the fasted state. The velocity o f the
propulsion determines the periodicity, for
as the complex concludes in the terminal
ileum it reappears in the duodenum. Spe
cifically, the activity front consists of
bursts of action potential superimposed
on control wave cycles of the intestine on
a one-to-one basis. The period of regu
lar activity is preceded and followed by
an irregular period. This is followed by
a period of quiescence.
Since the complex was first described
by Szurszewski1 in 1969 in the small in
testine, many others2’5 have established
the qualitative and quantitative nature of
these signals in a variety of species. Re
cently, the emphasis has been on estab
lishing the patterns of control which have
been variously suggested as being the
responsibility of the intrinsic or extrinsic
nervous system or the function of certain
hormones. Although motilin is enjoying
a resurgence of popularity as the putative
hormone responsible for initiation of the
complex, the last word is not yet out. Sarna and associates6 have elegantly shown
that the basic mechanism of initiation re
sides in the enteric plexus. Further, Weisbrodt and associates7 have shown that
migrating myoelectrical complex patterns
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are not disturbed by vagotomy or sym
pathectomy.
In our laboratory, we have defined the
role of the vagus nerve in the complex us
ing temporary electrodes implanted dur
ing elective surgery on the small intestine
in man. Electrodes were placed after the
following procedures: cholecystectomy,
three patients; colonic resection, three;
vagotomy and drainage, three; proximal
gastric vagotomy, three. The electrodes
were led out of the abdomen along with
the surgical drain and subsequently re
moved by gentle traction. Recordings
were made postoperatively when normal
eating patterns and elimination were re
stored and on postoperative days 6 and
7 under resting conditions after a small
meal and following the injection of mor
phine, 0.01 mg/kg, the usual analgesic
used postoperatively in our patients. In
formed consent was obtained.
Electrical control wave and response
waves were noted in all patients and were
not influenced by vagotomy. Normal
feeding patterns were seen when the sub
jects with partial or complete section of
their vagus nerves were fed, and their
records compared with patterns in the fed
controls. These observations led us to
conclude that post-cibal symptoms such
as gas cramps, diarrhea or dumping,
which may follow vagotomy, are not due
to alteration of the electrical patterns in
the small intestine, but more likely result
from the uncontrolled discharge of ef
fluent through a pyloroplasty or gastroen
terostomy.
Migrating myoelectrical complexes
were observed in all subjects studied and
no differences were found between those
who had intact or severed vagus nerves.
In man, therefore, the vagus nerve is not
a requirement for normal complexes.
However, extrinsic nerves do influence
the activity front; for example, in the
laboratory, the sudden and unexpected
appearance of a maintenance staff per
son with a large piece of machinery
abolished an ongoing complex. Clearly,
although the extrinsic nervous system is
not required for the occurrence of com
plexes, it can certainly switch them off.

A key to understanding local control
of the complex was provided by the find
ing that morphine precipitated a prema*
ture complex on each occasion it was
administered. This complex was abnor- *
mal in that it was more prolonged, of
greater velocity and dislocated the normal
cycling so that several abnormal complexes
were seen before the usual time frame of i
the intrinsic cycles was re-established. I*
is possible that morphine, by attaching to j
an opioid receptor in the small intestine, *
mimics the effect of an intrinsic agonist
in the initiation of the complex. Pre- ^
treatment of our subjects with naloxone,
0.4 mg intravenously, did not abolish this
response, suggesting that the effect is a
local one on the intestine and not medi- i
ated by the central or peripheral nervous*
systems.
Although the mechanisms controlling this complex are fascinating, the more
fundamental issue, function of the com- A
plex, remains unanswered. Almost two
decades have passed since Code and
Marlett8 suggested that the activity front,
serves as housekeeper of the small intes
tine, that the rhythmic propulsive con- „
tractions of the small intestine remove
epithelial debris, secretions and undigest- *
ed foods, such as cellulose, from the small
bowel in the interdigestive period. This
plausible suggestion is difficult to sustain |
in view of complexes found to occur in
the fed state in certain species. From an
engineering aspect, the intestine can be
seen to consist of a number of pumps ,
connected in series. For the most part, the
esophageal pump is switched off, except
during deglutition. The stomach pump is
continuously active with a control wave*
of about 3 cycles per minute (cpm) and
response waves are seen only when the ”
stomach contains food or fluid. Likewise,
in the small intestine where there is a
faster pump (12 cpm), response waves are
only seen during the digestion of a meal.
The ability to suppress the pump com4
pletely, as in the esophagus, from the
point of view of both motility and elec- >i
trical activity, is an evolutionary advance ,
of the intestine that one would expect in ’
the most primitive forms was continuous-
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ly active. In the small intestine, the de
veloping ability to turn off the pump
would cause the electrical and mechani
cal events to be periodic and one conjec
tu re s that the migrating myoelectric
complex is the fundamental characteris
tic of the developing small intestine with
a shift from continuous to periodic activi~ ty. Because of further modification and
specialization of function, local controls
present in the stomach, esophagus and
leolon have superseded and suppressed the
periodic kicking in of the primitive
propulsive pump, which now is only ob
served in man in the fasted state.

It is a characteristic of man to try and
ascribe a function to every biologic
phenomenon. The migrating myoelectrical complex may be housekeeper, but also
it may be no more than a developmental
heirloom.
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Postoperative Respiratory Failure in Congenital
Diaphragmatic Hernia
♦'Congenital diaphragmatic hernia remains
a challenge to pediatric surgeons. In many
cases, progressive pulmonary insuffi
ciency develops after a short period of
clinical improvement following repair of
the hernia. It has been shown1 that pul
monary artery hypertension leads to a
^right-to-left shunt, described as a persis
tent fetal circulation. Efforts are directed
towards the treatment of this lethal
complication.1
t
To study this anom aly, m any
researchers have used fetal surgery to
induce diaphragmatic hernia in newborn
y lambs. They have demonstrated that it is
associated with severe pulm onary
hypoplasia and therefore some advocated
that it should be corrected in utero.2
r
We reviewed our own cases of congen
ital diaphragmatic hernia. We strongly
suspect that pulmonary hypoplasia is
compatible with survival in most cases
* and that the so-called persistent fetal cir
culation is an iatrogenic and, therefore,
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a preventable complication. Our ther
apeutic approach was changed accord
ingly over the last 4 years, with consider
able improvement in survival.
Diaphragmatic hernia was induced in
lambs in order to test our hypothesis and
to understand the mechanism by which
congenital diaphragmatic complication
occurs. Newborn infants with the
anomaly were operated upon using vari
ous techniques; gas exchange and respira
tory mechanics were measured and mor
phometric studies done on the lungs.
Preliminary results confirmed our clini
cal impression.
After repair of the hernia, the follow
ing course of events is presumed to occur,
leading to respiratory insufficiency.
Although most authors have empha
sized that no vigorous attempt should be
made forcefully to expand the ipsilateral
lung, it is still recommended, in North
America, that a drain be left in place after
reduction of the herniated viscera from
the thoracic cavity. Insertion of a chest
tube has deleterious effects on both lungs
when they are severely hypoplastic. With
a chest tube attached to an underwater
seal left in place after operation, air is
progressively driven out with respiratory
fluctuations, even if no suction is applied
to the tube. There is no possibility for
back pressure to develop and so prevent
both lungs from expanding rapidly in a
cavity too large for them. Positive venti

lation or suction applied to the tube can
only worsen the situation.
This brings about overinflation and
barotraum a to the lungs, with secondary
anoxia, acidosis, pulmonary hypertension
and reversal to fetal circulation. It is log
ical to assume that the damage to the
lungs will be proportional to their
hypoplasia or to the discrepancy between
them and the thoracic cavity.
On the other hand, most children with
congenital diaphragmatic hernia who
undergo repair have sufficient pulmonary
tissue to support life, as shown by the
“ honeymoon” periods in nonsurvivors.
We found that to achieve efficient venti
lation in the most severe cases, it was bet
ter to use a rapid rate with smaller
volumes. This gives a sufficient expiratory
volume per minute, without overinflating
the lungs.
Some cases, however, are so severe that
operation cannot even be attempted.
Mathematical models are expected to help
us to demonstrate that if these cases are
diagnosed prenatally, premature delivery
would be a logical alternative to correc
tion in utero.
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Motilin and Postvagotomy Diarrhea in Dogs
We hypothesized that motilin could be
responsible for postvagotomy diarrhea.
The premises were: (a) increased blood
levels of motilin have been reported in
vagotomized patients1 and (b) motilin
can facilitate diarrhea by one or many of
its described effects, which include
accelerated gastric emptying and intestiFrom the *Department o f Surgery and
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Montreal, Montreal, PQ
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nal transit speed, decreased small intesti
nal absorption and increased colonic
motor activity.
Five female mongrel dogs, equipped
with eight intestinal electrodes implanted
on a long-term basis, were studied before
and after bilateral truncal vagotomy
(without drainage). Observations made
for 2 months after vagotomy demon
strated that each dog had altered stool
habits (well-formed stools became loose
or frankly diarrheic). Vomiting was also
noted and was corrected by a liquid diet
(Ensure, Ross Laboratories, Montreal,
PQ).
Interdigestive motor complexes were
still observed after vagotomy. Phase III
of the interdigestive motor complexes was
always associated with a sharp rise in the
motilin level, and the interdigestive moti
lin blood levels were not altered by sec

tioning the vagi. During a 4-hour period
following a meal (100 g canned dog food),
motilin cyclic rises were abolished simi
larly in normal and vagotomized animals.■»
With a 2-hour infusion of regular insulin
<
(0.1 U/kg-h ■), motilin cyclic release was '
obliterated in three normal dogs, and the
response was not altered by vagotomy. *
We conclude that motilin release in the
ij
blood during the interdigestive and the
j
digestive states appears very weakly,*
dependent on vagal integrity in the dog,
j
and our results suggest that diarrhea *
observed after vagotomy is not due to
:
altered motilin blood levels.
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Cause and Noninvasive Detection of Recurrent Stenosis
after Carotid Endarterectomy
The frequency of recurrent stenosis after
carotid endarterectomy was studied in 105
patients followed up for a mean interval
o f 28 months. Noninvasive testing was
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done with oculopneum oplethysm o
graphy, which has proved highly accurate
in detecting significant carotid stenosis
(more than 25% narrowing). In 12
patients (11.5%), test results that were
norm al immediately postoperatively
became abnormal over periods ranging
from 3 months to 6 years; 5 patients
became symptomatic (2 of these subse
quently suffered a stroke) and the other
7 remained asymptomatic. The study also
documented progression of disease in the
contralateral carotid artery. Test results
converted from normal to abnormal in
seven patients (6.7%). Six of these sub
sequently underwent angiography and
carotid endarterectomy. A review of the
operative notes revealed that in more than
80% of patients who had recurrent ste
nosis, tacking sutures were used to secure

i

"

’

the distal end point. This suggests that the <
presence of these sutures or failure to
carry endarterectomy higher plays an
1
important role in the development of <
recurrent carotid stenosis.
A substantial incidence of advanced
restenosis was demonstrated following
carotid endarterectomy, with many *
changes occurring within the first 6
months after the procedure. These
patients are at substantial risk of stroke
in spite of having undergone operation.
Noninvasive testing will identify this
important subset of patients and allow
evaluation and treatment before symp- f
toms or stroke develop. We recommend
th at baseline studies be obtained
'
postoperatively and that repeat testing
take place in 6 months. If the findings are '
normal, annual follow-up is adequate.
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The Odontoid Process
Although odontoid-process fractures
account for 7% to 13% of all cervical
spine fractures, there is still controversy
‘'as to the best method of treating these
injuries. Rates of nonunion have been
given as low as 10% and as high as 80%.
v Since odontoid fractures may lead to
atlantoaxial instability with potential spi
nal cord injury, it is important to establish
atlantoaxial stability. Sound union is the
k most efficient way of achieving this.

4
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Because the parameters used for decid
ing operative or nonoperative treatment
depend on measurements of angles and
displacement, it was necessary to carry
out a study of the normal odontoid
process before examining our experience
with the treatment of this injury. Of 100
roentgenograms of normal odontoid
processes reviewed, 56% had a straight
posterior cortex, termed post shaped,
26% had an hourglass configuration, and
18% were capped, having an enlargement
at the apex. Of these three major types,
some were posteriorly angulated in the
lateral roentgenogram and others were
vertically oriented. Obviously, this large
discrepancy in normal configuration
makes measurements of angulation dif
ficult and unreliable.
An analysis of 48 cases of odontoid
fracture, classified according to the
method of Anderson and D’Alonzo1list
types, showed that there was a lack of
clear indications for open versus closed

treatment at our institution. The rate of
nonunion for nonoperatively treated type
II fractures was 20% and for type III
fractures 8%. On final analysis of the var
ious methods of treatment, the halo
jacket was concluded to be a satisfactory
method of treating the type II fractures.
Type III fractures heal adequately when
immobilized in some form of collar;
a Philadelphia-type collar is recom
mended. Finally, surgery, as a primary
treatment for odontoid fractures, should
be reserved only for selected cases such
as type II fractures with extremely wide
separation, large fracture gaps or inabil
ity to use a halo jacket because of other
medical, social or surgical considerations.
In addition, fusion is indicated in cases
of delayed or nonunion.
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Suture “Staying Power”: Absorbable versus Nonabsorbable
A simple clinical experiment was used to
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able and nonabsorbable sutures. Imbri
cation of the rectus sheath (plication of
the aponeurosis of external oblique mus
cle) forms an integral part of an
abdominoplasty. In 30 women, the rectus
abdominis diastasis ranged from 4 to 6
cm and was always greatest in the
hypogastric region. Three surgeons ran
domly used either 2-0 polyglycolic acid
sutures (15 patients) or 2-0 nylon sutures
(15 patients) for this part of the proce
dure. The margin of the folded sheath
was tagged on either side with pairs of
metal vascular clips at four levels and an
upright anteroposterior abdominal film
was obtained on postoperative day 2 and

repeated 6 months later. The distances
between the clips were recorded on both
occasions and compared.
Slight separation of the clips was
apparent 6 months after operation but
there was no significant difference
between the results in the two groups.
It is therefore concluded that, under the
conditions of this clinical experiment, 2-0
polyglycolic acid suture and 2-0 nylon
suture have similar “ holding” power and
this supports the thesis that the strength
of the wound depends on the amount of
scar tissue rather than the type of sutures
used.
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Photokeratopathy and Other Deleterious Effects
of Light on the Eye
There is increasing interest among
ophthalm ologists in the effects of
ultraviolet light and visible light on the
human eye. These effects have been
studied on the cornea, lens and retina in
residents o f N ew foundland and
Labrador.

Cornea
The cornea absorbs ultraviolet light
radiation below 300 nm, but transmits
most energy above that wavelength. Snow
blindness (acute photokeratitis) is known
to be caused by intense reflected solar
radiation in the ultraviolet region; in rab
bits, the peak sensitivity is at 288 nm .1 In
this condition the corneal epithelial cells
are disrupted but rapid replication of the
basal layer replaces the missing cells and
there is usually no permanent damage.
The “ flash burns” produced by arc weld
ing have the same etiology.
“ Labrador keratopathy” is a bilateral
acquired degeneration of the cornea that
is prevalent among the Inuit, Indians and
white settlers living in the isolated coastal
communities of Newfoundland and
Labrador.2 It involves only the exposed
interpalpebral band of the cornea.
Severely affected corneas have a hazy
appearance, resembling ground glass and
obscuring iris details. Microscopic exami
nation reveals numerous small “ droplets”
of amorphous material, believed to con
sist of altered proteins, deposited in Bow
m an’s membrane and the superficial
stroma3 (Fig. 1).
Labrador keratopathy increases in fre-

quency with age and the geographic dis
tribution shows a peak of both prevalence
and severity at latitudes 55° to 56° north.
The prevalence decreases north and south
of these latitudes. There is no genetic
predisposition and no apparent dietary
deficiency. The prevalence correlates well
with the total annual ultraviolet light radi
ation reflected from snow and ice.4
In the Newfoundland region, Arctic
marine conditions are carried further
south than anywhere else in the world.
Firm sea ice persists in the bays of
Labrador at latitudes 55° to 57° north
until late June, when the sun is at its
highest. It is postulated that the main
cause of keratopathy is ultraviolet light,
reflected from the snow and ice and
absorbed by the photosensitive amino
acids of plasma proteins known to diffuse
through the cornea under normal condi
tions. These proteins are then degraded
and deposited.
Lens
The lens of the human eye is a natural
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The rods and cones of the retina exhibit *
rhythmic shedding of their outer portions
where the cell membranes are arranged in
a series of discs; this is balanced by new
disc formation. Each rod forms 90 new
discs daily.5 The rhythm is controlled by -*
the cycle of night and day. It has been
suggested6 that prolonged exposure to
light or exposure to very bright light can
damage the retina in experimented animals 4
and in man. Modern operating microsco
pes employ high levels of illumination.7
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Retina

The effect of light, and in particular r
ultraviolet light, on the eye assumes
greater importance with the prediction v
that the ozone layer of the atmosphere is
:
being depleted by industrial pollution,
allowing a greater intensity of ultraviolet ^
light to penetrate to the earth’s surface.
i
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ultraviolet light filter and absorbs '*
ultraviolet radiation below 400 nm.
Therefore, it protects the retina by
absorbing the ultraviolet light that has^
passed through the cornea. It is believed
that ultraviolet radiation is responsible for
the yellow colour of the lens that develops
with age. Loss of the lens filter after -*
cataract removal may expose the retina
to ultraviolet radiation down to 300 nm
and this may predispose to macular
degeneration.

FIG. 1—Electron micrograph of cornea
from 79-year-old fisherman with Labrador
keratopathy shows junction of epithelium
(above) with Bowman’s membrane containing
rounded electron-dense deposits (below).
Deposit indenting base of epithelial cell is sur
rounded by basement membrane (reduced by
58% from x 3192 x 2).

3. JOHNSON GJ, OVERALL M: Histology of spheroidal dege
neration of the cornea in Labrador. Br J Ophthalmol 1978;
62: 53-61
4. J ohnson GJ: Aetiology of spheroidal degeneration of the
cornea in Labrador. Br J Ophthalmol 1981; 65: 270-83
5. YOUNG RW: The Bowman lecture, 1982. Biological
renewal. Applications to the eye. Trans Ophthalmol Soc ,
UK 1982; 102(pt 1): 42-75
*
6. LERMAN S (ed): Radiant Energy and the Eye, Macmillan,
New York, 1980: 203-11
7. T s’O MO, F ine BS, Z immerman LE: Photic maculopathy produced by the indirect ophthalmoscope. 1. Clini
cal and histopathologic study. A M J Ophthalmol 1972;
73: 686-99

VOLUME 27, NO. 5, SEPTEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

R ichard F inley, md , frcs[C]

Maintaining Body Protein in Catabolic Patients
Patients suffering from major traum a or
uncontrolled infection have a rapid and
progressive loss of body protein. Initially,
protein is lost from skeletal muscle to sup
ply amino acids to the viscera for
gluconeogenesis and the synthesis of
serum and structural protein that is essen
tial for survival. If the trauma is sustained
or the infection is uncontrolled, skeletal
muscle proteolysis continues at an exag
gerated rate. Eventually, muscle weakness
develops, leading to respiratory distress
and finally multiorgan failure and death.
The exact mechanisms controlling the
loss of body protein following trauma
and uncontrolled infection are unknown
but are of obvious clinical importance.
The major factors appear to be the degree
of sympathoadrenal response to injury,
the protein and caloric intake and the
level of muscular activity of the immobi
lized patient. Increased activity of the
sympathetic nervous system seems to play
a central role in regulating protein
metabolism following trauma by decreas
ing insulin secretion, causing peripheral
insulin resistance and stimulating gluca
gon secretion.1’2 When glucagon is
increased relative to insulin, there is an
increase in hepatic glucose and urea
production and in the extraction of amino
acids from the circulating blood with
resulting decreased arterial levels of
amino acids.3 This hypoaminoacidemia,
along with a relative decrease in the serum
insulin level, results in breakdown of mus
cle protein and an increased flux of amino
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acids from muscle. Septic and trauma
tized patients are often confined to bed
and receive a hypocaloric, protein-free
diet which only accentuates this muscle
atrophy.
At the University of Western Ontario,
we have studied skeletal muscle amino
acid metabolism in patients with severe
trauma or uncontrolled infection by
measuring the flux of amino acids from
forearm muscle. Forearm blood flow is
measured by venous occlusion capaci
tance plethysmography. A deep vein in
the antecubital fossa that drains the
forearm muscles is cannulated along with
the radial artery. Flux of amino acids and
substrates across the forearm skeletal
muscles is calculated by multiplying the
arterial venous difference by the forearm
blood flow. Total body nitrogen balances
are also carried out.
To study the effects of m ajor trauma
under controlled conditions, patients who
were to undergo total esophagectomy
were given an intravenous infusion of
amino acids, 75 g/m 2 and 6050 kJ/m 2,
daily for at least 5 days before opera
tion.4 The patients were studied preoperatively and were found to be in normal
nitrogen balance. Three days after oper
ation there was a negative nitrogen
balance o f 6 g/m 2 daily. This was
accompanied by increased muscle pro
teolysis (83%) as measured by 3-methylhistidine excretion and increased amino
acid nitrogen efflux (440%) from muscle.
This marked loss of protein from muscle
was accompanied by notable increases in
the circulating levels of glucagon (94%),
cortisol (44%), norepinephrine (113%)
and epinephrine (95%) and decreased
levels of circulating insulin (49%).
In the same group of patients, the addi
tion of insulin 5 U /h to the hyperalimen
tation solution doubled the circulating
levels of insulin and decreased the urinary
losses of nitrogen (25%), 3-methylhistidine (18%) and the efflux of amino
acid nitrogen from muscle (50%). We
concluded from these two studies that
trauma resulted in an obligatory loss of
amino acids from muscle to the viscera.
The combination of increased muscle
breakdown and decreased synthesis of

muscle protein probably accounted for
this loss of muscle protein. The addition
of insulin to the hyperalimentation solu
tion decreased but did not stop this loss
following trauma. Hyperglycemia per
sisted despite the addition o f this insulin
to the parenteral nutrition solution.
Patients suffering from severe traum a
or sepsis are often immobilized in bed
because they are lethargic, and may
require skeletal traction, tubes or mechan
ical ventilation. The effect of skeletal
muscle work in preventing loss of mus
cle protein in sepsis and burns was studied
in a rat model where tenotomy of the gas
trocnemius muscle results in hypertrophy
of the ipsilateral soleus and plantaris mus
cles under normal conditions. Three
groups of rats with gastrocnemius tenot
omy were studied. Ten rats had no other
injury; all had sham operation on the con
tralateral limb. Ten had full-thickness
burns of 25% of their surface area and
10 were made septic by cecal ligation and
perforation. Five days after tenotomy and
injury, the catabolic, septic and burned
rats showed hypertrophy of the soleus
and plantaris muscles of the tenotomized
limb compared with those of the other,
sham-operated extremity. We concluded
that in rats suffering from thermal injury
or uncontrolled intra-abdominal sepsis,
muscle work preserves muscle protein
despite total body weight loss. Using the
forearm model in catabolic patients, we
found that exercise was a stronger stimu
lus than insulin for maintaining skeletal
muscle protein. From these experiments,
exercise, within the limits of the patients’
cardiorespiratory reserve, may preserve
muscle protein mass in catabolic, septic
or burned patients.
Increased activity of the sympathetic
nervous system is thought to be the
primary mediator of the hypercatabolic
response to trauma and infection. We
have attempted to reproduce the trau 
matic state by infusing epinephrine,
glucagon and cortisol. Infusions of these
three counterregulatory hormones in
creases splanchnic glucose production
and amino acid loss from skeletal mus
cle. These catabolic effects appear to be
blocked by an infusion of propranolol.
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Baracos and associates5 have also
raised the possibility that prostaglandin
E2 may be responsible for increased mus
cle proteolysis in catabolic states. Cyclo
oxygenase inhibitors such as Aspirin and
indom ethacin, which interfere with
prostaglandin E2 synthesis, may decrease
the negative nitrogen balance of injured
and infected patients.
With our present knowledge of the
catabolic response to trauma and uncon
trolled infection, protein loss can be
minimized by maintaining an adequate
intake of protein and energy, by adding

insulin to the parenteral nutrition solu
tions and by exercising the patients within
their cardiorespiratory reserve to preserve
muscle mass and strength. However, it is
unlikely that body protein will be restored
during a catabolic illness until the shock
is treated, the infection is controlled and
the wound is healed.
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Perspective on Myocardial Protection: Cold and Nourished
Primum non nocere has been an elusive
goal in cardiac surgery. In order to
achieve a quiet, bloodless operative field,
anoxic cardiac arrest, chemical cardiople
gia, coronary perfusion and electrically
induced ventricular fibrillation were tried.
In the process, catastrophic lesions unique
to cardiac surgery were produced, such
as “ stone heart” and massive hemor
rhagic necrosis of the inner myocardial
mass. Less dramatic yet im portant
myocardial damage leading to impaired
postoperative ventricular function was
not uncommon.
The meeting of two paradigms, Koestler observed, often leads to a flash of
creative idea. Hypothermia, which slows
metabolism, and hyperkalemia, which
induces rapid flaccid paralysis of the
heart, were each pioneered by Bigelow,
Melrose and others more than 25 years
ago. These two ideas met in the early
1970s with the advent of hypothermic
potassium cardioplegia, which was a
major breakthrough in myocardial pro
tection during cardiac surgery. Infusion
of a solution containing 15 to 30 mmol/L
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of potassium through the aortic root leads
to rapid cessation of cardiac contractions,
conserving high-energy phosphates. Cold
infusate lowers the myocardial tempera
ture to below 15° to 20°C, markedly
retarding the progression of ischemic
damage.
Following an extensive review of clini
cal and experimental studies, Maloney
and Nelson1 deduced a time-temperature
diagram for various degrees of myocar
dial injuries; for example, for severe
ischemic damage, the least squares
method was used to derive the equation:
T = 11.6 + 19.8e 0 0073t (where T = time
and t = temperature). Although the clin
ical usefulness of such a formula has not
been verified in prospective studies, it
nevertheless stresses a crucial point,
namely that adequate hypothermia plays
a dominant role in protecting myocar
dium during cardioplegia as it is currently
practised.
In an earlier clinical study, we noted the
heterogeneity of myocardial cooling dur
ing cardioplegic infusion in the presence
of high-grade coronary artery occlu
sion.2 Monitoring of intramyocardial
temperature is important in detecting such
temperature gradients and the tendency
of the heart to rewarm, and we believe it
is useful as a guide for multidose cardi
oplegia. Copious supplementary topical
hypothermia, with particular attention to
cooling the often-neglected and ventrally
located right heart,3 as well as a cold
flush through the coronary vein grafts
after each distal anastomosis is com
pleted, were found to be effective in
achieving reliable myocardial hypother
mia. Experimentally4 and clinically,

retrograde coronary sinus perfusion with
cold cardioplegic solution had been
shown to provide uniform cooling in spite
o f coronary artery occlusion, and com
pared with the conventional antegrade
cardioplegia, it may have technical advan|
tages in aortic root operations, because
the infusion cannula is out of the opera1
tive field.
Numerous additives for the cardi\
oplegic solutions have been proposed to
i
augment protection, ranging from vari
ous cations, amino acids, oxygen-carrying
vehicles such as blood and fluorocarbons,
to calcium channel blocking agents.
'
Although such supplements are undoubt
j
edly of value, one cannot overemphasize
the importance of paying meticulous ,
attention to the technical details of
myocardial cooling, especially in the
(
presence of risk factors such as coronary
j
artery occlusion, ventricular hypertrophy 4 j
and prolonged aortic cross-clamping.
j
After all, isolated hearts have been cold
preserved for up to 24 hours followed by ^
successful replantation.
'
Some of the difficulties and controver
sies associated with cardioplegia may be
i
due to the persistence of some myocardial '*
perfusion during aortic cross-clamping.5
For example, in isolated heart prepara
tions in vitro, addition of a metabolic substrate, glucose, was found to be detrimental during cardioplegia,6 but the in-vivo
j
studies showed glucose to have salutary
j
effects.7 This discrepancy may be f
explained by the accumulation of anaero!
bic metabolites such as lactate in the isoy
lated hearts, while washout takes place in
'
vivo by the persistent noncoronary and
bronchial circulations.
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A nother interesting concept in
myocardial protection is the enhancement
of myocardial tolerance to ischemia
before aortic cross-clamping. Administraa tion of glucose-insulin-potassium solution
preoperatively and the cardioplegic induc
tion of warm glutamate blood before aor
tic cross-clamping8 are examples of such
an approach. In canine experiments, we
also confirmed that higher levels of exist
ing myocardial glycogen content rendered
^ the hearts less vulnerable to ischemic
insult.9 Our studies showed that a brief
period of fasting and other nutritional
manipulations can increase the myocar
dial glycogen content. Increasingly, acute
myocardial ischemia due to coronary
occlusion has been successfully reversed

with various catheter interventions,
including transluminal balloon dilatation
and intracoronary infusion o f vasodila
tor or thrombolytic agents. Thus, “ buy
ing time” by enhancing myocardial
resistance to ischemia may have therapeu
tic implications extending beyond cardiac
surgery.
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Short-term Storage of Articular Cartilage in Tissue Culture
Allotransplantation of intact articular
surfaces along with subjacent cortical and
cancellous bone is beginning to play an
important role in musculoskeletal recon
struction, but this approach is still res
tricted to carefully controlled clinical
trials. Shell or small-fragment osteochon
dral allografts have been used mainly for
resurfacing severely destroyed joint sur
faces secondary to trauma or osteonecror sis of the hip and knee in younger
patients.1'2 Large-fragment grafts are
used primarily to fill large osteochondral
gaps after en bloc tumour resection.1’3
An area of concern in osteochondral
allografts is maintaining viable articular
cartilage between the time the donor
y cadaver graft is procured and implanta
tion. These grafts are currently being
implanted as “ fresh” allografts, with
implantation within 24 to 72 hours1'2 or
after deep frozen storage with no storage
time limit.3 Providing a wide selection of
readily available segments stored in a deep
w frozen bone bank, while at the same time
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maintaining cartilage viability, requires
the use of cryopreservatives, such as
dimethylsulfoxide and glycerol, that are
toxic to cartilage. Investigations delineat
ing the optimal conditions and exposure
time of these toxic agents along with the
appropriate freezing and thawing rates
have improved the survival of whole
cartilage.3,4
Fresh osteochondral allografting
implies implantation as soon as possible
after harvesting from the cadaver donor
without the use of deep freezing. Immedi
ate transplantation would be the most
advantageous, but one must consider a
reasonable time period to call in recipients
and provide the opportunity for tissue
transport to other centres, either for fresh
transplantation or to centres that are
equipped to carry out cryopreservation.
Investigations into the short-term storage
of fresh osteochondral allografts should
logically utilize the study of tissue-culture
techniques. Adult articular cartilage is an
ideal tissue to maintain in culture medium
as nutrition in vivo occurs by nutrient
diffusion. Many investigations have used
isolated chondrocytes and slices of intact
articular cartilage but few have addressed
the problem of finding the most practi
cal method of banking osteochondral seg
ments in an unfrozen state to maintain
cartilage viability before allotransplanta
tion. Tissue culture of articular cartilage
slices demonstrates that general viability
can be maintained for many weeks.5
However, progressive proteoglycan

breakdown does occur, starting almost
immediately, and abnormal proteoglycan
subunits are produced.6 There is evi
dence that proteoglycan breakdown and
secondary increase in glycosaminoglycan
synthesis is initiated and maintained by
the release of proteolytic enzymes from
the chondrocytes.6 The use of a-tocopherol, a lysosome membrane stabilizer,7
and added free proteoglycan subunit in
the media6 may possibly maintain matrix
proteoglycan and decrease proteoglycan
turnover. However, what effect they may
have on cell viability is not known.
Another alternative to the problem of
matrix breakdown is to store the tissue
culture at low temperature. This tech
nique is well proven for viable storage of
blood components and other tissues.
Present short-term techniques for storing
osteochondral allografts use a balanced
salt solution at 4°C for 24 to 72 hours.1'2
Articular surfaces are reported to have
functioned for many years using trans
plants stored in this fashion, but the per
centage cell viability and the degree of
matrix breakdown is not known. The
results of studies on articular cartilage
slices kept in culture media at low tem
perature, using tissue from various animal
species, have ranged from survival up to
48 days with storage at 4°C8 to no sur
vival up to 48 hours9 and 7 days7 after
storage at 4°C.
We investigated the storage of full
thickness articular cartilage slices from
mature rabbits maintained in tissue cul-
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Dotabid

Tablets 250 and 500 mg
ANALGESIC/ANTI-INFLAMMATORY

ACTION
Dlflunisal is a non-steroidal drug with analgesic,
anti-inflammatory and antipyretic properties.
The precise mechanism of the analgesic and anti
inflammatory actions of diflunisal is not known, however
it appears to he a peripherally-acting analgesic drug
Diflunisal is a prostaglandin synthetase inhibitor.
In animals, prostaglandins sensitize afferent nerves and
potentiate the action of bradykinin in inducing pain.
Since prostaglandins are known to be among the
mediators of pain and inflammation, the mode of action
of diflunisal may be due in part to a decrease of
prostaglandins in peripheral tissues.
Pharmacokinetics and Metabolism
Diflunisal is rapidly and completely absorbed following
oral administration with peak plasma concentrations
occurring between 2 to 3 hours. The drug is excreted
in the urine as two soluble glucuronide conjugates
accounting for about 90% of the administered dose.
Little or no diflunisal is excreted in the feces. Diflunisal
appears in human milk in concentrations of 2 - 7 %
of those in plasma. More than 99% of diflunisal in
plasma is bound to proteins.
As is the case with salicylic acid, concentrationdependent pharmacokinetics prevail when diflunisal is
administered; a doubling of dosage produces a greater
than doubling of drug accumulation.
The effect becomes more apparent with repetitive doses.
Following single doses, peak plasma concentrations
of 41 ± 11 ^g/rnL (mean * S.D.) were observed
following 250 mg doses, 87 ■ 17 ^g/rnL were observed
following 500 mg and 124 -t 11 ^g/m L following single
1000 mg doses. However, following administration of
250 mg b.i.d., a mean peak level of 56 ± 14 Mg/m L
was observed on day 8. while the mean peak level after
500 mg b.i.d. for 11 days was 190 ± 33 ng/mL.
The plasma half-life of diflunisal is 8 to 12 hours.
Because of its long half-life and nonlinear pharma
cokinetics, several days are required for diflunisal plasma
levels to reach steady state following multiple doses.
For this reason, an initial loading dose is necessary to
shorten the time to reach steady state levels, and 2 to
3 days of observation are necessary for evaluating
changes in treatment regimens if a loading dose is
not used.

INDICATIONS AND CLINICAL USE
DOLOBID* is indicated for:
— relief of mild to moderate pain accompanied by
inflammation in conditions such as musculoskeletal
trauma, post-dental extraction or post-episiotomy
- symptomatic relief of osteoarthritis.
DOLOBID* has slow onset and long duration of action.
DOLOBID* produces significant analgesia in one
hour and maximum analgesia in 2-4 hours. Analgesic
effect lasts 8 to 12 hours. These characteristics
should be considered when prescribing this drug.

CONTRAINDICATIONS
Patients who are hypersensitive to this product.
Patients in whom acute asthmatic attacks, urticaria, or
rhinitis are precipitated by acetylsalicylic acid or other
non-steroidal anti-inflammatory drugs.
Patients with active peptic ulcer or any other active
inflammatory disease of the gastrointestinal tract.

WARNINGS
When DOLOBID* is given to patients with a history of upper
gastrointestinal tract disease, it should be given only after
consulting the CONTRAINDICATIONS and ADVERSE
REACTIONS sections and under close supervision.
Pregnancy
The safety of this drug in pregnancy has not been
established, and its use during pregnancy is therefore
not recommended.
A dose of 60 mg/kg/day of diflunisal (equivalent to two
times the maximum human dose) was maternotoxic,

embryotoxic, and teratogenic in rabbits. In three of
six studies in rabbits, evidence of teratogenicity was
observed at doses ranging from 40 to 50 mg/kg/day.
Teratology studies in mice, at doses up to 50 m g/kg/
day, and in rats at doses up to 100 mg/kg/day,
revealed no harm to the fetus due to diflunisal. ASA
and other salicylates have been shown to be teratogenic
in a wide variety of species, including the rat and
rabbit, at doses ranging from 50 to 400 mg/kg/day
(approximately one to eight times the human dose).
In rats at a dose of one and one-half times the maximum
human dose, there was an increase in the average length
of gestation. Similar increases in the length of gesta
tion have been observed with ASA, indomethacin, and
phenylbutazone, and may be related to inhibition of
prostaglandin synthetase. Drugs of this class may
cause dystocia and delayed parturition in pregnant
animals.
Because of the known effect of drugs of this class on
the human fetal cardiovascular system (closure of ductus
arteriosus), use during the third trimester of pregnancy
is not recommended.
Nursing Mothers
Diflunisal is excreted in human milk in concentrations
of 2 - 7 % of those in plasma. Because of the potential
for serious adverse reactions in nursing infants from
DOLOBID*, a decision should be made whether to
initiate nursing or to administer the drug, taking into
account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness in infants and children have
not been established, and use of the drug in children
below the age of 12 years is not recommended.
(See TOXICOLOGY.)

PRECAUTIONS
Effect on Platelet Function
As an inhibitor of prostaglandin synthetase, diflunisal
has a dose-related effect on platelet function and
bleeding time. In normal volunteers, 250 mg b.i.d. for
8 days had no effect on platelet function, and 500 mg
b.i.d., had a slight effect. At 1000 mg b.i.d., diflunisal
inhibited platelet function. In contrast to acetylsalicylic
acid these effects of diflunisal were reversible. Bleeding
time was not altered by a dose of 250 mg b.i.d., but
was slightly increased at 500 mg b.i.d. At 1000 mg
b.i.d., a greater increase occurred, but was not statisti
cally significantly different from the change in the
placebo group. Therefore, patients who may be adversely
affected should be carefully observed when DOLOBID*
is administered.
Effect on Fecal Blood Loss
When diflunisal was given to normal volunteers at
500 mg twice daily, fecal blood loss was not significantly
different from placebo. Diflunisal at 1000 mg twice
daily caused a statistically significant increase in
fecal blood loss.
Effect on the Kidneys
Since diflunisal is eliminated primarily by the kidneys,
patients with significantly impaired renal function and
the elderly should be closely monitored; a lower daily
dosage should be anticipated to avoid excessive drug
accumulation.
Uricosuric Effect
In normal volunteers, an increase in the renal clearance
of uric acid and a decrease in serum uric acid was
observed when diflunisal was administered at 500 mg
or 750 mg daily in divided doses. Patients on long
term therapy taking diflunisal at 500 mg to 1000 mg
daily in divided doses showed a prompt and consistent
reduction in mean serum uric acid levels, which were
lowered as much as 1.4 mg%. It is not known whether
diflunisal interferes with the activity of other uricosuric
agents.
Edema
Peripheral edema has been observed in some patients
taking DOLOBID*. DOLOBID* should be used with caution
in patients with compromised cardiac function, hyper
tension, or other conditions predisposing to fluid
retention.
Effect on the Liver
As with other non-steroidal anti-inflammatory drugs,
borderline elevations of one or more liver tests may

occur in up to 15% of patients. These abnormalities
may progress, may remain essentially unchanged, or
may be transient with continued therapy. The SGPT
(ALT) test is probably the most sensitive indicator of
liver dysfunction. Meaningful (3 times the upper limit of
normal) elevations of SGPT or SGOT (AST) occurred in
controlled clinical trials in less than 1% of patients.*
A patient with symptoms and/or signs suggesting liver
dysfunction, or in whom an abnormal liver test has
occurred, should be evaluated for evidence of the develop-"
ment of more severe hepatic reaction while on therapy,
with DOLOBID*. Severe hepatic reactions, including ^
jaundice and cases of fatal hepatitis, have been reported
with non-steroidal anti-inflammatory drugs. Although such
reactions are rare, if abnormal liver tests persist or
worsen, if clinical signs and symptoms consistent vflth
liver disease develop, or if systemic manifestations
occur (e.g„ eosinophilia, rash, etc.), DOLOBID* should ,
be discontinued.
Effect on the Eye
-«
Because of reports of adverse eye findings with agents
of this class, it is recommended that patients who
develop eye complaints during treatment with DOLOBID*
have ophthalmologic studies.
T
Antipyretic Activity
Diflunisal is not recommended for use as an antipyretic •
agent. In single 250 mg, 500 mg, or 750 mg doses,
diflunisal produced measurable but not clinically useful*
decreases in temperature in patients with fever; however,
the possibility that it may mask fever in some patients,
particularly with chronic or high doses, should be
considered.
„

Drug Interactions
Oral anticoagulants: In some normal volunteers, the
*
concomitant administration of DOLOBID* and warfarin
or acenocoumarol resulted in prolongation of prothrombiif
time. This may occur because diflunisal competitively
displaces coumarins from protein binding sites.
Accordingly, when DOLOBID* is administered with oral
anticoagulants, the prothrombin time should be closely
monitored during and for several days after concomitant
drug administration. Adjustment of dosage of oral -»
anticoagulants may be required.
i
Tolbutamide: In diabetic patients receiving DOLOBID* .
and tolbutamide, no significant effects were seen on
j
tolbutamide plasma levels or fasting blood glucose. ^
Hydrochlorothiazide: In normal volunteers, concomitant
administation of DOLOBID* and hydrochlorothiazide
resulted in significantly increased plasma levels of
hydrochlorothiazide. DOLOBID* decreased the hyper-T
uricemic effect of hydrochiorothiazide.
Furosemide: In normal volunteers, the concomitant
administration of DOLOBID* and furosemide had no Y
effect on the diuretic activity of furosemide. DOLOBID*
decreased the hyperuricemic effect of furosemide.
*
Antacids: Concomitant administration of antacids may
reduce plasma levels of DOLOBID*. This effect is small
with occasional doses of antacids, but may be clinically
significant when antacids are used on a continuous'
schedule.
j
Acetaminophen: Concomitant administration of DOLOBID*
and acetaminophen to normal volunteers resulted in
significantly increased plasma levels of acetaminophen*
Acetaminophen had no effect on plasma levels of
DOLOBID*.
Non-steroidal Anti-inflammatory Drugs
Since no clinical data are available about the safety*"
and effectiveness of DOLOBID* when used in combina
tion with other non-steroidal anti-inflammatory drugs, no recommendation for their concomitant use can be
>j
made. The following information was obtained from ■ *
studies in normal volunteers.
Acetylsalicylic acid: In normal volunteers, a small
decrease in diflunisal levels was observed when
;i
multiple doses of DOLOBID* and acetylsalicylic acid f
were administered concomitantly.
Indomethacin: The administration of diflunisal to
normal volunteers receiving indomethacin decreased
the renai clearance and significantly increased the
f.
plasma levels of indomethacin. Further, the combined ,
use of indomethacin and DOLOBID* has been associated1
with fatal gastrointestinal hemorrhage. Therefore,
indomethacin and DOLOBID* should not be used

evidence of permanent sequelae. The most common signs
and symptoms observed with overdosage were drowsi
ness, disorientation or stupor. A dose that is usually
fatal has not yet been identified.
In the event of overdosage, the stomach should be
emptied by inducing vomiting or by gastric lavage, and
the patient carefully observed and given symptomatic
and supportive treatment. Because of the high degree
of protein binding, hemodialysis may not be effective.

i concomitantly.
Sulindac: The concomitant administration of DOLOBID*
and sulindac in normal volunteers resulted in substantial
but not statistically significant lowering of the plasma
levels of the active sulindac sulfide metabolite.
Naproxen: The concomitant administration of DOLOBID*
a r t naproxen in normal volunteers had no effect on the
plasma levels of naproxen, but significantly decreased
the urinary excretion of naproxen and its glucuronide
metabolite. Naproxen had no effect on plasma levels of
JOLOBID*.

DOSAGE AND ADMINISTRATION
For mild to moderate pain, an initial dose of 1000 mg
followed by 500 mg every 12 hours is recommended
for most patients.
A lower dosage may be appropriate depending on such
factors as pain severity, patient response, weight, or
advanced age; for example, 500 mg initially, followed
by 250 mg every 12 hours.
For osteoarthritis, the suggested dosage range is
500 mg to 1000 mg daily in two divided doses
according to patient response.
Maintenance doses higher than 1000 mg a day are not
recommended.
DOLOBID* may be administered with water, milk or
meals. Tablets should be swallowed whole, not crushed
or chewed.

ADVERSE REACTIONS
The adverse reactions observed in controlled clinical
trial encompass observations in 2427 patients.
Listed below are the adverse reactions reported in the
1314 of these patients who received long-term
treatment. Five hundred thirteen patients were treated
for at least 24 weeks, 255 patients were treated for at
•feast 48 weeks, and 46 patients were treated for
96 weeks. Also listed are the adverse reactions reported
in 1113 patients who received short-term treatment
(one week or less).
y
PERCENTAGE INCIDENCE
SHORT-TERM LONG-TERM
TRIALS
TRIALS
GASTROINTESTINAL
Sastrointestinal pain
1.4
8.7
Dyspepsia
8.4
0.8
Nausea
4.3
6.5
Diarrhea
0.7
5.4
Vdtniting
1.9
2.1
Constipation
0.1
1.4
LFlatulence
0.1
1.4
Anorexia
0.0
0.7
Eructation
0.2
0.3
Gastrointestinal bleeding
0.1
0.3
; Peptic ulcer
0.0
0.1
DERMATOLOGIC
Rash
0.3
4.0
Pruritis
0.1
1.0
Sweating
0.4
0.8
Stomatitis
0.0
0.8
. Dry mucous membranes
0.3
0.6
CENTRAL NERVOUS SYSTEM
.Headache
3.0
3.7
Dizziness
3.5
2.1
Somnolence
3.9
1.6
Tinnitus
0.4
1.4
Insomnia
0.2
1.1
Vertigo
0.1
0.9
Nervousness
0.7
0.3
Y OTHER
Tatigue/Tiredness
1.1
0.6
Edema
0.0
0.8
Asthenia
0.4
0.6

CAUSAL RELATIONSHIP UNKNOWN
Other reactions have been reported in clinical trials or
since the drug was marketed abroad, but occurred under
circumstances where a causal relationship could not be
established. However, in these rarely reported events,
that possibility cannot be excluded. Therefore, these
observations are listed to serve as alerting information
' to physicians.
DERMATOLOGIC: erythema multiforme and StevensJ)*hnson Syndrome.
RESPIRATORY: dyspnea.
- CARDIOVASCULAR: palpitation, syncope.
SPECIAL SENSES: transient visual disturbances.
NERVOUS SYSTEM: paresthesias
MUSCULOSKELETAL: muscle cramps.

r

r

PSYCHIATRIC: depression.
GENITOURINARY: dysuria.
MISCELLANEOUS: chest pain, fever, malaise, cholestatic
jaundice, hypersensitivity (including interstitial nephritis
' with renal failure), anaphylactic reaction with
bronchospasm.

' sym ptom s

and treatm ent

i OF overdosage
I Cases of overdosage have occurred and deaths have
been reported. Most patients recovered without

AVAILABILITY
Tablets DOLOBID* are capsule-shaped, film-coated
tablets supplied as follows:
8891X — 250 mg, peach coloured, coded DOLOBID on
one side, supplied in bottles of 60 tablets.
8 9 4 7 -5 0 0 mg, orange coloured, coded DOLOBID on
one side, supplied in bottles of 60 tablets.
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ture for a maximum of 72 hours at low
temperatures. At 37°C, explants showed
sequential, significant increases (p <
0.05) in the incorporation of radioactive
sulfate into the sulfated glycosaminoglycans after storage from 24 to 72 hours.
This pattern is well known and indicates
a response to proteoglycan breakdown.6
Explants stored at 4°C maintain sup
pressed levels of sulfate incorporation
(when labelled at 37°C) but maintain
values throughout the 72-hour storage
equivalent to control slices labelled with
isotope immediately upon harvesting
from the femoral condyles. Slice explants
stored at constant 4°C from 12 to 48
hours and then rewarmed to 37°C for the
final 12 or 24 hours respond to the sup
pressed uptake levels with substantially
increased sulfate incorporation (p <
0.05). These results seem to indicate that
articular cartilage can survive storage at
low temperatures for a “ practical” period
of at least 48 to 72 hours and that the sup
pression of proteoglycan turnover
appears to be reversible.
The optimal conditions for short-term
storage of fresh osteochondral allografts
to maintain viable and healthy articular
cartilage between the critical period of
donor procurement and implantation are
not yet established. Likewise, cryopreservation techniques for long-term storage
are still evolving. Continued research in
these and other areas concerned with
osteochondral allotransplantation should
expand the scope of this promising area
of joint reconstruction.
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Enterobacter sp., Pseudomonas aeruginosa, indole-positive Proteus sp., Proteus mirabilis, Bacteroides sp., including
B. fragilis, anaerobic cocci and enterococci.
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to other drugs, with appropriate adjustment of dosage (See DOSAGE).
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DOSAGE AND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously by injec
tion or infusion. Dosage and route of administration should be determined by the severity of the infection and
condition of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a 20 to 30
minute infusion administered intravenously.
The maximum daily dose usually administered to adults is 24 g/day, although higher doses have been used.

DOSAGE
Usual Total
Daily Dosage

Type of Infection
Serious infections such as septicemia, nosocomial pneumonia, intra abdominal infections, aerobic and anaerobic gynecologic infections,
and skin soft-tissue infections.
Complicated urinary tract infections.
Uncomplicated urinary tract infections and most community-acquired
pneumonia.
Uncomplicated gonococcal urethritis.

12-18 g I.V.
(200-300 mg/kg)

Frequency 1
Administrat
Every 4 to
6 hours

8-16 g I.V.
(125-200 mg/kg)
6-8 g I.M. or I.V.
(100-125 mg/kg)
2 g I.M*

Every 6 to
8 hours
Every 6 t£,
12 h o u r#
Single dose

*0 ne gram of probenecid given orally 1/2 hour prior to injection.
Dosage In Renal Impairment
Urinary Tract
Creatinine
Urinary Tract
Clearance
Infection
Infection
(complicated)
mL/min.
(uncomplicated)

Serious Systemic
Infection

>4 0
20-40

9 g/day 3 g every 8 hrs.

12 g/day 4 g every 8 hrs.

6 g/day 3 g every 12hrs.

8 g/day 4 g every iSAirs.

^

No dosage adjustment necessary

<2 0

No dosage adjustment necessary
6 g/day 3 g every 12 hrs.

Patients on
Hemodialysis*

•Hemodialysis removes 30-50% of piperacillin in 4 hours;
6 g/day 2 g every 8 hrs.
1 g additional dose should be administered following each dialysis period.

For patients with renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* will provic
additional guidance for adjusting dosage.
Infants and Children - Dosages in infants and children under 12 years of age have not been established
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in v
it is from 3 to 10 days; the duration should be guided by the patient’s clinical and bacteriological progress. For
acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptc
matic. Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 days
reduce the risk of rheumatic fever of glomerulonephritis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular administration of 6 to 8 g. da
of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for m:
nance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin so
treatment. Administration should not exceed 2 g. per injection at any one site.This route has been used prima
the treatment of patients with uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12Years of Age: The reconstituted solution is given by deep intramuscular injection. T
preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also may be given
mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and then only with cautii
to avoid radial nerve injury. Intramuscular injection should not be made into the lower or mid-third of the upp>
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted with 5 mL of suitable diluent listecfbelc
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein irrit
The reconstituted and diluted solution may be administered by intermittent or continuous drip. Intermittent inf
should be administered over a period of about 30 minutes. During intermittent infusion it is desirable to disco'
the primary intravenous solution. Any unused portion must be discarded. For continuous infusion the so iu ti#
be administered over a longer period of time.
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for Injection, or if required
‘ Bacteriostatic Water for Injection,
**Lidocaine HC1 0.5 or 1% (without epinephrine) - For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required,
‘ Bacteriostatic Water for Injection.
‘ Either parabens or benzyl alcohol.
**Lidocaine HC1 is contraindicated in patients with a known history of hypersensitivity to local anesthetic
the amide type.
RECONSTITUTION TABLE
Product
Size

VOLUME OF
Diluent to be added

Approximate
Available Volume

Vials 2 g
3g

4.0 mL
6.0 mL
7.8 mL

5.0 mL
7.5 mL
10.0 mL

15 mL
20 mL

17 mL
23 mL

4g

Infusion Bottles
3g

Approximate
Average Concentrat
1 g/2.5 mL
1 g/2.5 mL
1 g/2.5 mL

The prepared solution may be further diluted to the desired volume with any of the solutions for intravem
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag contain
any of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Admixtures:
Intravenous Solutions:
Normal Saline (+KCL 40 mEq).
5% Dextrose in Water [D5W]
0.9% Sodium Chloride (Normal Saline) [NS].
5% Dextrose/Water [D5W] (+KCL 40 mEq).
Dextrose 5% and 0.9% Sodium Chloride [D5NS].
5% Dextrose/Normal Saline [D5NS] (+($CL
Lactated Ringer’s Injection, U.S.P.
Ringer’s Injection, U.S.P. (+KCL 40 mEq;.
Dextran 6% in 0.9% Sodium Chloride.
Lactated Ringer's Injection, U.S.P. (+KCL 40
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted with reco;
mended diluents and further diluted with the indicated intravenous solution and intravenous admixtures.
Stability studies have demonstrated chemical stability (pH, potency and clarity) through 24 hours at rot
temperature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recGj|
mends discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated. 1
as a multi-dose container, the vials must be reconstituted only with the bacteriostatic diluents noted above
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous administrate*
solutions containing sodium bicarbonate
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently with aminoglycosides, it is recommended that both drugs braised
therapeutic doses, but administered separately. PIPRACIL* should not be mixed with an aminoglycoside in a
syringe or infusion bottle, since this can result in inactivation of the aminoglycoside.
DOSAGE FORMS: PIPRACIL* (sterile, lyophilized piperacillin sodium) is available in vials containing amounts of "*
cillin sodium equivalent to 2,3 and 4 grams of piperacillin. Available in boxes of 12 vials.
Product Numbers: 2 g /v ia l-3879-48 3 g/vial- 3882-49 4 g/vial - 3880-50
Available in 100 mL size infusion ("piggyback”) bottles, containing sterile, freeze-dried piperacillin sod!
powder equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles.
Product Numbers: 3 g/bottles - 3882 -41 4 g/bottles -3880-42
Piperacillin Sensitivity Discs impregnated with 100 ug of piperacillin are also available.
Storage:
PIPRACIL* vials and infusion bottles should be stored at controlled room temperatures of 15-30°C ($0-8(
Piperacillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on reques
'PIPRACIL is a trade mark of Lederle Piperacillin, Inc.

C Y A N A M ID C A N A D A INC.
Toronto

r

SYMPOSIUM ON TRAUMA
C.M. Burns, md, frcsic]

1. Surgery in the Resuscitation of Critically Injured Patients
immediate surgery is essential to resusci
tate and save 5 % to 1 0 % of those
v suffering life-threatening trauma.
Recently, emergency room surgery has
been proposed as the procedure to fol
low in stabilizing such patients.
Over a 3-year period, 41 moribund
^patients were treated by the trauma
service at the Health Sciences Centre in
K Winnipeg. All were managed in the main
operating theatre following a "crash pro
tocol" for immediate surgery. Tw entythree patients arrived in cardiac arrest or
with an unrecordable blood pressure; of
these, 4 (1 7 % ) survived. Eighteen
patients had a blood pressure of 70 mm
*4g systolic or less and failed to respond
to massive 0 positive blood transfusion;
r of these, 14 (7 7 % ) survived.
The mix of mode of injury and injury
severity scoring is important to compare
results from within and between centres.
The author's experience indicates that
^the use of a high-priority crash protocol
for managing moribund patients with lifey. threatening traumatic injury in the main
operating room provides a standard of
care equal to or better than that reported
for emergency room surgery.

r

^Une intervention chirurgicale immediate
est essentielle pour reanimer et sauver la
vie de 5 % a 1 0 % de ceux qui subissent
un traumatisme menacant le pronostic
vital. Recemment, on a propose la chirur-
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gie en salle d'urgence comme mesure a
suivre pour stabiliser ces patients.
En 3 ans, 41 patients moribonds ont
ete traites au service des traumatises du
Centre des sciences de la sante de Win
nipeg. Tous ont ete traites a la salle
d'operation selon un protocole d'urgence
pour chirurgie immediate. Vingt-trois
patients furent recu en arret cardiaque
ou avec une tension arterielle impercepti
ble; parmi ceux-ci, 4 (1 7 % ) ont survecu.
Dix-huit patients avaient une tension
systolique interieure ou 6gale a 70 mm
de Hg qui ne reagit pas a la transfusion
massive de sang O positif; 14 d’entreeux (7 7 % ) ont survecu.
Afin de comparer les resultats obtenus
a I'interieur de ou entre chaque centre, il
est important d'associer revaluation des
types de blessures et une echelle
depreciation de la gravite des
blessures.
L'experience des auteurs indique que
I'emploi dans la salle d'operation d'un
protocole d'urgence pour la prise en
charge des patients moribonds victimes
de traumatismes menacant le pronostic
vital assure une norme de soin au moins
egale a celle qui est signalee pour la chi
rurgie en salle d'urgence.

Over the past 10 years, numerous reports
have recommended thoracotomy in the
emergency room to resuscitate and estab
lish an effective core circulation in the
moribund patient. Such a policy may be
appropriate in an institution that has a
fully equipped operating room in the
emergency department with stand-by per
sonnel including trained surgeons,1-6 but
these ideal circumstances exist in very few
hospitals. Thoracotomy performed in
less-sophisticated emergency departments
could produce disastrous results.
How Do We Organize to Save Lives?
The staff on the trauma service at the
Health Sciences Centre in Winnipeg fol
low the guidelines of a “crash protocol”
for the management of the patient arriv

ing moribund, secondary to severe shock
and blood loss (Table I). The status of the
patient is recognized immediately on arri
val. Cardiopulmonary resuscitation and
mechanical ventilation are carried out and
massive transfusions are given immedia
tely. The status of circulation, ventilation
and renal function are monitored on
the electrocardiogram, by blood-gas anal
ysis, and by measurement of urine out
put and central pressures. Four-cavity
intubation identifies the site or sites of
hemorrhage.
Within 20 minutes of arrival, the
patient is transferred to the wellequipped, well-staffed emergency theatre
in the main operating room. Operative
and general resuscitative action is taken
immediately. Hemorrhage is controlled
and homeostasis achieved. Only after the
patients’s condition has stabilized is
definitive surgery performed.
Immediate Resuscitation
The resuscitation room is fully
equipped with intravenous lines and O
positive blood is hanging ready for use.
Military antishock trousers (MAST) are
open on the resuscitation table. Person
nel include trauma service staff who per
form resuscitation and investigation, the
emergency physician who establishes and
maintains an airway, three resuscitation
nurses, and radiology and laboratory
technicians. These people are fully trained
for their particular jobs, are available
immediately, or, when warned in
advance, are on stand by.
Cardiopulmonary resuscitation is be
gun by establishing an endotracheal air
way and using manual positive-pressure
Table 1-Criteria for Introducing
the Crash Protocol
Cardiac arrest with effective cardiopulmonary
resuscitation
Arrival with a blood pressure of 0 mm Hg
Arrival with a systolic blood pressure of
70 mm Hg, dropping despite transfusion
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ventilation. One of the three resuscitation
nurses establishes two large-bore transfu
sion lines and initiates normal saline and
albumin transfusion followed with O
positive blood as rapidly as pressure
transfusion will permit. Fresh frozen
plasma and platelets are given every five
units. This supplement is usually given
after the patient has been transferred to
the operating room. Urinary catheteriza
tion is carried out and MAST are applied
by the second nurse; the third nurse
records all data, dispatches samples and
orders outgoing calls. Radiology and
laboratory technicians are available for
immediate investigations if time permits.
Investigation

Investigation is kept to the minimum.
A large sample of blood is taken when
intravenous transfusion lines are estab
lished. This sample is sent for measure
ment of electrolyte, blood gas, urea nitro
gen, creatinine and sugar levels and for
grouping and matching.
Four-Cavity Intubation Is the Definitive
Investigation

The trauma service staff immediately
insert intercostal chest tubes (no. 28 to 32
French) in the right and left chest cavi
ties using local anesthesia. Separate
underwater-seal drains collect each
pleural cavity effluent for measurement.
A peritoneal dialysis catheter is inserted
into the abdominal cavity to perform
standard abdominal lavage. If immediate
aspiration produces frank blood, the
procedure is considered positive. If no
blood is obtained on aspiration, then 1000
mL of normal saline is introduced into the
abdominal cavity and abdominal lavage
is performed.
The fourth cavity, the pericardial sac,
is intubated if the nature of the injury,
such as a central penetrating chest wound,
is associated with the signs of Boeck’s
triad (shock with a narrowed pulse pres
sure, distended jugular veins and distant
heart sounds in the absence of a left ten
sion pneumothorax).
The cavities with major blood loss are
identified and this serves as a guide to
appropriate planning of operation to
arrest hemorrhage.
Roentgenography of the chest, abdo
men and cervical spine, combined oneshot intravenous pyelography and cysto
graphy are performed only if time per
mits. These procedures, along with
monitoring of basic functions, can be
accomplished within 10 to 15 minutes by
the well-trained emergency room and
trauma service staff.
Our goal is to prevent the death of any
patient arriving in the emergency depart
ment with detectable signs of life.
46 2

Operative Procedures as an Integral Part
of Resuscitation

The emergency theatre in the main
operating suite is available at all times
with prepared bundles for any surgical
procedure. If another emergency proce
dure is under way, the elective slate is
interrupted. Since there are 10 to 17
theatres servicing the elective slate, one
room is invariably available with a mini
mum of delay. The operating room is
given advance notification of a potential
emergency.
The patient is transferred at the 10- to
15-minute point by the resuscitation team
which moves with the patient into the
operating room and continues resuscita
tion. Transition of responsibility occurs
as rapidly as possible, allowing the oper
ating room staff time to complete the
preparation for operation. Two anes
thetists and the operating room staff
maintain the general resuscitation; the
trauma service staff proceed with the
operative procedure to control hemor
rhage.
The appropriate operative procedure is
begun regardless of the patient’s circula
tory status. The guide to the surgical
approach is provided by the result of
four-cavity intubation (Table II).
A Hemodynamics Cell Saver III is used
for autotransfusion; it is responsible for
saving lives as well as cells. The aorta may
be occluded or compressed in the chest
or abdomen to support resuscitation of
the core circulation in the patient suffer
ing cardiac arrest. It may be occluded to
permit the time necessary to evacuate
massive hemoperitoneum, to identify the
site of blood loss or to prevent a hypoten
sive crisis on opening the abdomen.7-10
Massive hemorrhage from the liver is
controlled by compression, a bleeding
spleen by direct clamping of the splenic

Table 11-General Guide to Surgical Approach
to Resuscitation
Control of major blood loss
Posterolateral thoracotomy for unilateral
chest bleeding (2 L + continuing loss)
Sternal split for cardiac or great-vessel injury
Midline incision from xiphisternum to pubis,
for abdominal bleeding
Extended abdominal incision through sternum
and right interspace 5 for liver or hepatic
vein injury
Resuscitation
Compression to control bleeding
Use of cell saver, bank blood, platelets and
fresh frozen plasma
Definitive treatment
After patient is stabilized
Craniotomy
Simultaneously or immediately following
resuscitative surgery
Computerized tomography (after patient is
stabilized)

pedicle. Mesenteric hemorrhage is
arrested by ligation at the bleeding point.
Cardiac, major mediastinal vessel, hilat^
and lung hemorrhage may be controlled
by using noncrushing clamps or by com- 4pression. Intercostal chest-wall bleeding
may be stopped by whip stitching, elec
trocautery or direct pressure. It may be
necessary later to have direct access to
intercostal bleeding through a separate^
minithoracotomy at the intercostal space
involved.
^
The basic principle followed is to con
trol hemorrhage by the simplest, quick
est measure possible and delay definitive
surgical control until resuscitative meas- ^
ures have stabilized the patient’s condi
tion and achieved homeostasis. Only then*
is definitive surgery performed.
Craniotomy is usually delayed until
major hemorrhage is controlled. On occa
sion craniotomy has been performed for
massive extradural hemorrhage simul- -t
taneously with other procedures. The
value of early craniotomy for intracranial
hematoma has been described by Seelig
and associates11 and others.12
Our Experience

From January 1980 to December 1982,
on the Trauma Service at the Health
Sciences Centre, Winnipeg we treated
41 moribund patients. Twenty-three*
died.

FIG. 1—Age and mortality. Of 70% who
were under 40 years of age, 50% survived, but
of 30% who were older than 40 years, only
30% survived. Hatched bars = deaths, white
bars = survivors.

FIG. 2—Injury severity score and survival
in 31 patients with blunt injuries. Hatched
bars = deaths, white bars = survivors.
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Seventy percent of our 41 patients were
under the age of 40 years; 50% survived.
^Of those over the age of 40 years, 30%
survived (Fig. 1). Youth obviously
►favours survival. It is heavily represented
in multiple trauma.
k
On admission, 12 of the 41 patients had
cardiac arrest; 2 of these survived. In 11
others, the blood pressure could not be
^measured; again, 2 survived. The other
r18 patients had a blood pressure which
^ dropped below 70 mm Hg systolic; 14 of
these patients (77%) survived. These findi
ings compare favourably with reports of
emergency room thoracotomy and also
► with reports describing similar injury
severity.1-5
y Fig. 2 analyses the injury severity score
(ISS) distribution in 31 patients with blunt
” injuries; the deaths and survivals are
shown in each category. Of 16 patients
with an ISS of 50 or greater, 2 (12.5%)
v
survived. Fifteen patients had an ISS of
less than 50; of these, 11 (73%) survived.
>The seven patients with an ISS of 20 to
29 had an undue delay between injury and
k arrival at hospital. In several instances the
patient had been taken to an inappropri
ate hospital before transfer to the Win^ nipeg Health Sciences Centre.
All of the 10 patients with penetrating
injuries (Table III) had at least one
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abbreviated injury score (AIS) of 5. Five
of these patients died. The results com
pare favourably with those reported in the
literature.
We recommend the adoption of errorfree computer scoring of injury severity,
which minimizes human error and bias.
It is essential that uniform AIS and ISS
scoring methods be adopted and im
proved for meaningful comparison of
results from one period to another, or for
comparison of experience of one institu
tion with that of another. Our trauma
registry uses a computer algorithm to
score all accident injuries at every hospi
tal within the Province of Manitoba.
Table IV lists multiple organ injuries
by body region and shows the importance
of four-cavity intubation. Without it, one
cavity may be explored and hemorrhage
controlled, while bleeding in another
body cavity leads to death. Note the
preponderance of serious injuries in the
abdomen but also the large number of
life-threatening injuries in other body
cavities.
There were 75 skeletal injuries,
emphasizing the severity of total body
trauma. Our experience has led us to per
form immediate internal fixation of longbone fractures to enable early mobiliza
tion. This has been particularly valuable
in patients with head injury and lung
contusion.
Of the 17 cases of head injury, 15 died
and 2 survived, an 88% mortality. Five
of the 15 died in the operating room, 8
within 1 day and 2 in 2 to 4 days.
Review of all patients admitted to the
trauma service showed that the mortal
ity of those with a single head injury of
similar severity without shock was 21%
while in those suffering head injury of
similar severity without prolonged shock
but with multiple injuries the mortality
was 64%. The 88% mortality in patients
suffering additional hypotension and
poor cerebral perfusion supports the pri
ority of establishing circulatory and ven
tilatory homeostasis first and then deal
ing with the specific head injury without
delay.11
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The results obtained in a series of 41
patients over a 3-year period who were
moribund with multiple injuries and
hemorrhagic shock when admitted to our
hospital compare favourably with those
reporting emergency room thoracotomy.
The crash protocol system is suited to
Canadian hospital resources. The results
justify the tremendous effort and dedica
tion provided by an organized trauma
service program composed of highly
trained and dedicated nursing, house and
attending staff.
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2. Le syndrome de la ceinture de securite:
une pathologie abdominale nouvelle
V

De janvier 1976 a decembre 1980, 43
accidentds de la route qui portaient une
ceinture de s£curit6 furent traites a
I'Hopital du Sacre-Coeur de Montreal.
Trente-sept de ces patients presentaient
des signes et symptomes de traumatisme
abdominal relics au port de la ceinture de
s£curit6 et furent op£res. On nota une
incidence anormalement elevee de
lesions gastro-intestinales chez ces
patients. Trente-deux d'entre-eux montraient des atteintes de I'intestin ou du
m6sent6re. Cet eventail different de
I6si6ns est le plus probablement relie aux
effets de la deceleration brutale causee
par la ceinture e trois points d'attache.
Between January 1976 and December
1980, 43 patients involved in automobile
accidents while wearing passive
restraints were treated at I'Hopital du
Sacre-Coeur in Montreal. Thirty-seven
showed signs of abdominal trauma and
were operated upon. There was a stri
kingly high incidence of gastrointestinal
injury. Thirty-two of the 37 had injury to
the bowel or its mesentery. This spec
trum of injury is most likely related to
the rapid deceleration caused by the
restraint with the three-point harness.

Des 1955, plusieurs marques d’automobile offraient en option les effets benefiques de la ceinture de securite. II s’agissait alors de la ceinture ventrale. En 1968,
De 1‘Unite de Traumatologie,
Hopital du Sacre-Coeur, Montreal, PQ
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cette derniere fut amelioree par l’ajout
d’un baudrier. L ’installation des ceintures ventrales devint obligatoire aux EtatsUnis en 1964 (documentation non publiee) et c’est en 1973 que la ceinture a
trois points d ’attache fut standardisee. II
fallut attendre en 1971 pour que la loi
federate canadienne emboTte le pas a l’initiative americaine.
En 1967, la compagnie Volvo de Suede
patronnait une etude sur l’efficacite de la
ceinture a trois points; 28 780 accidents
impliquant 37 511 passagers avant furent
examines. Cette etude a demontre que,
sans ceinture, on retrouvait des accidents
mortels a des vitesses aussi basses que 19
km /h.1 Avec le port de la ceinture, il n’y
eut aucun accident mortel a des vitesses
inferieures a 95 km /h. De plus, on nota
une diminution des blessures graves de
40% a 90% selon la vitesse lors de l’accident. Le port de la ceinture a trois points
d’attache, en diminuant la force d’impact
de 92%, a fait chuter de plus de 50% la
mortalite routiere. D’autre part, il semble bien que le port de la ceinture de secu
rite peut avoir grandement modifie la
nature des lesions auxquelles le chirurgien
a a faire face.2'6
Le but de cette etude est de definer ce
nouveau type de lesion de deceleration
et d’en evaluer les mecanismes de produc
tion.

Etude clinique et resultats
Du ler janvier 1976 au 31 decembre
1980, 382 patients ont ete traites a l’Unite

de Traumatologie de I’Hopital du Sacre- -r
Coeur pour traumatisme abdominal. De
ce nombre, on a pu affirmer avec certi
tude que 43 (25 hommes et 18 femmes,
j
age moyen de 21.6 ans [10 a 67 ans]) por- <
taient leur ceinture au moment de^
j
l’impact: 12 portaient la ceinture a trois
points, 8 la ceinture horizontale et le type „
de ceinture n’a pu etre precise pour les 23
autres. Trente-sept des 43 patients ont
»
subi une laparotomie. D ’apres le seul
tableau clinique, 13 furent operes A
d ’emblee. Vingt-six subirent un lavage
peritoneal diagnostique. Celui-ci fut posi;
tif pour 21, negatif pour 3 et douteux
;
pour 2 patients.
|
Le denominateur commun de cette ^
serie se revela etre le nombre extremement
eleve de lesions du tube digestif. Trentedeux des 37 operes, soit 86.5%, presen
taient des lesions soit de I’intestin soit du ■*
mesentere. On notait des lesions des
mesenteres, des ischemies, contusions et*
eraillures des parois, des perforations ou
sections de I’intestin, et enfin un arrachement complet de l’appendice (tableau I).
Seize de ces 32 patients (50%) souffraient
de lesions intestinales multiples.
y
Les tableaux II et III nous montrent
l’ample variete de lesions associees des*
differents systemes chez ces patients.
!
Quatre des 43 patients decederent, 2 de *
condition neurologique depassee et 2 de
complications directement reliees a leur
pathologie (choc septique et choc <
hypovolemique).
[
L ’appreciation des lesions des patientsde cette serie fut faite d’apres l’echelle de
j
severite des lesions (Abbreviated Injury •"

Tableau -Lesions du tube digestif
Type de
lesion
Contusion
Paroi
Ischemie
Perforation/section
Laceration mesos
Hematome mesos

Duodenum
2
—

3
—

—

Intestin
5
4
5
10
16
7

Colon
3
6
7
5
4
5

Appendice

_
—
—

1
—
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Scale, 1980) publiee par PAmerican Asso
ciation for Automotive Medicine (tableau
MV).7 Quarante patients ages de 0 a 49
r ans presentaient une cote (Injury Severity
Score) moyenne de 23.6 (valeurs extremes
de 1 a 38) et 3 patients ages de 50 a 69
ans presentaient une cotre moyenne de
38.7 (entre 25 et 50). Ces chiffres furent
incorpores sur les courbes de Baker afin
de comparer les taux de m ortalite.8,9 On
^peut constater (tableau V) que pour le
groupe de patients de 0 a 49 ans, le pour-
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centage de deces (7.5%) concorde avec la
moyenne de probabilite de letalite pour
Page (8%). Le nombre de patients ages
de 50 a 69 ans etant tres faible les resultats
pour ce groupe ne sont pas significatifs.
Discussion
Le port de la ceinture de securite a
effectivement reduit le taux de mortalite
et de morbidite des accidents de la route.
L ’etude de la compagnie Volvo a bien
demontre que le port de la ceinture a trois
points d’attache previent les blessures
mortelles a des vitesses allant jusqu’a 95
km /h.5 La ceinture ventrale peut proteger l’occupant de Tautomobile en empechant Tejection hors du vehicule mais ne
Pempeche toutefois pas completement de
heurter les structures internes de Pauto
mobile. L ’addition du baudrier augmente
done Pefficacite de la ceinture ventrale en
empechant cette “ seconde collision” .6
La ceinture de securite a amene une
diminution du nombre des lesions faciales et craniennes, des atteintes des organes pleins de Pabdomen et des fractures
des os longs.
Avant le port de la ceinture de securite,
la majorite des lesions traumatiques fermees de Pabdomen impliquait les organes pleins. Jordan et Beall10 rapporterent, en 1971, un taux de 61% d ’atteintes
du foie et de la rate pour 28% de lesions
du tube digestif.
En comparaison, notre serie revele
86.5% de lesions gastro-intestinales.
De 1976 a 1980, a l’Hopital du SacreCoeur, 59 patients furent traites pour
traumatisme hepatique, 18 montrant des
lesions majeures et 41 des lesions mineures. II est a noter qu’aucun patient porteur de ceinture de securite n’a presente
de traumatisme hepatique majeur. Actuellement, on note done une incidence
beaucoup plus elevee de lesions des visceres creux de Pabdomen, lesions qui peuvent etre letales et plus difficiles a diagnostiquer.

Les causes de ces lesions sont sans
doute reliees a une augmentation soudaine de la pression intraluminale ou a
une traction brutale exercee sur les mesos
ou sur les attaches ligamentaires, lors de
la deceleration. L ’atteinte directe ou exterieure, ou Pecrasement des organes entre
les corps vertebraux et la paroi anterieure
paraissent moins probables. II semble
bien que Papplication de la ceinture de
securite engendre une deceleration bru
tale qui modifie Peventail de lesions
anatomiques.
Des etudes plus avancees sur la preven
tion de cette “ seconde collision” et de
cette deceleration devraient pouvoir
reduire le haut pourcentage de lesions du
tube digestif que nous avons constate. En
attendant, le port de la ceinture de secu
rite et la reduction de la vitesse routiere
dem eurent encore n o tre m eilleure
protection.
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3. Chest Injuries in Children
Chest injuries of varying severity occur
commonly in children, much more as a
result of motor vehicle accidents and
falls from a height than from penetration.
The author reviews the injuries that
occur with reference to mechanism,
immediate and late treatment and
monitoring. The differences between the
injuries of children and those of adults
stem from the greater resilience of most
structures in children; bony injuries are
not necessarily extensive even when dis
ruptions of the lung and blood vessels
are serious.
Pneumothorax may occur alone or
with other injuries. A chest tube should
be inserted early. Persistence of the
pneumothorax may indicate the presence
of a tracheobronchial tear which must be
repaired by thoracotomy. A flail chest
may be treated without intubation if
blood-gas levels are normal. In the
presence of paradoxical motion and
increased carbon dioxide pressure, intu
bation and positive-pressure ventilation
are required for a few days. Penetrating
wounds require the same care as in
adults. Diaphragmatic tears occur from
falls from excessive heights or direct
passage of vehicle wheels over the chest
or abdomen. Ventilation becomes
progressively more inefficient.
Esophageal tears occur from irregular
foreign bodies. Great-vessel injuries
occur by penetration.
The author establishes priorities in
management to assure adequate oxygen
utilization, arrest of hemorrhage and
restoration of circulation. Following
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stabilization efforts, monitoring proce
dures are instituted. These include inser
tion of central venous pressure and
arterial lines to measure pH, carbon diox
ide and cardiac output as well as for
other biochemical and hematologic
measurements.
Des blessures thoraciques d'intensite
variable sont frequentes chez I'enfant;
elles resultent plus frdquemment d'un
accident de la circulation ou d'une chute
que d'une penetration. L'auteur revoit les
divers types de blessures et etudie leurs
mecanismes, leur traitement immediat et
retarde et la surveillance des suites therapeutiques. Les differences observees
entre les blessures de I'enfant et de
I'adulte viennent de la plus grande elasti
city de la plupart des structures chez
I'enfant; les blessures osseuses ne sont
pas necessairement etendues meme en
presence de perturbations serieuses des
poumons et des vaisseaux sanguins.
Un pneumothorax peut survenir de
fapon isolee ou en association avec
d'autres blessures. Une sonde thoracique
doit etre posee rapidement. La persistance du pneumothorax peut indiquer la
presence d'une dechirure tracheobronchique, laquelle necessite une repa
ration par thoracotomie. Un volet thoraci
que peut etre traits sans intubation si les
gaz sanguins sont normaux. Devant un
mouvement paradoxal et une augmenta
tion de la tension d'anhydride carbonique, une intubation avec ventilation a
pression positive doit etre institute pour
quelques jours. Les plaies ouvertes
necessitent les memes soins que pour
les adultes. Les ddchirures du diaphragme surviennent a la suite d'une chute
d'une hauteur excessive ou de I'ecrasement du thorax ou de I'abdomen par les
roues d'un vehicule. La ventilation
devient progressivement moins efficace.
Les ddchirures oesophagiennes sont causdes par des corps etrangers alors que
les blessures des grands vaisseaux sur
viennent par penetration.
L'auteur dtablit I'ordre prioritaire de la
marche a suivre afin d'assurer une oxy
genation satisfaisante, arreter les hdmor-

ragies et retablir la circulation. Apres ces v
efforts pour stabiliser le malade, les pro
cedures de surveillance sont mises sur
<
pied: installation de catheters veineux
centraux et arteriels permettant de mesurer le pH, I'anhydride carbonique et le
debit cardiaque, ainsi que d'autres parametres biochimiques et hematologiques.

Chest injuries are quite common in chil- -*
dren, although the mechanism of injury
differs from that in adults. Children have
far fewer penetrating injuries and sustain
most chest-wall trauma as passengers in
automobiles or in falls from a height.
Since their ribs are more elastic broken
ribs occur much less frequently in children -i
than in adults for a given force applied
to the chest. Similarly, a child may sus- -*
tain serious intrathoracic injury without
having fractured ribs. This paper reviews
the types of thoracic injuries that may be
found in children who have suffered chest
trauma.
Pneumothorax

Any sharp blow to the chest can cause
pneumothorax. If the child has the glot
tis closed at the moment of the blow, its
direct force is applied to the alveoli. This

FIG. 1—Small right pneumothorax and
hemothorax which followed patient’s fall from
horse. Note rib fracture in midaxillary line.
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FIG. 2—This 50% right pneumothorax was
Sustained in fail from height of 6 m. Absence
of subcutaneous emphysema suggests no rib
v fractures.

FIG. 3—Healing fractures in left ribs 6 to
9 and right ribs 9 to 11. This resulted from child
abuse.

can cause local alveolar rupture and
appreciable pneumothorax (Fig. 1). In
such injuries there is usually no associated
cutaneous emphysema and no rib frac
tures are evident on the chest film (Fig.
2). There may be a small amount of sub
cutaneous emphysema in the neck, but
this is a relatively late finding.
If the blow is sufficient to fracture a
rib (Fig. 3), the sharp ends of the rib are
driven into the lung causing a superficial
laceration. In such instances there is
usually associated hemothorax and con
siderable subcutaneous emphysema in the
chest wall. The air escapes into the sub
cutaneous tissues through the tear in the
parietal pleura caused by the sharp rib
ends. The rib fractures may or may not
be apparent on the roentgenogram, but
the association of a traumatic pneu-

FIG. 5—Crushed chest with flail segment on
left. This and severe pulmonary contusion on
right made intubation and ventilation neces
sary for 5 days.

mothorax with extensive subcutaneous
emphysema in the chest wall usually indi
cates that the child has sustained a severe
chest injury.
Initial therapy should consist of aspi
ration of the pneumothorax if a chest
tube is not readily available, but a chest
tube should be inserted early whenever
possible in these circumstances.
Flail Chest

The standard teaching is that to have
a flail chest there must be two or more
fractures in several contiguous ribs. In the
child the second point of fracture is fre
quently through the costochondral junc
tion so that only one fracture is apparent
on the roentgenogram. When the flail seg
ment is appreciable, however, there is
usually marked overriding of the rib ends
at the site of the fracture (Fig. 4).
Whenever a blow sufficient to produce
a flail segment has been delivered, there
is almost always extensive pulmonary
hemorrhage and contusion (Fig. 5).
Therefore, the child’s ventilatory function
is markedly compromised, both because
of the flail segment and because of the
damaged alveoli which prevent normal
gas exchange.
Assisted ventilation with a positivepressure ventilator may be necessary in
these cases, although it is not commonly
required. If the child is able to maintain
adequate blood-gas levels, taking oxygen
by mask, no intubation is required. It has
been stated that positive-pressure venti
lation helps reapproximate the rib ends
and minimize chest-wall deformity as the
fractures heal. In the child, however,
where the ribs are molded rapidly with
growth, this is not a concern. It is rare
to encounter a late chest-wall deformity
secondary to childhood fractures, since
the ribs seem to remodel as extensively as
do the long bones in the growing child.
If the flail segment is sufficiently large
to give visible paradoxical motion or to
cause elevation of the carbon dioxide
pressure, intubation and positive-pressure
ventilation are usually preferable to
attempts at immobilizing the chest wall.
At about 3 days after injury, the chest
wall has usually become sufficiently rigid
to permit spontaneous respiration.
Post-traumatic Pneumatocele

As areas of marked pulmonary contu
sion heal, extensive pneumatoceles may
form. These can be several centimetres in
diameter, but they rarely rupture or cause
symptoms.

FIG. 4—Healing flail right chest after crush
injury. There is marked overriding of rib ends.

FIG. 6—Penetration of left chest by
32-calibre bullet. Course of bullet is outlined
by metal fragments. There is minimal
hemothorax and no clinical pneumothorax.
Operation is not indicated unless empyema
develops.

Penetrating Chest Wounds

While penetrating chest wounds are
uncommon in childhood, the general
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principles of therapy are the same as those
in the adult. A chest film will usually give
a good indication of the organs that may
be injured. A lead bullet usually leaves a
small trail of fragments of the radiopaque
metal along its tract (Fig. 6). This gives
an excellent idea of possible associated
injuries. Once the bullet has entered the
chest, it may be deflected several times by
the curved surfaces of the ribs and its
course is unpredictable.
Pneumothorax is almost always present
when any object has entered the chest
cavity. If no pneumothorax is present, the
object or missile was probably deflected
by a rib and penetrated only the soft tis
sues of the chest wall. An appreciable
associated hemothorax usually indicates
that the bullet or object penetrated close
to the hilum of the lungs or the mediasti
num. Mediastinal widening indicates sub
stantial injury to the esophagus or great
vessels. Mediastinal emphysema also indi
cates probable penetration of the medi
astinum. An enlarged cardiac silhouette
indicates possible hemopericardium and
impending cardiac tamponade.
In all cases in which penetration of the
thorax is suspected, a chest tube should
be inserted as early as possible. Continued
passage o f blood, a large clotted
hemothorax and passage of saliva or
digestive juices all are relative indications
for urgent thoracotomy.
Diaphragmatic Injuries

Most injuries to the diaphragm in chil
dren occur as a result of falls from
extreme heights or from the wheels of a
vehicle passing directly over the upper
abdomen or lower thorax (Fig. 7). Ini
tially, there is usually grunting respiration
associated with a marked decrease in ven
tilation. The combination of pain in the
chest wall from the direct injury and loss
o f diaphragmatic function makes venti
lation extremely inefficient. As the child
breathes, the negative phase of its respira
tory cycle tends to draw more and more
of the abdominal viscera into the chest.
This further compromises lung expan
sion.
While an injury to the diaphragm may
be suspected from a supine chest roent
genogram, a lateral decubitus or upright
film is much more easily interpreted.
Rarely, however, is a child that severely
injured able to stand or sit for the
examination.
Urgent measures include passing a
nasogastric tube to prevent further disten
sion of the intrathoracic viscera, a chest
tube to remove any associated blood or
bowel contents and early intubation with
positive-pressure ventilation, if indicated.
The surgical approach to the ruptured
diaphragm is dictated by associated inju
ries. If there appears to be a ruptured
468

spleen or other abdominal viscus, then a
transabdominal route is preferable. If
there is severe intrathoracic injury, then
a thoracotomy may be preferable. In
either case, the patient should be prepared
and draped so that the incision can be
extended in the chest or abdomen.
Small tears in the diaphragm that are
not recognized immediately usually cause
late symptoms of pain or bowel obstruc
tion. In such instances, small loops of
bowel are drawn up through a tiny rent
in the diaphragm and become trapped in
the chest. When this occurs, the bowel
loops are usually densely adherent in the
chest and must be reduced through a
thoracic incision.

or in whom the lung cannot be re
expanded to fill the thorax should be con
sidered to have a major bronchial injury *
Endoscopic visualization of this is essen
tial as soon as the patient is sufficiently
stable to permit the study. Once the injury
has been confirmed, thoracotomy and

Esophageal Injuries

In childhood, most esophageal injuries
are sustained by ingestion of irregular for
eign bodies. In such cases, the child
presents with severe dysphagia, fever,
tachypnea and tachycardia. Roentgeno
grams will frequently show the foreign
body and air in the mediastinum or a full
blown mediastinal abscess.
Initial therapy should include replace
ment of fluids, administration of broadspectrum antibiotics, antipyretics and
oxygen if necessary.
Endoscopic removal of the foreign
body may be all that is indicated, since
the rent in the esophagus is often suffi
ciently large to allow the abscess contents
to drain back into the esophagus (Fig. 8).
Rarely do such foreign bodies perforate
into the pleural space, so an associated
pneumothorax is rare. A small pleural
effusion, especially on the left, is com
monly seen and needs no specific therapy.
If an air-fluid level or persistent abscess
is observed on roentgenography or if the
child’s clinical condition does not
improve, it may be necessary to drain the
abscess cavity directly by a transthoracic
or transmediastinal route.
I prefer to insert a nasopharyngeal
sump as soon as the endoscopy is com
pleted. This reduces the amount of saliva
that passes down the esophagus and gives
the abscess cavity a chance to drain. It
also helps keep the pharynx clear and
makes the child less likely to aspirate if
he is having sufficient dysphagia to pre
vent him from swallowing his secretions
normally.

FIG. 7—Wheels of light truck passed over
lower chest of this 2-year-old child, tearing left
diaphragm. In absence of definite bowel loopst
above diaphragm, diagnosis is difficult from
supine chest film.

FIG. 8—Large fragment of turkey bone
lodged in cervical esophagus. There is local
abscess form ation. T reatm ent was by
endoscopic removal, pharyngeal sump drainage
and administration of antibiotics.
«

^
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Tracheobronchial Injuries

The trachea or bronchi may be torn
either in falls from heights or more com
monly when the wheels of a vehicle pass
over the chest (Fig. 9). The cardinal signs
are persistent pneumothorax in spite of
insertion of a chest tube, hemoptysis and
extensive atelectasis. Any patient with a
chest injury who has a very large air leak

FIG. 9—Torn left mainstem bronchus
suffered by 4-year-old child when automobile
passed over chest. There was persistent collapse
of left lung and extensive subcutaneous
emphysema.
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direct suture is usually the treatment of
choice.
►Unrecognized bronchial injuries will
frequently seal spontaneously within 4 or
►5 days. In such cases, however, the child
often returns in 4 to 5 weeks with either
pneumonia or persistent atelectasis of one
or several lung lobes. This results from
a stricture that forms at the site of the
original bronchial injury. Endoscopic
visualization is diagnostic and direct sur
gical resection of the stricture usually
gives a satisfactory result.
Injuries to the Great Vessels

* Because of the extreme flexibility of the
great vessels in children, injury by deceler
ation or crushing is uncommon. Virtually
all great-vessel injuries are inflicted by a
penetrating object. The principal findings
y suggestive of great-vessel injuries are a
bruit or thrill, asymmetry in the pulses,
& widened mediastinum and extensive
hemothorax. Aortography is confirma
to ry in most cases. Direct surgical repair
is advisable as soon as the patient is suffi
ciently stable to permit a major surgical
procedure.

An electrocardiogram will show the
presence of bradycardia, elevated ST seg
ment or T-wave inversion in the presence
of important myocardial injury.
Serial hematocrit, urine output and
specific gravity are also essential to moni
tor the blood-volume replacement and
hydration. Obviously no one set of meas
urements is diagnostic, and serial meas

urements with an accurate recording of
trends are essential.
Children have an amazing ability to
heal even the most extensive injuries if
they are kept in satisfactory fluid and
electrolyte balance, if ventilation is sup
ported as necessary, metabolic require
ments are supplied by hyperalimentation
and if infection is treated aggressively.
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Monitoring the Child with a
Thoracic Injury

Table I outlines the priorities in the
stabilization of a child with a major chest
injury. Once this procedure has been
completed, most patients require place
ment of a central venous pressure moni
tor or a Swan-Ganz catheter. Either an
Arterial catheter or a transcutaneous oxy
g e n monitor is also essential. In most
cases an arterial catheter is preferable,
since it allows frequent evaluation of pH
and carbon dioxide pressure as well as
y providing ready access for blood speci
mens for other laboratory tests. The
Arterial line can also be connected directly
to a pressure monitoring device to give
''rapid, accurate assessment of cardiac
output.
As early as possible the patient should
undergo ultrasonography of the heart and
anterior mediastinum. This will fre
quently outline a hemopericardium or
injury to specific heart valves.

Table I—Priorities in
Chest Injuries

'

'

1.
*2.
3.
4.
5.
6.
7.
8.

Establish patent airway
Occlude sucking wounds
Step bleeding
Expand lungs
Stabilize chest wall
Drain pleural space
Restore circulation
Evaluate ventilation (blood gases)

D UICOlclX

bisacodyl

Dulcolax — A family laxative with rapid
and predictable action
Dulcolax tablets work overnight
Dulcolax suppositories or
Micro-Enema within one hour

( M , ; Boehringer

Tablets 5 mg
Suppositories 10 mg
Suppositories 5 mg for children
Micro-Enema 10 mg/5 mL
FULL PRESCRIBING INFORMATION
AVAILABLE ON REQUEST

ingelheim

Boehringer Ingelheim (Canada) Ltd. / Lt6e
977 Century Drive. Burlington, Ontario L7L 5J8

VOLUME 27, NO. 5, SEPTEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

469

Now
control
hyperacidity
w ithout d ru g,
interactions.
Effective in the prophylaxis of acid aspira
tion syndrome with fewer patients at risk.®

Prevents acid aspiration syndrome without
the hepatic drug interactions found with
other H2 antagonists.

“This study suggests that (Zantac)...increases
the mean gastric pH and decreases
the num ber of ‘at risk days’ in seriously ill
patients.”®

Effectively inhibits gastric acid secretion one of the major factors involved in the
pathogenesis of stress ulcers.

Glaxo Laboratories
A Glaxo Canada Limited Company
Toronto, Ontario Montreal, Quebec

v

PAAB
CCPP

►

Prescribing Information
ZANTAC® INJECTION (ranitidine hydrochloride)
PHARMACOLOGICAL CLASSIFICATION

¥

Histamine Hj-receptor antagonist

ACTION

►

r
T

*■

Ranitidine is a selective antagonist of histamine at gastric H2-receptor sites. Thus
ranitidine inhibits both basal gastric secretions and gastric acid secretion induced
by histamine, pentagastrin and other secretagogues. On a weight basis, ranitidine is
between 4 and 9 times more potent than cimetidine. Inhibition of gastric acid secre
tion has been observed following intravenous, intraduodenal and oral admin
istration of ranitidine and it is dose related, a maximum response being achieved at
an oral dose of 150 mg.
Pepsin secretion is also inhibited but secretion of gastric mucus is not affected.
Ranitidine does not alter the secretion of bicarbonate or enzymes from the pancreas
in response to secretin and pancreozymin.
Ranitidine is rapidly absorbed after oral administration, peak plasma concentra
tions being achieved within 2 to 3 hours. These plasma concentrations are not
significantly influenced by the presence of food in the stomach at the time of the
oral administration nor by regular doses of antacids.
Bioavailability of ranitidine administered orally is approximately 50%. Serum
protein binding of ranitidine in man is in the range of 10% to 19%. The elimina
tion half-life is approximately 3 hours. The principal route of excretion is the urine
(40% recovery of free and metabolised drug in 24 hours).
Intramuscular ranitidine is fully bioavailable in comparison to intravenous
ranitidine. The median elimination half-life of ranitidine injection 50 mg, adminis
tered intravenously or intramuscularly was found to be 140 minutes (range 120 to
160 minutes.) The half-life of ranitidine in patients with renal dysfunction is
prolonged. However, in a study of 27 patients with varying degrees of renal impair
ment therapeutic plasma levels of ranitidine were shown to be achieved without
risk of drug accumulation, using half the normal dose of ranitidine in patients with
plasma creatinine concentration greater than 300 /imols/litre.
There is a significant linear correlation between the dose administered and the
inhibitory effect upon gastric acid secretion for doses up to 150 mg orally.
A plasma ranitidine concentration of 50 ng/mL has an inhibitory effect upon stimu
lated gastric acid secretion of approximately 50%. Estimates of the IC50 range from
36 to 94 ng/mL. Following the administration of 150 mg ranitidine orally, plasma
concentrations in excess of this lasted for more than 8 hours and after 12 hours the
plasma concentrations were sufficiently high to have a significant inhibitory effect
upon gastric acid secretion. In patients with duodenal ulcer, 150 mg ranitidine
given by mouth every 12 hours significantly reduced mean 24 hour hydrogen ion
activity by 69% and nocturnal gastric acid output by 90%.
Following intramuscular injection of 50 mg ranitidine, plasma concentrations
in excess of 100 ng/mL were achieved within five minutes of administration and
remained above this level for 4 to 6 hours.
Intravenous infusion of ranitidine in seriously ill patients at a rate of
0.125 mg/kg/hour produced a rise of intragastric pH between 5.6 and 7.0 after two
hours and maintained this level over the test period. The volume of gastric secre
tion was reduced by more than 55%. Doubling the infusion rate to
0.25 mg/kg/hour produced no further increases in gastric acid inhibition.
A single 50 mg intravenous bolus dose of ranitidine produced significant acid
inhibition 8 to 9 hours after administration. When 13 seriously ill patients with two
or more risk factors (shock, sepsis, respiratory failure, jaundice, renal insufficiency
and peritonitis) were treated with a 50 mg intravenous bolus dose of ranitidine
followed by a continuous infusion of 0.2 mg/kg/hour the number o f ‘at risk’ days
when gastric pH was less than 3.5 on three consecutive four-hourly aliquots, was
approximately half that for placebo treated patients.
Furthermore, in respect of both 24 hour acidity and nocturnal acid output,
ranitidine, 150 mg twice daily was superior to cimetidine 200 mg three times daily
and 400 mg at night (P <0.001 and <0.05, respectively).
Ranitidine injection is well tolerated following intravenous administration at
dose levels of up to 100 mg four times daily for ten days. These levels are in excess
of those recommended for normal clinical use.
Treatment of volunteers with ranitidine 150 mg twice daily for 7 days did not
cause bacterial overgrowth in the stomach.
Volunteers treated with ranitidine have reported no significant gastrointestinal
or central nervous system side effects; moreover, pulse rate, blood pressure, electro
cardiogram and electroencephalogram were not significantly affected in man
following ranitidine administration.
In healthy human volunteers and patients, ranitidine did not influence plasma
levels of the following hormones: cortisol, testosterone, estrogens, growth
hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating
hormone, aldosterone or gastrin - although like cimetidine, ranitidine reduced
vasopressin output. Treatment for up to 6 weeks with ranitidine 150 mg twice
daily by mouth did not affect the human hypothalamic-pituitary-testicular-ovarian
or -adrenal axes.
At 50 mg intravenously, ranitidine had no effect on prolactin levels. Only at
the 300 mg i.v. dose level was an increase in prolactin secretion, equivalent to that
produced by 200 mg of cimetidine i.v., observed.
At the high dose levels used in the tolerance studies, minor, transient increases
in serum alanine transaminase (ALT/SGPT) and aspartate transaminase
(AST/SGOT) levels were observed in some patients. No other liver function tests
were abnormal for these subjects and the cause and clinical significance of these
findings are unknown.
Laboratory studies have shown that ranitidine has negligible affinity for the
cytochrome P450-linked hepatic mixed function oxidase system. In man, ranitidine
treatment has been shown not to impair the metabolism of antipyrine,
aminopyrine, warfarin or diazepam.

PRECAUTIONS
Use in pregnancy and nursing mothers - The safety of Zantac in the treatment
of conditions where a controlled reduction of gastric secretion is required during
pregnancy has not been established. Reproduction studies performed in rats and
rabbits have revealed no evidence of impaired fertility or harm to the fetus due to
Zantac. If the administration of Zantac during pregnancy is considered to be neces
sary, its use requires that the potential benefits be weighed against possible hazards
to the patient and to the fetus. However, therapeutic doses of Zantac administered
to obstetric patients in labour or undergoing caesarean section have been without
adverse effect on labour, delivery, or subsequent neonatal progress.
Ranitidine is secreted in breast milk in lactating mothers but the clinical
significance of this has not been fully evaluated.
Use in impaired renal function - Ranitidine is excreted via the kidney and in
the presence of severe renal impairment, plasma levels of ranitidine are increased
and prolonged. Accordingly, in the presence of severe renal impairment, clinicians
may wish to reduce the oral dose to half of the usual dose taken twice daily, simi
larly it is recommended that ranitidine injection be administered in doses of 25 mg
to patients with renal dysfunction.
Children - Experience with Zantac in children is limited and such use has not been
fully evaluated in clinical studies. It has however been used successfully in children
aged 8-18 years in doses up to 150 mg orally twice daily without adverse effect.

ADVERSE REACTIONS
No serious adverse effects have been reported to date in patients treated with
Zantac. There has been no clinically significant interference with endocrine,
gonadal or liver function, nor has the drug adversely affected the central nervous
system even in elderly patients.
The incidence of adverse events among Zantac-treated patients (8.1%) was very
little greater than that among placebo-treated patients (7.7%). Only five adverse
events, namely, tiredness (0.38%), headache (0.90%), dizziness (0.32%), diarrhea
(0.52%) and skin rashes (0.52%) had a greater incidence in the ranitidine treated
group than in the control group.
A small proportion (1.99%) of patients treated with ranitidine injection experi
enced itching or burning at the injection site. This reaction was mild and usually
subsided within 10-15 minutes.
Headache was experienced by 2.54% of patients receiving ranitidine injection.
The majority of these cases were not thought to be treatment-related. In some in
stances the headache was thought to be due to over-rapid injection of ranitidine,
and did not recur on rechallenge with slow intravenous injection. Similarly, some
patients experienced nausea after rapid injection of the drug, but on subsequent
occasions with slow-intravenous injection, experienced no ill-effects.

OVERDOSAGE
Zantac is very specific in action and accordingly no particular problems are
expected following overdosage with the drug. Symptomatic and supportive therapy
should be given as appropriate. If need be, the drug may be removed from the
plasma by haemodialysis.

DOSAGE AND ADMINISTRATION
Adults: Zantac injection may be given either as a slow (over one minute) intra
venous injection of 50 mg, which may be repeated every six to eight hours; or as an
intravenous infusion at a rate of 25 mg per hour for two hours; the infusion may be
repeated at six to eight hour intervals.
In the prophylaxis of haemorrhage from stress ulceration in seriously ill
patients or the prophylaxis of recurrent haemorrhage in patients bleeding from
peptic ulceration, parenteral administration may be continued until oral feeding
commences. Patients considered to be still at risk may then be treated with Zantac
tablets 150 mg twice daily.
In patients considered to be at risk of developing acid aspiration syndrome
Zantac injection 50 mg may be given intramuscularly or by slow intravenous injec
tion (over one minute) 45-60 minutes before induction of general anaesthesia.
Experience with Zantac in children is limited and it has not been fully eval
uated in clinical studies - see PRECAUTIONS.

AVAILABILITY
Zantac Injection is available as 2mL ampoules each containing 50 mg ranitidine
(as hydrochloride) in 2mL solution for intravenous or intramuscular administra
tion. Packages of 10 ampoules.
Zantac Tablets are available as white film-coated engraved ZANTAC 150 on
one face and GLAXO on the other containing 150 mg ranitidine (as the
hydrochloride), in packs of 28 & 56 tablets.
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Zantac injection is indicated for the treatment of duodenal ulcer, benign gastric
ulcer, post-operative ulcer, reflux esophagitis, Zollinger-Ellison syndrome and
other conditions where reduction of gastric secretion and acid output is desirable.
These include the prophylaxis of gastrointestinal haemorrhage from stress ulcera
tion in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients
with bleeding peptic ulcers and before general anaesthesia in patients considered to
be at risk of acid aspiration (Mendelson’s) syndrome, particularly obstetric patients
during labour.
For appropriate cases Zantac Tablets are also available.

CONTRAINDICATIONS
There are no known contraindications to the use of Zantac (Ranitidine).

WARNINGS
Gastric ulcer - Treatment with a histamine H 2-antagonist may mask symptoms
associated with carcinoma of the stomach and therefore may delay diagnosis of the
condition. Accordingly, where gastric ulcer is suspected the possibility of malig
nancy should be excluded before therapy with Zantac is instituted.
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4. Abdominal Injuries in Children
The problem of abdominal trauma in chil
dren is briefly reviewed to show how the
etiology, diagnosis and treatment differ
from those in adults. Although in many
ways management is the same in both
groups, certain problems more commonly
affect children, and the approach to
diagnosis and treatment must be adapted
to their needs. The importance of fre
quent clinical assessment and the rather
limited role of peritoneal lavage in chil
dren with abdominal trauma are
stressed. Experience with splenic injuries
in 63 patients treated between 1974 and
1979 is reviewed to provide guidelines
for conservative management to assist
surgeons who seldom treat children.
Since splenectomy in pediatric patients
carries a risk of overwhelming infection,
distinguishing those whose spleens can
be salvaged is extremely important.
Le probleme du traumatisme abdominal
chez I'enfant est rapidement passe en
revue dans le but de mettre en Evidence
comment, chez lui, l etiologie, le dia
gnostic et le traitement different par rap
port a I'adulte. Bien que, de plusieurs
fagons, la marche a suivre soit la meme
pour les deux groupes, les enfants sont
plus souvent touches par certains probl&mes, d'ou la necessite d’adapter la tech
nique diagnostique et le traitement a
leurs besoins. On insiste sur ('importance
d'examens cliniques frequents et sur le
role plutot limite du lavage peritoneal
chez I'enfant souffrant de traumatisme
abdominal. L’experience accumulee chez
63 patients trait£s entre 1974 et 1979
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pour blessures spleniques est revue afin
de degager les lignes directrices d'un
traitement conservateur susceptibles
d'aider les chirurgiens qui ont rarement a
soigner les enfants. II est extremement
important de savoir identifier les patients
pediatriques a qui on peut conserver la
rate puisque chez eux la splenectomie
entrafne un risque d'infection
irrepressible.

The consequences of surgical treatment
in children may not become apparent for
many years and therefore pediatric sur
geons usually direct their efforts towards
preserving normal structure and function.
As a result, their management methods
often differ markedly from those of sur
geons who usually work with adults.
Nowhere is this difference more obvious
than in the management of abdominal
injuries. To help surgeons who treat chil
dren with abdominal trauma only occa
sionally, this paper describes briefly what
pediatric surgeons do differently and
why.
Mechanism of Abdominal Injuries
in Children

In many respects, the mechanisms of
injury, pathophysiology, diagnosis and
treatment of abdominal injuries in chil
dren are identical to those in adults. There
are two basic patterns of injury: solid
organ injury, which causes bleeding, and
hollow viscus injury, which leads to
inflammation and sepsis. Most early
deaths are due to bleeding, whereas most
late deaths are due to sepsis. In both
adults and children, all deaths due to
abdominal trauma should be considered
preventable.
Within the context of these similarities,
however, there are important differences.
Blunt injuries are much more common
than penetrating injuries; in fact,
penetrating injuries are rarely seen at The
Hospital for Sick Children in Toronto.
Boys are injured more frequently than
girls and there is a seasonal variation in
the occurrence of serious abdominal inju
ries, with the peak occurring during the
warm summer months. Although lifethreatening injuries can result from seem
ingly minor trauma caused by falls against
bicycle handlebars or hockey sticks, the

most serious injuries usually result from
motor-vehicle accidents or falls from
a height. Often multiple injuries are a
present.
It is important to remember two causes
of abdominal injury that are unique to
pediatric patients. The first is birtlf
trauma, usually from a difficult or
precipitate delivery. Most commonly the
injury involves the liver or spleen, with +
stripping of the capsule, subcapsular
hematoma or parenchymal laceration*;, i
Pallor, shock, abdominal distension and
a falling hemoglobin level follow. Irf
many cases the bleeding stops spontane- i
ously but occasionally surgical repair is
required. Because the liver and spleen are .
very friable and because there is a seri- ^
ous risk of overwhelming infection fol
lowing splenectomy in the newborn,1 I
great care must be taken in repairing the^s |
injuries.
The second unique cause is child abuse*
This is often missed because it is not sus- |
pected. The possibility of child abuse ■
should be considered in any of the follow
ing circumstances: an unexplained injury, *
variations in the explanation, incompati
bility between the explanation and the
observed injuries, unexplained delay iq i!
seeking medical help, history of selfinjury and the presentation of any mori- v
bund or unconscious child with little or
no accompanying history.
4
Diagnosis and Treatment
of Blunt Trauma in Children

j

Diagnosis and treatment must begin
immediately and proceed simultaneously.
The advanced trauma life support course 4
developed by the American College of
Surgeons provides a useful framework fdr
the initial management of children with
multiple injuries. As in treating adults, if
is helpful to keep two questions in mind:
what injuries are present and is there sub
stantial intra-abdominal bleeding or 4
peritonitis that necessitates urgent
laparotomy? Sometimes bleeding dr
peritonitis demand laparotomy in the 5
absence of a specific anatom ical^
diagnosis.
It is essential in managing very young
patients to remember that they are prone ^
to hypothermia, which can seriously
impair their ability to respond to blood
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‘ loss; every effort must be made to keep
■ these children warm.
| . Acute gastric dilatation is common
lifter blunt abdominal trauma in children
^ of all ages. Consequently, all those with
important abdominal injuries require a
nasogastric tube to prevent vomiting and
|
aspiration, to increase comfort and to
► prevent confusion on physical examinaj tion. A nasogastric tube immediately
! Relieves the abdominal distension, tender|
ness and apparent rigidity caused by gas
tric dilatation that can easily be mistaken
'! for signs of serious injury by the unwary.
I[
Diagnosis can be facilitated by obtaining a thorough history, especially if a
’ detailed description of the accident is
; Available. Obviously the child who is
struck by a motor vehicle travelling at
! r high speed or who falls from a great
height is likely to have serious injuries.
It is important to note the time and place
► of the accident and any changes in the
patient’s level of consciousness thereafter.
Oetails of the child’s previous health and
any history of allergy should also be
*■obtained.
Clinical evaluation is the most useful
[ diagnostic tool during the first hour after
4 the patient reaches hospital. It includes
serial measurements of the vital signs,
i
careful, repeated abdominal examinations
by the same individual and assessment of
*the initial response to blood-volume
j
replacement. This evaluation separates
patients who require immediate operation
from those who can safely be admitted
for observation or further diagnostic
+ tests.
Physical examination should include
Careful assessment of the peripheral cir
culation, including the colour and temr perature of the extremities and the
strength of the peripheral pulses. In chil
dren, peripheral vasoconstriction causes
y pallor and coolness of the extremities
before profound tachycardia and
hypotension develop. Frank shock indi
cates the loss of at least one third of the
* blood volume or approximately 25
mL/kg body weight. Hypovolemic shock
in children usually results from bleeding
y into the pelvis, abdomen or chest and sel
dom from superficial lacerations, frac
tures or head injuries.
The abdominal examination begins
* with inspection, looking for external signs
of injury, such as seat-belt or tire marks.
In children, the abdominal girth should
be measured early and repeatedly. Most
' children with serious intra-abdominal
^bleeding show a measurable increase in
abdominal girth. Gentle, repeated palpation and auscultation for bowel sounds
are still the most useful ways to diagnose
peritonitis due to hollow-viscus injury.
.
Major injuries to the kidneys, ureters
' or bladder may cause only microscopic
I hematuria. Therefore, urinalysis, specif

ically for hematuria, is necessary in every
case.
In addition to a complete blood count
and cross-matching, the serum amylase
level is routinely determined in cases of
blunt abdominal trauma. Although it is
not of much use in the first hour or two,
a persistently elevated or rising serum
amylase value usually indicates serious
pancreatic injury.
Patients who are stable after the initial
resuscitation may safely undergo further
diagnostic tests provided they are
observed continuously. Plain supine and
erect abdominal films may be useful and
should be checked for the presence of free
intraperitoneal air or loculated
retroperitoneal air in the region of the
duodenum. However, in only about 50%
of patients with small-bowel lacerations
will pneumoperitoneum develop. The
contour of the diaphragm, especially on
the left, should be carefully noted, keep
ing in mind that the radiologic signs of
diaphragmatic rupture may be subtle.
Patients with gross or microscopic
hematuria require intravenous urography.
Bladder injuries cannot be ruled out on
the basis of the usual intravenous uro
gram. When bladder injuries are sus
pected, a cystogram should be obtained.
It has been routine at our hospital to
use radionuclide imaging to confirm sus
pected injuries of the liver or spleen. This
procedure has proved useful in clinical
practice, although recent reports have
pointed out the advantages of computer
ized tomography in this situation.2'3
The detail obtained with computerized
tomography is superior to that afforded
by radionuclide imaging or ultrasonogra
phy and is not affected by ileus. Com
puterized tomography is not organspecific and may reveal unsuspected inju
ries. It is superior to intravenous urogra
phy for defining renal injuries, especially
extravasation of urine. It is cheaper,
quicker and probably safer than angio
graphy, although the latter still has a role
when specific vascular injuries are sus
pected.
Peritoneal lavage, done either percutaneously or through a minilaparotomy
incision, has become standard practice in
many adult trauma centres to rule out
occult intra-abdominal hemorrhage or
peritonitis. However, the procedure is sel
dom used at The Hospital for Sick Chil
dren for two reasons. First, although
peritoneal lavage is highly accurate in
detecting blood in the peritoneal cavity,
most patients with minor blood loss do not
require operation and those with substan
tial bleeding who do require laparotomy
are usually obvious candidates on clini
cal grounds. Second, in detecting injuries
to the bowel, especially the retroperi
toneal duodenum and colon, peritoneal
lavage has not been shown to yield bet
ter overall results than careful physical

examination and plain or contrast radiologic studies, which in our hands have
been highly satisfactory. However, we
have found peritoneal lavage helpful in
two specific situations. The first is in
patients with severe head injuries involv
ing the brain stem, who are hemodynamically unstable without other obvious
explanation. In these cases, a negative
peritoneal lavage may obviate the need
for laparotomy. The second is in patients
who are to undergo prolonged neurosur
gical, orthopedic or plastic surgical proce
dures under general anesthesia and will
therefore be difficult to monitor closely.
Emergency Laparotomy

Operation is part of the initial resusci
tation in some cases, usually because of
profuse bleeding from the liver or spleen.
We begin the resuscitation of patients in
shock with Ringer’s lactate, 20 mL/kg
body weight, and then switch to whole
blood or a combination of packed red
cells and plasma. Patients who remain in
shock or go back into shock from intra
abdominal bleeding after transfusion of
whole blood or its equivalent, 20 to 40
mL/kg body weight, require immediate
laparotomy. Before the abdomen is
opened, it is desirable to document the
presence of two functioning kidneys by
“ one-shot” intravenous pyelography.
When the abdomen is open, the tamponading effect of the abdominal wall
and the MAST garment, if in use, is
released. This may cause a disastrous fall
in blood pressure. It is therefore impera
tive to explore the abdomen rapidly and
control bleeding by direct pressure. In
some cases we have begun by making a
very small midline epigastric incision and
collecting the blood for autotransfusion
before the abdomen is widely opened.
This provides a large volume of warm,
compatible blood with normal oxygen
carrying capacity which can be rapidly
transfused using the autotransfuser if
necessary when the abdomen is fully
opened. It should be kept in mind that
autotransfused blood is deficient in plate
lets and clotting factors and that sup
plementation with platelets and fresh
frozen plasma may be necessary.4
Splenic Injuries

General surgeons, treating adults, and
pediatric surgeons tend to differ more
over the management of splenic injuries
than of any other type of intra-abdominal
injury. Injuries to the spleen are the most
common cause of major intra-abdominal
bleeding following blunt trauma. Early in
this century, splenectomy was the stan
dard treatment for all splenic injuries.
However, it should be kept in mind that
this was long before intensive care units
or blood transfusions were readily avail-
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able. Today, there are major reasons why
the blanket policy of excising all injured
spleens regardless of the severity of the
injury is no longer justifiable.
The spleen is essential to normal
immune function. It filters particulate
matter, including bacteria and other
microorganisms from the blood, and con
tributes to the production of antibody,
the opsonization of foreign antigens and
the regulation of lymphocyte function.
The risk of overwhelming postsplenec
tomy infection, which was first pointed
out by King and Shumacker,1 varies with
the age of the patient at the time of
splenectomy and the underlying disease,
but a recent review by O ’Neal and
McDonald5 found the risk of fatal bac
terial sepsis following splenectomy to be
540 times that in the general population.
A misconception that has been very
difficult to dispel is the notion that bleed
ing from the spleen can be stopped only
by splenectomy. In the 1940s, Wansborough first discovered that this was not
so when he observed spontaneous heal
ing of the spleen in an adolescent.6 Since
then, we have followed a policy of selec
tive, conservative management of patients
with splenic injuries, reserving operation
for those with severe bleeding. This
approach7 is now standard practice in
many major pediatric surgical centres
across North America.8’9 In many cases
when nonoperative management fails,
splenorrhaphy or partial excision can be
used to repair severe splenic injuries and
preserve splenic function.10'11
To establish guidelines that would be
useful in the management of individual
patients with splenic trauma, we reviewed
our experience with documented splenic
injuries in 63 patients from 1974 to
1979.11 Only 19 of the 63 required oper
ation. Associated injuries were much
more common in those who required
operation. None of the patients in the
nonoperative group died, whereas 7 of the
19 in the operative group died, 6 of head
injuries and 1 of massive bleeding. In the
nonoperative group, 16 patients required
blood transfusions. The average total
volume transfused was 31 m L/kg body
weight (Table I). All patients in the oper
ative group were given blood before oper
ation; the mean volume was 80 m L/kg
body weight. All these patients were oper
ated on within 16 hours of admission and
12 of the 19 within 4 hours. On the basis

of our review, we concluded that
nonoperative treatment is safe in selected
cases, the need for operation is usually
obvious within the first few hours after
admission and operation is indicated if
the blood requirement is more than 40
mL/kg body weight.
The nonoperative treatment of splenic
injuries can be undertaken only where
there is an adequate intensive care unit
with 24-hour medical and nursing super
vision, a blood bank and an operating
room immediately available at all times.
Although these conditions are met in
most modern hospitals, in some small,
remote centres operative intervention may
be necessary when immediate transfer to
a regional traum a unit is not feasible.
Patients who are stable from the begin
ning or after initial resuscitation should
be observed in the intensive care unit for
24 to 48 hours. At our institution, they
are hospitalized for about 1 week and
then rest at home for a further 2 weeks.
After this they can gradually resume nor
mal activities, including going to school.
However, they are advised against par
ticipating in physical education classes,
sports and rough play, including bicycle
riding, for 3 months. Follow-up scanning
is done to ensure that healing of the
splenic hematoma has taken place and to
rule out cyst formation, which has
occurred twice in our experience.
Patients who bleed profusely from the
beginning or who bleed more slowly but
require more than 40 mL/kg body weight
of blood are operated upon. If possible,
the spleen is salvaged by direct repair or
partial excision. When the spleen is
damaged beyond repair or when there are
other injuries that demand immediate
attention, it may be more appropriate to
remove the spleen. However, when the
patient is stable, splenic salvage should be
attempted. This requires complete mobili
zation of the spleen by dividing its
superior, lateral and inferior attachments
so that it can be brought into the wound.
Topical agents, such as microfibrillar col
lagen or simple sutures of 2-0 chromic
catgut, with or without Teflon pledgets
or omental patches, may suffice. Occa
sionally, partial splenectomy, leaving at
least 30% of the spleen, will be required.
Buntain and Lynn13 have reviewed the
various reported techniques.
After splenectomy, the patient, the
family and the family physician should be

T a b le 1--T ra n s fu s io n o f P a tie n ts w ith S p le n ic Injuries
a t T h e H o s p ita l fo r S ic k C hildren, T o ro n to , fro m 1 9 7 4 to 1 9 7 9

T ra n s fu s ed , no . (% )
P re o p e ra tive v o lu m e , m L /k g
T o ta l volum e, m L /k g
*M e a n ± s ta n d a rd e rro r.
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N o n o p e ra tiv e
(n - 4 4 )

O p e ra tiv e
(n = 1 9 )

1 6 (3 6 )

19 (1 0 0 )
8 0 .4 ± 1 0 .1 *

—

3 1 .2 ± 5 .3 *

1 7 4 .7 ± 2 3 . 3 *

advised of the lifelong risk of overwhelm
ing postsplenectomy infection. The
patient should seek immediate rnedic^.
attention for any acute febrile illness
because such infections can be fatalf
within 12 to 24 hours if untreated. We
routinely give pneumococcal vaccine to ’
patients after splenectomy, although this
is not of proven value. In addition, antibi- 1
otics such as penicillin and amoxicillin a ij
prescribed prophylactically in most cases
but are also of unproven value.
To summarize our experience from
1972 to 1981, 129 patients with splenic
injuries were treated at The Hospital for
Sick Children. Of these, 41 required
operation; in 8 of them the spleen was
saved. The mean injury severity score was
41 (maximum possible 75) in those who
required operation and 14 in those who*
did not. The mode, or most common
injury severity score, in the nonoperative
group was 9, indicating that the typical ^
patient had an isolated splenic injury.
Hebeler and associates14 from th£
University o f Texas have recently
reported their experience with splenicA
injuries in 172 patients aged 2 to 73 years
(mean 28 years). In 65 cases the spleen
was saved. Of these 65, 33 had operative ^
repair of the spleen, but the other 32 were
not explored. This report suggests that
selective nonoperative management of
splenic injuries may also be safe in adults.-'
Perhaps, in time, the pediatric surgeon’s
conservative approach to this problem ”
will become standard treatment for adult
;
patients as well.
;
■4 *

This paper was prepared with the assistance
o f the Medical Publications Department. ^
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Activity comparable to doxorubicin
Effective as first and second line therapy
Responses at all major sites of metastases
Long duration of response

Less than 6% severe alopecia
Little or no severe nausea and vomiting
No tissue necrosis on extravasation reported
Low potential for cardiotoxicity
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mitoxantrone hydrochloride
intravenous injection

ANTINEOPLASTIC
AGENT
C A U TIO N
NOVANTRONE* IS A POTENT DRUG AND SHOULD BE USED ONLY
BY PHYSICIANS EXPERIENCED WITH CANCER CH EM O
THERAPEUTIC DRUGS (SEE WARNINGS AND PRECAUTIONS).
BLOOD COUNTS SHOULD BE TAKEN AT FREQUENT INTER
VALS PRIOR. DURING AND POST THERAPY. CARDIAC M ONI
TO RING IS ADVISED IN T H O SE PATIENTS WHO HAVE R E
C EIV ED PRIOR ANTHRACYCLINES. PRIOR M EDIA STINAL
RADIOTHERAPY OR WITH PRE-EXISTING CARDIAC DISEASE.
PH A RM A CO L O G IC A L ACTION
Although its mechanism of action has not been determined, mitoxantrone
is a DNA-rcactivc agent. It induces nuclear aberrations with chrom o
some scattering in cell cultures (human colon carcinoma line) and is a
potent inhibitor of RNA and DNA synthesis. Compared on an equimo
lar basis, mitoxantrone is seven times more potent than doxorubicin in
inhibiting the uptake of 3H-uridine and four times more potent in inhibiting
the uptake o f ’H-thymidine by mouse lymphoma L 5178Y cells in vitro.
IND IC ATION S
NOVANTRONE* is indicated for chemotherapy in patients with carci
noma o f the breast, including locally advanced and metastatic disease.
C O NTR AIND IC ATION S
NOVANTRONE* is contraindicated in patients who have demonstrated
prior hyper- sensitivity to anthracyclines.
W ARNING S
Since NOVANTRONE* produces m yelosuppression (see ADVERSE
EFFECTS), it should be used with caution in patients in poor general
condition or with pre-existing myelosuppression.
Cases ot functional cardiac changes, including congestive heart failure
and decreases in left ventricular ejection fraction have been reported.
These cardiac events have occurred almost exclusively in patients who
have had prior treatment with anthracyclines, prior mediastinal radio
therapy or with pre-existing heart disease. Cardiac monitoring is advisable
in such patients. It is suggested that cardiac monitoring also be p er
formed in other patients during therapy exceeding 12 courses of NOVAN
TRONE*, as experience during prolonged treatment is limited.
NOVANTRONE* may impart a blue-green colouration to the urine for 24
hours after administration, and patients should be advised toexpect this
during active therapy. Safe use o f NOVANTRONE* in pregnancy has not
been established. No information is available concerning the presence
o f NOVANTRONE* in the milk o f nursing mothers.
PR EC A U TIO N S
Full blood counts should be undertaken serially during a course o f
treatment. Dosage adjustments may be necessary based on these counts
(sec DOSAGE section).
It is recommended that NOVANTRONE* not be mixed in the same infu
sion with other drugs.
AD V ERSE EFFEC TS
NOVANTRONE* is clinically well tolerated, demonstrating a low overall
incidence of adverse events, particularly those o f a severe, irreversible
or life-threatening nature.
Some degree of leukopenia is to be expected following recommended
doses of NOVANTRONE*. However, suppression o f WBC counts below
1000/mm1is infrequent. With dosing every 21 days, leukopenia is usu
ally transient, reaching its nadir at about 10 days after dosing, with
recovery usually occurring by the 2 1st day. Thrombocytopenia can occur,
and anaemia occurs less frequently. Myelosuppression may be more
severe and prolonged in patients having had extensive prior chemother
apy or radiotherapy or in debilitated patients.
The most commonly encountered side effects are nausea and vomiting,
although in the majority of cases these are mild (WHO Grade I) and
transient. Alopecia may occur, but is most frequently o f minimal sever
ity and reversible on cessation of therapy.
O ther side effects which have occasionally been reported include
anorexia, diarrhoea, dyspnoea, fatigue and weakness, fever, gastroin
testinal bleeding, stomatitis/ m ucositis, and non-specific neurological
side effects.
Changes in laboratory test values have been observed infrequently, e.g..
increased liver enzyme levels, elevated serum creatinine and blood urea
nitrogen levels.
C ardiovascular effects, which have only occasionally been o f clinical
significance, include decreased left ventricular ejection fraction (de
termined by ECHO or MUGA scan), EKG changes and acute arrhythmia.
Congestive heart failure has been reported. Such cases generally re
sponded well to treatment with digitalis and/or diuretics.
C L IN IC A L RESULTS
Introduction
Clinical trials experience has established the dosage range, efficacv and
safety profile ofNOVANTRONE*.
y
A single dose can be given intermittently every three or four weeks.
The recommended initial treatm ent dose in good risk patients is 14
m g/m 2.
Efficacy
Efficacy data arc available on 349 patients with locally advanced or
metastatic breast carcinoma. Results are dependent on many predispos
ing factors including prior chemotherapy and/or radiotherapy, the health
o f the patients, sites of metastases, and dose o f the agent employed. In a
European multi-centre first- line single-agent trial using an initial dose
o f 14 m g/m 2, the overall response rate was 39% . which com pared
favourably to doxorubicin therapy at a dose o f 60-75 m g/m 2when given
to patients with similar stage disease. In an ongoing study o f a direct
comparison with doxorubicin, given as second-line therapy to breast
cancer patients who failed a standard first-line combination, response
rates arc 27% for NOVANTRONE* and 23% for doxorubicin. The mean
duration o f response observed after NOVANTRONE* was greater than
those reported after doxorubicin. Responses have been seen in all major
sites o f metastases including lymph nodes, lung, bone, skin and viscera, in
patients both with and without prior hormonal therapy. Available data
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suggest that NOVANTRONE’ is comparable in efficacy with doxorubicin
in the treatment ol advanced breast cancer. Myelosuppression with 21 -day
treatment intervals is comparable with that observed with doxorubicin.
Multiple courses o f single-agent NOVANTRONE* therapy, in some cases
for longer than twelve cycles, have been administered with excellent
tolerance and a good response. NOVANTRONE* showed incomplete crossresistance with doxorubicin since responses have been observed in pa
tients in whom doxorubicin had failed or who relapsed after response to
that drug. A continuing large-scale clinical trials program with combi
nation therapy also demonstrated early positive results for efficacy and
safety. In seven studies, over 100 cycles of combination therapy have
been given to 77 patients.
Safety
Data on the overall safety profile ofNOVANTRONE* (based on 989 patients)
demonstrated advantages ofNOVANTRONE* compared to the anthracy
clines with respect to both the quality o f life and tne long-term safety of
patients. The majority o f side effects with NOVANTRONE* are mild in
nature . Removal o f patients from NOVANTRONE* treatment for reasons
o f toxicity has been rare in clinical studies. A number o f patients have
reported no side effects at all. In addition, the relatively low risk of
serious side effects has permitted treatment o f patients on an out-patient
basis. The most common acute effects were nausea and/or vomiting
(only 3.5% severe or very severe with NOVANTRONE*. compared to
10-15% reported with doxorubicin), stomatitis/mucositis (only 0.3%
severe or very severe with NOVANTRONE*) and alopecia (only 0.9%
severe or very severe, and 15% overall with NOVANTRONE* compared
with 85% severe or very severe and 100% overall reported with
doxorubicin). Serious local reactions have not been reported following
extravasation ofNOVANTRONE* at the infusion site.
With respect to myelosuppression, initial NOVANTRONE* doses of 14
mg/m2 every three weeks are well-tolerated in good-risk patients. Se
vere degrees o f myelosuppression have been rare. The median white
cell nadir in a European second-line study was 2 .5 x l0 \ in a European
first-line study only 4.8% (2/42) o f patients experienced a nadir o f less
than 1.000. The nadir usually occurs around day 10 or 11 and returns to
normal baseline value by day 2 1. in time for the next course of treatment.
After multiple courses ofNOVANTRONE*. white blood cell and platelet
nadirs show no further decrease beyond those observed in the first few
cycles, indicating no cumulative or permanent effects of NOVANTRONE*
on marrow reserves.
Cardiotoxicity
Adverse cardiac experiences have been infrequent. In contrast, doxoru
bicin has been reported to produce chronic cardiomyopathy and irre
versible congestive heart failure in up to 11 % o f patients given nine or
more courses o f that drug at the usual dose schedule (60 mg/m2 every
three weeks). Whether or not related to NOVANTRONE*, only 119 cardiacrelated episodes have been reported from a total data-base of more than
3,200 treated patients, including only 29 (0.9%) reports o f clinical con
gestive heart failure, of which only one had no other known predispos
ing factors. The risk o f cardiotoxicity is increased with prior antineoplastic drug or radiation therapy. In patients without predisposing
factors, development o f congestive heart failure with NOVANTRONE*
therapy is rare.
Clinical experience suggests there is no need to lower the dose for pa
tients with existing renal or hepatic disease.
In summary, NOVANTRONE* is well tolerated and provides a better
quality of life for patients with breast cancer, compared with doxorubicin
and yet shows comparable efficacy.
NOVANTRONE* has been used alone or in combination in patients with
or without prior chemotherapy, as well as in those who have received
prior adjuvant therapy. It is less cardiotoxic than anthracyclines such as
doxorubicin and thus represents a clear therapeutic advance over cur
rently available compounds.
SY M PTOM S AND TR EA TM EN T O F OVERDOSAGE
There is no known specific antidote for NOVANTRONE. As would be
expected from the pharmacological actions of the drug, haematopoietic,
gastrointestinal, hepatic and renal toxicity may be seen, depending on
the dosage given and the physical condition of the patient. The manage
ment of overdosage is symptomatic and supportive and patients should
be monitored closely. (See also the sections “ WARNINGS". “ PRE
CAUTIONS" and “ ADVERSE REACTIONS")
DOSAGE
The recommended initial dosage for use as a single agent is 14 mg/m2of
body surface area, given as a single intravenous dose, which may be
repeated at 2 1-day intervals. A lower initial dose (12 mg/m2 or less) is
recommended in patients with inadequate marrow reserves due to prior
therapy or poor general condition.
Dosage modification and timing o f subsequent dosing should be deter
mined by clinical judgem ent depending on the degree and duration of
myelosuppression. If 2 1- day white blood cell and platelet counts have
returned to adequate levels, prior doses can usually be repeated. The
following Table indicates a guide to dosing based on myelosuppression.
W BC AND
P L A T E L E T N A D IR

T IM E T O
RECOVERY

SUBSEQUENT
D O S IN G

IF W B C N A D IR
> 1 500
AND
P L A T E L E T N A D IR
> 5 0 000
IF W B C N A D IR
> 1 500
AND
P L A T E L E T N A D IR
> 5 0 000
IF W B C N A D IR
< 1 500
OR
P L A T E L E T N A D IR
< 5 0 000
IF W B C N A D IR
< 1 000
OR
P L A T E L E T N A D IR
< 2 5 000

RECO VERY
< 2 1 DAYS

R E P E A T P R IO R D O S E O R
IN C R E A S E B Y 2 m g /m ! IF
M Y E L O S U P P R E S S IO N N O T
C O N S ID E R E D A D E Q U A T E .

RECO VERY
> 2 1 DAYS

W IT H H O L D U N T IL
RECOVERY THEN
R E P E A T P R IO R D O S E .

A N Y D U R A T IO N

D E C R E A S E B Y 2 m g /m 2
F R O M P R IO R D O S E A F T E R
R E C O V ER Y .

A N Y D U R A T IO N

D E C R EASE B Y 4 m g /m 2
F R O M P R IO R D O S E A F T E R
R E C O V ER Y .

While no unforeseen problems have been encountered when NOVAN
TRONE* is used in combination with other antineoplastic therapy, data
are limited: therefore. NOVANTRONE* in combination therapy should
be used with caution until wider experience is obtained.
As a guide, when used in combination chemotherapy with another
myelosuppressive agent, the initial dose ofNOVANTRONE* should be
reduced by 2-4 m g/m 2 below the doses recommended above for single
agent usage; subsequent dosing, as outlined above, depends on the de
gree and duration of myelosuppression.

Cyanamid Canada Inc.
Toronto

ADM INISTRATION O F SO LUTIO N
NOVANTRONE* solution should be diluted to at least 50 mL with either
Sodium Chloride for Injection (U.S.P.) or 5% Dextrose for Injection
(U.S.P.). This solution should be introduced slowly into the tubing of a
freely-running intravenous infusion of Sodium Chloride for Injection
(U .S .P ) or 5% Dextrose for Injection (U .S.P) administered over not
less than three to five minutes intravenously. If extravasation occurs,
the administration should be stopped immediately and restarted jgi an
other vein. However, serious local reactions have not been reported
following extravasation.
NOVANTRONE* should be administered by individuals e x p e rie n ce ^ n
the use o f antineoplastic therapy.
▼
Caution in the handling and preparation of NOVANTRONE* solutions
must be exercised and the use o f protective eyeglasses, gloves and other
protective clothing is recommended. (See "SA FE HANDLING BY
HOSPITAL PERSONNEL" section).
STO RA GE DIRECTION S
y
NOVANTRONE* should be stored at room tem perature — DO N O T
FREEZE. With recommended storage. NOVANTRONE* remains stable
for two (2) years.
+
Following preparation of the infusion, the diluted solution should be
stored at room temperature and used within 24 hours. Any original
solution which remains in the vial should be discarded. NOTE: L44KE
THE ORIGINAL SOLUTIONS. THE DILUTIONS SHOULD ALSO
NOT BE FROZEN.
DRUG CO M PATIBILITY
Until specific compatibility data are available, it is recommended that
NOVANTRONE* not be mixed in the same infusion with other drugs.
G U ID ELIN E S FO R SAFE USE BY H O SPITAL PERSONNEL**
Handling:
1. Preparation o f antineoplastic solutions should be done in a vssrtical
laminar flow hood (Biological Safety Cabinet — Class II).
'
2. Personnel preparing NOVANTRONE* solutions should w ear PVC
gloves, safety glasses and protective clothing such as disposable
gowns and masks.
i
3. Personnel regularly involved in the preparation and handling of
antineoplastics should have bi-annual blood examinations.
Disposal:
1. Avoid contact with skin and inhalation o f airborne particles by use
o f PVC gloves and disposable gowns and masks.
*
2. All needles, syringes, vials, ampoules and other materials which
have come in contact with NOVANTRONE* should be segregated in
plastic bags, sealed and marked as hazardous waste. Incinerate at
I000°C or higher. Sealed containers may explode if a tight seal
exists.
,'i
3. If incineration is not available, mitoxantrone hydrochloride m ay^e
detoxified by adding 5.5 parts by weight of calcium hypochlorite to
each 1 part by weight of mitoxantrone hydrochloride in 13 parts by
weight o f water.t The calcium hypochlorite should be added GRA
DUALLY and the procedure carried out with adequate ventilation
since chlorine gas is liberated.
j
Vials:
^
Prepare an adequate quantity o f calcium hypochlorite solution (eg: Add
43.5 g calcium hypochlorite to 100 mL o f water*). W ithdraw any
NOVANTRONE* remaining in the vial with the aid o f a hypodermic syringe.
Add to the prepared calcium hypochlorite solution slowly, preferably in
chemical fume hood or biological safety cabinet — Class II. Add an
appropriate quantity o f the calcium hypochlorite solution to the via) to
detoxify any remaining drug. W ithdraw the solution and discard in the
sewer system with running water. Dispose o f the detoxified vials in a
safe manner.
^
Needles, syringes, disposable and non-disposable equipment:
Rinse equipment w ith an appropriate quantity o f calcium hypochlorite
solution (43.5 g per 100 mL o f water*). Discard the solution in the
sewer system w ith running water and discard disposable equipment in a
safe manner. Thoroughly wash non-disposable equipment in soap and
water.
x
Spillage/Contamination :
Wear gloves, mask, protective clothing. Place spilled material if* an
appropriate container (i.e. cardboard for broken glass) and then in a
polyethylene bag; absorb remains with gauze pads or towels; wash area
with water and absorb with gauze o r towels again and place in bag; seal.
double bag and mark as a hazardous waste. Dispose o f waste by inciner
ation or by other methods approved for hazardous materials. Personnel
involved in cleanup should wash with soap and water.
+ Appropriate safety equipment such as goggles and gloves should be
worn while working with calcium hypochlorite solution since it is
corrosive.
v
AVAILABILITY
NOVANTRONE* mitoxantrone hydrochloride for injection is supplied as
a sterile aqueous solution at a concentration equivalent to 2 mg mitd^antrone free base per mL. and is available in the following vial sizes:
lOmL/vial (20mg) Product C o d e............................................... 9393-34
!2.5m L/vials (25mg) Product C o d e.......................................... 9393-'92
Identification:
Glass vials containing 10 and !2.5m L o f a clear, dark blue solution.
C H EM ISTRY
Composition
NOVANTRONE* mitoxantrone hydrochloride, a synthetic anthracenedione^
is a potent antineoplastic agent. Its molecular formula is C 22H28N40 6 *
2HC1 and its molecular weight is 517.4. It is a hygroscopic dark blue
solid supplied as a sterile, aqueous solution containing mitoxantfone
hydrochloride equivalent to 2 mg/mL mitoxantrone free base, with so
dium chloride, sodium acetate, and acetic acid as inactive ingredients.
The product does not contain antibacterial preservatives. Its structurtil
formula appears below.
|
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molecular form ula: C 22H 2gN40 6.2HCI
molecular weight: 5 17.4.
Chemical Name
1. 4-Dihydroxy-5,8-bis[|2-|(2-hydroxyethyl)amino|ethy11 amino) -9 ,10-anthraeenedione dihydrochloride

PAAB
CCPP
Product monograph available on request.
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►

Shock Trauma
|s
I'

"Trauma — accidental or in te n tio n a l in ju ry
— is a m ajor health and social problem .
It is s till th e ch ie f cause o f death in p eo
ple betw een th e ages o f 1 and 3 8 years.
In th e United States, th e m o rta lity due to
r
traum a b etw een the ages o f 1 5 and 2 4
years increased by 1 3 % fro m 1 9 6 0 to
|
‘ 1 9 7 8 . During the same period, th e m o r
ta lity fo r people aged 2 5 to 6 4 years
*" declined by 16 % . M urders have
increased fro m 8 4 6 4 in 1 9 6 0 , to
26 0 0 0 in 1 9 8 2 . The overall death rate
^
o f Am erican teenagers and yo u n g adults
l;
is 5 0 % higher than th a t o f th e ir co u n te r
parts in Britain, Sweden and Japan.
I*
Trauma a ffe c ts young, p ro d u ctive
►citizens, and th e estim ated c o sts fo r
death, d isa b ility and loss o f p ro d u c tiv ity
y exceed $ 2 3 0 m illion a day. The m ost
trag ic s ta tis tic is th a t a t least 4 0 % o f
th e deaths are needless and preventable
if b e tte r tre a tm e n t and p re ve n tio n p ro 
gram s w ere available.
f
r Trauma deaths th a t m ig h t be preventj
ed are those due to m o to r ve h icle accir dents, hom icide, burns, and alco h o l and
j
drug abuse. In this paper su g g estio n s fo r
prevention are made. They in clu d e im 
proved crash w o rth in e ss o f m o to r vehir
cles, revocation o f drunk d riv e rs ' li
c e n c e s , use o f devices th a t lim it drunk
drivers, increased ta x on alco h o l and ranj dom breathalyser te sts, and th e use o f
seat belts and m oto rcycle helm ets. C on
tro l o f hand-guns and burn c h a ra cte ris
tic s o f cigarettes could also reduce
► deaths.
The problem s and issues in traum a
*ca re can be divided in to tw o broad
categories: syste m and pro fe ssio n a l.

S ystem problem s include p re h o sp ita l
care, in -ho sp ita l care, re h a b ilita tio n and
pre ve n tio n . Professional problem s include
e d u catio n , research, econom ics, and
q u a lity. M any o f these issues and
problem s are related to th e d e velopm ent
o f a regionalized traum a program .
Les blessures, accidentelles ou vo lo n tairem ent provoquees, co n s titu e n t un probleme sanitaire et social m ajeur. Elies
dem eurent la cause p rincipale de deces
chez les personnes de 1 a 3 8 ans. Aux
Etats-U nis, la m o rta lite par trau m a tism e
chez les 15 a 2 4 ans a augm ente de
1 3 % entre 1 9 6 0 et 1 9 7 8 . Pendant la
m em e periode, la m o rta lite chez les 25 $
6 4 ans s 'e s t abaissee de 1 6 % . Les
m eurtres on au g m e n t^ de 8 4 6 4
en 1 9 6 0 $ 2 6 0 0 0 en 1 9 8 2 . La
m o rta lite globale chez les adolescents et
les jeunes adultes am ericains est 5 0 %
plus $levee que chez les jeunes Britanniques, Suedois ou Japonais. Les traum atism es a ffe c te n t des sujets jeunes e t prod u c tifs ; les pertes econom iques relatives
aux deces, $ I'in cap a cite ph ysiq u e et a la
perte de p ro d u c tiv ity depassant les $ 2 3 0

Les problem es re la tifs aux so in s aux
tra u m a tise s p e u ve n t etre c la s s if ie s dans
deux grandes ca te go rie s: c e u x du reseau
de soin e t les problem es p ro fe ssio n n e ls.
Les p ro b im e s de reseau to u c h e n t les
soins p re -h o sp italiers et h o s p ita lie rs , la
readaptation e t la p re ve n tio n . Les p r o b im es p ro fe ssio n n e ls c o n ce rn e n t la fo rm a 
tio n , la recherche, les ressources e co n o 
m iques e t la q u a lite . Plusieurs de ces
problem es s o n t relies $ l e ta b lisse m e n t
d 'u n program m e regional de so in s aux
trau m a tise s.

Trauma is the primary health and social
problem of our society. It is still the chief
cause of death in persons from 1 to 38
years of age. In 1981, there were 165 000
deaths from trauma and 9 400 000 dis
abling injuries of which 350 000 were per
manent. Recent statistics from the United
States Department of Health and Human
Services show that the mortality for
Americans aged 15 to 24 years has
increased by 50% since 1976 due to
automobile accidents, homicide and sui
cide. Motor vehicle accidents are the lead
ing cause of death among young white
m illio n s par jo u r. La sta tis tiq u e la plus
people (40%), while homicide is the lead
trag iq u e revele q u 'a u m oins 4 0 % des
ing cause of death among young black
deces so n t in u tile s et p o u rra ie n t etre prepeople (39%). In large urban centres,
venus si de m eilleurs tra ite m e n ts e t pro
black males have a 1 in 20 chance of not
gram m es p re ve n tifs e ta ie nt disponibles.
reaching the age of 30 years because of
Les d$ces par trau m a tism e s susceptihomicide.
bles d 'e tre prevenus so n t ceux resu lta n t
Trauma affects young, productive
des a ccid e n ts de la circu la tio n , les h o m i
citizens; the estimated cost for death, dis
cides, les m o rts par brulure et par abus
ability and loss of productivity exceeds
d 'a lc o o l ou de drogue. On propose dans
$230 million/d. The total annual cost is
ce t a rticle des suggestions p reventives:
staggering, $87.4 billion in wage losses,
am elioration de la resistance des vehicumedical expenses, insurance administra
les au tom o b ile s $ la collisio n , revo ca tio n
tion, fire loss, motor vehicle and property
du perm is de co nduire des co n d ucte u rs
*Chief of Surgery, San Francisco General
damage and indirect work loss.
Hospital, San Francisco, Calif.
trou ve s en e ta t d 'e b rie te , u tilis a tio n
Trauma patients consume 19 million
* Presented at the 6th annual meeting of the d 'ap p a re ils p e rm e tta n t de reduire le nom- hospital days annually, more than all
Canadian Association o f General Surgeons, bre de co n d u cte u rs ivres, aug m e n ta tio n
heart patients and four times those needed
4 held in conjunction with the 52nd annual
ta xe s sur I'alcoo l, a p p lica tio n au
by cancer patients. In the past decade, the
meeting of the Royal College o f Physicians des
hasard de I'a lc o o te s t e t u tilis a tio n de la
mortality for heart disease and stroke has
and Surgeons of Canada, Calgary, Alta.,
ce in tu re de securite, et du casque profallen by 22% and 32% respectively. The
7 Sept. 20, 1983
te cte u r pour les m o to cycliste s. Le conoverall mortality for cancer increased by
Accepted for publication June 27, 1984
trole des arm es $ feu e t la d im in u tio n
only 6% from 1950 through 1977, but
Reprint requests to: Dr. D.D. Trunkey,
des brulures a ttrib u a b le s a des incendies
mortality for stomach, rectal, cervical and
S Chief of Surgery, San Francisco General
allum es par une cig a re tte so n t aussi sus
uterine cancer has decreased. In contrast,
Hospital, 1001 Potrero Ave.,
ce p tib le de r$duire la m o rta lity.
San Francisco, Ca 94110
since 1977 the death rate for accidents has
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risen by approximately 1°/o per year.
Trauma is clearly a major health and
social problem.
I do not have accurate figures on death,
disability and costs for Canada but I have
no reason to believe they are substantially
different from those of the US with the
possible exception that Canada has less
violent crime. I do know that Canada has
approximately 15 000 accidental deaths
annually or 62.5/100 000 population.
This is comparable to the United States
where the rate is 68.7/100 000 popula
tion.
If we are to address the trauma
problem in a rational way, we must
understand the pathophysiology and
epidemiology, as we would in approach
ing any other disease process. Data from
our institution1 and others2 have shown
that death from trauma has a trimodal
distribution (Fig. 1). These deaths can be
characterized as immediate, early and
late. The pathophysiology is different for
each peak.
Immediate deaths are due to lacerations
of the brain, brain stem, upper spinal
cord, heart and aorta or other large ves
sels. Although few of these patients can
be saved, some deaths have been avoided
in large urban areas with the capability
for rapid transportation of trauma
patients.3,4
Early deaths are those that occur within
the first 2 to 3 hours. These are usually
due to subdural and epidural hematomas,
hemopneumothorax, ruptured spleen,
lacerations of the liver, fractured femur
or multiple injuries associated with severe
blood loss. Almost all of these injuries are
treatable; however, the interval between
injury and definitive treatment is critical.
The late deaths occur days or weeks
after the injury, and in nearly 80% of
cases the causes are sepsis, infection and
multiple organ failure.
These three groups will now be exa
mined in more detail to find out how
mortality and disability can be reduced.
Immediate Deaths
More than 50% of all trauma deaths
fall into this category. With the exception
of a few urban centres, there is little to
offer these patients. Furthermore, there
is virtually no hope that new or improved
methods o f care can reduce these deaths.
The only way of reducing these numbers
is through prevention. However, I am
pessimistic that we can mount an effec
tive prevention campaign since the issues
are social and exceedingly complex. Let
us examine a few of these problems,
which may result in immediate death of
the traumatized patient.
M otor Vehicle Accidents
There were 50 800 deaths in 1981 in the
US due to motor vehicle accidents. An
480

estimated 55% involved drivers who were
legally drunk. Efforts to control drunk
driving have met with modest success
recently. However, while there is initially
a decrease in accidents, deaths and inju
ries when stricter laws are passed, invari
ably law enforcement is relaxed, leading
to a return to the original death and injury
rates.5
A number of promising interventions
to reduce deaths and injuries involving
drunk drivers have been made.
Improved crash worthiness o f motor
vehicles.—The most advanced vehicle is
the research safety vehicle developed and
built by firms including Chrysler and
Volkswagen under contract to the US
Department o f Transportation. The road
safety vehicle was designed so that the
occupants could walk away from an 85
km /h head-on crash. No new technology
was needed; the vehicle includes air bags,
fuel cells (as used in racing cars), antiskid
brakes, roll bars, Securiflex windshields
(which greatly reduce facial injuries),
brake lights installed at rear window level
and “ soft” front ends. According to the
N ational H ighw ay T raffic Safety
Administration, all the safety features of
the road safety vehicle added $1200 to the
price of a $6000 car.
Administrative revocation o f drivers’
licences.—A driver’s licence could be
immediately revoked by an arresting
officer if the driver’s blood alcohol level
was 0.10 or greater. This provides swift
punishment that is followed by a trial in
court. The penalty for driving without a
licence must be increased to deter those
who have had their licences suspended.
The 1982 experience in Iowa6 with
administrative revocation showed an
important reduction in deaths and inju
ries involving drunk drivers; some esti
mate this at nearly 50%.
Devices that limit drunk drivers.—
Although they are in the prototype stage,
devices have been developed in vehicles
that may help prevent an alcohol- or
drug-impaired person from driving. These
include a breathalyser connected to the
ignition system sp that the vehicle will not
start if a high blood-alcohol content is
registered, a microprocessor that requires
a code or psychomotor skills to start the
vehicle and a device that activates the
horn and blinks the headlights when there
is faulty or erratic driving. So far, field
testing has been limited and results have
been variable.
Increased excise tax on alcohol.—It has
been demonstrated in various countries
that with an increase in the price of alco
hol there is a corresponding decrease in
the occurrence of cirrhosis and accidents
involving drunk drivers. This tax could
be a double benefit if it were used to pay
for any increases in trauma care costs,
particularly in rural areas where govern
ment subsidy is probable.

Random breathalyser tests.—Random
breathalyser tests at the roadside have
recently been instituted in Australia. If thq
driver is found to have an alcohol level
of 0.05, there is a fine of $300. If the alco- y
hoi level is 0.08, the fine is $1000 and the
licence is revoked immediately. Although
this program has only been in effect for
5 months, there has been a dramatic 1
reduction in alcohol-related motor acci
dents causing death and disability.
It is noteworthy that by improving the^
crash worthiness of motor vehicles, all
occupants of the vehicles involved are
protected, whether drunkenness is a fac
tor or not.
-y
Seat belts.—Yet another effective way
of reducing motor-vehicle accident deaths
is the use of seat belts or passive res
traints. US statistics are dismal since only ^
ll% of large vehicle and 14% of small
car occupants wear a seat belt. The Road
Safety Committee of the Australasian v
College of Surgeons recognized that seat
belts could effectively reduce motor vehi-»
cle deaths and disabilities. By instituting
a public campaign, legislation w a s4
introduced requiring mandatory use of
seat belts in Australia in 1970. By 1977,
there had been a 27% reduction in motor *
vehicle fatalities. Similar or better results
could be achieved by the use of passive
restraints such as the air bag.
j
Motorcycle helmets.—Another con--*
troversial prevention issue relates to the
mandatory use of motorcycle helmets. 4
From 1967 to 1976, a federal highway
.
safety standard required that all states
enact and enforce motorcycle helmet
laws. During this period, fatalities were
reduced by 50%. In 1976, the US Con,
gress removed the federal sanctions
against states not complying with the hel- ■<
met standard. As a consequence, at least
i
35 states have repealed or weakened the
helmet laws. This has resulted in a 40%
increase in fatalities. A study from the 'r
University of California concluded that,
“ use of a safety helmet is the single criti
cal factor in the prevention or reduction ,
of head injuries” .6 Two other studies
!
document the societal burden contributed
to by unhelmeted motorcyclists.6 Of 71
}

deaths. MOF = multiple organ failure.
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motorcyclists hospitalized at Denver
General Hospital, only 38% were covered
►by commercial insurance or workmen’s
compensation. Fifty-nine percent of the
!►unpaid bills were borne by taxpayers. In
a similar study from the Maryland Insti
tute for Emergency Medical Services, 26
of 65 patients did not have any insurance
' coverage.
*•

Homicides

Of the 26 000 murders in the US in
1982, a handgun was used in approxi
mately 11 000. It is well known that it is
easier to kill with a handgun than it is with
a knife. In our experience at San Fran
cisco General Hospital, 1 out of 6
v attempts at homicide with a gun is suc
cessful whereas only 1 out of 16 succeed
with a knife. There are 60 million hand
guns in the US and it seems impossible
r to do away with them. A more realistic
approach would be to control their use
‘by mandatory registration. This would
allow responsible citizens to own a hand
gun and make it easier for police to iden
tify the person who has an unregistered
handgun in his possession. Such an
► approach has been tried in Michigan and
Massachusetts with a substantial reduc
tion in homicides in which a handgun was
used. Enactment of handgun, control by
* each state does not seem realistic; the law
should be federal.
YBurn Deaths

There are approximately 8000 burn
deaths annually and 75 000 admissions to
hospitals in the US; more than half the
r patients are left with a permanent disa
bility or disfigurement. Cigarettes are
> responsible for more than one third of the
deaths and approximately one tenth of
the disabilities. The average American
cigarette has additives, both to the paper
‘ and tobacco, which cause the cigarette to
burn for approximately 28 minutes. If
these additives are removed, the average
cigarette would burn out in less than 4
minutes. Coincidentally, most American
jp- upholstered furniture and mattresses
require more than 4 minutes of exposure
Kto a cigarette before they will ignite. The
problem and the solution are obvious. We
* should remove the additives which do not
change the taste but would make the
cigarette relatively more fire-safe. Unfor^
tunately, the tobacco manufacturers will
not do this without federal legislation.
4 Just as in the case of motor vehicle acci
dents caused by the drunk driver, the
) smoker causes death and disability to
innocent victims. There are other ways of
preventing burns that are equally compel, ling, including the wearing of flameresistant bed clothing, the use of smoke
alarms, shorter cords on appliances and

reduction in water temperatures to pre
vent scalding of children.
Drug Use
Equally controversial is the issue of
legalizing drugs. I would be the first to
admit that legalization of drugs will not
solve the drug problem. During the past
15 years at San Francisco General Hospi
tal, the number of innocent victims
injured by penetrating trauma has
increased to approximately 40% of all
cases of penetrating trauma. Almost all
of these incidents are the result of drug
use and the need of addicts to finance
their addiction. Most addicts do this by
illegal methods. At the very least, one or
two states should establish pilot programs
to evaluate our current drug laws and the
effect of decriminalizing drug use.
Experience in this country suggests that
use of alcohol was not decreased by pro
hibition and may even have been
increased because of the aura or mystique
surrounding the forbidden fruit. Drug use
is probably similar, and there is no rea
son to think usage would be affected by
decriminalization. All of the negative
effects that accompany it, however,
would be reduced.
It is unfortunate that prevention is the
only way to reduce the immediate trauma
deaths. It is also ironic that prevention is
not only the best way to save lives but also
the cheapest — crisis intervention is
always expensive. Ultimately, prevention
would also affect the other two
categories, which I shall now address.
Early Deaths

Approximately 30% of all trauma
deaths fall into this category. Most of
these result from brain injuries and
hemorrhage. In order to reduce death and
disability from these two, some fun
damental principles must be followed.
Both require definitive surgical care as
soon as possible. Reducing the interval
from injury to definitive surgical care
involves at least two components of any
traum a system, prehospital and
in-hospital.
Prehospital Trauma Care
Three types of injury account for vir
tually all prehospital deaths. Direct
cerebral and upper spinal cord injuries
cause 50% to 55% of deaths. Exsanguination due to thoracic, abdominal and
other major vascular injuries or severe
pelvic or long bone fractures accounts for
30% to 40%. Airway obstruction, open
or tension pneumothorax and hypoxia
from other causes account for 10% to
15% of the total.

In patients with head injuries who die
but could be saved, the usual cause of
death is airway obstruction or aspiration
causing acute hypoxia. Patients with
extensive head injuries which result in
apnea or brain-stem herniation early are
not salvageable. In those who might be
saved, extreme elevation of intracranial
pressure does not usually develop for at
least 30 to 60 minutes. Preventable death
in the field is, therefore, usually due to
the airway problems that occur with
unconsciousness, not to the head injury
directly. Therefore, the essential skill the
paramedic can provide is endotracheal
intubation, which at once provides ven
tilation and airway protection. A secon
dary benefit is to reduce cerebral edema
by hyperventilation. The neurologic
lesion itself cannot be treated in the field
and is best handled by rapid transporta
tion to an appropriate centre.7 Spinal
protection in appropriate cases, particu
larly of the cervical spine, is also an essen
tial maneuver that can be quickly accom
plished. Since edema does not usually
develop for 30 to 60 minutes, mannitol
given in the field is unlikely to be of
benefit and might aggravate coexisting
hypovolemia.
The second most common cause of
death is exsanguination. What can the
paramedic offer? For isolated sources of
external bleeding, direct pressure to con
trol it is the obvious answer. The majority
of patients, however, have internal bleed
ing that can only be controlled by surgi
cal intervention. The only treatments that
are potentially beneficial are the establish
ment of an intravenous line with rapid
fluid administration and the use of the
pneumatic military antishock trousers
(MAST). Neither of these seems to be
controversial, but when the failure rate
(probably 20% to 30%) and time taken
for establishment of an intravenous line
are considered, these measures are more
questionable. In a study of 100 patients
with cardiac arrest reported by McSwain
and associates,8 the average time to
establish an intravenous line was 11
minutes. In a patient who may exsan
guinate in 15 to 40 minutes, the bleeding
rate must be 60 to 200 mL/min, as it
requires a loss of 40% to 50% of the
blood volume to cause hypovolemic
arrest. An average delay of 11 minutes to
start an intravenous infusion will allow
a blood loss of 700 mL to 1800 mL while
the attempt is being made, in addition to
losses before and after. Since the para
medic cannot normally infuse more than
1000 to 2000 mL of balanced salt solu
tion in the 10 to 20 minutes between
establishment of the intravenous line and
arrival at a hospital, the trade-off is not
a good one. To effect equivolemic
replacement of blood loss requires three
times as much balanced salt solution.
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Hence a 700-mL blood loss would require
at least 2000 mL of balanced salt solution
to compensate for it. The patient threa
tened with exsanguination in less than 40
minutes, therefore, loses more circulating
blood volume while the intravenous line
is being set up than can be given subse
quently by the paramedic to make up for
it. If total field time is more than 40
minutes, the benefits of an intravenous
infusion might outweigh its disadvan
tages. This would occur with prolonged
extrication or long transportation dis
tances. Where transport times of 5 to 20
minutes are usual, it is clear that starting
an intravenous infusion in traum a
patients is illogical; patients who are
bleeding rapidly and urgently need
volume replacement will be harmed by the
delay in starting it, and those who are not
bleeding rapidly do not need the volume
replacement.
Military antishock trousers have
enjoyed widespread use in civilian systems
since their introduction in Vietnam. There
are no randomized studies in the litera
ture demonstrating their effectiveness. It
is clear that arterial hypotension can often
be partially corrected by MAST applica
tion. Originally, this was thought to be
due to autotransfusion of blood from the
legs and lower abdomen. More recently,
it has been shown that only 200 mL of
blood is autotransfused and that the
major effects are due to increased
peripheral resistance due to the tourniquet
effect below the waist.
The beneficial effects of MAST are
thus a rise in proximal aortic pressure and
potential tamponade of bleeding sources
that lie within the area covered by the gar
ment, such as a badly fractured pelvis.
Potential negative effects are increased
bleeding from sources above the level of
the garment, compromise of ventilation
due to restricted rib-cage expansion and
elevation of the diaphragm, and ischemic
damage to tissues within the garment if

it is kept inflated too long. Also, there is
a sudden hypotensive effect when it is
deflated, with a concurrent washout of
lactic acid from ischemic tissues analo
gous to that which occurs with aortic
declamping.
It seems impossible to analyse the nega
tive and positive effects of MAST appli
cation and decide whether there is benefit
or not; a randomized clinical trial is the
only way to verify its usefulness. We
advocate such a trial, preferably multicen
tric, to develop data as rapidly as possi
ble. In the interim, it seems reasonable to
continue MAST use.
Most serious airway problems are
effectively treated by endotracheal intu
bation, as it protects the patient from
aspiration and provides a closed pneu
matic system for ventilation. Until now,
the esophageal obturator airway was
thought to be an effective alternative to
endotracheal intubation that did not
require a high level of training for usage.
It has now been shown in two different
centres (Sacramento and San Francisco)
that the esophageal obturator airway does
not function well, and that the incidence
of inadequate ventilation is unacceptably
high.9 Endotracheal intubation, though
more demanding in training time and skill
required, is sufficiently superior to justify
this investment.
For the remainder of the acute chest
problems, there seems little that can be
done in the field. Placement of chest darts
to relieve pneumothorax has been advo
cated but given the difficulty of making
this diagnosis on clinical grounds, it seems
unlikely that the field use of these devices
will ever be practical. The harm resulting
from placement of these darts in patients
with respiratory distress of other origin
outweighs the benefits in the small num
ber of patients with tension pneumotho
rax. Rapid transport is an essential fac
tor in obtaining good results with major
airway problems, since it is only in an

emergency department or surgical suite
that adequate facilities for diagnostic
evaluation, tube thoracostomy and thora- *
cotomy will be provided.10
Clearly, the principal reduction in mor- 1
tality for prehospital traumatic injury
comes from endotracheal intubation and
rapid transport. Trauma patients are fun
damentally different from cardiac arrest ^
patients who are customarily resuscitated
and stabilized before transport. Yet, both
share the same emergency medical serv- ^
ices system and ultimately both benefit
from rapid transport. It does not make
sense to plan separate cardiac and trauma
prehospital rescue and delivery. Yet, some
detractors of trauma systems argue that
trauma care will increase prehospital'
time. Nothing could be further from the ^
truth. Many communities have success
fully planned and implemented prehospi
tal rescue and treatment that do not
involve increasing the time of prehospi-u
tal transport or lead to unnecessary loss
'
of life.
*
In-hospital Trauma Care
The case for prompt definitive surgi
cal care for the trauma patient, once at
a hospital, is even more compelling than
the prehospital care. This care involves a
team of surgeons, anesthesiologists and ^
nurses, either in-house or available to
treat the trauma patient as soon as possi- i
ble after his arrival. This concept has
recently been dramatically demonstrated
in the care of patients with neurologic
trauma. Seelig and colleagues7 have
shown a dramatic change in outcome
when the neurosurgical procedure was
done within 4 hours of injury. The same ,
data suggest that results are even more
favourable when definitive surgery is
provided within 2 hours of injury.
Is this prompt surgical care being
provided? The evidence is overwhelm
ingly to the contrary. Studies done in the 4
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US to document hospital trauma care
clearly show that one third of all hospi
t a l trauma deaths could be prevented
(Table I2'11'21). The data further suggest
* that this is primarily a human problem
and not a facility, equipment or resource
problem. For example, one study2
t showed that the average response time of
surgical consultants was 1.26 hours. It is
►impossible to provide prompt, definitive
surgical care under such conditions.
For more than 40 years the American
College of Surgeons Committee on
Trauma has been an advocate of
improved trauma care. Since 1976, the
Committee on Trauma has formalized its
^recommendations in the form of guide
lines for optimal care of the trauma
►
- patient.22 Some are skeptical of this
approach; one of the reasons given is that
there is no evidence that regionalized
trauma care makes a difference. This is
nonsense. At least three examples now
t prove the efficacy of regionalized trauma
care: the experiences of the US military,
t. West Germany and Orange County,
California.
During World War I, the time lag from
injury to surgery was 12 to 18 hours and
^ the overall mortality was 8.5%. This was
reduced during World War II to 6 to 12
hours with a mortality of 5.8%. One of
the most dramatic reductions in the time
lag from injury to definitive care occurred
Y during the Korean conflict. The US Army
Medical Corps decided to bypass the bat
talion aid station and take the injured
soldier directly from the field to the
Mobile Army Surgical Hospital (MASH).
This is analogous to bypassing emergency
r rooms where prompt definitive surgical
care is not available and going to the

FIG. 2—Years of life lost (adapted from the
Surgeon General’s report, 1975) and federal
research dollars spent (adapted from the
National Institutes of Health, 1980).

regionalized trauma centre. The average
time lag from injury to definitive care
during the Korean conflict was 2 to 4
hours and overall mortality was 2.4%.
This tactic was improved upon in the
Vietnam conflict when casualties were
taken directly from the battlefield to the
corps surgical hospital, bypassing the bat
talion aid station and MASH. One study
showed that the average time lag from
injury to emergency surgical care was 65
minutes and another 81 minutes. Mortal
ity was reduced to 1.7%. This military
experience should have been an incentive
and a model for improvement in civilian
trauma care. Unfortunately, this gener
ally has not been the case.
The second example of improvement of
trauma care by trauma care systems
comes from West Germany. During the
late 1960s, West Germany studied our
methods and techniques of providing
battlefield care in Vietnam. In 1970, the
West Germans applied these methods vir
tually throughout the country and estab
lished trauma centres along the major
autobahns. Integral to their concept is
rapid prehospital transportation which
primarily involves the use of helicopters.
Ninety percent of all citizens in Germany
are no more than 15 minutes from a
designated trauma centre.
As a consequence of this regionalized
system, the annual mortality from motor
vehicle accidents, since 1970, has dropped
by 25% from 16 000 to 12 000. The Ger
man system is not only strong in prehospi
tal and hospital care but also has an excel
lent rehabilitation program . Most
survivors return to productive lives. By
applying simple arithmetic and assuming
that the 4000 patients who now survive
each year return to work, the financial
benefit to society is immense. If one
assumes that each survivor earns
$10 000/yr and pays $2500 in taxes, the
gross national product would be increased
by $220 million and tax revenues by $55
million. The value of a trauma centre,
therefore, becomes not only a reduction
in lost lives and disability but a positive
financial contribution to society as well.
Other countries, including Switzerland,
Austria and Israel, also have excellent
trauma systems. The US has islands of
excellence where trauma systems have
been developed such as in Maryland,
Houston, Dallas, Louisville, Seattle and
Detroit. One of the best such examples
is that in Orange County, California. As
a consequence of the second Orange
County study, five trauma centres were
designated in June 1980. A study done in
198323 examined the results and impact
of these designated trauma centres. This
is the first time that data are available
comparing trauma care before and after
the establishment of a centre. The data
showed that preventable deaths were

reduced from 73% to 9% when the
patients were treated in one of the five
designated trauma centres. If the patient
was inappropriately sent to a hospital that
was not a trauma centre, the mortality
remained high at 67%. The study further
noted that appropriate surgery was per
formed in the trauma centre. Patients did
not die because other hospitals were
bypassed en route to the trauma centre.
This finding is consistent with that from
Vietnam where battalion aid stations were
bypassed.
The evidence is overwhelming that
regionalized trauma systems improve the
immediate outcome in life-threatening
injuries and, in the long-term, the degree
of disability. We must develop a rational
prehospital care system. Future needs
include aggressive neurosurgical care and
brain edema research; we need to under
stand better the pathophysiology of brain
edema. A particularly vexing basic
research problem is spinal cord injury.
We need additional research in resuscita
tion, particularly in volume expanders,
shock and management o f pelvic
fractures.
Late Deaths

This final category accounts for
approximately 20% of all trauma deaths.
Eighty percent of these are due to sepsis
and multiple organ failure which seem to
be causally related. Risk factors include
shock, head injury, peritoneal contami
nation and malnutrition, which lead to
infections late in the course of the injury.
This may in turn be related to the failure
of the host defence and immune system.
The exact causes have not been eluci
dated. Once sepsis is established, progres
sive failure of heart, kidneys, liver, lung,
brain and hemopoietic system develops.
The mortality is high and is directly
related to the number of organ systems
involved.
The answer to why the trauma patient
is at risk for sepsis and multiple organ
failure lies in research and increased
knowledge. The need for basic trauma
research and improved education in
trauma led the American College of Sur
geons Committee on Trauma to the con
clusion that we need more level I (univer
sity) trauma centres to provide these
resources. Fig. 2 shows that the National
Institutes of Health spends very little of
its research dollar on trauma research.
Our national priorities are clearly directed
towards cancer and heart disease, yet,
trauma accounts for more years of lost
life than cancer and heart disease com
bined. I believe the US and Canada must
spend more money on research into
trauma even if it means a change in our
priorities. We should understand the rela
tion between traumatic shock, immune
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For surgical use
INDICATIONS:

Adjunctive use in surgery to help control capillary,
venous and small arterial hemorrhage when other
conventional methods are impractical or ineffective.
CONTRAINDICATIONS:

Packing or wadding, implantation in bone defects,
or around the spinal cord, the optic nerve and
chiasm unless it is removed after hemostasis is
achieved; to control hemorrhage from large arteries
or non-hemorrhagic serous oozing surfaces.
WARNINGS:

SURGICEL* is supplied sterile and should not be
autoclaved (autoclaving causes product breakdown).
SURGICEL* is not intended as a substitute for
careful surgery and the proper use o f sutures and
ligatures. Its closure in a contaminated wound without
drainage may lead to complications.
The hemostatic effect o f SURGICEL* is greater
when it is applied dry— it should not be moistened
with water or saline. It should not be impregnated
with anti-infective, buffeting or hemostatic agents.
Although SURGICEL* may be left in situ when
necessary, it is advisable to remove it once hemostasis
is achieved. It must always be removed front the
site o f application in hone after use in laminectomy
procedures and from foramina.
Although SURGICEL* is bactericidal against a wide
range o f pathogenic microorganisms, it is not intended
as a substitute for systematically administered
therapeutic or prophylactic antimicrobial agents to
control or prevent post-operative infections.

dysfunction and subsequent sepsis and
organ failure.
The late mortality can also be reduced
by the use of regionalized trauma centres.
By concentrating the most seriously ill
patients in one centre we can bring
optimal expertise to bear on the problems.
This also allows for clinical research
which recently has been de-emphasized in
the US.
In summary, I have tried to approach
trauma by analysing why the patient died.
I have identified three general areas
associated with deaths and each area has
its own set of solutions.
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SESAP IV Critique
IT E M S 50-51

Although the entire colon may be distended on plain films of the abdomen,
in patients suffering from acute toxic megacolon the transverse colon is most
prominently distended. The upper limit of the normal diameter of the trans
verse colon is 5.5 cm.
Corticosteroids are often used in the initial management of toxic megaco
lon. Their value is unproven, but they have never been shown to aggravate
this complication. If medical management fails, emergency operation is indi
cated to resect or decompress the colon. Barium enema, anticholinergics, opi
ates, antidiarrheal drugs, and hypokalemia have all been implicated as precipitat
ing factors.
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stenotic effect when applied as a wrap, prolongations
o f drainage in cholecystectomies; difficulty passing
urine per urethra after prostatectomy; blocked ureter
after kidney resection; burning after hemorroidectomy. Headache, burning, stinging, and sneezing in
epistaxis and other rhinological procedures; stinging
when applied on surface wounds.

\

18. WEST JG, TRUNKEY DD, LlM RC: Systems o f trauma
care. A study o f two counties. A rch Surg 1979; 114:
455-60

PRECAUTIONS:

Use only as much as necessary for hemostasis,
holding it in place until bleeding stops. SURGICEL*
should lie applied loosely against the bleeding
surface. Wadding or packing should be avoided,
especially within rigid cavities. Remove any excess
before surgical closure.
In urological procedures, use minimal amounts.
Care must be taken to prevent plugging the urethra,
ureter, or a catheter by dislodged portions o f the
products.
Use o f SURGICEL’ should not be preceded by
application of silver nitrate or any other escharotic
chemicals. SURGICEL* used temporarily to line
the cavity of large open wounds should be placed
so as not to overlap the skin edges and should be
removed after bleeding has stopped.
Take care in otorhinolaryngologic surgery to ensure
none o f the material is aspirated by the patient.
Do not apply SURGICEL* too tightly when it is used
as a wrap during vascular surgery.
Use sterile technique in removing SURGICEL* from
its envelope. Opened, unused SURGICEL* should be
discarded; it cannot be resterilized.
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Computerized Arthrotomography in Recurring Shoulder
Dislocations and Subluxations
r

'

k

A prospective study of 14 patients
demonstrated the value of computerized
arthrotomography in the unstable shoul^der. This technique allows the visualiza
tion of soft-tissue and bone anomalies
that cannot be detected otherwise.

A

*

Une etude prospective entreprise chez
14 patients a demontre I'utilite de I'arthrotomographie computerisee dans les
problemes d'instabilite de I'epaule. Cette
technique a permis de mettre en evi
dence des changements des tissus mous
et osseux non-detectables par d'autres
methodes.

The diagnosis of dislocating or subluxat
ing shoulder can usually be made by a
- well-documented clinical history and
physical examination and demonstrated
*by roentgenography with special views,
arthrography and arthrotomography; in
r difficult cases, more data may be needed
to demonstrate the pathologic features.

raphy confirmed the condition in nine but
not in five.
Computerized arthrotomography,
using a GECT/T8800 scanner (General
Electric Co., Milwaukee, Wise.), was'
done in all cases before operation follow
ing intra-articular injection of 4 mL of
60% iodine solution and 10 mL of room
air. The injection was performed from the
front, under fluoroscopic control and in
earlier cases both shoulders were injected
to obtain a comparison between the
asymptomatic and the affected shoulder.
Computerized arthrotomography de
monstrated soft-tissue and bone abnor
malities in all but one patient in whom an
artefact was produced by a metallic sta
ple. Those abnormalities consisted of
increased anterior recess (13 patients),
septae or adhesions (7 patients), labral

tear (5 patients) and glenoid rim fracture
or amputation (3 patients) (Figs. 1 to 3).
All these anomalies were demonstrated at
operation.
Discussion

The diagnosis of shoulder instability is
often suggested by the clinical history and
physical examination and is documented
by plain films with special views, arthro
graphy or arthrotomography; in some
cases the diagnosis may remain uncertain,
as in the case of patients having had a
previous operation for their condition and
those having the “ dead arm syndrome” ,
described by Rowe and Zarins,1 in which
the patient experiences paralysing pain
without necessarily having a feeling of
instability.

Patients and Methods

F We studied 14 patients (10 men, 4
women) who presented between 1980 and
> 1983 with a painful, unstable shoulder.
The mean age of the patients was 28 years
(range from 19 to 36 years).
The history was conclusive in 11
T patients and the apprehension test was
y positive for all 14. Routine roentgenog
v From the *Department o f Orthopedics and
the fDepartment o f Radiology, Faculty
o f Medicine, Universite de Sherbrooke,
Sherbrooke, PQ
Presented at the 52nd annual meeting o f
the Royal College o f Physicians and
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Reprint requests to: Dr. P. Kinnard,
Department o f Orthopedics, Centre
Hospitalier Universitaire de Laval,
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FIG. 1—-Normal shoulder on left. On right, small glenoid rim fracture not detected by
plain films (one arrow). Anterior recess (two arrows) is increased.
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Computerized arthrotomography re
presents a sophisticated method o f evalu
ating shoulder instability and is recom
mended for cases in which the diagnosis
is difficult .2
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Palliation after Operation and after Radiotherapy
for Cancer of the Esophagus

Because of the negligible cure rate in
»cancer of the esophagus, treatment is
aimed principally at providing good pallia
tion. This paper compares the degrees of
palliation achieved after the two main
'treatments for symptomatic carcinoma of
the esophagus. The degree of palliation
was measured by a grading system
^designed to assess only the subjective
responses of each patient. The results
show that palliation as defined and
measured in this study is the same after
Radiotherapy as after surgical excision.
Since the expected survival is the same
after radiotherapy as after operation, the
expected morbidity and mortality of radi
ation are lower and radiotherapy may be
^used where operation is not possible, the
authors suggest that radiotherapy is the
better primary treatment for symptomatic
squamous cancer of the esophagus.

Vu le taux negligeable de guerison
obtenu dans le cancer de i'oesophage, le
traitement vise principalement a assurer
un bon soulagement provisoire. Cet arti
cle compare le degre de soulagement
provisoire obtenu avec les deux princi
p a ls modalites therapeutiques du cancer
symptomatique de I'oesophage. Le degre
de soulagement a ete etabli a I’aide
r d'une echelle d ep reciation de la
reponse subjective des patients. Les
resultats revelent que le soulagement
^provisoire tel que defini et mesure dans
cette etude, est le meme apres radiotherapie comme apres excision chirurgicale.
Puisque la survie anticipee avec ces deux
►modes de traitement est aussi la meme,
que la morbidite et la mortalite reliees
aux radiations sont plus faibles et que la
radiotherapie peut etre utilisee la ou la
^chirurgie est impossible, les auteurs font
valoir que la radiothdrapie est le meilleur
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traitement primaire de I'epithelioma malpighien de I'oesophage.

Cancer of the esophagus and cardia has
one of the lowest cure rates o f any solid
tum our regardless of treatm ent.1'6
Some7’8 believe that the main goal of
treatment in this disease is to achieve good
palliation. Unfortunately, most fail to
define palliation, even though it is used
as a criterion of success or failure of the
treatment they describe. Palliation means
the toning down, mitigation or lessening
of a disease process or complaint;9 this
definition is too vague and is only useful
for anecdotal evaluations. For this rea
son a grading system was devised,4 high
lighting only the subjective responses of
the patient. No objective criteria such as
radiologic findings, blood counts or
weight changes are included. The grad
ing system has been used to assess the
results of bypass surgery in unresectable
tumours10 and to evaluate the use of per
manent endoesophageal tubes.11 In this
study, the grading system was used to fol
low up patients whose primary treatment
was either radiotherapy or surgery. We
have attempted to discover which of these
two treatments for esophageal carcinoma
will provide the best palliation.

Method
At the Cancer Control Agency of Brit
ish Columbia a weekly gastrointestinal
follow-up clinic is held. Most patients
attending the clinic are receiving
chemotherapy or radiotherapy, or both.
Surgeons and physicians are encouraged
to send surgically treated patients for
regular follow-up also, even though they
may not be receiving either of these treat
ments. While all irradiated patients were
seen immediately after the end of their
therapy, surgical patients were sometimes
not referred for several months after
operation.
On arrival at the clinic, each patient
with esophageal disease was interviewed
by the clinic nurse. A data collection sheet
(Fig. 1) was completed and a score and
grade were assigned for each visit. As

previously described,4 a score of 85 to
100 points was considered excellent and
graded A, 65 to 84 points was considered
good and graded B, 40 to 64 fair and
graded C and a score of 39 or less poor
and graded D. Other data on each pa
tient were collected from the records of
the British Columbia Cancer Control
Agency. The data collection sheet was not
affixed to the patient’s record because we
did not want to interfere with treatment
plans that might be made in the normal
follow-up pattern. During the period of
review some patients required secondary
treatment for deteriorating palliation. The
decision to perform dilatations, endoeso
phageal intubation or bypass surgery was
based on clinical evaluation without heed
to what grade had been assigned.
While a limited number of surgeons
take a special interest in esophageal dis
ease, there is no centralized unit dealing
with these problems in British Columbia.
Therefore, surgical treatment varied from
hospital to hospital and from surgeon to
surgeon. However, all patients who
underwent resection had the esophagus
reconstructed at the time of the initial
operation with varying lengths of
stomach, colon or jejunum, depending on
whether the anastomosis was made in the
left or right thorax or in the neck. Radi
ation was given by either cobalt-60 or
MeV4 machines, the dosage ranging from
2000 to 5500 rad in fractions over a vary
ing number of days depending on clini
cal factors. Most patients received 4500
rad.
Secondary intervention by dilatation
was usually performed with flexible
mercury-loaded dilators of the Hurst or
Maloney type. The Eder-Puestow guidewire system was used for more difficult
cases. Endoesophageal intubation was
performed using the technique described
by Atkinson and associates.12 Bypass
operations were extrathoracic in a substernal or subcutaneous plane, using
whole stomach, colon or, on one occa
sion, jejunum .13

Findings
There were 82 patients, 55 men and 27
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women. One man had two squamous
tumours making a total of 83 lesions. Fig.
2 shows the age distribution. The histol
ogy and level of the lesions are noted in
Table I. Table II breaks down the 82
patients according to the histologic type
of the tumour and treatment.
Fig. 3 compares the average palliation
levels over five time intervals. A patient
sometimes made more than one visit to
the clinic in the time intervals shown. The
average score of these visits is depicted as
one observation. The changing numbers
of surgical patients occurred because
some patients were not registered for
follow-up for several months after oper
ation. All irradiated patients were com
pared with all resected patients regardless
of the histologic type of the tumour. This
is justified because our concern is with
palliation levels not longevity after treat
ment. Examination of each time period
in Fig. 3 shows that there is no statisti
cally significant difference between the
two treatment groups (Mann-W hitneyWilcoxon rank sum test).
O f 53 irradiated patients, 24 (45%)
underwent one or more secondary proce
dures in attempts to maintain their palli
ation level. O f these, 21 were improved
and 3 were not. However, seven patients
(13.2%) died within 30 days of the secon
dary intervention. Two of these patients
had what the authors believe were illadvised major late salvage procedures
(esophagectomy).
Of the surgical series, 8 of 29 patients
(27.6%) required secondary intervention
in attempts to maintain palliation levels.
These interventions included dilatation,
a Roux-en-Y procedure for reflux esopha
gitis, pyloroplasty or gastroenterostomy
for gastric outlet obstruction, feeding
enterostomy and one extrathoracic colon
bypass for anastomotic recurrence. One
of these 29 patients (3.4%) died within 30
days of secondary intervention. Also,
several patients with adenocarcinoma
who were treated by primary operation
had chemotherapy later. The mortality of
the surgical series is not available because
we have no knowledge of the total pool
from which the referred patients origi
nated.
Discussion

come bonus of good palliation.8 The
recently reported Chinese experience14' 16
may be an outstanding exception to this
rule. The endemic nature of the disease
in northern China is reported to allow
early diagnosis at an asymptomatic stage.
Even if this is so, such results are not
applicable to the sporadic cases that occur
in British Columbia. Here, as elsewhere
in the western world, the disease presents
with dysphagia, a symptom indicating a
late phase of the disease.16 This is surely
the root cause of our poor results regard
less of the treatment used.4
Still more disturbing is that in addition
to the poor results of either major mode
of treatment, it has been suggested that
prolonged survival may have more to do

CANCER

with the inherent biologic activity of the
tumour than anything that might have
been done to attenuate it. Belsey and*
Hiebert8 reported that of 119 patients
who had resection for palliation only, 9
survived for between 2 and 17 years; fur
ther, 7 of these 9 were considered to hav£
had inadequate resection by the examin- 4
ing pathologist.
For these reasons attempts at curative
treatment should perhaps be abandoned
and all our efforts directed to achieve -»
maximum palliation. So far, only anec
dotal assessments have been made of thA
palliative value of treatment methods. In
this study, we attempted to fill that gap 4
in our knowledge by assigning a grade at
each follow-up visit. The grading system
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Evaluating the results of treatment for
carcinoma of the esophagus is an exercise
in assessing varying degrees of failure.
Indeed, from a review of the world
experience,5-6 it is clear that while
sporadic reports have revealed some sur
prisingly good 5-year survival rates, most
centres cannot duplicate these successes
even by seemingly adopting the same
treatment protocols. It is sadly true that
cures are a curiosity, and one must regard
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492

i.

N o .......................................

(4)

2.

Y e s ....................................

______ ( 0)

(If

yes,

Current

answer
Work

i.

Not

2.

Light

below)

Activity

working
work

3.

Lighter

4.

Previous

.........................
—

work

part-time

or

part-time
—

.

full-time

equivalent

(0)

.

.

.

( 2)

.

.

.

(3)

—

............................

(3)

FIG. 1—Data collection sheet and scores; 85-100 points = grade A, 65-84 = grade B,
40-64 = grade C and 39 points or less = grade D.
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is heavily weighted towards the assess
ment of dysphagia and pain, but some
attention is given to the ability to sleep
and enjoy leisure time. Few people of the
age at which there is a high frequency of
esophageal cancer are still gainfully
employed but old people must do work
at home. This activity is as much a day’s
work as any other and therefore has been
included in the assessment. Perhaps the
grading system is imperfect in that it
refers to a particular age, socioeconomic
and cultural group who live in western
Canada, a region with a relatively high
standard of living and with welldeveloped social support services. We
agree that such scoring systems may
require adjustments to suit age, economic
and cultural factors in other locations,
but this does not vitiate the principle
involved. We hope this study will
encourage a move away from anecdotal
reports on the results of palliative treat
ments in esophageal cancer and in other
so-called incurable tumours.

FIG. 2—Age of patients at time of diagnosis.
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Our surgical group contained patients
with adenocarcinoma while the radiother
apy group contained only patients with
either squamous or undifferentiated car
cinomas. The prognosis differs little for
patients with adenocarcinoma at the
cardia or lower third of the esophagus
and since the study was not concerned
with longevity, we saw no reason why
patients who underwent resection could
not be compared with all those who had
radiotherapy. We agree with the widely
held view5 that all resectable adenocarciromas should be excised since radiation
is not an acceptable option for these.
Perhaps in the hands of other clinicians
some of the squamous tumours would
have been surgically treated, but we have
not assessed this aspect of the series. The
preponderance of patients receiving
primary radiotherapy reflects the frequent
direct referral to the Cancer Control
Agency of British Columbia for radiation
by family physicians and specialist inter
nists without a surgical opinion.
The results of this study (Fig. 3) indi
cate that there is no difference between
palliation levels achieved by primary sur
gical excision of squamous tumours and
by primary irradiation followed by secon
dary procedures as they become neces
sary. As might be expected, 45% of the
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irradiated group required secondary treat
ments either due to fibrous postradiation
stenosis or, more often, to recurrence of
tumour. Of the three patients not helped,
two died very soon after late (and illadvised) major salvage attempts to excise
the original primary lesion. Excluding
these two cases, 5 of the 53 irradiated
patients (9.4%) died within 30 days of
secondary intervention. We do not have
a primary surgical 30-day mortality to use
for comparison but a 10% mortality
would be considered better than average
in the current surgical literature.5 Com
parison with primary surgical mortality
is more complex because these seven
patients had had the benefit of a period
of acceptable grade A or B palliation,
which they would not have had if they
had died of a primary surgical excision.
Further examination of the surgical ser
ies shows a disturbing need for secondary
intervention. As noted by others,17
primary surgical excision is not the end
of the story for almost one third of
patients. Thus, 27.5% of the patients
reported here were so treated and one
patient (3.4%) died. In our experience,
most surgeons are not fully aware of these
consequences of resection. O f course,
many patients present with a squamous
tumour so advanced that it could not have
been treated surgically. We did not define
this group in advance for special study but
their inclusion in the total group did not
obviously affect the overall results, and
indeed would be expected to produce a
bias against radiotherapy.
In Fig. 4, we present a flow diagram
suggesting an overall scheme for the
management of squamous and undif
ferentiated cancer of the esophagus. This
approach refers only to symptomatic dis
ease since a philosophy of treatment for
cure may prove to be realistic if the dis
ease is detected while still asymptomatic.
In summary, taking into account (a)
that palliation levels are as good follow
ing radiotherapy as after operation, (b)
that expected survival is the same after
radiotherapy as after operation, (c) that
early morbidity and mortality are lower
after radiotherapy than after operation
and (d) that radiotherapy may be used

where operation is not possible, we sug
gest that radiotherapy is the better
primary treatment for symptomatic squa
mous or undifferentiated cancer of the
esophagus.
We are grateful for the assistance of Mrs.
E. Yamamoto at the Cancer Control Agency
of British Columbia follow-up clinic in collect
ing data from the patients. We also thank Mrs.
M .J. Moreton for preparing the manuscript.
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Patent Urachus and Infected Urachal Cyst in an Adult: „
a Case Report
Urachal abnormalities are usually diag
nosed early in life, so the finding of a
patent urachus associated with an
infected urachal cyst in a 21 -year-old
man as reported by the author is rare
and of interest. The condition was
managed by excision of the urachus, the
cyst, the umbilicus and dome of the
bladder, which is the preferred treatment.
The author reviews other urachal
anomalies and the complications
arising from them.
Les anomalies de I'ouraque sont habituellement diagnostiquees tot aprfes la naissance d'ou I'interet de la ddcouverte
chez un homme de 21 ans d'un ouraque
permeable associd a un kyste infecte.
Le cas decrit a ete traite par excision de
I'ouraque, du kyste, de I'ombilique et
de la coupole de la vessie; c'est Id le
traitement de choix. L'auteur passe
en revue les autres anomalies de I'ouraque
et les complications qui en decoulent.

Abnormalities of the urachus are rare and
are generally noted at birth or in early
childhood. However, their occurrence in
the adult is occasionally recognized, as in
the patient reported here.
Case Report
Dysuria, frequency and cloudy urine had
been present for several weeks before this
21-year-old man was admitted to hospital.
Antibiotics initially controlled the symptoms,
but then lower abdominal pain developed
together with a red, swollen umbilicus that dis
charged pus. His family physician diagnosed
an infected patent urachus.
Cultures of urine and the umbilical discharge
showed mixed enteric floral growth. An excre
tory urogram appeared normal. A fistulogram
revealed an infected urachal cyst with commu
nication to both the bladder and umbilicus
(Fig. 1). At cystoscopy, an edematous area at
the bladder dome was noted. Before operation,
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antibiotics were administered systemically and
instilled through a transumbilical catheter.
The patent urachus and urachal cyst were
excised together with the umbilicus and the
dome of the bladder. The postoperative course
was smooth and the patient had no further
symptoms during a 3-year follow-up.

Discussion
Congenital abnormalities of the urachus
are uncommon; only three cases were
reported out of 200 000 admissions to the
Children’s Hospital Medical Center in
Boston.1,2 Males predominate in a ratio
of 5 to 1. Reported cases in adults are very
rare.3-5
The urachus is derived from two
sources — the allantois and the ventral
cloaca — but the exact contribution of
each remains controversial.6 The allan
tois is a finger-like blind-ending process
of the yolk sac that extends into the body
stalk and is continuous in its internal
aspect with the ventral cloaca (Fig. 2).
Eventually, the body stalk becomes the
umbilical cord and the ventral cloaca the
urinary bladder. After 3 months’ gesta
tion, the allantois becomes an obliterated
fibrous band, but the urachus elongates
with fetal growth, then narrows to an
epithelialized tube after 4 months. At
birth, the urachus is a three-layered tubu
lar structure connecting the bladder dome
to the umbilicus. It is extraperitoneal with
the transversalis fascia forming its
anterior relationship, the peritoneum its
posterior; on each side are the obliterated
umbilical arteries. The lumen is lined by
transitional or columnar epithelium.
There is a middle connective tissue layer
with blood vessels and lymphatics and an
outer layer of muscle continuous with the
detrusor.
Urachal anomalies may take one of
several form s.7 The patent urachus
results from failure of the urachal lumen
to obliterate, and as a result a free com
munication between the bladder and the
umbilicus is present. While lower urinary
obstruction is occasionally associated with
urachal patency, it is not considered to
be a contributing factor.8
The diagnosis is usually made at or
shortly after birth. The umbilical cord
may be thickened and tense9 or urine
may be noted to drain from the umbili-

cus. Contrast fistulography, analysis of
the fluid, cystography and cystoscopy will
confirm the diagnosis and differentiate
i
this condition from a patent omphalome-' i
senteric duct. The recommended treat- y
ment is complete excision including the
umbilicus and a cuff of bladder. A ura*
chal cyst develops usually in the lower
third of the duct, when the urachal lumen ■*;
fails to obliterate completely. It may be
asymptomatic and discovered incidentally' -.
or it may present as a lower abdominal |
cystic mass.10 Symptoms usually arise as *
a result of secondary infection which is4
the most common presentation in the
adult. Complete excision is preferred to 4
marsupialization and if there is infection,

FIG. 1—Umbilical fistulogram shows patent
urachus with infected urachal cyst in lower-*
third of duct.

VOLUME 27, NO. 5, SEPTEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

Pfizer Introduces

h AN IMPORTANT INNOVATION IN
r HOSPITAL ANTIBIOTIC THERAPY

Is

C ELLEN T
L IN IC A L
jF E C T IV E N E S S 1
X TE N D E D
l VITR O
N TI B A C TE R IA L
PECTRUM 1

N O A D JU S T M E N T
G E N E R A LLY
R E Q U IR E D
IN U S U A L
D O S A G E FO R
PATIENTS
W ITH R E N A L
O R HEPATIC
IM P A IR M E N T 1

i

IG H P E A K
pR U M L E V E L S 1
\jE R A P E U T IC
V N C E N T R A T IO N S
1A VAR IETY O F
IS S U E S A N D
p D Y F L U ID S 1
iLD . D O S IN G
OR A L L
1D IC A T IO N S 1

l

I

-V

E X C E LLE N T
S A F E T Y P R O F ILE
A N D W ELL
TO LE R A TE D 7
S U B S TA N TIA L
SAVING S IN
A D M IN IS T R A T IO N
C O STS D U E TO
B.I.D . D O S IN G 2

Pfizer Introduces

cefoperazone sodium /pfizer

IV/IM

AN IMPORTANT INNOVATION
IN HOSPITAL ANTIBIOTIC THERAPY
Prescribing Information
CEFOBID*
(cefoperazone sodium)

For Intravenous or Intramuscular Injection

Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of CEFOBID (cefoperazone sodium) results from the
inhibition of bacterial cell wall synthesis.
INDICATIONS AND CLINICAL USES
CEFOBID (cefoperazone sodium) may be indicated lor the treatment ot the following infections when
caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae. Haemophilus in
fluenzae. Staphylococcus aureus. Streptococcus pyogenes. Klebsiella species (including Klebsiella
pneumoniae). Pseudomonas aeruginosa, Escherichia coli. Proteus mirabihs. indole-positive Proteus
species and Enterobacter species
URINARY TRACT INFECTIONS caused by Escherichia coli. Pseudomonas aeruginosa. Enterobacter
species, Klebsiella species, Enterococcus, Proteus mirabilis, Staphylococcus aureus. Staphylococ
cus epidermidis and indole-positive Proteus species
Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas
infections of the lower respiratory and urinary tracts, a good clinical response accompanied by
bacterial eradication may not be achieved despite evidence of in vitro sensitivity
ACUTE BILIARY TRACT INFECTIONS ASSOCIATED WITH CHOLECYSTITIS OR CHOLANGITIS caused
by Escherichia coli.
SEPTICEMIA caused by Staphylococcus aureus. Streptococcus pneumoniae. Streptococcus aaalactiae. Escherichia coli and Klebsiella species
WOUND INFECTIONS (SURGICAL AND TRAUMATIC) caused by Staphylococcus aureus. Streptococ
cus pyogenes and Pseudomonas aeruginosa.
GYNECOLOGICAL INFECTIONS (SUCH AS PELVIC INFLAMMATORY DISEASE AND ENDOMETRITIS)
caused by Streptococcus agalactiae, Neisseria gonorrhoeae. Escherichia coli. Bacteroides species
(including Bacteroides fragihs), Peptococcus species and Peptostreptococcus species
Specimens for bacteriologic culture should be obtained prior to therapy in order to identify the causative
organism and to determine its susceptibility to CEFOBID (cefoperazone sodium). Therapy may be in
stituted before results of susceptibility testing are known; however, modification of the treatment may be
required once these results become available
CONTRAINDICATIONS: CEFOBID (cefoperazone sodium) is contraindicated in patients with known
allergy to the cephalosporin class of antibiotics.
WARNINGS: Before therapy with CEFOBID (cefoperazone sodium) is instituted, careful inquiry should be
made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins
penicillins or other drugs CEFOBID (cefoperazone sodium) should be administered with caution to
penicillin-sensitive patients or to any patient who has demonstrated some form of allergy, particularly to
drugs. If an allergic reaction to CEFOBID (cefoperazone sodium) occurs, discontinue administration of
the drug and treat the patient with the usual agents (e g epinephrine, antihistamines, pressor amines or
corticosteroids)
Pseudomembranous colitis has been reported to be associated with the use of CEFOBID (cefoperazone
sodium). Therefore, in those patients administered CEFOBID (cefoperazone sodium) who develop diar
rhea, it is important to consider such a diagnosis
Treatment with broad-spectrum antibiotics, including CEFOBID (cefoperazone sodium) alters the
normal flora of the colon and may permit overgrowth of Clostridia. Studies indicate that a toxin produced
by Clostridium difficile is one primary cause of antibiotic-associated colitis
Mild cases of colitis may respond to drug discontinuance alone Moderate to severe cases should be
managed with fluid, electrolyte, and protein supplementation as indicated When the colitis is not reliev
ed by the discontinuance of CEFOBID (cefoperazone sodium) or when it is severe, consideration should
be given to the administration of oral vancomycin.
PRECAUTIONS
General: The concomitant administration of aminoglycosides and some cephalosporins has caused
nephrotoxicity. Although transient elevations of BUN and serum creatinine have been observed, there is
no evidence that CEFOBID (cefoperazone sodium) when administered alone causes significant
nephrotoxicity However, the effect of administering CEFOBID (cefoperazone sodium) concomitantly
w ith aminoglycosides is not known
^ EF? £)DJ ce,ODerazone s°d|um) '.s excreted in both the bile and urine. In normal volunteers, 19 to
4 1 /o of the dose is excreted in the urine, the remainder being excreted by the hepato-biliary system The
serum half-life of CEFOBID (cefoperazone sodium) is usually prolonged and urinary excretion of the drug
increased in patients with hepatic disease and/or biliary obstruction Serum concentrations of
cefoperazone should be monitored in these patients treated with doses in excess of 2 grams daily and
dosage should be adjusted as necessary
Because renal excretion is not the main route of elimination of cefoperazone, adult patients with renal
failure usually require no adjustment in dosage when daily doses of 2 to 4 grams (1 to 2 grams every 12
hours) are administered. If higher doses of CEFOBID (cefoperazone sodium) are used, serum concentra
tions of cefoperazone should be monitored. If there is evidence of accumulation, dosage should be
decreased accordingly
In one study in patients with chronic renal failure, the half-life of CEFOBID (cefoperazone sodium) was
reduced from 4 17 to 1.67 hours during hemodialysis Thus, dosing should be scheduled to follow a
dialysis period
In patients with both hepatic dysfunction and renal impairment, the initial dosage of CEFOBID
(cefoperazone sodium) should not exceed 1 to 2 grams daily and serum concentrations of cefoperazone
should be monitored closely
Vitamin K deficiency has occurred in a few patients treated with CEFOBID (cefoperazone sodium) The
mechanism is most probably related to the suppression of gut flora which normally synthesizes this
vitamin Those at risk include patients with poor diet or malabsorption states (e g cystic fibrosis) and
patients on prolonged intravenous alimentation regimens. Prothrombin time should be monitored in
these patients and exogenous vitamin K administered as indicated
A reaction characterized by flushing, sweating, headache, and tachycardia has been reported when
alcohol is ingested during and as late as the fifth day after CEFOBID (cefoperazone sodium) administra
tion Patients should be cautioned concerning ingestion of alcoholic beverages in conjunction with ad
ministration of CEFOBID (cefoperazone sodium). For patients requiring artificial feedmq orally or
parenterally, solutions containing ethanol should be avoided
CEFOBID (cefoperazone sodium) should be administered with caution to individuals with a history of
gastrointestinal disease, particularly colitis.
Overgrowth of nonsusceptible organisms may occur during prolonged use of CEFOBID (cefoperazone
sodium) Patients should be observed carefully during treatment. If superinfection occurs, appropriate
measures should be taken
K

Drug Laboratory Tost Interactions
^
A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution
Pregnancy: The safety of CEFOBID (cefoperazone sodium) in pregnancy has not been established. The
use of CEFOBID (cefoperazone sodium) in pregnant women requires that the likely benefit from the d ry *
be weighed against the possible risk to the mother and fetus
Reproduction studies have been performed in mice, rats and monkeys at doses up to 10 times the
human dose and have revealed no evidence of impaired fertility or teratogenic effects di>& to
cefoperazone sodium Animal reproduction studies, however, are not always predictive of human
response
Nursing Mothers: Cefoperazone is excreted in low concentration (0 4 to 0.9 /xg/mL) in human milk v
Caution should be exercised when CEFOBID (cefoperazone sodium) is administered to a nursing mother
Children: The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been
established
^
ADVERSE REACTIONS
Hypersensitivity: Macuiopapular rash, urticaria, pruritis. eosinophilia. drug fever
Hematology - Decreases in hemoglobin and/or hematocrit have occurred Slight decreases if?
neutrophil count have been reported, and reversible neutropenia may occur with prolonged administra
tion Transient eosinophilia has occurred. Hypoprothrombmemia has been observed Some individuals
have developed positive direct Coombs' test during treatment
-4
Liver — Transient elevations in SGOT, SGPT and alkaline phosphatase levels have been noted One pa
tient with a history of liver disease developed significantly elevated liver function enzymes during
therapy with CEFOBID (cefoperazone sodium). Clinical signs and symptoms of nonspecific hepatitis ac- *
compamed these increases After CEFOBID (cefoperazone sodium) therapy was discontinued, the pa
tient s enzymes returned to pre-treatment levels and the symptomatology resolved
Kidney - Transient elevations of blood urea nitrogen and serum creatinine have been noted.
Gastrointestinal - Altered bowel habits (loose stools or diarrhea) have been reported. Most of these
events have been mild or moderate, but some have been severe In all cases, these symptoms respond
ed to symptomatic therapy or ceased when cefoperazone therapy was stopped Nausea and vomitinq
have been reported rarely
Pseudomembranous colitis has been reported rarely in patients administered CEFOBID (cefoperazone*
sodium) Symptoms of pseudomembranous colitis can appear during or for several weeks subsequent to
antibiotic therapy
Oisulfiram-like Reaction
<
Disulfiram-like reactions have been reported when alcohol was ingested during and as late as the fifth
day after CEFOBID (cefoperazone sodium) administration
Central Nervous System — Headache and dizziness occur rarely
s
Local Reactions — CEFOBID (cefoperazone sodium) is well tolerated following intramuscular administra
tion Occasionally, transient pain may follow administration by this route When CEFOBID (cefoperazone
sodium) is administered by the intravenous route, some patients develop phlebitis at the site ot 3*
ministration
Other — Diaphoresis/chills
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Since no case of overdosage has been reported to date with CEFOBID (cefoperazone sodium), no
specific information on symptoms or treatment of overdosage is available. Treatment should be sycaotomatic.
Hemodialysis is not effective in the removal of cefoperazone.
DOSAGE AND ADMINISTRATION
DOSAGE
CEFOBID (cefoperazone sodium) may be administered intravenously or intramuscularly.
*
Dosage and route of administration should be determined by severity of infection, susceptibility of the
causative organism, and condition of the patient
Aduft
A
The recommended daily dose of CEFOBID (cefoperazone sodium) is 2 to 9 grams administered in equal
ly divided doses every 8 to 12 hours (See table below). The usual duration of treatment is 7 to 14 days
Adult Dosage
*
Type of Infection
Daily Dose
Frequency and Route
Mild to moderately severe
2 to 4 grams
1 to 2 grams
infections such as pneumonia,
every 12 hours
acute urinary tract infection,
l M or I V.
wound infection
Severe infections or infections
4 to 8 grams
2 to 4 grams
caused by less sensitive
every 12 hours
organisms
IV .
Infections commonly requiring
9 grams
3 grams every
antibiotics in higher dosage
8 hours I V
(e g septicemia and lifethreatening infections)
The maximum adult daily dose should not exceed 9 grams.
For infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days
Impaired Renal Function
Because renal excretion is not the main route of elimination of cefoperazone, adult patients with renal
failure usually require no adjustment in dosage when daily doses of 2 to 4 grams (1 to 2 grams every Ifi
hours) of CEFOB'D (cefoperazone sodium) are administered If higher doses of CEFOBID (cefoperazone
sodium) are used, serum concentrations of cefoperazone should be monitored. If there is evidence of
accumulation, dosage should be decreased accordingly. For patients whose glomerular filtration rate isi.
r lc n m n , « L/mm or whose serum crea,inine level is greater than 3 5 m g/dL, the maximum
CEFOBID (cefoperazone sodium) dosage should be 4 grams per day
In patients undergoing hemodialysis, dosing should be scheduled to follow a dialysis period
Hepatic Disease and Biliary Obstruction
The serum half-life of cefoperazone is increased 2 to 4 fold in patients with hepatic disease and/or
biliary obstruction Serum concentrations of cefoperazone should be monitored in patients treated with I
doses in excess of 2 grams daily and dosage should be adjusted as necessary
Hepatic Dysfunction and Renal Impairment
^ePat'c dysfunction and concomitant renal impairment, the initial dosage of
CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and serum concentrations of
cefoperazone should be closely monitored
Children
The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been established
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ADMINISTRATION
Intramuscular:
CEFOBID (cefoperazone sodium) should be administered by deep intramuscular injection into a large
muscle mass such as the gluteus maximus or anterior thigh. The maximum dose of CEFOBID
(cefoperazone sodium) should be two (2) grams.
Intravenous:
Direct Intravenous (bolus) Injection: The reconstituted solution should be injected slowly over a
period of no less than three (3) minutes. The maximum dose of CEFOBID (cefoperazone sodium)
should be two (2) grams.
Intermittent Intravenous Infusion: The reconstituted solution may be infused over a period of 15
minutes to 1 hour through the tubing of an administration set while any of the intravenous solutions
(See Solutions for I V. Infusion) are being infused. During infusion of the solution containing
CEFOBID (cefoperazone sodium), it is desirable to temporarily discontinue administration of the other
solution.
Continuous Intravenous Infusion: CEFOBID (cefoperazone sodium) may also be administered over a
longer period of time.
Note: If therapy with CEFOBID (cefoperazone sodium) is carried out in combination with an
aminoglycoside antibiotic, each should be administered at different sites because of a physical in
compatibility. An aminoglycoside should not be mixed with CEFOBID (cefoperazone sodium) in the
same container,
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFOBID
Proper Name: Cefoperazone sodium
Chemical Name:
Sodium (6R,7R)-7-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-(p-hydroxyphenyl)
acetamidoJ-3 [[(1 -methyl-1 H-tetrazol-5-yl)thio]methyll-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylate
1

►

Molecular Formula: C25H26NQ0QS2Na Molecular Weight: 667.65
Description:
Cefoperazone sodium is a white powder, soluble in water, sparingly soluble in methanol, poorly soluble
in ethanol, and insoluble in ethyl ether, acetone, chloroform, or n-hexane
Composition:
CEFOBID vials contain cefoperazone sodium (expressed in terms of free acid). The sodium content of
each gram of CEFOBID is approximately 34 mg (1.5 mEq sodium ion). The pH of a 25% (w /v) solution
is 4.5 to 6.5 and the solution is colorless to straw yellow depending on the concentration.
4

RECONSTITUTION
For Intramuscular Use:
Solution for Reconstitution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
0.5% Lidocaine Hydrochloride Injection
Reconstitute as follows:
Volume to be
Vial Size
Added to Vial
(0)
(mL)

Approximate
Available
Volume (mL)

Approximate
Average Concentration
(mg/mL)

1.0
3.5
4.0
250
2.0
7.0
8.0
250
Shake well until dissolved. Solutions should be allowed to stand after reconstitution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization. Vigorous and prolonged
agitation may be necessary to solubilize CEFOBID (cefoperazone sodium).
For Intravenous Use:
Solutions for Reconstitution and Dilution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
Reconstitute as follows:
Volume to be
Approximate
Approximate
Vial Size
Added to Vial
Available
Average Concentration
(g)
(mL)
Volume (mL)
(mg/mL)
1
9.5
10.0
100
2___________________19T)___________________ 20T)_________________
100

r
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Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any
of the solutions for I.V. infusion listed below.
For direct intravenous (bolus) injection: Reconstitute as directed above.
For intermittent intravenous infusion: Reconstitute as directed above
For continuous intravenous infusion: Reconstitute with Sterile Water for Injection. The-reconstituted
solution may be added to an appropriate intravenous bottle/bag containing any of the solutions for I V
infusion listed below:
Solution for I.V. Infusion
5% Dextrose Injection (USP)
10% Dextrose Injection (USP)
5% Dextrose and Lactated Ringer’s Injection
Lactated Ringer's Injection (USP)
5% Dextrose and 0.9% Sodium
0.9% Sodium Chloride Injection (USP)
Chloride Injection (USP)
NormosoP M and 5% Dextrose Injection
5%Dextrose and 0.2% Sodium
Normosol® R
Chloride Injection (USP)
Stability of Solutions
Storage:
Reconstituted solutions for intramuscular injection should be used within 24 hours if kept at room
temperature, or 72 hours if stored under refrigeration (5°C).
Reconstituted solutions for I.V injection or infusion should be used within 24 hours if kept at room
temperature, or 72 hours if stored under refrigeration (5°C).
Incompatibility
CEFOBID (cefoperazone sodium) should not be added to blood products, protein hydrolyzates, or amino
acids. CEFOBID (cefoperazone sodium) should not be mixed together with an aminoglycoside
DOSAGE FORMS
Availability:
CEFOBID (cefoperazone sodium) is available as a lyophilized powder:
1 .Og vial — cefoperazone 1.0 g as sodium salt
2 Og vial — cefoperazone 2.0 g as sodium salt
Storage
CEFOBID (cefoperazone sodium) should be stored protected from light and refrigerated (2 to 8°C).
References:
1. Official product monograph.
2. Data on file.
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FIG. 3—Anomalies of urachus. Sagittal sec
tion.

the procedure may be preceded by inci
sion and drainage (Fig. 3).
Vesicourachal diverticulum and ura
chal sinus are blind-ending structures that
originate at the umbilicus or bladder, but
are not in free communication. They
develop as a result of partial obliteration
of the urachus. The urachal sinus may
present as an inflamed discharging
umbilicus or umbilical granuloma. When
it is symptomatic it should be excised.
Urinary infection and calculi may com
plicate a vesicourachal diverticulum, in
which case it should be excised. However,
the majority of these diverticula are
asymptomatic and are noted during cys
tography, done for other reasons.
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Use of a Pylon for Early Ambulation after
Below-Knee Amputation: a Preliminary Report
The fitting of a prosthesis immediately
after amputation offers many advan
tages. These include early ambulation,
more rapid healing of the amputation site
and a decrease in the number of compli
cations resulting from prolonged bed
rest. The major problems preventing the
widespread use of immediate fitting are
the specialized prosthetic care required
and the high cost of the appliance. The
authors describe a new pylon designed
for early ambulation after below-knee
amputation. Its application does not
require special training, it is inexpensive,
safe and effective. This pylon was used
in the early postoperative period in 20
amputees, without any major com
plications.
L'ajustement d'une prothese aussitot
apres I'amputation offre plusieurs avantages: lever precoce, cicatrisation plus
rapide du moignon et reduction du nombre de complications resultant d'un alitement prolonge. Les problemes majeurs
qui empechent le recours generalise &
l'ajustement immediat sont les soins spe
cialises requis et le cout eleve des pro
theses. Les auteurs decrivent un nou
veau support concu pour I'ambulation
precoce apres une amputation sous le
genou. Son emploi n'exige pas de forma
tion speciale, il est peu couteux, sur et
efficace. Ce support a ete utilise dans la
p6riode postoperatoire precoce chez 20
amputes, sans complication majeure.

In 1926, Le Mesurier1 reviewed the
experience with Canadian amputees of
World War I and concluded that temFrom the Division o f Orthopedic Surgery,
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porary artificial limbs hastened stump
shrinkage and conditioning. Burgess and
Romano2 are credited with introducing
to North America immediate postsurgical fitting of prostheses. The relative
advantages and disadvantages remain
controversial.3-7 Unquestionably, one of
the m ajor problems preventing its
w idespread use is the specialized
prosthetic care required. The method of
immediate prosthetic fitting described in
the literature often cannot be carried out
in smaller hospitals where facilities are
limited. Furthermore, because the appli
cation of the prosthesis postoperatively is
technically demanding and requires the
expertise of a prosthetist, there is often
disinclination to remove it for wound
inspection. Most problems require urgent
evaluation and usually a cast change.
When delay occurs, breakdown of the
amputation site is inevitable; healing is
prolonged and reamputation at a higher
level becomes a possibility. There is need
for a trained team of surgeon, physiatrist,
prosthetist and nursing personnel availa
ble for night and weekend consultation.
An alternative to such a team and easier
access to the wound site are needed.
Kerstein8 described an air splint for use
after below-knee amputation. Various
commercial temporary prostheses have
also been described.9 The main disad
vantage is their high cost. With these con
cerns in mind, we set out to develop a
prosthesis that could be used in the early
postoperative phase and that could be
applied without special expertise, obviat
ing the need for a prosthetist during the
early phase of in-hospital rehabilitation.
Furthermore, it had to be inexpensive.

direct support to the posterior flap por--v
tion of the stump (Fig. 2). The tip of the
pylon is fitted with a rubber plug for no
slip floor contact.
The pylon has been used in 17 patient?
(20 amputations) (11 men, 6 women).
Two, cases 9 and 12 (Table I), had
bilateral below-knee amputations and one^
patient, no. 17, had a below-knee ampu
tation on one side and an above-knee
amputation on the other. The patients
ranged in age from 20 to 82 years; 14*
patients were more than 60 years old.
Fifteen had dysvascular disease; 9 of them
were insulin-dependent diabetics. All
patients had frank gangrene or pregangrenous changes necessitating amputa-.^
tion. The remaining two below-knee
amputations were performed for trauma;
one was a compound fracture of the tibia
and the other a frostbite injury.
Technique

A rigid plaster dressing is applied at the

Patients and Methods

A simple pylon constructed of 2.5 cm
copper tubing was developed. The pylon
is fabricated by splitting the copper tube
at one end to provide a tripod base (Fig.
1). Each metal flange of the tripod is
approximately 12.5 cm long. The tripod
is secured to the end of a well-moulded
plaster that extends to the upper thigh,
keeping the knee extended and providing

FIG. 1—Copper tubing pylon with tripod
flange and no-slip rubber tip.
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time of amputation. This cast extends to
the upper thigh and keeps the knee
^extended. As the plaster is applied, the
stump is lifted off the operating table by
♦ the distal length of stockinette (Fig. 3).
In this way the cast supports the posterior
■Sap and takes tension off the anterior

ing is removed and if the stump appears
viable, a new, well-moulded plaster is
applied. A pylon, of 2.5 cm copper tub
ing, is secured to the end of the plaster
dressing (Fig. 4). The patient is
encouraged to be fully ambulatory. Full
weight-bearing is allowed as tolerated.

suture line. This is an important techni
cal detail thought to be necessary for
stump healing since wound failure can
often be attributed to tension, shear
stress, or direct pressure from the cut end
of the tibia at the anteriorly placed suture
line. One week after operation, the dress

Results

Of the 20 amputations performed, it
was possible to apply the pylon 1 week
after operation in 13 instances. In the
other seven cases, the wound was either
closed secondarily or needed extra wound
care, delaying the application of the pylon
to a mean of 22 days after amputation.
Patient 12, a severe diabetic who had had
a previous below-knee amputation of the
left leg fitted with a pylon, had multiple
medical complications following belowknee amputation of the right leg 2 years
later and did not begin walking until 6
weeks after operation. In another patient,
case 4, one of the earliest of this series,
we experimented with the use of an air
splint. This rather expensive device
sprung a leak so the patient was fitted
with a pylon 1 month postoperatively.
All patients reacted extremely well to
the pylon, usually becoming ambulatory
within 48 hours of its application. Two
elderly patients who were not able to walk
independently with the pylon were able
to transfer from bed to chair much more
easily. One patient, no. 9, who underwent
simultaneous bilateral below-knee ampu
tations, was able to walk independently
2 weeks after operation. He then man
aged well on bilateral pylons with the
aid of either crutches or a walker.

FIG. 2—Well-moulded plaster extends to upper thigh with knee extended and pylon secured
>to end of plaster cast.
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Another patient, no. 17, with an above
knee amputation on one side and a belowknee amputation on the other, was able
to walk with the assistance of a walker
and bilateral pylons. There were no major
complications attributable to the use of
the pylon. It had to be discontinued in
only one patient (no. 14) because of
wound breakdown.

the usual advantages of the early fitting
of a prosthesis, the pylon we designed has
other important benefits. Its application
does not require special training or the
help of a prosthetist or access to a
rehabilitation unit. The technique is sim
ple and can easily be mastered by sur
geons working in small community hospi
tals which do not have the costly facilities
or expertise of larger centres. The pylon
Discussion
can be removed and reapplied at any
time, lessening the attending surgeon’s
Many authors have described the anxiety regarding the wound. Because of
advantages of early fitting of prostheses its unique application, the cast supports
after amputation. The benefits may be the posterior flap and takes tension off
psychologic or physical. The former have the anterior suture line. Body weight is
been described in detail by Waddell.10 distributed throughout the length of the
The physical advantages are numerous. limb and is not concentrated at the end
By promoting early ambulation, the num of the stump. The use of a rigid plaster
ber of complications resulting from dressing extending to the upper thigh
prolonged bed rest — pneumonia, pulmo keeps the knee in extension, stabilizing it
nary embolism, pressure ulcers — is for weight transfer on the pylon. The cast
reduced. Clearly, patients experience less also prevents knee flexion contracture, a
discomfort and pain, gain psychological common complication of the soft bandag
benefits and obtain quicker healing of the ing of stumps. Development of a fixed
amputation site. Indeed, because stump flexion contracture of the knee following
blood flow increases with active stump amputation makes definitive limb fitting
muscle contraction, early ambulation difficult and encourages future stump
with a prosthesis theoretically should breakdown.
enhance wound healing. In our series,
A nonclinical, but nevertheless impor
only one patient had to discontinue use tant, consideration, particularly in these
of the pylon because of a wound problem. days of Medicare funding, is the cost of
Also, early prosthetic fitting effectively the device. It is inexpensive; the total cost
controls stump edema, allowing earlier is well under $15.00. The copper pylon
fitting of the definitive artificial limb. is reusable. Copper is an ideal metal for
Further advantages include the early the pylon because it is corrosion resistant
preservation of balance and kinesthetic and has excellent malleability when
senses required for gait. In 13 of our annealled.
patients, full weight-bearing was possible
Although we recognize that this is not
1 week after amputation. In addition to a prospective, randomized trial, the suc

FIG. 3—Application of stump cast in operating room. Tension is removed from anterior
suture line by lifting stump off operating table with distal portion of stockinette as plaster is
applied.
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cess we have enjoyed with our patients to
date suggests that the pylon is an effec
tive, safe, inexpensive and simple device*
that facilitates early ambulation after
below-knee amputation. The benefits of •*
a rigid dressing, the ease of application
and removal are important. As well, earf?i'
rehabilitation can be carried out without
requiring the expertise of a prosthetic *
rehabilitation team.
References
1. L e MESURIER AB: Artificial limbs: their relation to the
different types of amputation stumps. J Bone Joint Surg
[Am] 1926; 8: 292-324
2. BURGESS EM, Rom ano RL: The management of lower
extremity amputees using immediate postsurgical prosthe^*
sis. Clin Orthop 1968; 57: 137-56

^
j
|
•

3. Cohen s i , G oldman l d , salzm an e w , glotzer
DJ: The deleterious effect of immediate postoperative
prosthesis in below-knee amputation for ischemic disease
Surgery 1974; 76: 992-1001

!

4. JEFFERY AK: Below-knee amputation and immediate
prosthetic fitting in vascular disease. N Z Med J 1974; 80:
343-9
4

t

j
!
|

i

5. Warren R, MOSELEY RV: Immediate postoperative
]
prostheses for below the knee amputations. A m J Surg A
1968;116:429-32
I
6. BURGESS EM, Marsden FW: Major lower extrem it^
amputations following arterial reconstruction. Arch Surg
1974; 108: 655-60

i

7. H unter GA, Waddell JP: Management of the patient
requiring leg amputation for peripheral vascular disease.
Can M ed Assoc J 1976; 115: 634-8
8. KERSTE1N MD: Utilization of an air splint after belowknee amputation. A m J Phys Med 1974; 53(3): 119-26
9. Ortho Aid. Camp International Inc., Jackson, Mich, US
patent 4, 161, 042
<

S

|
{

|
:
!
|

10. Waddell JP: Below-knee amputation. In KOSTUIK JP

(ed): Amputation Surgery and Rehabilitation: the
Toronto Experience, Churchill, New York, 1981: 63-80

FIG. 4—Pylon attached to end of cast.
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Continent, Nonrefluxing Urinary Reservoir Constructed
from Ileum: Report of Two Cases
Most procedures for diverting urine
sacrifice continence, but Kock's modifi
cation of the ileal conduit promises the
ideal of appliance-free urine storage with
voluntary control of emptying. The
authors report on two men who under
went this procedure. One was a para
plegic who had total urinary incontinence
after a sphincterotomy. The other had a
carcinoma of the rectosigmoid obstruct
ing the right ureter. He had congenital
bladder exstrophy and had undergone
ureteric implantation into the sigmoid
colon at 3 years of age. In both patients,
the reservoir was created from an iso
lated 60-cm segment of the middle por
tion of small bowel. Tw o nipple valves
were created — one to prevent reflux
and one to provide continence of urine.
Follow-up was 27 and 17 months
respectively. One patient had his
outlet valve revised because of sliding
and incontinence. He is now completely
continent of urine and he intubates his
reservoir three to four times daily.
Postoperatively, the second patient had a
leak at the ureteroileal anastomosis, but
this healed spontaneously.
The continent urinary diversion is a
major intestinal operation and should not
be performed in conjunction with exen
teration. It should be confined to a few
centres where greater experience can be
accumulated.

La plupart des interventions chirurgicales
destinees a deriver les urines sacrifient la
continence; cependant la modification de
Kock de la canalisation ileale offre I'ideal
d'un reservoir d'urine exempt de dispositif mecanique et le controle volontaire de
la vidange. Les auteurs rapportent les
cas de deux hommes qui ont subi cette
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intervention. Dans un cas, il s'agissait
d'un paraplegique qui souffrait d'incontinence urinaire totale a la suite d'une
sphincterotomie. L'autre 6tait atteint
d'un cancer recto-sigmoidien obstruant
I'uretere droite. Souffrant d'ectopie vesi
cate congenitale, il avait subi a I'age de
3 ans une implantation des ureteres dans
le colon sigmoide. Chez les deux
patients, le reservoir fut cree & partir
d'un segment de 60 cm isole de la partie
mediane du grele. Deux soupapes a clapet furent construites, une pour prevenir
le reflux et une autre pour assurer la
continence urinaire.
La periode d'observation posttherapeutique couvre 27 et 17 mois respectivement. Un patient a necessity une
revision de la soupape d'evacuation pour
cause de glissement et d'incontinence.
La continence urinaire est maintenant
c o m p le m e n t retablie et il intube son
reservoir trois ou quatre fois par jour.
Apres son operation le second patient a
eu une fuite de I'anastomose uret6roileale qui guerit spontanement.
La derivation urinaire continente est
une operation intestinale majeure qui ne
devrait pas etre pratiquee a I'occasion
d'une exenteration. Sa realisation devrait
etre limitee a quelques centres susceptibles d'accumuler une plus grande
experience.

-

tation, ulceration and nonadherence of
appliances.
r
Alternatives to an ileal segment reser
voir include antireflux procedures, using ^
the ileocecal valve and submucosal tun
nels in a colonic conduit. Superior long^
term renal function has been re
ported. 5’6’8’9 Continence-producing tech
niques have been described using-i
antiperistaltic bowel segments and the
ileocecal valve.9,10 To avoid appliances,
these require the construction of an inter
nal reservoir for urine. Recently, Kock4
and colleagues11 have reported on 12
patients in whom a continent, nonreflux
ing ileal reservoir has been constructed
utilizing two nipple valves created from
intussuscepted segments of intestine.-*
Their results have been encouraging and
renal function has remained normal in
these patients for an average of 32 months
after operation. This report presents our'
experience with the continent urinary
diversion in two patients.
Case Histories

Case 1

v

At the age of 33 years, this white man,
now 46 years old, was involved in a motor
vehicle accident that rendered hind
paraplegic at T4. During rehabilitation,
a sphincterotomy temporarily enabled
The task of providing permanent diver him to void spontaneously. However,
sion of urine that is both convenient and large residual volumes of urine necessi
cosmetically acceptable to the patient, as tated catheter drainage. Eventually, the
well as physiologically compatible with bladder neck was ligated elsewhere and
the upper urinary tracts, has challenged a suprapubic tube inserted. This func-v
surgeons for nearly a century.1 Current tioned well until several months before
methods may cause chronic deterioration admission when a chronic, purulent, ure
of renal function.2 4 This is commonly thral discharge developed. It was thought
attributed to ureteric reflux, high pressure to arise from stasis of prostatic secretions?
within the urinary tract and infection.5’6 The patient had had a colostomy con
Furthermore, external appliances must be structed 3 years earlier for fecal inconti
worn and are associated with social and nence with excellent function so that a cap ^
cosmetic difficulties. The most popular only was used. The continent ileostomy
form of permanent diversion is the ileal was offered as a new alternative follow
conduit, originally described by Bricker.7 ing planned total prostatectomy.
This is a freely refluxing system that
drains into an appliance fixed to the skin. Case 2
Although this is usually acceptable,
problems may arise from peristomal irri
A 30-year-old white man was born with
27, NO. 5, SEPTEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

bladder exstrophy and epispadias. The
condition was first treated when he was
►3 years old by bilateral ureterosigmoid
anastomoses. The patient remained well
with occasional episodes of pyelonephritis
that responded to antibiotic therapy. At
**20 years of age, a skin graft was per
formed to improve the structure of his
penis and the urethra was accidentally
Jig ated without sequelae. Approximately
4 months before the present admission,
►- he had a recurrent urinary tract infection
and blood in his stool. An adenocarci
n o m a of the colon was found, obstruct
ing the right ureterosigmoid junction. The
f
resultant right-sided hydronephrosis and
hydroureter required initial decompres
s i o n with a percutaneous nephrostomy
y tube. Various forms of urinary diversion
were discussed with the patient, includ
in g the continent ileostomy. He elected to
receive the continent ileostomy for cosf
metic reasons although he was fully aware
that this was a new procedure. At opera* tion, an anterior resection was performed.
A Dukes’ stage C carcinoma12 of the
colon was found, obstructing the right
^ureterosigmoid junction. A continent ileal
urinary diversion was constructed.
K

Operative Technique

y

The method of constructing the conti
nent ileal reservoir has been described and
y illustrated in detail by Kock and
associates.11
A 60- to 70-cm segment of the middle
portion of the small bowel is isolated (at
least 60 cm proximal to the ileocecal junc*r tion) (Fig. 1). The central 30 cm of ileum

is then folded into two 15-cm limbs to cre
ate a U-shaped structure with the antimesenteric borders adjacent. The limbs of
the U are then sutured together using
absorbable material. A plate o f intestinal
wall is fashioned by slitting open the limbs
of the U just lateral to the suture line on
both sides and then opening the ileum to
expose the mucosa.
The incision is carried 3 cm further on
the distal limb in order to offset the inlet
and outlet. A second layer of absorbable
suture is then placed to secure the
posterior wall.
The remaining segments of ileum
(proximal and distal to the limbs of the
U) are then cleared of fat and peritoneum
to facilitate construction of the nipple
valves. They are formed by intussuscepting a 5-cm segment of ileum at each end
(Fig. 2). The nipple valves are secured in
position with three to four rows of sta
ples using the GIA stapler with SGIA sta
ples (Auto Suture Co., Division of United
States Surgical Corp., Norwalk, Conn.)
(Fig. 3). The intestinal plate is folded on
itself and the sides are closed in two layers
(Fig. 4). A window is then created in the
mesentery at a position approximating the
base of the outlet and a strip of Prolene
mesh is wrapped around the ileum pass
ing through this opening. The reservoir
edge is then sutured to the Prolene mesh
with absorbable suture (Fig. 5).
The ureters are implanted in the inlet
segment of ileum and splinted with poly
ethylene catheters. A stoma is created in
a convenient location just above the pubic
hair-line and the reservoir is secured to
the undersurface of the ileostomy open
ing (Fig. 6).

FIG. 1 Segment of middle portion of small bowel 65 cm
long is isolated. Central 30 cm is arranged to form U using two 15-cm
limbs.

The Prolene mesh is fixed to the
anterior rectus fascia with nonabsorbable
suture to secure the reservoir in position
and to prevent sliding of the outlet nip
ple valve. The reservoir outlet is then
brought out through the ileostomy open
ing and the stoma is fashioned flush with
the skin. A Medina catheter is left within
the reservoir and connected to a straight
drainage system.
Results

Early Complications
Patient no. 2 had an anastomotic leak
from the left ureteroileal anastomosis and
a urocutaneous fistula. He was discharged
from hospital after 8 weeks on continu
ous reservoir drainage. A small tube was
placed in the fistula. Initially, this drained
approximately 40% of the total urine
volume. However, 5 months postoperatively the fistula closed spontaneously.
Late Complications
Patient no. 1 was continent postoperatively, but several months later inconti
nence developed so that he had to wear
an appliance during the day as well as for
continuous reservoir drainage at night. A
retrograde contrast study of the pouch
revealed that the continence-producing
nipple valve had slipped out of the pouch.
A second operation was done to revise the
valve.
Follow-up
Both patients were evaluated by labora
tory and radiologic studies. In both cases,

FIG. 2—Intestinal plate has been formed; distal and proximal small
bowel are intussuscepted within pouch to form nipple valves, each 5
cm l0"g-
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values for hemoglobin, erythrocytes, elec
trolytes, serum urea and creatinine were
normal (Table I). Urine cultures grew
Escherichia coli in one patient on one
occasion, but the infection was not
treated. An endoscopically directed
biopsy of the pouch mucosa revealed
slight blunting of the villi in patient no.
2, and a patchy submucosal plasma-cell
infiltrate in both. Intravenous pyelogra
phy showed no evidence of ureteral reflux
(Fig. 7). Intact nipple valves with no
deterioration of the upper tracts are
demonstrated by distension of the pouch
with contrast material (Fig. 8).
Patient no. 1 has been followed up for
27 months. Patient no. 2 died of
metastatic disease 17 months after oper
ation. Both patients were fully continent
during the follow-up period. No appli
ances or night-time drainage was needed.
The pouch was drained by inserting a
catheter through the outlet nipple valve

three to five times daily, and a small
bandage was worn over the stoma dur
ing drainage intervals. Both patients
claimed to be satisfied with the cosmetic
result as well as the convenience of the
continent ileal pouch.
Discussion
The continent nonrefluxing ileal reser
voir was developed by modifying the con
tinent fecal reservoir originally described
by Kock.13 There is, however, little pub
lished experience with the continent ileal
urinary reservoir.11’14,15
Both our patients who received the con
tinent urinary reservoir were ultimately
fully continent. One patient required
reoperation to repair the outlet (con
tinence-producing) nipple valve and the
other had a urocutaneous fistula that
closed spontaneously after 5 months.

FIG. 3—Nipple valves are secured with three to four rows of staples.

FIG. 5— Strip of Prolene mesh passed through window in mesen
tery, then around base of nipple valves to secure their position.

Complications of this type have been
common with ileal reservoirs.11,14'17
In Kock’s report of 12 patients who A
received a continent ileal urinary diver
sion, 7 required reoperation due to mal- +
function of the continence-producing nip
ple valve. There were no chronic urocu.*
taneous fistulas.
Experimental work in dogs has been
used to investigate the physiology of the
continent urinary diversion.8,18,19 It has*"
been demonstrated that dynamic free
water and electrolyte exchange occurs
across the ileal mucosa lining in the reser-*
voir; however, no electrolyte or acid-base
abnormalities have been demonstrated
clinically and normal renal function has
been maintained.18 Hydrodynamic inves- t
tigations in patients and dogs have re
vealed low pressures within the reservoir
until the volume capacity is approached.
With continued use of the reservoir and''
gradual lengthening of the time intervals

FIG. 4—Pouch is completed by folding intestinal plate on itself.

FIG. 6—Completed reservoir in situ. Ureters are anastomosed to
afferent loop of small bowel which has subsequently been closed. Pouch
is anchored by Prolene mesh sutured to anterior rectus sheath.
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between reservoir drainage, the volume
capacity can increase substantially. Pres
s u r e studies on the continent fecal ileal
reservoir revealed that the nipple valve
^ contains a high-pressure zone relative to
the pouch.20 This pressure gradient is
*jnaintained, even when intra-abdominal
pressure is raised, contributing to conti
nence of the pouch.

FIG. 7—Intravenous pyelogram 3 months
after operation. There is no evidence of parenchymal change.

FIG. 8—Pouch has been distended with con
trast material, showing antireflux nipple valve
*■ (arrows). There is no evidence of reflux into
ureters.

Changes that we have seen in the pouch
mucosa, such as blunting of the villi and
plasma-cell infiltrates, are similar to those
reported by other investigators. Hansson
and associates21 observed complete flat
tening of the villi in reservoirs from two
patients 12 months after operation. This
reduces the absorptive capacity of the
pouch, diminishing electrolyte shifts.
Neither of the patients included in Hansson’s study had hyperchloremic metabolic
acidosis or other fluid and electrolyte
abnormalities after discharge from hospi
tal. There has been no evidence of altered
renal function to date.
A nonrefluxing ileal reservoir provides
protection to the renal parenchyma.
Long-term renal function must be consi
dered in all patients for whom prolonged
survival is expected. This group would
include all children, especially those with
congenital abnormalities such as bladder
exstrophy, and young adults with nonmalignant disease, or those in whom
treatment of a malignant tumour is
believed curative.
Construction of a continent urinary
reservoir requires meticulous attention to
detail. The morbidity associated with the
procedure is notably greater than for
Bricker’s ileal conduit procedure. Care
must be taken to preserve a sufficient
length of distal ileum to maintain ade
quate absorption of bile salts and vitamin
B12. One technical problem that becomes
apparent with the nonrefluxing reservoir
is difficulty in fitting two nipple valves
inside the reservoir during initial construc
tion. Gerber15 has modified the tech
nique by constructing the reservoir from
S-shaped rather than U-shaped loops of
small intestine. This places the bases of
the nipple valves further apart and allows
them more space within the reservoir. We
intend to use an S-shaped pouch for sub
sequent ileal urinary reservoirs at our
institution.
A careful assessment of the risks and
benefits of the procedure is warranted for
each individual who might be considered
a candidate. It is of paramount impor
tance that the patient understands the
experimental nature of the continent ileal
urinary reservoir as well as the available
alternatives.
Our objective was to provide a perma
nent urinary diversion that was continent

Na, mmol/L
K, mmol/L
Cl, mmol/L
C02 mmol/L
Creat, (imol/L

Patient 2

Patient 1
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Table I—Preoperative and Postoperative Values for
Electrolytes and Creatinine___________
Electrolytes/
creatinine

and potentially protected the kidneys
from the deleterious sequelae of urinary
stasis and reflux. Although the follow-up
period has been limited, we believe this
goal has been achieved on both counts.
It is too early in the development of the
continent nonrefluxing ileal reservoir to
be conclusive as to its clinical potential.
We shall continue to offer this procedure
to selected patients as an alternative form
of permanent urinary diversion.

Preop

Postop

Preop

Postop

139
3.9
99
30
71

140
4.2
105
28
71

139
3.3
108
27
124

137
4.1
108
23
87
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Magnetic Resonance Imaging and Surgical Clips

*■ Magnetic resonance imaging produces

V diagnostically useful images of softtissue structures within the body.
Implanted magnetic materials degrade
these images and are subject to mag
netic forces from the imaging process.
The authors evaluated 54 surgical clips
(38 aneurysm and 16 hemostatic) for
compatibility with magnetic resonance
imaging. From their findings, they recom
h. mend that the use of ferromagnetic clips
be discontinued and that until this is
accomplished, a record of the type of
i
clips used be noted so that the patient is
not placed at risk by the use of magnetic
resonance imaging or deprived of the
y diagnostic benefits associated with its
use.

r La visualisation par resonance magneti-

que produit, pour fin de diagnostic, des
images des tissus mous de I'organisme.
Les materiaux magnetiques implantes
r alterent ces images et sont soumis aux
forces magnetiques du procede. Les
auteurs ont evalue 54 clips chirurgicaux
(38 clips d'anevrismes et 16 h6mostati►ques) pour leur compatibility avec la
resonance magnetique. A partir de leurs
observations, ils recommandent que I'on
► cesse ('utilisation des clips ferromagnetiques et que I'on garde un dossier des
r
clips utilises afin que les patients ne
soient pas exposes d un risque du a la
►resonance nucldaire ou prives des avantages diagnostiques relies a son emploi.

uations even a replacement of) ultrasono
graphy, radioscintigraphy, roentgenogra
phy and computerized tomography. One
advantage of magnetic resonance imag
ing lies in its ability to visualize soft tis
sue with much greater contrast than do
other modalities. Since cortical bone gives
no image in magnetic resonance imaging,
this new approach complements roentgenographic techniques and circumvents
the bone-induced artefacts that handicap
computerized tomography in the pelvis
and posterior fossa.
Another advantage of magnetic res
onance imaging is that it presents no risk
to the patient. No untoward side effects
have been reported,2'3 no molecular or
cellular damage has been detected in basic
studies4,5 and as presently applied it is
difficult to conceive of any possible
mechanisms of harm .6,7 One exception
to this generalization is the interaction of
the magnetic field used in this technique
with artificially introduced magnetic
materials in the patient. This interaction
has two consequences: the magnetic
objects disrupt the resonance image and
the magnetic field of the imager may
cause displacement of the magnetic
object.

Fig. la , a nuclear magnetic resonance
image in the sagittal plane through the
skull o f a healthy volunteer, shows the
excellent soft-tissue contrast and clear
anatomical detail achieved by the tech
nique. Fig. lb is an image produced by
an identical procedure, except that a small
ferromagnetic surgical clip has been taped
to the forehead. The clip produces a
large image artefact and degrades the con
trast and resolution through the entire
image, seriously diminishing its diagnos
tic usefulness.

Fig. la

Fig. lb

The consequence of forces on a fer
romagnetic object in a patient are difficult
to assess. The forces are of two types: dis
placement forces, as the patient is moved
into the magnet through a magnetic field
gradient, and rotational forces within the
uniform magnetic field, attempting to
align the major axes of the object with the
external m agnetic field. New and
associates8 have reported that magnetic
forces were sufficient to twist a recently
applied aneurysm clip off the femoral
artery of a rat, allowing hemorrhage.
Although the risk of this occurring
decreases with time due to the progres
sive granulation around the clip, it

Diagnostic imaging using the principles of
nuclear magnetic resonance1 is emerging
as a promising addition to (or in some sitr-

1

[*
F
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FIG. 1—(a) Nuclear magnetic resonance image in sagittal plane through skull of heallhy
volunteer, showing excellent soft-tissue contrast and anatomical detail, (b) Image obtained when
ferromagnetic surgical clip is taped to forehead. Large artefact is produced and contrast and
resolution degraded. (0.15 Tesla resistive nuclear magnetic resonance imager [Technicare Corp.],
30 ms echo, pulse repetition time of 0.5 s.)
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remains a risk to the patient and must be
viewed with concern.
This paper reports measurements of
magnetic properties in 16 hemostatic and
38 aneurysm clips used by Canadian sur
geons. A few other metallic implants are
also considered.
Methods

The magnetic properties of the 54 clips
were assessed as follows: (a) displacement
in a field gradient, (b) rotation to align
with a field and (c) artefacts in a magnetic
resonance image.
Displacement
Clips were suspended by 110 cm of fine
cotton thread in a magnetic field gradient
of 1.5 x 10~3 Tesla(T)/cm produced by
a small permanent magnet. This gradient
simulates a maximum gradient of 1.8 x
10'3 T/cm going into a Technicare 0.15 T
resistive nuclear magnetic resonance
imager magnet (Technicare Corp., Solon,
Ohio). Displacements of up to 10 mm
were measured, with clear differentiation
between clips that were displaced and
those that were not.
Rotation
This was assessed by suspending each
clip on a thread, 5 cm long, attached to
a plastic support in a uniform 0.15 T mag
netic field in the imager. The attachment
point was rotated through 360° from
equilibrium applying a torque of 6 x
10 5 Nm to the clip. If the clip remained
aligned, it was considered to be locked
into the field and hence magnetic. If it
rotated with the pivot it was nonmagnetic.
Artefacts
Image artefacts were measured by per
forming magnetic resonance imaging of

a high-resolution test phantom with the
clip attached in the plane of the image.
Any visual change in the image was
scored as an artefact and the clip was
deemed to be magnetic.

♦
T

Findings

The findings were consistent among the
three criteria used to assess whether or not
a clip was magnetic (Table I). Where iden
tical clips have been studied, the findings
were in complete agreement with those of
similar studies by New and associates8
and Kean (unpublished data, 1983). All
of the non-steel clips (i.e., tantalum or sil
ver) were not magnetic. The stainless steel
clips segregate into two classes.9 The
high chromium-nickel alloys such as 316
are austenitic stainless steels which are
nonmagnetic, but the inaustenitic stain
less steels such as the 301 and 304 were
generally magnetic. Because of the wide
spectrum of proprietary steels used in the
m anufacture of surgical im plants,
knowledge of the steel type cannot always
be used to determine whether the implant
is magnetic.
A less-comprehensive study of other
surgically introduced metallic devices
including suture wire, two hip prostheses
and a tracheostomy device showed that
all were nonmagnetic. Dental materials
are variable, some produce no interfer
ence and others are highly magnetic.
However, since these present no particu
lar risk to the patient, they are of less
concern.
Recommendations

Because nuclear magnetic resonance
imaging will play an increasingly impor
tant role in diagnostic imaging and
because ferromagnetic implants are
incompatible with this technique, either
by placing the patient at risk or by depriv-

T a b le 1-- M a g n e t i c P r o p e r t ie s o f S u r g ic a l C lip s
No.
Type

te s te d

M a t e r ia l

M a g n e t ic

H e m o s t a t ic
H e m o c iip

2

S t a in le s s s t e e l 3 1 6 L

No

H e m o c lip

2

T a n t a lu m

No

H e m o s t a t ic c lip s ( J a p a n )

4

Unknow n

No

L ig a c lip

4

S t a in le s s s t e e l 3 1 6 L

No

L ig a c lip

2

T a n t a lu m

No

S t e v e n s (b ra in )

2

S il v e r a llo y # 5 0 - 4 1 9 0

No

A n e u ry s m
D ra k e

2

S t a in le s s s t e e l 3 0 1

Yes

H e if e t z

2

S t a in le s s s t e e l 1 7 - 7 M

Yes
Yes

M a y f ie ld

5

S t a in le s s s t e e l 3 0 1

M cFadden

1

S t a in le s s s t e e l 3 0 1

S c o v ille —L e w is

2

S t a in le s s s t e e l E n - 5 8 J

F
Yes

S u g it a

3

S t a in le s s s t e e l e lg ilo y

S u n d t-K e e s

No

3

S t a in le s s s t e e l 3 0 1

Yes

V a r i- A n g le M c F a d d e n

1

S t a in le s s s t e e l M P 3 5 N

No

V a r i- A n g le M ic r o

4

S t a in le s s s t e e l 1 7 - 7 P M

Yes

V a r i- A n g le S p r in g

2

V a s a r g il

510

13

S t a in le s s s t e e l 1 7 - 7 P M

Yes

S t a in le s s s t e e l 3 1 6

No

4
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Prescribing Information

Marcaine*
(bupivacaine hydrochloride injection U.S.P.).
Indications:
Peripheral nerve block including retrobulbar block, infiltration, sympa
thetic blockade, caudal, epidural, and pudendal blocks.
Contraindications:
Bupivacaine is contraindicated in persons with known sensitivity to
local anesthetics of the amide type.
The use of bupivacaine is contraindicated in the presence of sepsis
near the site of proposed injection, in severe shock and in heart block.
Warnings:
Usage in Pregnancy: There are no adequate and well-controlled studies
in pregnant women of the effect of bupivacaine on the developing
fetus. Decreased pup survival in rats and an embryocidal effect in rab
bits have been observed when bupivacaine hydrochloride was adminis
tered to these species in doses comparable to nine and five times
respectively the maximum recommended daily human dose (400 mg).
Bupivacaine hydrochloride should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. This does not
exclude the use of Marcaine 0.25% or 0.50% at term for obstetrical
anesthesia or analgesia.
Obstetrics: The highest (0.75%) concentration is not recommended for
obstetrical anesthesia. There have been reports of cardiac arrest with
difficult resuscitation or death following its use for epidural anesthesia
in obstetrical patients.
Due to the high risk to the fetus, paracervical block is no longer recom
mended.
The obstetrician is warned that severe persistent hypertension may
occur after administration of certain oxytocic drugs, if vasopressors
have already been used during labor (e.g. in the local anesthetic solu
tion or to correct hypotension).
Until further experience is gained in children younger than 12 years,
administration of bupivacaine in this age group is not recommended.
Precautions:
Marcaine (bupivacaine) should be used cautiously in persons with
known drug allergies or sensitivities, particularly to the amide-type local
anesthetics.
Caution is advised in administration of repeat doses of bupivacaine to
patients with severe liver disease.
The lowest dosage that gives effective anesthesia should be used, to
avoid high plasma levels and serious systemic side effects. Injection of
repeated doses of bupivacaine may cause a significant increase in
blood levels due to accumulation of the drug or its metabolites or slow
metabolic degradation.
Tolerance varies with the status of the patient. Debilitated, elderly and
acutely ill patients may require reduced doses commensurate with age
and physical condition.
It should be remembered that solutions containing a vasopressor
agent, e.g. epinephrine, should be used with caution, if at all, in patients
who are receiving monoamine oxidase inhibitors or anti-depressants
of the triptyline or imipramine type, because severe, prolonged hyper
tension may result. Dose-related cardiac arrhythmias may occur if
preparations containing epinephrine are employed in patients during or
immediately following the administration of chloroform, halothane,
cyclopropane, trichloroethylene or other related agents. In deciding
whether to use these products concurrently in the same patient,
the combined action of both agents upon the myocardium, the concen
tration and volume of vasoconstrictor used, and the time since injec
tion, when applicable, should be taken into account.
The decision to use a local anesthetic containing a vasoconstrictor in
areas with a limited blood supply or in patients with peripheral vascular
disease, will depend on the physician's appraisal of the relative advan
tages and risks.
Local anesthetics which contain preservatives, i.e. those supplied in mul
tiple dose vials, should not be used for caudal or epidural anesthesia.
Epidural Use: It is advised that a test dose, generally 2-3 mL of 0.5%
bupivacaine (or other amide anesthetic) containing 1:200,000 epine
phrine (10-15 micrograms) be administered to check that the spinal
canal or a blood vessel has not been entered while locating the epidural
needle or catheter.
In the event of spinal injection clinical signs of spinal block would
become evident in a few minutes.
In the event of intravascular injection a transient increase in pulse rate
and possibly momentary increase in systolic blood pressure are
usually detectable with a monitor. The other symptoms and signs of
“epinephrine response" are less dependable. The effects of other medi
cation the patient has received may modify this response.
When reinforcing doses are required the test dose should be used
again to check the catheter location.
Use in Ophthalmic Surgery: When Marcaine 0.75% is used for retrobulbar block, complete corneal anesthesia usually precedes onset of clini
cally acceptable external ocular muscle akinesia. Therefore, presence
of akinesia rather than anesthesia alone should determine readiness of
the patient for surgery.
Adverse Reactions:
Reactions to bupivacaine are characteristic of those associated with
amide-type local anesthetics. A major cause of adverse reactions to
this group of drugs is excessive plasma levels, which may be due to
over-dosage, inadvertent intravascular injection, or slow metabolic
degradation. Other causes of reactions to these local anesthetics may
be hypersensitivity, idiosyncrasy, or diminished tolerance.
Excessive plasma levels cause systemic reactions involving the central
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nervous system and the cardiovascular system. The central nervous
system effects are characterized by excitation or depression The first
manifestation may be nervousness, dizziness, blurred vision, or tre
mors, followed by drowsiness, convulsions, unconsciousness, and pos
sibly respiratory arrest. Since excitement may be transient or absent,
the first manifestation may be drowsiness, sometimes merging into
unconsciousness and respiratory arrest.
Other central nervous system effects may be nausea, vomiting, chills,
constriction of the pupils, or tinnitus. The cardiovascular manifesta
tions of excessive plasma levels may include depression of the myocardium, blood pressure changes (usually hypotension), and cardiac
arrest. Recent clinical reports and animal studies suggest this may be
more likely to occur with the long acting amide local anesthetics such
as bupivacaine.
Allergic reactions are characterized by cutaneous lesions (e.g. urticaria,
edema) and other manifestations of allergy.
Reactions following epidural or caudal anesthesia may include: high or
total spinal block, urinary retention; fecal incontinence, loss of perineal
sensation and sexual function; persistent analgesia, paresthesia, and
paralysis of the lower extremities; headache and backache; and slow
ing of labor and increased incidence of forceps delivery.
It should be noted that reactions due to systemic absorption may be
slow or rapid in onset. Those of rapid onset include respiratory depres
sion, cardiovascular collapse and cardiac arrest. This type of reaction
necessitates a high degree of preparedness since it can occur with little
warning.
In co-ordinated studies of 3200 procedures carried out by 15 investiga
tors, there were 2 severe systemic reactions. Both patients experienced
convulsions as a result of inadvertent vascular injection.
Fetal bradycardia has been observed with the use of bupivacaine. Most
cases, including a few fatalities, occurred when the paracervical route
was used (see “Warnings”).
In some subjects bupivacaine may produce marked peripheral vaso
constriction in unanesthetized areas which may last for several hours.
Treatment of Overdose and Severe Reactions:
Toxic effects of local anesthetics require symptomatic treatment; there
is no specific cure. The physician should be prepared to maintain an
airway and to support ventilation with oxygen and assisted or con
trolled respiration as required. Supportive treatment of the cardiovas
cular system includes intravenous fluids and, when appropriate, vaso
pressors (preferably those that stimulate the myocardium).
Convulsions may be controlled with oxygen and intravenous adminis
tration, in small increments, of a barbiturate or muscle relaxant, as
follows: preferably, an ultra short-acting barbiturate such as thiopental
or thiamylal; if this is not available, a short-acting barbiturate (e.g. seco
barbital or pentobarbital) or a short-acting muscle relaxant (succinylcholine). Intravenous muscle relaxants and barbiturates should only be
administered by those familiar with their use.
Dosage and Administration:
The duration of anesthesia with bupivacaine is such that, for most pro
cedures, a single dose is sufficient. Maximum dosage limit must be indi
vidualized in each case after evaluating the size and physical status of
the patient, as well as the usual rate of systemic absorption from a par
ticular injection site. Most experience to date is with single doses of
bupivacaine up to 225 mg with epinephrine 1:200,000, and 175 mg
without epinephrine; more or less drug may be used depending on indi
vidualization of each case.
At present there is insufficient clinical evidence with multiple dosage or
intermittent dose techniques to permit precise recommendations for
such procedures to be given. However, limited clinical experience in this
area of use indicates that bupivacaine may be repeated in 3 to 6 hours
up to a maximum dose of 400 mg in 24 hours. In most cases the dura
tion of anesthetic effect is prolonged by the addition of epinephrine.
The following doses have generally proved satisfactory for the average
adult. They may require adjustment in relation to age and the physical
condition of the patient.
Local infiltration: up to a maximum dosage of 0.25% solution.
Peripheral nerve block: 5 to 30 mL of 0.50% or 5 to 60 mL of 0.25%
solution.
Sympathetic: 20 to 50 mL of a 0.25% solution.
Epidural: 10 to 20 mL of a 0.25%. 0.50%, or 0.75%t solution.
Caudal: 15 to 30 mL of a 0.25% or 0.50% solution.
tO.75% not recommended for obstetric use.
Supplied:
Each 20 mL single dose vial contains: bupivacaine 0.25%, 0.50% or
0. 7 5 . with or without epinephrine 1:200,000. Boxes of 5 vials.
Each 50 mL multiple dose vial contains: bupivacaine 0.25% or 0.50%.
Boxes of 1 vial.
Note: Bupivacaine solutions without epinephrine may be autoclaved.
Product Monograph available on request.
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ing the patient o f potential future diag
nostic benefit, we recommend that the use
o f ferromagnetic implants be discon-4
tinued as soon as possible and that, in the
interim, the type o f clips used be noted
on the surgical record.
We thank those companies and individuals
who made clips available to us for this study.
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sion o f abstracts is Nov. 15, 1984. For,,
further information contact Dr. Rene
Malek, 6, rue Erlanger, 75016 Paris,
France or SOCFI, 14, rue Mandar, 75002
Paris, France.

Annual Fall Symposium on
Gastrointestinal Pathology
The E.T. Bell Institute o f Pathology,
Department o f Laboratory Medicine and -»
Pathology of the University of Minnesota
will present its annual fall symposium
entitled “ Current Concepts in Gastroin
testinal Pathology” . The symposium w ill""
be held on Nov. 9, 1984 at the Mayo
Memorial Auditorium, University of
Minnesota, Minneapolis. This meeting f
will meet the criteria for 6 hours o f AMA
category 1 credit. The fee is $120 US. For
further information please contact: Con
tinuing Medical Education, University of 4
Minnesota, Box 293, Mayo, 420 Delaware
St. SE, Minneapolis, MN 55455 or phone:
(612) 373-8012.
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„ Vibration-Induced White Finger Disease: a Case Report
*

A syndrome of pain, stiffness and numb
ness associated with vascular changes
that develops in the hands of those who
►Aise vibrating tools has been termed
vibration-induced white finger disease.
The authors describe such a case that
occurred in a 22-year-old man. A change
of job and a course of physiotherapy
alleviated the symptoms and improved
circulation. A review of the literature and
^the authors' findings suggest that this
condition is a result of marked changes
in the vascular supply to the hand from
repetitive blunt trauma. Arteriographic
evidence of deficient palmar arch vas
culature is presented.

»

Un syndrome associant douleur, raideur,
engourdissement et changements vasAculaires, qui affecte les mains de personnes qui manipulent des instruments
vibratoires, a dte surnomme en anglais
"vibration-induced white finger disease",
T que Ton pourrait traduire par ischdmie
des extrem es provoquee par les vibra
tions. Les auteurs decrivent un cas
observe chez un homme de 22 ans. Un
changement d'emploi et des seances de
physiotherapie ont permis de soulager les
symptomes et d'ameliorer la circulation.
F Une revue de la litterature et les observa
tions des auteurs indiquent que cette
maladie est le resultat d'alterations de
I'apport vasculaire a la main a la suite de
traumatismes fermes a repetition. On

r From the Department o f Surgery, Faculty
o f Medicine, University o f Toronto,
Toronto, Ont.
*Senior Lecturer, University Department o f
T Orthopedic Surgery, Singapore General
Hospital, Singapore
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montre les preuves artdriographiques
d'une deficience du systbme vasculaire
de I'arcade palmaire.

Since the introduction of pneumatic tools
in the French mines in 1839, many cases
of vascular disturbance in the hands of
workers using these tools have been
reported. In North America, Rothstein1
and Hamilton2 were the first to write
about what they termed spastic anemia in
the hands of stone cutters who used air
hammers in the Indiana limestone quar
ries. The Workmen’s Compensation
Board of Ontario processed more than
180 claims for vibration-induced white
finger disease in miners up to the end of
1977.3 In this paper we report a typical
case of this unusual condition.
Case Report
A 22-year-old man worked as a chipper,
using an air gun. Initially, he complained to
his family doctor of pain and stiffness in the
fingers of his right hand. A diagnosis of

tenosynovitis was made and he was treated with
rest and anti-inflammatory agents, without
benefit. One month later a fusiform swelling
of his middle finger developed. The finger was
paler than the adjacent fingers, all of which
had limited flexion and extension (Fig. 1).
When Allen’s test was performed, the hand
remained blanched when the radial artery was
occluded and the pressure on the ulnar artery
was released, indicating occlusion of the ulnar
artery.
Electromyography and a nerve conduction
study of the right forearm gave normal results.
On arteriography, performed through the
brachial artery, the deep palmar arch was illdefined and the superficial palmar arch was
absent. The ulnar artery ended abruptly
between the bases of the fourth and fifth
metacarpals. Moreover, the collateral circula
tion between radial and ulnar arteries was defi
cient (Fig. 2). Arteriography in the left hand
showed normal arterial supply (Fig. 3).
We concluded that this patient’s symptoms
and signs were a direct result of the vascular
abnormalities in his hand. He was advised to
stop using the pneumatic gun and was given
a course of physiotherapy to mobilize his
fingers. When seen 2V4 months later, his range
of flexion had improved considerably (Fig. 4).

Fig. lb
Fig. la
FIG. 1—Restricted range of (a) flexion and (b) extension especially of middle finger. Note
fusiform swelling of middle finger.
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An Allen test done at subsequent follow-up
demonstrated improved circulation from the
ulnar artery. However, the filling time was still
not equal to that of the opposite side. A change
of job was recommended; he has had no
symptoms for the past 3 years.
Discussion
Rothstein1 and H am ilton2 concluded
that this syndrome was brought about by
long, continued, vascular contraction,
holding the air-powered tool too tightly,
cold exhaust air from the tools and vibra
tion. Of the four factors, vibration has
been the com m on denom inator in pro
ducing the typical symptoms and signs.
Hoerner4 reported that vibration o f a
frequency o f 3300 to 3500 cpm was most

commonly associated with production of
this condition. There seems to be a latent
period between initial use o f the tool and
onset o f th e disease. T elford and
associates5 have shown that it usually
appears after about 6 m onths o f use but
can be delayed as long as 40 months.
The pathogenesis o f this condition still
remains unclear. It has been characterized
by terms like “ dead h an d ” , “ white
fingers” , “ vasospastic disease” and
“ spastic anem ia” . Unlike some vascular
disorders, smoking has not been impli
cated as a contributing factor. Pain
(usually throbbing), blanching and stiff
ness o f the fingers are the m ost constant
complaints, followed by weakness and
numbness. In our patient, all four fingers

were involved; the middle finger was most
severely affected. This is likely related to
the way the air gun was held, producing*
maximum traum a to the middle finger.
Stiffness o f the fingers is mainly due to *
soft-tissue swelling. Some efforts have
been made to study this condition in more*
detail. Peters6 was able to dem onstrate
that the affected skin was appreciably
cooler (mean o f 2.6°C) and more than.,
half the patients he tested had a decreased
capillary blood supply to the nail bed. -t
Barker and Hines7 showed arteriographically that a mechanic who worked with"
a vibrating tool had occlusion o f the ulnar
artery at the wrist and absence o f the '
ulnar portion o f the palmar arch. Our
patient dem onstrated a similar condition.^
We believe that repetitive blunt traum a ,
to the hand from vibrating tools results
in partial obstruction to the blood sup-*
ply to the hand and fingers. There seems
to be preferential involvement of the '
ulnar artery and its contribution to the
palm ar arch and the digital vessels. The"*1
nature o f the obstruction is not clear. In A
our patient, rest and change o f work *
brought about improvement.
,
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FIG. 2—Arteriogram showing abrupt termi
nation of ulnar artery, loss of palmar arches
and poor collateral circulation.
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FIG. 3—Arteriogram of left hand shows
normal vascular pattern.
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Fig. 4b

Both hands 2-1/2 months after stopping use of air gun, showing increased range of (a) flexion and (b) extension in right hand.
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because he felt that even his most senior
residents couldn’t do these things well
enough. It was Cone who repaired Penfield’s facial laceration from skiing and
did at least as good a job as anyone else
could.
In spite of Cone’s intense interest in,
and involvement with, neurosurgery and
neuropathology, he m aintained an
interest in other fields. During the war he
collaborated with Herbert Jasper to
improve the treatment of burns and
develop antibiotics for use in treatm ent
of brain injuries. He made extensive use
of an ultrasonically precipitated triple
sulfa preparation which came to be
known as “ Cone’s celestial paste” .
The midnight ward rounds, the cons
tant wet dressings, the deep long sigh of
desperation, his interest in everything
from cockroach research to ultraviolet
sterilization of the operating rooms —
these are details known by those who
worked with him. To patients, who were
his prime concern, he was a considerate,
kind, warm, tender, concerned master
surgeon.

| Y Reprint requests to: Dr. J.L. Shugar,
I
Editorial Office, Canadian Journal o f Surrgery, PO Box 8650, Ottawa, Ont.
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My thanks go to Dr. Herbert Jasper for his
collaboration. The photograph of Dr. Cone is
reproduced by permission from the Montreal
Neurological Institute.

It is 25 years since Dr. W.V. Cone died.
He was an extraordinary man, set apart
Afrom and above most others. He was a
great thinker, daring innovator, inspired
i. teacher, skilful operator and indefatiga
ble worker. He gave of himself to his
►patients, to his students, to his institution
and to his art. Just where he placed him■ self in this scheme was always difficult to
say and here lay the enigma of his life and
his death.
William Vernon Cone was born in a
’ small town in Iowa, Conesville, named
Y after an ancestor who settled there in the
middle of the 17th century. While still in
^medical school, he developed an interest
in the nervous system and worked in the
field of neuropathology during his spare
time. He was a neurosurgeon from the
’'beginning; he was associated with Wilder
Penfield in New York before Penfield
r came to Montreal in 1928 and maintained
^a close but particular relationship for 35
c

years. Such an association invites compar
isons. The two men were very different.
Penfield planned his greatness and used
situations and people to further his per
sonal aims. It was difficult to penetrate
his armour and to get close to him. He
had motives and prejudices for everything
that he did. He could delegate authority.
Cone felt that he had to do everything
himself. It was Cone who did his own
dressings and closed his own wounds

Senior Associate Editor, Canadian Journal
o f Surgery
*■

William Vernon Cone

r
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Reminiscences of William Cone
William Vernon Cone — master neu
rosurgeon, caring physician, teacher,
taskmaster, friend, father-figure; he was
all of these to me, from our first meeting
to the day of his untimely passing.
I was a member of one of McGill
University’s wartime accelerated medical
classes, in which the standard 4 years were
completed in 3; we graduated in the sum
mer of 1944. My first rotation of 4
months as a novice hospital intern was
spent at the Montreal Neurological Insti
tute (it was not a formal hospital then),
and I was allocated to Dr. Cone’s serv
ice, the Second Neurosurgical Service.
Moreover, one of the first patients
assigned to me was none other than Dr.
Wilder Penfield, the “ chief” himself.
That gave me an early opportunity to
observe the rather ambigous relationship
between those two pioneers of neurosur
gery in Montreal.
Dr. Penfield’s hospitalization at the
institute, on Dr. Cone’s service, was for
the purpose of undergoing a tonsillectomy
at the Royal Victoria Hospital and I was
instructed to do the usual complete work
up on the patient. I did so, with my heart
in my mouth, of course; Dr. Penfield
cooperated fully, as I worked my way
carefully through the many details of a
complete general physical and neurologic
examination. However, he balked when
I began to prepare for the rectal, and I
did not insist. I quickly made my exit, but
ran into Dr. Cone in the corridor! He
wanted to know whether my work-up had
included a rectal examination. I told him
what had occurred; he led me back into
Dr. Penfield’s room, where he chided him
for not permitting that essential part of
the examination, and he watched (rather
gleefully, I thought) as I performed the
required procedure.
*Emeritus Neurosurgeon-in-Chief, Sir
Mortimer B. Davis-Jewish General
Hospital, Montreal, PQ
Accepted fo r publication May 23, 1984
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Dr. Penfield, the “ chief” , and Dr.
Cone, the “ boss” , (as they were referred
to by their residents), although they
respected and valued each other, were fre
quently guilty of needling, either verbally
or otherwise, and enjoyed the other’s dis
comfiture to the full. Dr. Cone’s reaction
under those circumstances was almost
childlike at times.
Other evidence of the competitive
aspect of their relationship was the
proprietary attitude that they adopted
towards their respective residents. For
example, when I was Dr. Cone’s chief
resident, I occasionally (when time per
mitted) attended Dr. Penfield’s weekly
epilepsy conferences. Usually, as I
emerged from such a session, I would find
Dr. Cone pacing about the hallway near
the amphitheatre doors. He would
quickly indicate his displeasure at my dis
appearance, although he obviously knew
where I was, and could easily have
brought me out.
It is well known that Dr. Cone spent
all but a few sleeping hours of every day
at the institute. Indeed, it was not until
just a few years before he died that he
agreed, perhaps under duress, to spend at
least an hour each evening at home, to
have dinner with Mrs. Cone. Moreover,
he expected his residents to have the same
attitude to their hospital duties, and he
only grudgingly recognized their very
occasional “ times off” — one evening
per week, and one weekend in two, start
ing at Saturday noon. However, there
would almost always be some urgent
project to complete or operation to per
form when Saturday noon approached,
and we would be forced to steal away late
in the afternoon in order to enjoy a brief
respite with family and friends. On
returning on Monday morning, Dr. Cone
would acknowledge my presence with a
perfunctory greeting and when we were
at the scrub-sink later that day, the con
versation between us would still be scant.
It was only towards the end of the oper
ation, as we began to close the wound,
that he would say, after heaving his very
characteristic deep sigh: “ Well, Harold,
you sure missed a barrel of fun while you

were away.” He would then relate the*
weekend’s events in detail.
Yet, long and hard as we all worked,
none of us resented it. Dr. Cone was parj,
of our small team, and by deed and by
word he taught us how to be the “ compleat” physician and the meticulous neu
rosurgeon. We roamed the wards to-A
gether, on many occasions far past
midnight, examining and re-examining *
our patients, pulling and pushing their^
beds into and out of the all-purpose dress
ing room, munching on chocolates pil
fered from their bedside tables, making
decisions about management, doing lum
bar punctures, changing dressings, twist
drilling the skull in preparation for early 4
morning ventriculography, making friedegg sandwiches in the second floor v
kitchen, and finally drawing up a detailed^
list of the next day’s multitude of chores.^
Dr. Cone had the knack of dozing off,
while sitting on a chair (even if it was
located in the always-busy radiology read-.,
ing room), and when he awakened from
such a 10-minute nap, he would feel completely refreshed and ready to keep going
-«

Drs. Penfield and Cone outside the Montreal
Neurological Institute.
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for many additional hours. When the
“ boss” noted that his “ boys” were
^developing an undue indoor pallor, he
would order us into a designated cubicle
r called the “ sun-room” , to spend a few
minutes under an ultraviolet lamp, so that
ywe might look good, at least superficially.
Dr. Cone’s proprietary attitude to his
residents was so ingrained that he got to
E-feel that they never left him. Several years
after Dr. Bertram Selverstone had com' pleted his training, and when he was
already in practice in Boston, he returned
*7o visit the institute. Dr. Cone spied him
coming out of the elevator leading to the
radiology suite, and he absent-mindedly
^said: “ Oh, Bert, pick up Mr. M’s x-rays
and bring them to the OR; he’s already
anesthetized, and they’re waiting for us.”
On the other hand, if you were one of
“ Willy’s Boys” , you were his boy in every
respect. He was not only the “ boss” , he
was a second father to you, and he shared
A all your troubles, as well as your tri
umphs, to the full. On one occasion, my
wife was ill with what was possibly menin
gitis. When Dr. Cone heard about it, he
^gathered up several instruments and drove
us to my home. He carefully examined
Mrs. Rosen, and it was soon apparent
that she was not seriously ill. After leav
ing a few helpful instructions regarding
► her further care, he retrieved his instru
ments, and me, and we quickly returned
to the institute to resume our interrupted
tasks.
* There is no doubt that part of Dr.
Cone’s dedication to his work at the insti
tute was based on his social immaturity.
Within the institute walls he was a virtual
king. Outside those walls he was like a
fish out of water. He was uncomfortable
and shy with individuals who were not his
Apatients, or their families, or members of
the institute staff. He hardly ever stayed
long at functions held outside the instiy. tute, such as the annual dinner. Almost
invariably, after he had made his appear
ance for a short time, he would excuse
himself and return to the institute. Even
e when members of the resident staff were
invited to his own home for dinner, and
although he was a gracious host at the
start, he would depart shortly after the
meal itself, leaving us to complete the
evening with Mrs. Cone on our own.
Dr. Cone appeared to dread having to
* present a paper at a medical meeting, and
such presentations on his part were there
fore relatively rare. Indeed, this resulted
in many valuable additions to the neu
rosurgical literature being filed away,
never to be completed for formal presen
tation or publication. He would become
enthusiastic about a project and would
work himself and us to a frazzle for
several weeks, gathering the material and
discussing and reworking the various

aspects of the problem many times. Then,
once we had learned all he felt we needed
to learn from the available data, he would
lose interest and let the matter drop, as
precipitously as he took it on in the first
place. Our attempts to put the finishing
touches on such projects, so that they
might be presented for publication,
usually met with studied neglect on his
part, and the matter was permitted to die
a natural death.
If there was one paramount charac
teristic of Dr. Cone’s work at the insti
tute, it was the detailed care that each
of his patients received. When those
patients left the hospital, they were well
aware that they had had the benefit of
truly full treatment, and they worshipped
the man who had orchestrated that treat
ment for them. The patient who had to
undergo surgery for an atlantoaxial insta
bility, I feel, particularly exemplified the
total care provided by Dr. Cone, from the
moment of admission to the day of dis
charge. First, there were the initial exami
nations and neuroradiologic studies. The
findings were carefully reviewed and dis
cussed with the radiologist. The situation
was then fully and frankly deliberated
with the patient and appropriate members
of the family. In preparation for the
actual surgery, the patient was placed in
skull tong traction, a procedure per
formed in the ward dressing room. The
operation itself included careful position
ing of the patient in the prone position,
with the skull tong traction in place,
meticulous exposure of the posterior
suboccipitocervical region, wire fixation
of atlas to axis (with the help of a special
wire twister devised by Dr. Cone), curet
tage of the lateral C1-C2 articular joints,
control of the resultant bleeding, appli
cation of appropriate bone grafts (using
specially fashioned bone bank bone) and,
finally, layer-by-layer approximation of
the wound. Then came repeated postoper
ative dressing changes (including daily
changes of the special strip dressings at
the skull tong entry sites), and periodic
follow-up roentgenograms. When the
operative site was well healed, the skull
tongs were removed, and the head, neck
and upper trunk were immobilized in a
carefully moulded Minerva cast, which
was a smoothly sculptured work of art in
itself. Gradual mobilization of the patient
with the help of the physiotherapist was
next, and finally discharge from hospital.
No wonder that such a patient remained
deeply grateful to his doctor for all time.
Dr. Cone was a master surgeon,
meticulous to a fault. The operative site
was always maintained in a photographi
cally ready state, with his personal ord
erly assistant (Stanley Ellis) skilfully
maneuvering the overhead lights and
snapping the stroboscopic camera at cru
cial intervals, to provide a permanent

slide record, in order of sequence, of the
entire procedure. One of the lessons that
I learned in Dr. Cone’s operating room
was that every surgical procedure —
minor or major, peripheral or central,
superficial or deep — deserves equal
attention to detail, since to veer from
one’s routine, even if the operation is not
serious, is to court disaster. His credo was
that a minor procedure can lead to major
complications, if it is not carefully and
methodically performed.
Dr. Cone and Stanley Ellis had a spe
cial relationship over a period of many
years. In addition to standing behind him
at every operation, Stanley gave Dr.
Cone’s surgical instruments — some of
which he helped the “ boss” to design —
constant care. They were about equal in
age, and they frequently used to tease
each other as to who was the older of the
two. Stanley died one Friday afternoon,
in the fifth floor operating theatre area,
while Drs. Penfield and Cone were con
ducting the weekly neuropathology con
ference on the sixth floor. The famous
photographer Karsh was at the institute
that same day, taking photographs of var
ious aspects of the institute’s activities
(for a brochure used in seeking donations
for a new wing, to replace the wartime
annex). Dr. Cone was called away from
the session and was told that Stanley had
experienced sudden severe chest pain. He
found him lying on the couch of the sur
geons’ change-room. As Dr. Cone
entered, Stanley looked up at him, smiled
wanly and said, “ Well, Dr. Cone, I guess
I’m older,” and promptly died. Dr. Cone
returned to the pathology conference
room a short time later with the bad news,
and there is a well-known photograph
taken by Karsh at that moment, showing
Drs. Penfield and Cone at their micro
scopes, with a group of fellows and resi
dents ranged behind them, all with sad
and introspective looks on their faces, as
they contemplated the narrow divide
between life and death.
Dr. Cone’s own passing followed a
period o f what seemed to be increasing
depression. I was in touch with him by
telephone from time to time, from Saint
John, New Brunswick, seeking his advice
in the management of problem patients,
and I visited him at the institute during
my occasional trips to Montreal. When
I would sometimes complain to him about
my professional loneliness in Saint John,
he would counter by speaking of the
advantage of having one’s independence.
I knew that he was more than unusually
unhappy in those days, but I was not
aware of the reasons. Perhaps he felt that
he had accomplished all he could as a neu
rosurgeon, and that what was left for him
was only more of the same — with little,
if anything, outside the institute to round
out his life.
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When I left Montreal for Saint John
in late 1952, Dr. Cone gave me a photo
graph of himself, with the inscription:
“ To Harold Rosen, my old age insur
ance” . Unfortunately, he did not live long
enough for me to fulfil that designated
role, so far as he was concerned.

Nevertheless, during my own career as a
neurosurgeon for more than 30 years, I
have thought of my mentor many times,
and I have done my best to emulate him,
in his emphasis on meticulous surgery and
on tender loving care for the patient as
a whole individual. I remember him with

gladness and pride for what he was, and
with sadness and regret for what he could
not be.
-*v

The illustration in this paper is reproduced f
by courtesy of The Montreal Neurological
Institute.
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William Vernon Cone
One cannot think of Bill Cone without
warm feelings of affection for this
remarkable man, a neurosurgeon par
excellence, who would tolerate only the
best, a man of vision and with a complex
personality.
He had been my teacher in medical
school but it was not until my first stay
at the Montreal Neurological Institute
that I came to know and admire him.
A fter sea duty, I was taking a refresher
course. Dr. Cone had just returned from
overseas where he had set up the neu
rosurgical team at No. 1 Canadian Neu
rological H ospital in Basingstoke,
England. He and his colleague Arthur
Elvidge were carrying the major load of
neurosurgery. His working hours were
legendary. He seldom left the hospital
before midnight and was back on the job
early in the morning, 7 days a week. If
he took holidays, it was in the neu
ropathology laboratory. He expected the
same devotion from his residents, and
they seldom got home. He loved to teach
at night. He was always available for help
with any neurologic problem, and he
always found time to teach the fine
points. In those days, most examinations
and procedures were done in the dressAccepted fo r publication May 23, 1984
Reprint requests to: Dr. J.P. Robb,
Box 43, Lyn, Ont. KOE lMO

ing rooms. It was there he developed the
twist-drill technique, did ventriculogra
phy, lumbar punctures, changed dressings
and invented new tidal drainage systems.
Bill always welcomed an audience. Later,
when I was in practice, I hesitated to go
to the operating room as he would insist
that I gown and enter the OR, then I was
stuck. Regardless of how busy I was, I
could not get away. He loved to operate,
particularly on Saturdays. A good day
would start at 8 am and would end at
midnight. He had tremendous confidence
and was convinced that no one could do
things as well as he did. He would open
and close all wounds and do his own
dressings. He was always interested in disc
surgery and developed new techniques to
improve the result and stabilize the back.
He loved to do radical mastoidectomies
and expose the dura. The procedure was
usually done with an otolaryngologist,
but it was Bill who changed the dressings
much to the frustration of the ENT
residents.
The patients loved him — and well they
might. His warm and sympathetic
approach, combined with his consumate
skill, inspired a great feeling of confidence
and he seldom let his patients down. He
had a particular concern for paraplegics,
which led him to develop safer and bet
ter tidal drainage systems.
He was always looking for new ideas

and techniques to improve his neurosur--*
gical skill. Indeed, he was foremost in
developing new instruments to improve "*
patient care. There can be little question
that the high standard of patient care at*
the institute was due to Bill Cone. The
introduction of spray baths, stretch chairs
and the rocking bed were all his idea. One
of his tricks was to order things on
approval and keep them so long that we A
had to buy them. He was ahead of his
time. The administration felt that many w
of the pieces of equipment he wanted
were too advanced, but time proved him*
correct.
He loved any kind of an emergency and
often would take off in a plane to bring ^
back some unfortunate patient. This led
him to develop the helicopter service, by i
which patients were brought by helicop
ter to the McGill stadium, behind the^
institute. I can remember one Saturday
afternoon when the stadium was packed
with football fans and the game was ^
stopped to land a patient. Such excite
ment — and all over in 5 minutes.
<
One could go on telling of his scientific
papers, his great skill and leadership as-*
a neurosurgeon, or the distinguished
careers of his residents, but I think of him
as a friend, always available in time of
need. With all his eccentricities, he was *
a warm and kindly man, beloved by all
who knew him.

v
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The
deadline is 1 month before issue date. Regular classified rates (for each insertion): $35.00 for the first 40 words or less, additio
n a l words 35C each (additional $13.00 for frame). Special Display under 75 words, 2 1/4" X 2" $85.00. $5.00 charge (first inser
tion only) for CJS box numbers. Display rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
GENERAL SURGEON
&
O T O R H IN O L A R Y N G O L O G IS T
NB
Required for
accredited 90-bed
general hospital
McGill affiliation.

S t. J o s e p h 's H o s p ita l
D a lh o u s ie , N B
E0K 1B 0
— S84-015
PLASTIC SURGEON — with Canadian fellowship
v required for Toronto hospital, for the fall 1984, or
the spring 1985. Please send letter and curriculum
vitae. Reply to: 89 Humber College Blvd., Suite
> 114, Rexdale, ON M9V 4B8.
-S84-027
GENERAL SURGEON: ON - required in a group
practice in northwestern Ontario. Duties would in
clude general practice in a modern clinic that ac
commodates four practitioners who alternate call at
the area's 44-bed hospital. Community has a stable
F economic base and is located on a large lake —

L INDICATIONS: For the relief of moderate to moderately severe pain,
^ in c lu d in g conditions accompanied by fever,
j CONTRAINDICATIONS: Status asthmaticus, pre-existing respiratory
f depression or convulsive states, hypersensitivity to oxycodone or
acetaminophen.
WARNINGS: Drug dependence: Oxycodone can produce drug depen
dence of the morphine type and, therefore, has the potential for being
abused. Psychic dependence, physical dependence and tolerance may
develop upon repeated administration of PERCOCET, and it should be
prescribed and administered with the same degree of caution appropriate
to the use of other oral medication containing narcotics.
Usage in ambulatory patients: Oxycodone may impair the mental and/or
r physical abilities required for the performance of potentially hazardous
tasks such as driving a car or operating machinery. The patient using
PfcRCOCET should be cautioned accordingly.
Interaction with other central nervous system depressants: Patients
receiving other narcotic analgesics, general anesthetics, monoamine
oxidase inhibitors, tricyclic antidepressants, phenothiazines, other
tranquilizers, sedative-hypnotics or other CNS depressants (including
alcohol), concomitantly with PERCOCET may exhibit an additive CNS
depression. When such combined therapy is contemplated, the dose of
one or both agents should be reduced.
» Usage in pregnancy: Safe use in pregnancy has not been established
relative to possible adverse effects on fetal development. Therefore,
PERCOCET should not be used in pregnant women unless, in the
judgment of the physician, the potential benefits outweigh the possible
hazards. The administration of PERCOCET to obstetrical patients in labour
may be associated with respiratory depression of the newborn.
Usage in children: The more potent formula. PERCOCET, should not be
administered to infants or children. However, PERCOCET-DEMI, containing
Tialf the amount of oxycodone, can be considered for children of six years
or older.
PRECAUTIONS: Head injury and increased intracranial pressure: The
respiratory depressant effects of narcotics and their capacity to elevate
cerebrospinal fluid pressure may be markedly exaggerated in the
[fe e n c e of head injury, other intracranial lesions or a pre-existing
elevated intracranial pressure. Furthermore, narcotics may produce
adverse reactions which can obscure the clinical course of patients with
head injuries.
Acute abdominal conditions: The administration of PERCOCET or other
narcotics may obscure the diagnosis or clinical course in patients with
acute abdominal conditions.
Special risk patients: PERCOCET should be given with caution to certain

recreational facilities are excellent. Underserviced
Area Grant available. Contact: Dr. V.W . Aniol, PO
Box 311, Red Lake, ON P0V 2M0, (807) 727-2751.
— S84-020

GENERAL SURGEON: BC - Wanted to join
another surgeon, serving Cariboo Chilcotin in large
clinic and well equipped 84-bed hospital. Contact:
Dr. P.A. Cullum, Yorston Medical Clinic,
e203-143 4th Ave. S., Williams Lake, BC V2G
1J8, (604) 398-6757.
-S84-031

C L IN IC A L F E L L O W S H IP S
Ewart Angus Intensive Care Unit
Wellesley Hospital
Toronto
Two positions available July 1, 1985 for a
period of 1 year in a Medical-Surgical Unit with
on-site computer support facilities. Duties com
prise clinical research in a strong academic and
teaching unit. Present research includes nutri
tional studies in critical illness, sepsis and noninvasive respiratory monitoring and respiratory
muscle function.
Reply to: Dr. D.P. Jones, Director
EAICU, Suite 219, E.K. Jones Bldg., 160
Wellesley St. E., Toronto, ON M4Y 1J3,
(416)966-6656.
-S84-024

patients such as the elderly or debilitated, because of the danger of
cardiac or respiratory depression, as well as to those patients with
hemorrhage, severe impairment of hepatic, respiratory or renal function,
hypothyroidism, Addisons' disease, prostatic hypertrophy or urethral
stricture.
Headache: Because headache often involves a significant psychological
component, a narcotic analgesic should only be employed for the
treatment of headache when no other treatment is effective, in order to
minimize the risk of psychological and physical dependence.
Drug interactions: The CNS depressant effects of PERCOCET may be
additive with those of other CNS depressants. See WARNINGS.
Other: Patients should be instructed to store PERCOCET, as for any
medication, safely out of the reach of children.
ADVERSE REACTIONS: The most frequently observed adverse reactions
include light-headedness, dizziness, sedation, nausea and vomiting.
These effects seem to be more prominent in ambulatory than in non
ambulatory patients, and some of these adverse reactions may be
alleviated if the patient lies down.
Other adverse reactions include euphoria, dysphoria, constipation and
pruritus.
SYMPTOMS AND TREATMENT OF OVERDOSAGE: Signs and symptoms:
Serious overdosage with PERCOCET is characterized by respiratory
depression (a decrease in respiratory rate and/or tidal volume. CheyneStokes respiration, cyanosis), extreme somnolence progressing to stupor
or coma, skeletal muscle flaccidity, cold and clammy skin, and
sometimes bradycardia and hypotension. In severe overdosage, apnea,
circulatory collapse, cardiac arrest and death may occur. The ingestion
of very large amounts of PERCOCET may, in addition, result in acute
acetaminophen intoxication, characterized by anorexia, nausea, vomiting
and sweating within two or three hours of ingestion, and possibly cyanosis
with methemoglobinemia. Within 48 hours, liver function tests rise
abnormally, and the liver becomes enlarged and tender. Within three to
five days jaundice, coagulation defects, myocardiopathy, encephalopathy,
and renal failure occur, followed by death due to hepatic necrosis. The
ingestion of 10 g of acetaminophen is considered to result in intoxication,
with the possibility of a fatal outcome if the amount exceeds 15 g.
Hepatotoxicity occurs when plasma levels of 300 ^g/m l are observed
within four hours of ingestion.
Treatment: Primary attention should be given to the re-establishment of
adequate respiratory exchange through provision of a patent airway and
the institution of assisted or controlled ventilation. The narcotic antagonist
naloxone is a specific antidote against the respiratory depression which
may result from overdosage or unusual sensitivity to narcotics, including

MONITEUR D E N S E IG N EM EN T (TEACHING
FELLOW) — Le departement de chirurgie g6nerale
de la faculty de m6decine de I'Universite de Sher
brooke recherche un chirurgien comme moniteur
d'enseignement (teaching fellow). Pour de plus
amples renseignements, com m uniquez avec:
Docteur Andr6 Rioux, M D , FRCS(C), FACS,
D irecteur du d e p a rte m e n t de chiru rg ie
gen£rale, Faculte de M6decine, Universite de
Sherbrooke, 3001, 12e avenue nord, Sher
brooke, Quebec J1H 5N4.
— S84-034
THE CA N A DIAN CONSENSUS G R O U P - for
the Surgical Treatment of Morbid Obesity, a group
of physicians interested in the surgical treatment of
morbid obesity, met in May 1983 w ith the intention
of exchanging knowledge and forming a National
Canadian Obesity Surgical Registry. The pro
ceedings of this meeting were published in the
Canadian Journal o f Surgery (Vol. 27, No. 2, March
1984, pages 119-136 and Vol. 27, No. 3, May 1984,
pages 227-238). A second consensus meeting was
held in May 1984. If you or any of your colleagues
would like to be placed on the mailing list for future
participation in this organization, please send your
name, address and hospital affiliation to: Dr. J.B.
Freeman, University of Ottawa, Division of
General Surgery, O ttawa General Hospital, 501
Smyth Rd., Ottaw a, ON K1H 8L6.
— S84-025

oxycodone. Therefore, an appropriate dose of this antagonist should be
administered, preferably by the intravenous route, simultaneously with
efforts at respiratory resuscitation. Since the duration of action of
oxycodone may exceed that of the antagonist, the patient should be kept
under continued surveillance and repeated doses of the antagonist should
be administered as needed to maintain adequate respiration. The
instructions contained in the package insert provided by the manufacturer
should be carefully observed.
An antagonist should not be administered in the absence of clinically
significant respiratory or cardiovascular depression.
Oxygen, intravenous fluids, vasopressors and other supportive
measures should be employed as indicated.
Gastric emptying by emesis or lavage may be useful in removing
unabsorbed drug, and should be carried out at an early stage of
treatment. Plasma levels of acetaminophen should be determined. If
hemodialysis is carried out within ten hours of ingestion, it may be of
some value.
The drug PARVOLEX® (N-acetylcysteine, Allen & Hanburys) is a specific
antidote for acetaminophen intoxication. For directions for use. refer to
the manufacturer’s Product Monograph or the CPS.
DOSAGE AND ADMINISTRATION: Dosage should be adjusted according
to the severity of the pain and the response of the patient. It may
occasionally be necessary to exceed the usual dosage recommended
below in cases of more severe pain or in those patients who have become
tolerant to the analgesic effect of narcotics. The usual adult dose is one
tablet every six hours as needed for pain.
DOSAGE FORMS: PERCOCET, supplied as white, scored tablets each
containing oxycodone hydrochloride, 5.0 mg and acetominophen 325 mg
in bottles of 100 and 500 tablets. Also available as PERCOCET-DEMI,
containing half the amount of oxycodone, and with the same amount of
acetaminophen, in bottles of 100 tablets.
Precaution: This product has the
potential for being abused._____
Full product monograph available on request
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A p p lica n ts invited fo r Postdoctoral
M edical F ellow ships in N ephrology or
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D. J. Crawford, Medical Director, Prince Albert ^
Community Clinic, 110-8 St. E., Prince Albert,
SK S6V 0V7. Tel: (306) 763-6464.
-S 8 4 -0 3 ?

CRITICAL CARE FELLOWSHIP
Surgical Intensive Care Unit, University Hospital,
University of Saskatchewan, Saskatoon, Saskat
chewan. One year, renewable once, for physicians who M
are eligible for the Royal College certification examina
tion in general surgery or anesthesia.
Experience offered in: Surgical critical care ^
multidisciplinary unit in multiple trauma, open heart
surgery, major complications following general surgical
procedures, neurosurgical post-up care and infections
in critically ill patients. Competitive salary. Oppor
tunities for clinical research available. Position open im- . i
mediately.
In accordance with Canadian Immigration re£
quirements, this advertisement is directed to Canadian
citizens and permanent residents.
Send curriculum vitae to: JA IM E C. P inilla, MD,
FRCS(C), D irector, Surgical Intensive Care U nit, H
D e partm ent o f Surgery, U n iversity H ospital,
S a skatoon, SK S7N 0W0.
- S84-036

F ellow ship is fo r one year but second
year a p p lica tio n anticipated.

Parke-Davis Canada Inc.

C efobid

KIDNEY FOUNDATION
RESEARCH FELLOWSHIPS ALBERTA, CANADA 1985-86

KIDNEY FOUNDATION OF CANADA,
Alberta Branch,
1 0 3 , 5 9 2 0 - 1A St. SW,
Calgary, Alberta, Canada
T2H 0G 3.

512

Agarol*

APPLICATIONS POSTMARKED AFTER
OCTOBER 15, 1984 WILL NOT BE
ACCEPTED.
—S84-023

•4 PRESCRIBING INFORMATION ^
INDICATIONS: Acute functional constipation:
debilitating disorders complicated by inadequate
bowel action; in post-operative cases, hyper
tensive or chronic cardiac disorders where
forcing a stool must be avoided; in constipation
of pregnancy; in bed-ridden or elderly patients.
CONTRAINDICATIONS: Symptoms of
appendicitis. Idiosyncrasy to phenolphthalein.
PRECAUTIONS: Frequent or prolonged use
of this preparation may result in dependence
on laxatives. If a skin rash develops, discontinue
the use of this or any other phenolphthaleincontaining preparation.
DOSAGE: Adults—2 to 4 teaspoonfuls at
bedtime; if necessary repeat this dosage the
next morning, two hours after breakfast.
Children (three to six years )—'A to 1 teaspoon
ful; (over6 years)— 1 to 2 teaspoonfuls; (under
three years)— proportionately smaller doses
according to age May be taken alone or in
milk, water, fruit juice or any miscible food.

GENERAL SURGEON: SK - required for a
multispecialty and seven-member family practice
group in central Saskatchewan city of 35 000, with
an extended rural catchment area. Excellent clinic
facilities including x-ray, laboratory, physiotherapy,
pharmacy, plus extensive minor surgical facility with
full range of endoscopic equipment. Two local
hospitals of 150 beds each. City within easy reach of
national park and wide range of recreational lakes
and countryside. Suitable applicant should have as
wide as possible a range of general surgery, prefer
a b ly including endoscopic and/or orthopedic ex
perience. Please direct replies and enquiries to: Dr.

COLO RECTAL SURGEON
The Sir Mortimer B. Davis-Jewish General
Hospital, a 590-bed McGill University teaching
hospital, is searching for a fully qualified colo
rectal surgeon with a strong academic orienta
tion. Interested candidates should forward a
copy of their curriculum vitae to:

P L. Heilpern, M D , FRCP(C)
D irector o f Professional Services
Sir M o rtim er B. DavisJew ish General Hospital
3755 Cote St. Catherine Rd., Rm. A-142
M on treal, PQ H3T 1E2
— S84-028

GENERAL SURGEON

SUPPLIED: Each 5 mL of creamy white,
marshmallow-flavoured, calorie-free emulsion
contains: mineral o il-1.60 mL. glycerin200.0 mg, phenolphthalein-65.0 mg. Also
contains agar. Sodium content: 8.3 mg/5 mL.
Available in 250 mL, 500 mL and 750 mL
plastic bottles.
Full information is available on request.

PARKE-DAVIS

Mr. J.G . McEachern
Executive Director
YARMOUTH REGIONAL HOSPITAL
Yarmouth, NS, B5A 2P5

paab I
c cp p !

520

’ Reg T M Warner-Lambert Company r —
Parke-Davis Canada Inc auth user L l!

1

RESIDENCY PROGRAM — Applications are be
ing accepted for a 3-year approved residency pro
gram in the Division of Cardiovascular and Thoracic "1
Surgery, University of British Columbia, Vancouver,
BC, Canada. Positions are open beginning July<
1986. Separate rotations are provided on adult car
diovascular, general thoracic and pediatric car
diovascular and thoracic surgical services. For addi
tional information and applications, contact: G .^
Frank O, Tyers, M D, FRCS(C), FACS, Division
of Cardiovascular and Thoracic Surgery, Van
couver General Hospital, Vancouver, BC V5Z ^
1M9.
— S84-035

W e are a Regional Health Centre w h ich includes a fu lly
accredited 175-bed h o sp ital w ith an e xcellent o p p o rtu n ity
fo r a qualified general surgeon.
Located in a seaport to w n in s o u th w e ste rn Nova Scotia,
w e serve a population o f approxim ately 50 0 0 0 and our loca
tio n o ffe rs an a ttra c tiv e non-urban life style w ith convenient
fa cilitie s and tra n sp o rta tio n services to larger centres.
Interested parties w h o possess ce rtific a tio n or fe llo w sh ip
o f the Royal College o f Physicians and Surgeons o f Canada
or e ligibility fo r same are in vited to su b m it a curriculum vitae
to , or fo r fu rth e r in fo rm a tio n co n ta ct:

Parke-Davis Canada Inc, Scarborough, Ontario

’

_______________________________________________________

—S84-026
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Agarol
Laxative

Belief without discomfort
Ah effective, pteiuot tistiif huntiw for the whole fimilf
Provides reliet el cantlpitioa ted promotes rtfaiarity.
SHAKE WELL
Adults: 2 to 4 teaspoons. Children: 3-6 years, 1 /2 to 1
teaspoon, over 6 years, t to 2 teaspoons. To be ta ken on
retiring: if necessary, repeat dose next morning 2 hours
after eating. May be mixed w ith m ilk, water or fr u it juice.
Each teaspoon (5 m l) contains: Mineral Oil 1.60 m l.
Glycerin 2 0 0 mg Pbenolphthalein 6 5 mg.
Also contains Agar.

500 mL

Agarol* goes to work overnight gently encouraging bowel motility.
Depend on it for the short-term m anagem ent of constipation;
and,
consider the tim ely action of Agarol as an initial step to long-term therapy.

$ occasional constipation
; '/ geriatric patients
post-op patients
Popular m arshm allow flavour for greater patient acceptance!

PARKE-DAVIS

Parke-Davis Canada Inc., Scarborough, Ontario

The first name in self-medication
P AA B
CCPP

*Reg. T.M. Warner-Lambert Company, Parke-Davis C anada Inc. Auth. User

| P M A C |

Davis + Geek Introduces

Sv FT(jUT
Surgical Chromic Suture

Something
you’re used to
without
the problems
you’re used to
You told us that you liked using catgut but you didn’t like its
problems. So we took catgut and made it
soft and supple
easy to tie
less likely to curl, “pigtail” and tangle
easy to handle and control

In fact, we made it

FTGLIT
Surgical Chromic Suture

Better than catgut — but still catgut

DAVIS+GECK
Cyanamid Canada Inc.

A TRADITION OF INNOVATION

Atria North, 2255 Sheppard Avenue East, Willowdale, (Ontario) M2J 4Y5
•Trademark American Cyanamid Company

*

